data_2mn1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mn1 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.398 -3.885 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 24.8 tp -120.93 120.91 29.12 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -177.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -70.89 83.26 0.91 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.295 1.997 . . . . 0.0 111.804 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.0 m -130.61 11.02 2.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.483 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.1 m -80.56 -28.4 37.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.443 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.24 4.69 90.43 Favored Glycine 0 N--CA 1.427 -1.95 0 CA-C-N 114.93 -1.032 . . . . 0.0 112.009 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.28 -176.65 3.56 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.237 0.541 . . . . 0.0 110.204 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.7 p -133.23 160.33 37.57 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.124 -177.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.5 p -126.49 84.84 2.31 Favored 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.461 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.65 -31.3 41.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.18 5.09 55.61 Favored Glycine 0 N--CA 1.44 -1.081 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.795 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 81.44 11.93 82.6 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.198 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 m -116.64 110.72 18.87 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -178.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.7 m -89.54 146.5 24.55 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-O 120.981 0.42 . . . . 0.0 110.479 177.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -81.38 -62.14 1.74 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.255 -177.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.414 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.5 m -51.19 118.18 10.19 Favored Pre-proline 0 C--O 1.251 1.133 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -59.45 118.49 5.39 Favored 'Trans proline' 0 C--N 1.354 0.858 0 C-N-CA 122.887 2.391 . . . . 0.0 109.936 175.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.23 -12.12 14.32 Favored Glycine 0 C--N 1.293 -1.857 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.414 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 78.8 m -99.13 154.98 17.7 Favored 'General case' 0 N--CA 1.433 -1.314 0 CA-C-O 121.633 0.73 . . . . 0.0 110.082 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -141.55 153.26 44.74 Favored 'General case' 0 C--N 1.268 -2.958 0 C-N-CA 125.465 1.506 . . . . 0.0 107.697 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.473 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 31.0 t -96.69 83.91 3.54 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-O 121.38 0.61 . . . . 0.0 110.06 -179.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.4 m -88.11 -51.78 5.6 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.017 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.5 m95 -102.03 75.27 1.51 Allowed 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.064 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -55.6 136.43 70.91 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.13 -178.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -99.42 36.22 6.95 Favored 'Cis proline' 0 CA--C 1.541 0.85 0 C-N-CA 124.874 -0.886 . . . . 0.0 113.918 4.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.6 t -110.58 143.06 21.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.2 m -87.76 155.32 19.96 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-O 122.201 1.0 . . . . 0.0 110.5 -178.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.8 p -138.79 153.66 48.43 Favored 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.814 -1.539 . . . . 0.0 109.329 -174.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.9 tpp180 -89.82 -67.37 0.85 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.873 -0.731 . . . . 0.0 109.91 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 -177.026 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -3.001 0 N-CA-C 108.918 -1.673 . . . . 73.03 108.918 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -120.94 111.49 34.12 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.517 -1.29 . . . . 73.03 107.517 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.61 78.63 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 122.093 1.862 . . . . 74.31 113.604 -177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.01 27.84 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 122.381 1.086 . . . . 72.05 108.645 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.4 m -90.2 -21.79 22.0 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 114.129 -1.396 . . . . 61.01 110.468 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.87 -4.29 53.57 Favored Glycine 0 C--N 1.303 -1.298 0 CA-C-N 114.42 -1.263 . . . . 72.34 113.983 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.407 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.6 pt-20 -117.11 179.33 4.06 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 122.24 -0.565 . . . . 75.02 111.438 -178.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.3 p -124.21 157.36 34.98 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.359 -0.837 . . . . 75.52 110.979 -175.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -127.89 83.66 2.18 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.718 -0.475 . . . . 73.42 109.718 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.36 -35.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.481 -0.933 . . . . 64.22 108.481 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.8 -14.57 59.35 Favored Glycine 0 N--CA 1.435 -1.368 0 CA-C-N 115.237 -0.892 . . . . 61.44 110.977 177.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.27 32.9 7.97 Favored Glycine 0 N--CA 1.432 -1.594 0 C-N-CA 120.131 -1.033 . . . . 74.11 111.537 179.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -142.84 122.45 13.3 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-O 121.274 0.559 . . . . 73.11 109.777 177.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.3 m -104.06 145.38 30.26 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 115.057 -0.974 . . . . 61.42 110.572 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 38.3 m-80 -86.57 -49.87 7.23 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.522 0.729 . . . . 71.32 111.527 -176.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 65.4 m -50.27 116.2 6.33 Favored Pre-proline 0 C--O 1.249 1.072 0 O-C-N 124.039 0.837 . . . . 73.25 112.101 -178.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.81 118.87 5.71 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 123.365 2.71 . . . . 75.23 111.611 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.13 -3.23 33.33 Favored Glycine 0 N--CA 1.426 -1.977 0 CA-C-N 115.699 -0.682 . . . . 71.01 111.552 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.467 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 84.9 m -102.44 155.53 18.2 Favored 'General case' 0 N--CA 1.432 -1.351 0 CA-C-O 122.043 0.925 . . . . 73.32 111.582 178.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -140.5 156.8 46.22 Favored 'General case' 0 C--N 1.27 -2.863 0 CA-C-N 113.715 -1.584 . . . . 74.51 107.903 179.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.4 t -92.64 80.93 4.76 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.901 -0.778 . . . . 73.24 108.901 175.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.2 m -83.66 -39.92 19.61 Favored 'General case' 0 N--CA 1.405 -2.69 0 CA-C-N 115.779 -0.646 . . . . 65.55 111.221 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.507 ' CD1' HG21 ' A' ' 28' ' ' THR . 23.3 m95 -118.08 82.4 1.83 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.014 -0.735 . . . . 75.22 109.014 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 84.0 t90 -57.99 132.71 83.61 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.517 0.727 . . . . 75.14 110.752 -175.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -104.97 41.73 2.95 Favored 'Cis proline' 0 CA--C 1.545 1.037 0 CA-C-N 119.157 0.735 . . . . 74.42 113.797 4.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.95 139.86 31.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.178 -1.045 . . . . 71.32 108.178 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.407 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 88.6 m -87.97 146.89 25.29 Favored 'General case' 0 CA--C 1.474 -1.948 0 CA-C-O 122.562 1.172 . . . . 63.02 110.55 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.507 HG21 ' CD1' ' A' ' 23' ' ' TRP . 15.5 p -135.19 157.69 46.26 Favored 'General case' 0 C--N 1.256 -3.487 0 CA-C-N 113.0 -1.909 . . . . 75.33 110.325 -171.044 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.467 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 27.0 mmm180 -88.87 -65.42 1.02 Allowed 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.866 0.841 . . . . 74.04 110.61 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 C--N 1.284 -2.251 0 N-CA-C 105.415 -2.068 . . . . 75.41 105.415 -177.976 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.397 -3.922 0 N-CA-C 108.749 -1.74 . . . . 43.22 108.749 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 tp -120.23 115.32 32.96 Favored Pre-proline 0 N--CA 1.442 -0.871 0 N-CA-C 107.844 -1.169 . . . . 74.13 107.844 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.34 81.38 1.5 Allowed 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.309 2.006 . . . . 73.2 112.442 -177.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 m -132.62 9.63 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 115.038 -0.983 . . . . 65.44 110.64 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.7 m -76.66 -22.7 53.67 Favored 'General case' 0 CA--C 1.491 -1.307 0 CA-C-O 121.473 0.654 . . . . 73.44 111.295 -177.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.96 -2.01 82.27 Favored Glycine 0 N--CA 1.422 -2.249 0 CA-C-N 114.713 -1.13 . . . . 63.44 112.939 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -122.51 177.71 5.3 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.548 -0.861 . . . . 74.32 111.121 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.1 p -124.76 154.36 41.02 Favored 'General case' 0 N--CA 1.422 -1.858 0 CA-C-N 114.513 -1.222 . . . . 61.54 110.656 -178.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -122.14 85.52 2.43 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 123.549 0.74 . . . . 55.43 109.162 178.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -72.12 -33.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-O 121.566 0.698 . . . . 74.23 109.338 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.28 -16.77 56.89 Favored Glycine 0 N--CA 1.438 -1.227 0 CA-C-N 115.384 -0.826 . . . . 72.23 111.636 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.436 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.31 15.27 23.83 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.075 -1.059 . . . . 74.21 112.907 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.4 m -137.31 124.46 21.68 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.938 -1.134 . . . . 72.4 107.938 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.98 149.35 21.89 Favored 'General case' 0 C--N 1.273 -2.717 0 CA-C-N 115.953 -0.567 . . . . 61.32 111.44 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -75.06 -54.04 7.85 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.596 -0.729 . . . . 64.15 109.646 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -51.71 111.52 2.49 Favored Pre-proline 0 C--O 1.256 1.41 0 C-N-CA 124.144 0.978 . . . . 75.52 112.241 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -62.87 118.06 4.96 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.385 2.057 . . . . 74.14 109.556 176.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.9 -11.31 13.52 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 111.363 -0.695 . . . . 72.53 111.363 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.5 m -102.39 155.64 18.12 Favored 'General case' 0 CA--C 1.499 -0.996 0 CA-C-O 122.244 1.021 . . . . 64.32 111.802 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.5 p -132.16 151.69 51.66 Favored 'General case' 0 N--CA 1.401 -2.905 0 CA-C-N 113.797 -1.547 . . . . 73.4 108.858 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.436 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 20.8 t -93.18 53.08 1.88 Allowed 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.858 0.837 . . . . 73.11 108.989 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 m -70.53 -22.81 62.57 Favored 'General case' 0 N--CA 1.414 -2.244 0 CA-C-N 115.587 -0.733 . . . . 73.44 111.938 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.9 t-105 -128.99 80.43 1.97 Allowed 'General case' 0 C--O 1.205 -1.278 0 N-CA-C 108.237 -1.023 . . . . 71.43 108.237 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -62.88 135.32 95.98 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 116.094 -0.503 . . . . 74.44 110.898 -173.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -102.31 36.4 5.91 Favored 'Cis proline' 0 C--N 1.354 0.851 0 C-N-CA 125.008 -0.83 . . . . 74.54 113.304 2.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.8 t -105.35 141.44 20.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 109.275 -0.639 . . . . 73.0 109.275 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 74.7 m -88.92 144.58 26.09 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-O 122.794 1.283 . . . . 75.32 111.029 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 p -129.74 155.05 46.55 Favored 'General case' 0 C--N 1.258 -3.371 0 CA-C-N 112.867 -1.97 . . . . 74.14 110.037 -173.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 -89.55 -66.42 0.92 Allowed 'General case' 0 N--CA 1.425 -1.706 0 CA-C-O 121.763 0.792 . . . . 74.11 109.878 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 105.388 -2.079 . . . . 74.54 105.388 -178.708 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.971 0 N-CA-C 109.961 -1.255 . . . . 72.14 109.961 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.0 tp -118.24 111.53 38.45 Favored Pre-proline 0 N--CA 1.439 -0.998 0 N-CA-C 108.279 -1.008 . . . . 73.0 108.279 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -74.96 79.11 2.73 Favored 'Trans proline' 0 N--CA 1.444 -1.41 0 C-N-CA 121.879 1.719 . . . . 64.24 112.675 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.88 22.65 2.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 CA-C-O 121.821 0.819 . . . . 74.33 109.662 176.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 52.2 m -85.12 -32.65 22.66 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.906 -1.146 . . . . 62.32 107.906 176.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.51 -2.58 87.04 Favored Glycine 0 N--CA 1.43 -1.759 0 CA-C-N 114.055 -1.43 . . . . 75.43 112.694 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -112.12 175.83 5.27 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.647 0.737 . . . . 64.23 111.624 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -127.32 158.64 36.7 Favored 'General case' 0 C--N 1.284 -2.273 0 CA-C-N 114.465 -1.243 . . . . 72.4 109.732 -177.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.1 p -119.64 96.6 5.26 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.37 -0.974 . . . . 65.32 108.37 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.8 t -80.0 -38.87 19.09 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 109.084 -0.71 . . . . 73.23 109.084 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.88 -10.69 61.15 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.402 -0.817 . . . . 65.43 111.149 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.482 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 99.56 13.73 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.522 -0.847 . . . . 72.23 112.573 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.6 m -127.66 128.78 46.07 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 107.925 -1.139 . . . . 75.51 107.925 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 36.1 m -104.48 159.38 15.79 Favored 'General case' 0 C--N 1.272 -2.779 0 CA-C-N 115.741 -0.663 . . . . 75.12 109.578 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -91.62 -58.07 2.55 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.386 -0.37 . . . . 74.14 110.519 -179.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.443 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 35.6 m -46.65 116.95 4.1 Favored Pre-proline 0 CA--C 1.545 0.771 0 O-C-N 124.374 1.046 . . . . 71.41 112.219 -175.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.93 117.09 3.73 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 123.257 2.638 . . . . 72.2 110.941 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.09 -2.51 31.46 Favored Glycine 0 N--CA 1.427 -1.936 0 CA-C-N 115.554 -0.748 . . . . 72.31 111.543 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.464 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 63.2 m -106.25 150.21 26.14 Favored 'General case' 0 CA--C 1.488 -1.435 0 CA-C-O 121.789 0.804 . . . . 74.34 110.113 176.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 p -136.72 152.46 50.38 Favored 'General case' 0 C--N 1.268 -2.973 0 CA-C-N 114.165 -1.38 . . . . 73.4 109.927 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.482 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 38.8 t -88.58 65.17 7.72 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.855 -1.165 . . . . 74.24 107.855 176.362 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.6 m -72.7 -29.39 63.34 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-N 114.489 -1.232 . . . . 72.23 110.798 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.3 t-105 -134.29 82.77 1.99 Allowed 'General case' 0 N--CA 1.433 -1.322 0 CA-C-O 121.179 0.514 . . . . 72.32 110.135 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.1 t90 -56.1 139.12 72.38 Favored Pre-proline 0 C--O 1.244 0.799 0 CA-C-N 115.245 -0.889 . . . . 72.23 109.875 -177.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -97.87 30.19 13.62 Favored 'Cis proline' 0 CA--C 1.538 0.711 0 C-N-CA 125.033 -0.82 . . . . 74.02 113.483 1.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 44.5 t -107.64 136.73 41.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 N-CA-C 109.558 -0.534 . . . . 71.31 109.558 -178.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.7 m -88.46 152.49 21.85 Favored 'General case' 0 N--CA 1.419 -1.996 0 C-N-CA 119.268 -0.973 . . . . 74.32 109.113 177.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -139.25 164.32 30.13 Favored 'General case' 0 C--N 1.264 -3.149 0 CA-C-N 114.742 -1.117 . . . . 74.12 109.016 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.464 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 24.3 mmm180 -88.14 -74.14 0.46 Allowed 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.775 0.798 . . . . 74.13 110.463 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 . . . . . 0 C--N 1.275 -2.631 0 N-CA-C 104.647 -2.353 . . . . 73.31 104.647 -179.42 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.415 -2.713 0 N-CA-C 109.68 -1.368 . . . . 74.32 109.68 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -121.06 112.92 33.04 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.514 -0.55 . . . . 75.13 109.514 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -71.79 81.56 1.33 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.3 2.0 . . . . 74.14 112.981 -179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m -133.24 15.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 114.982 -1.008 . . . . 75.21 110.187 177.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.2 m -88.73 -26.75 21.61 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.725 -0.67 . . . . 74.22 111.05 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.32 6.09 86.09 Favored Glycine 0 N--CA 1.427 -1.914 0 CA-C-N 114.875 -1.057 . . . . 74.33 112.987 177.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.413 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.3 pt-20 -120.09 173.97 6.77 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.249 -0.98 . . . . 73.02 111.557 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.8 p -124.45 153.71 41.56 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-N 114.191 -1.368 . . . . 72.24 110.001 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -123.26 85.12 2.37 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 123.54 0.736 . . . . 64.25 110.389 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.0 t -80.75 -23.87 11.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.89 0.852 . . . . 74.5 108.838 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -13.7 60.22 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.594 -1.002 . . . . 55.23 110.594 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.33 17.37 46.53 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.508 -0.853 . . . . 74.05 112.071 177.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 m -139.36 131.16 27.54 Favored 'General case' 0 N--CA 1.419 -2.005 0 N-CA-C 108.368 -0.975 . . . . 73.53 108.368 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.76 156.79 16.18 Favored 'General case' 0 C--N 1.275 -2.636 0 CA-C-N 115.853 -0.612 . . . . 72.41 109.5 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -94.42 -49.71 5.56 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 116.235 -0.439 . . . . 75.22 110.947 -176.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.515 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 13.2 m -51.27 118.27 10.47 Favored Pre-proline 0 C--O 1.246 0.919 0 C-N-CA 123.913 0.885 . . . . 74.42 111.169 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.99 118.18 4.99 Favored 'Trans proline' 0 C--N 1.354 0.855 0 C-N-CA 122.728 2.285 . . . . 63.44 110.529 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.32 -1.44 32.93 Favored Glycine 0 N--CA 1.427 -1.906 0 C-N-CA 120.963 -0.636 . . . . 51.52 111.993 -178.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.515 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.3 m -105.01 154.81 19.63 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.982 0.896 . . . . 63.31 112.067 178.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 p -137.8 153.52 49.65 Favored 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 125.126 1.37 . . . . 74.52 109.74 -176.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.9 t -97.13 87.22 4.14 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.316 -0.994 . . . . 74.34 108.316 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.1 t -81.65 -57.86 3.26 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.365 -0.605 . . . . 61.2 109.365 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -107.29 96.54 6.48 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 109.223 -0.658 . . . . 73.24 109.223 -178.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 75.7 t90 -63.93 138.23 97.34 Favored Pre-proline 0 C--N 1.296 -1.717 0 N-CA-C 109.233 -0.654 . . . . 74.15 109.233 -178.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -102.63 37.84 5.03 Favored 'Cis proline' 0 CA--C 1.544 0.984 0 C-N-CA 124.464 -1.057 . . . . 75.11 114.018 1.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.5 p -108.97 143.6 18.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 O-C-N 121.516 -0.74 . . . . 70.22 110.059 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.413 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.6 m -88.5 160.75 17.36 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 122.288 1.042 . . . . 64.15 111.353 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.2 p -142.14 166.17 25.43 Favored 'General case' 0 C--N 1.267 -3.002 0 CA-C-N 113.613 -1.631 . . . . 72.21 108.154 -178.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 22.1 tpt180 -89.01 -70.93 0.62 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.736 -0.838 . . . . 74.13 108.736 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.417 -2.109 0 N-CA-C 104.775 -2.305 . . . . 73.4 104.775 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.417 -2.627 0 N-CA-C 109.219 -1.552 . . . . 64.24 109.219 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.6 tp -115.08 111.69 44.81 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 114.658 -0.771 . . . . 73.44 109.023 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.93 74.67 3.37 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 122.671 2.247 . . . . 74.21 113.678 -176.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -125.32 18.49 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 115.459 -0.792 . . . . 74.14 109.908 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.7 m -88.21 -22.26 24.09 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-O 121.996 0.903 . . . . 75.43 109.562 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.08 -15.79 19.95 Favored Glycine 0 N--CA 1.438 -1.197 0 CA-C-N 114.116 -1.402 . . . . 63.23 113.549 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -99.52 175.5 5.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 121.557 0.694 . . . . 73.35 110.733 -177.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.8 p -125.38 149.0 48.55 Favored 'General case' 0 N--CA 1.409 -2.482 0 CA-C-N 114.54 -1.209 . . . . 74.11 110.28 -178.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -116.76 93.11 4.07 Favored 'General case' 0 C--N 1.284 -2.244 0 N-CA-C 108.749 -0.834 . . . . 63.14 108.749 177.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 65.7 t -80.3 -35.22 15.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.158 -0.682 . . . . 74.14 109.158 179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.52 -10.44 65.47 Favored Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.389 -1.085 . . . . 62.51 110.389 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.464 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 92.82 17.21 45.33 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.707 -0.759 . . . . 42.44 111.802 178.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 m -123.24 122.49 38.5 Favored 'General case' 0 N--CA 1.418 -2.049 0 N-CA-C 108.474 -0.935 . . . . 73.13 108.474 -178.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 67.6 m -99.38 141.2 32.48 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-N 115.836 -0.62 . . . . 71.01 111.89 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -83.07 -50.96 7.97 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.038 -0.983 . . . . 74.22 111.639 -176.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 53.4 m -52.29 118.56 12.76 Favored Pre-proline 0 C--O 1.254 1.318 0 C-N-CA 122.531 0.333 . . . . 73.22 111.74 176.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -67.38 114.0 3.1 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.163 1.908 . . . . 74.41 109.724 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 121.19 -7.28 10.7 Favored Glycine 0 N--CA 1.417 -2.618 0 C-N-CA 120.246 -0.978 . . . . 43.22 110.916 -176.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.2 m -108.77 153.27 23.71 Favored 'General case' 0 CA--C 1.495 -1.14 0 CA-C-O 121.433 0.635 . . . . 73.34 110.54 176.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.7 p -134.25 152.86 52.04 Favored 'General case' 0 N--CA 1.406 -2.634 0 CA-C-N 114.571 -1.195 . . . . 75.41 108.137 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.464 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 36.0 t -89.28 83.06 6.44 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.26 -1.015 . . . . 73.42 108.26 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.8 t -105.23 1.04 27.8 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.632 -0.713 . . . . 75.13 110.451 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.7 t-105 -147.57 63.88 1.14 Allowed 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.341 -0.985 . . . . 72.31 108.341 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 84.5 t90 -51.61 132.8 35.97 Favored Pre-proline 0 C--N 1.318 -0.797 0 CA-C-N 114.615 -1.175 . . . . 73.14 110.482 -177.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -101.24 34.22 7.75 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.662 -0.974 . . . . 73.43 113.64 4.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -109.89 142.02 23.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.866 -0.79 . . . . 74.2 108.866 179.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.9 m -88.26 147.23 24.92 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.711 1.243 . . . . 72.11 110.835 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -130.0 158.88 38.37 Favored 'General case' 0 C--N 1.26 -3.318 0 CA-C-N 112.889 -1.959 . . . . 74.43 109.733 -172.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -89.42 -66.93 0.87 Allowed 'General case' 0 N--CA 1.416 -2.149 0 C-N-CA 119.751 -0.78 . . . . 74.34 109.767 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 N--CA 1.426 -1.67 0 N-CA-C 105.541 -2.022 . . . . 72.23 105.541 -179.324 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.331 0 N-CA-C 109.937 -1.265 . . . . 73.44 109.937 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.9 tp -118.5 120.67 31.68 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.623 -0.51 . . . . 73.3 109.623 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -70.61 82.87 0.89 Allowed 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.127 1.885 . . . . 75.12 112.521 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.4 m -130.47 19.45 2.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-O 121.759 0.79 . . . . 71.41 109.391 176.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 79.4 m -93.0 -29.61 15.75 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 115.007 -0.997 . . . . 62.32 110.251 -178.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.87 3.43 73.98 Favored Glycine 0 N--CA 1.432 -1.593 0 CA-C-N 114.832 -1.076 . . . . 73.4 113.621 177.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -120.3 175.27 6.04 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.742 0.782 . . . . 75.15 111.254 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -128.88 155.45 45.24 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-N 114.427 -1.26 . . . . 72.51 109.759 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -125.64 85.81 2.45 Favored 'General case' 0 C--N 1.278 -2.529 0 CA-C-N 116.234 -0.439 . . . . 74.15 109.924 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 41.2 t -80.3 -25.25 11.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.291 -0.963 . . . . 74.32 109.005 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.95 -15.94 56.98 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 110.927 -0.869 . . . . 55.2 110.927 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.96 14.79 38.45 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.811 -0.709 . . . . 63.1 112.263 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.8 m -130.76 124.36 31.25 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.206 -0.665 . . . . 72.33 109.206 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.9 m -98.92 152.93 19.23 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 115.847 -0.615 . . . . 71.01 109.686 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -87.88 -55.96 3.54 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.595 -0.275 . . . . 72.14 111.18 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 19.9 m -50.97 112.15 2.77 Favored Pre-proline 0 CA--C 1.56 1.34 0 O-C-N 124.29 0.994 . . . . 60.44 112.728 -176.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -58.61 121.97 10.86 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 123.115 2.543 . . . . 72.42 110.512 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.75 -3.73 30.6 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 110.766 -0.934 . . . . 72.54 110.766 -177.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 86.0 m -104.81 159.17 16.0 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.539 0.685 . . . . 72.34 110.824 176.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.5 p -137.82 146.09 43.09 Favored 'General case' 0 C--N 1.28 -2.442 0 C-N-CA 124.924 1.289 . . . . 72.41 109.233 -176.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 49.2 t -91.44 77.2 5.81 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.26 -1.385 . . . . 75.11 107.26 174.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -90.28 -36.29 14.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.689 -0.687 . . . . 75.41 110.96 -175.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 92.6 m95 -120.34 76.03 1.15 Allowed 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.209 -0.663 . . . . 73.41 109.209 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 79.9 t90 -53.75 136.91 54.51 Favored Pre-proline 0 C--N 1.313 -1.008 0 CA-C-N 114.895 -1.048 . . . . 73.15 110.372 -175.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -97.24 32.85 10.39 Favored 'Cis proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.523 -1.032 . . . . 74.12 113.295 2.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.0 t -106.15 138.18 32.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 109.549 -0.537 . . . . 75.25 109.549 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.95 153.51 20.97 Favored 'General case' 0 N--CA 1.41 -2.438 0 CA-C-O 122.104 0.954 . . . . 73.55 109.225 177.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 5.2 p -133.08 165.5 24.6 Favored 'General case' 0 C--N 1.252 -3.633 0 CA-C-N 114.408 -1.269 . . . . 64.42 108.572 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpt180 -88.95 -76.63 0.4 Allowed 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 108.678 -0.86 . . . . 73.31 108.678 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.42 -1.928 0 N-CA-C 104.852 -2.277 . . . . 74.33 104.852 179.471 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.407 -3.244 0 N-CA-C 109.27 -1.532 . . . . 74.11 109.27 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 35.0 tp -123.86 121.35 26.48 Favored Pre-proline 0 N--CA 1.44 -0.942 0 N-CA-C 108.94 -0.763 . . . . 73.32 108.94 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.83 84.52 0.41 Allowed 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.624 2.216 . . . . 74.31 111.97 178.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 m -136.42 30.53 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 CA-C-N 114.997 -1.001 . . . . 75.05 108.48 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.2 m -101.19 -24.69 14.22 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 114.836 -1.075 . . . . 65.23 110.492 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.84 -14.06 33.58 Favored Glycine 0 C--N 1.305 -1.193 0 CA-C-N 114.959 -1.019 . . . . 71.13 113.754 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -110.68 -178.05 3.38 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 121.154 0.502 . . . . 74.34 110.887 -177.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 p -131.2 154.86 47.96 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.987 -1.006 . . . . 63.42 111.386 -176.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -121.66 88.25 2.9 Favored 'General case' 0 N--CA 1.416 -2.129 0 N-CA-C 108.874 -0.787 . . . . 74.54 108.874 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -74.43 -36.25 41.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.046 -0.724 . . . . 72.05 109.046 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 -22.72 35.55 Favored Glycine 0 N--CA 1.436 -1.35 0 CA-C-N 115.392 -0.822 . . . . 73.1 111.08 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.07 12.79 13.26 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.017 -1.087 . . . . 72.44 113.325 178.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 46.7 m -136.99 124.98 22.76 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.652 -0.87 . . . . 73.35 108.652 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 38.3 m -91.97 169.86 10.32 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 115.352 -0.84 . . . . 75.41 110.874 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -92.77 -52.56 4.56 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 123.315 0.646 . . . . 74.31 110.468 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.7 m -51.13 113.94 4.36 Favored Pre-proline 0 C--O 1.25 1.117 0 C-N-CA 123.947 0.899 . . . . 71.52 113.095 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -65.48 105.98 0.81 Allowed 'Trans proline' 0 C--N 1.359 1.1 0 C-N-CA 122.53 2.153 . . . . 72.32 109.629 176.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.95 5.33 Favored Glycine 0 N--CA 1.427 -1.913 0 N-CA-C 110.782 -0.927 . . . . 70.33 110.782 -177.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.3 m -102.13 162.01 13.24 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 121.609 0.719 . . . . 60.32 111.146 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -141.0 153.13 45.42 Favored 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 114.252 -1.34 . . . . 71.04 108.325 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.88 83.17 4.33 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.018 -1.105 . . . . 73.13 108.018 175.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 21.4 t -89.77 -49.26 6.74 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.911 -0.774 . . . . 73.43 108.911 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -107.5 80.7 1.43 Allowed 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.39 -0.596 . . . . 75.5 109.39 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 92.4 t90 -55.79 139.73 69.07 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.413 -0.812 . . . . 74.41 110.033 -178.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -99.95 32.32 9.91 Favored 'Cis proline' 0 CA--C 1.534 0.493 0 C-N-CA 124.935 -0.86 . . . . 73.33 113.121 1.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 55.8 t -104.91 142.54 17.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.993 -0.743 . . . . 72.52 108.993 -179.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.3 m -87.89 144.93 26.3 Favored 'General case' 0 N--CA 1.415 -2.2 0 CA-C-O 122.707 1.241 . . . . 73.43 110.417 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -128.28 152.04 48.59 Favored 'General case' 0 C--N 1.259 -3.365 0 CA-C-N 113.104 -1.862 . . . . 71.12 111.101 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -94.82 -55.86 2.97 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-O 121.765 0.793 . . . . 74.1 111.237 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.414 -2.225 0 N-CA-C 105.01 -2.218 . . . . 73.31 105.01 -179.161 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.409 -3.134 0 N-CA-C 109.744 -1.342 . . . . 74.51 109.744 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.0 tp -103.79 116.27 62.04 Favored Pre-proline 0 C--O 1.241 0.614 0 N-CA-C 108.808 -0.812 . . . . 75.31 108.808 179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -78.37 76.69 4.31 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.179 1.919 . . . . 70.4 112.304 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -128.1 18.54 2.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.905 -1.043 . . . . 73.12 109.775 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.1 m -87.82 -26.35 22.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 CA-C-N 115.236 -0.893 . . . . 72.32 109.951 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.93 -0.88 64.78 Favored Glycine 0 N--CA 1.438 -1.17 0 CA-C-N 114.619 -1.173 . . . . 54.0 113.557 176.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.461 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 11.3 pt-20 -112.93 175.52 5.4 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.242 -0.583 . . . . 72.14 110.27 178.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 p -128.41 154.71 45.75 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 115.055 -0.975 . . . . 74.42 110.752 -174.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.415 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 7.6 p -129.86 89.68 2.85 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 109.622 -0.51 . . . . 74.13 109.622 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -80.18 -31.25 13.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 108.707 -0.849 . . . . 73.52 108.707 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.4 -12.21 61.6 Favored Glycine 0 N--CA 1.439 -1.167 0 CA-C-N 115.424 -0.807 . . . . 64.22 111.315 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.471 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 93.14 19.48 36.02 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.478 -0.868 . . . . 63.34 112.609 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.9 m -135.85 119.66 17.32 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.1 -0.704 . . . . 61.3 109.1 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 56.4 m -99.13 167.51 10.65 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.312 -0.858 . . . . 72.12 110.955 -176.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -103.83 -49.28 3.69 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.648 0.379 . . . . 73.43 111.875 -178.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.8 m -51.29 114.17 4.68 Favored Pre-proline 0 C--O 1.257 1.465 0 N-CA-C 113.081 0.771 . . . . 65.52 113.081 -179.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -62.93 115.67 3.08 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.883 2.389 . . . . 73.35 109.571 175.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -10.42 11.5 Favored Glycine 0 C--N 1.298 -1.568 0 N-CA-C 110.94 -0.864 . . . . 73.54 110.94 -176.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.4 m -112.95 162.37 15.93 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.235 0.54 . . . . 62.3 110.545 176.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 p -145.35 160.93 40.79 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 124.933 1.293 . . . . 74.02 108.337 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.471 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 46.2 t -92.27 85.24 5.36 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.536 -0.913 . . . . 70.24 108.536 177.483 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -103.36 -31.17 10.17 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.828 -0.623 . . . . 70.31 110.124 -178.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.1 m95 -112.66 64.84 0.63 Allowed 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.186 0.517 . . . . 74.13 109.701 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 89.1 t90 -52.88 135.32 47.18 Favored Pre-proline 0 C--O 1.247 0.971 0 CA-C-N 114.567 -1.197 . . . . 72.44 110.498 -176.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -96.3 33.35 9.94 Favored 'Cis proline' 0 CA--C 1.549 1.261 0 N-CA-C 114.518 0.93 . . . . 75.45 114.518 3.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 69.1 t -111.09 143.69 20.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 108.861 -0.792 . . . . 63.24 108.861 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.461 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 63.0 m -88.69 145.49 25.62 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-O 122.301 1.048 . . . . 74.43 109.345 178.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.4 p -129.5 165.03 22.47 Favored 'General case' 0 C--N 1.254 -3.546 0 CA-C-N 113.786 -1.552 . . . . 71.1 110.688 -174.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -88.22 -67.43 0.83 Allowed 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.897 -0.779 . . . . 74.43 108.897 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 . . . . . 0 N--CA 1.423 -1.816 0 N-CA-C 105.906 -1.887 . . . . 64.33 105.906 176.068 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.654 0 N-CA-C 110.596 -1.002 . . . . 75.22 110.596 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.5 tp -112.59 110.04 52.9 Favored Pre-proline 0 C--O 1.239 0.516 0 N-CA-C 109.704 -0.48 . . . . 70.21 109.704 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -72.86 79.32 1.98 Allowed 'Trans proline' 0 C--O 1.24 0.586 0 C-N-CA 122.421 2.081 . . . . 65.1 112.528 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.8 m -137.09 23.37 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.93 -1.032 . . . . 75.52 109.737 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.3 m -84.99 -21.68 29.39 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.56 -0.745 . . . . 74.33 110.839 -178.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.07 -0.24 79.94 Favored Glycine 0 C--N 1.294 -1.781 0 CA-C-N 114.794 -1.094 . . . . 75.33 113.678 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -121.62 177.92 5.04 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.278 -0.569 . . . . 74.21 109.639 177.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.3 p -130.91 158.85 39.1 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 116.051 -0.522 . . . . 73.11 110.675 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -129.72 88.77 2.72 Favored 'General case' 0 C--N 1.282 -2.351 0 C-N-CA 123.041 0.536 . . . . 74.41 109.665 -179.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.7 t -76.76 -31.74 19.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 119.955 -0.698 . . . . 73.31 109.351 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.68 -19.71 47.11 Favored Glycine 0 C--N 1.306 -1.084 0 N-CA-C 111.068 -0.813 . . . . 73.12 111.068 176.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.21 17.08 19.09 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.806 -0.711 . . . . 74.24 112.136 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.6 m -122.73 122.19 38.16 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 108.706 -0.85 . . . . 75.53 108.706 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 60.5 m -102.47 147.59 26.56 Favored 'General case' 0 C--N 1.274 -2.704 0 CA-C-N 115.746 -0.661 . . . . 62.42 110.198 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -90.99 -49.83 6.2 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.921 -0.581 . . . . 75.04 110.909 -178.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.2 m -50.73 113.26 3.52 Favored Pre-proline 0 C--O 1.25 1.119 0 O-C-N 123.987 0.804 . . . . 74.15 112.194 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.45 116.77 3.48 Favored 'Trans proline' 0 C--N 1.358 1.047 0 C-N-CA 123.19 2.593 . . . . 75.44 110.831 179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.86 -10.85 20.89 Favored Glycine 0 N--CA 1.424 -2.121 0 C-N-CA 120.3 -0.952 . . . . 74.51 112.214 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 80.4 m -103.97 156.82 17.55 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 121.636 0.731 . . . . 75.34 111.31 178.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.79 154.94 47.51 Favored 'General case' 0 C--N 1.271 -2.811 0 CA-C-N 114.465 -1.243 . . . . 74.22 108.89 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.48 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 t -91.47 87.45 6.41 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.923 -0.769 . . . . 72.54 108.923 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.3 t -96.84 -59.87 1.71 Allowed 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 116.137 -0.483 . . . . 73.13 109.711 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 64.2 t-105 -92.07 77.74 5.32 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.678 -0.86 . . . . 73.04 108.678 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -54.98 139.53 63.24 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 114.818 -1.083 . . . . 74.22 110.553 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -98.18 36.94 6.53 Favored 'Cis proline' 0 C--N 1.353 0.793 0 C-N-CA 124.663 -0.974 . . . . 71.01 112.56 1.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -109.47 142.32 22.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 108.588 -0.893 . . . . 74.45 108.588 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.0 m -87.96 150.4 23.48 Favored 'General case' 0 N--CA 1.416 -2.155 0 C-N-CA 119.355 -0.938 . . . . 53.25 109.34 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.1 p -128.66 160.72 31.58 Favored 'General case' 0 C--N 1.254 -3.548 0 CA-C-N 113.735 -1.575 . . . . 65.34 109.472 -176.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -88.73 -67.75 0.81 Allowed 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 121.872 0.844 . . . . 72.45 110.083 -177.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 104.726 -2.324 . . . . 72.55 104.726 178.548 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.345 0 N-CA-C 109.39 -1.484 . . . . 73.24 109.39 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 39.4 tp -104.69 120.68 49.48 Favored Pre-proline 0 C--O 1.248 1.023 0 N-CA-C 108.932 -0.766 . . . . 74.41 108.932 -177.171 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.71 80.76 2.28 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.255 1.97 . . . . 75.34 112.741 -178.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.04 22.37 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.803 -1.09 . . . . 73.21 109.029 177.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 78.5 m -100.46 -27.91 13.2 Favored 'General case' 0 N--CA 1.431 -1.375 0 CA-C-N 115.303 -0.862 . . . . 73.32 110.381 -178.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.83 -10.99 43.5 Favored Glycine 0 C--N 1.303 -1.3 0 CA-C-N 114.977 -1.01 . . . . 64.15 113.484 177.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -109.9 176.64 4.99 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.768 0.794 . . . . 75.22 110.942 -177.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.3 p -128.05 163.22 25.05 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 114.315 -1.311 . . . . 71.24 109.747 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 6.7 p -128.82 87.38 2.57 Favored 'General case' 0 N--CA 1.408 -2.568 0 N-CA-C 108.894 -0.78 . . . . 74.33 108.894 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 25.7 t -77.96 -33.62 18.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 108.171 -1.048 . . . . 75.32 108.171 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.01 -20.05 44.46 Favored Glycine 0 N--CA 1.439 -1.106 0 CA-C-N 114.982 -1.008 . . . . 74.14 111.325 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.414 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 100.06 18.66 21.53 Favored Glycine 0 C--O 1.221 -0.674 0 C-N-CA 120.611 -0.804 . . . . 53.33 112.342 178.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.1 m -131.04 117.54 19.29 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 108.802 -0.814 . . . . 72.51 108.802 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 59.8 m -96.38 152.68 18.37 Favored 'General case' 0 C--N 1.281 -2.405 0 CA-C-N 115.94 -0.573 . . . . 63.2 111.838 -177.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -91.71 -54.1 4.02 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.689 -0.687 . . . . 74.14 111.194 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.1 m -51.47 112.29 3.0 Favored Pre-proline 0 C--O 1.249 1.04 0 O-C-N 123.952 0.783 . . . . 65.31 111.329 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.39 113.57 2.32 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.172 1.915 . . . . 72.4 110.981 -178.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.84 -10.63 8.93 Favored Glycine 0 N--CA 1.42 -2.431 0 N-CA-C 110.738 -0.945 . . . . 62.52 110.738 -177.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.6 m -104.25 155.31 18.84 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.314 0.578 . . . . 72.53 109.911 176.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 p -137.55 160.21 39.79 Favored 'General case' 0 C--N 1.275 -2.647 0 CA-C-N 115.043 -0.98 . . . . 75.0 108.835 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.414 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 12.3 t -85.63 63.54 8.12 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.948 -1.131 . . . . 64.43 107.948 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.4 t -69.09 -36.33 77.46 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.432 -0.804 . . . . 62.14 110.573 -177.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -129.91 87.81 2.58 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 108.713 -0.847 . . . . 74.24 108.713 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -58.17 138.56 84.24 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 123.34 0.656 . . . . 75.33 109.742 -177.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -99.54 40.19 4.49 Favored 'Cis proline' 0 CA--C 1.54 0.792 0 C-N-CA 125.129 -0.78 . . . . 72.04 112.956 1.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.1 t -112.53 136.17 49.62 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.794 -0.566 . . . . 73.53 110.303 -179.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 72.0 m -88.03 139.85 30.1 Favored 'General case' 0 N--CA 1.408 -2.531 0 N-CA-C 107.558 -1.275 . . . . 65.4 107.558 174.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -138.34 165.18 27.39 Favored 'General case' 1 C--N 1.238 -4.272 0 CA-C-N 113.514 -1.676 . . . . 74.11 109.582 -171.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.409 ' HA ' ' HD3' ' A' ' 29' ' ' ARG . 7.4 tpp180 -88.53 -68.1 0.79 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.598 -0.841 . . . . 74.41 110.232 -175.242 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 C--N 1.289 -2.062 0 N-CA-C 104.925 -2.25 . . . . 72.55 104.925 177.496 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.512 0 N-CA-C 111.109 -0.796 . . . . 70.55 111.109 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 24.2 tp -132.07 117.09 15.81 Favored Pre-proline 0 N--CA 1.45 -0.445 0 N-CA-C 108.866 -0.79 . . . . 74.14 108.866 177.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -72.34 78.45 1.93 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.583 2.189 . . . . 64.21 112.482 -178.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.3 m -128.77 17.87 2.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 115.456 -0.793 . . . . 74.2 110.413 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.4 m -85.36 -25.43 27.09 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.433 -0.803 . . . . 73.15 110.371 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.29 2.73 89.49 Favored Glycine 0 N--CA 1.428 -1.849 0 CA-C-N 114.686 -1.143 . . . . 71.41 111.945 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -119.53 179.37 4.23 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-O 121.632 0.729 . . . . 74.34 111.707 -179.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.1 p -129.58 162.13 28.95 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.397 -1.274 . . . . 75.22 110.513 -175.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -131.91 88.04 2.51 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.567 -0.742 . . . . 64.44 109.208 179.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.7 t -74.21 -35.36 40.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.834 0.826 . . . . 75.23 109.293 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.04 -17.97 48.88 Favored Glycine 0 C--N 1.311 -0.846 0 CA-C-N 115.289 -0.869 . . . . 65.44 111.139 176.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.9 14.54 20.81 Favored Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.423 -0.894 . . . . 65.5 112.385 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.9 m -126.11 132.54 51.86 Favored 'General case' 0 N--CA 1.416 -2.147 0 N-CA-C 109.051 -0.722 . . . . 75.13 109.051 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.0 m -109.7 149.39 29.82 Favored 'General case' 0 C--N 1.273 -2.753 0 CA-C-N 114.924 -1.035 . . . . 70.31 109.581 178.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -89.83 -50.29 6.13 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.474 0.484 . . . . 75.01 112.137 -176.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 84.8 m -50.73 123.37 18.02 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 113.184 0.809 . . . . 75.43 113.184 -176.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -59.72 113.76 1.77 Allowed 'Trans proline' 0 C--N 1.357 0.997 0 C-N-CA 123.096 2.53 . . . . 71.14 111.462 178.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.88 -1.46 24.4 Favored Glycine 0 N--CA 1.424 -2.133 0 CA-C-N 115.596 -0.729 . . . . 74.31 111.524 -178.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.89 156.09 20.85 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-O 121.58 0.705 . . . . 74.1 111.119 178.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.39 160.88 42.05 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 113.889 -1.505 . . . . 75.31 108.207 178.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.2 t -97.86 84.87 3.41 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.411 -0.588 . . . . 74.22 109.411 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 20.4 m -93.08 -26.69 17.36 Favored 'General case' 0 N--CA 1.408 -2.573 0 CA-C-N 116.001 -0.545 . . . . 71.53 111.131 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -123.21 70.93 1.04 Allowed 'General case' 0 CA--C 1.503 -0.831 0 CA-C-O 120.713 0.292 . . . . 74.11 110.293 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -52.47 134.34 43.77 Favored Pre-proline 0 C--N 1.318 -0.77 0 CA-C-N 115.319 -0.855 . . . . 74.35 110.407 -178.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -99.38 34.2 8.53 Favored 'Cis proline' 0 CA--C 1.543 0.935 0 CA-C-N 119.259 0.771 . . . . 71.14 113.824 3.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.51 142.07 23.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 108.744 -0.836 . . . . 65.13 108.744 178.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 90.5 m -88.03 154.82 20.18 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.322 1.058 . . . . 72.43 110.585 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.62 161.83 31.78 Favored 'General case' 0 C--N 1.247 -3.854 0 CA-C-N 113.468 -1.697 . . . . 75.51 108.777 -176.727 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -88.44 -66.76 0.89 Allowed 'General case' 0 N--CA 1.409 -2.477 0 N-CA-C 107.963 -1.125 . . . . 75.32 107.963 177.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 . . . . . 0 N--CA 1.416 -2.167 0 N-CA-C 105.469 -2.048 . . . . 71.44 105.469 179.016 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.318 0 N-CA-C 109.774 -1.331 . . . . 55.02 109.774 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.2 tp -113.23 116.69 46.48 Favored Pre-proline 0 C--O 1.24 0.577 0 N-CA-C 109.091 -0.707 . . . . 72.35 109.091 -178.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.97 81.48 1.66 Allowed 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.089 1.859 . . . . 74.2 112.542 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.9 m -133.08 22.56 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 114.913 -1.04 . . . . 72.43 109.412 177.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 72.1 m -92.02 -18.3 23.84 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 122.017 0.913 . . . . 75.53 109.963 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.43 -19.7 17.73 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-N 114.15 -1.386 . . . . 74.24 113.599 174.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -102.83 177.15 4.93 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-O 121.505 0.669 . . . . 73.35 111.767 -174.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -124.14 154.75 39.59 Favored 'General case' 0 N--CA 1.414 -2.253 0 CA-C-N 114.555 -1.202 . . . . 75.1 110.597 -177.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.2 p -123.77 87.32 2.72 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 123.776 0.83 . . . . 74.3 108.826 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.1 t -73.19 -35.21 46.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 109.108 -0.701 . . . . 75.13 109.108 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.45 -5.18 63.6 Favored Glycine 0 C--N 1.312 -0.801 0 N-CA-C 111.35 -0.7 . . . . 65.31 111.35 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.05 9.67 61.99 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.903 -0.665 . . . . 63.43 112.731 178.152 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.2 m -122.53 120.32 33.49 Favored 'General case' 0 N--CA 1.427 -1.598 0 N-CA-C 107.987 -1.116 . . . . 74.54 107.987 -176.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 66.1 m -92.7 151.83 19.85 Favored 'General case' 0 C--N 1.274 -2.715 0 CA-C-N 115.838 -0.619 . . . . 72.12 111.808 -177.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -80.69 -55.8 4.59 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.52 -0.764 . . . . 74.31 109.716 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.4 m -51.26 111.13 2.13 Favored Pre-proline 0 C--O 1.251 1.179 0 C-N-CA 124.215 1.006 . . . . 72.32 111.791 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -65.58 110.73 1.69 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 122.266 1.977 . . . . 74.3 109.474 177.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.87 -20.75 5.38 Favored Glycine 0 C--N 1.293 -1.855 0 N-CA-C 110.892 -0.883 . . . . 71.21 110.892 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.1 m -100.76 157.37 16.75 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 121.332 0.587 . . . . 61.25 109.894 177.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -139.0 161.76 36.58 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 114.822 -1.081 . . . . 73.3 109.339 -178.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.1 t -95.18 82.58 3.77 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.523 -0.547 . . . . 75.24 109.523 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.0 t -96.31 -13.73 23.1 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 116.377 -0.374 . . . . 74.41 110.463 -178.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 55.6 t-105 -136.2 79.04 1.75 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 108.621 -0.881 . . . . 71.33 108.621 177.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.1 t90 -58.25 136.89 84.91 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 115.322 -0.854 . . . . 71.33 110.375 -176.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -100.53 36.05 6.78 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.717 -0.951 . . . . 65.34 113.529 2.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -110.31 144.4 18.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 109.124 -0.695 . . . . 74.11 109.124 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.5 m -88.62 147.62 24.47 Favored 'General case' 0 N--CA 1.418 -2.07 0 CA-C-O 122.592 1.187 . . . . 65.14 111.168 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.6 p -127.4 156.19 42.45 Favored 'General case' 0 C--N 1.256 -3.474 0 CA-C-N 113.258 -1.792 . . . . 75.53 110.789 -173.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 21.1 tpt180 -89.75 -67.1 0.86 Allowed 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.824 0.821 . . . . 72.25 111.154 -176.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 N--CA 1.42 -1.954 0 N-CA-C 104.978 -2.231 . . . . 74.23 104.978 179.377 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.408 -3.172 0 N-CA-C 109.997 -1.241 . . . . 73.14 109.997 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.8 tp -127.0 118.68 22.17 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.065 -0.717 . . . . 61.23 109.065 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -74.59 78.47 2.74 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 122.198 1.932 . . . . 75.34 112.998 -178.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 m -129.86 16.21 2.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 CA-C-N 114.897 -1.047 . . . . 72.4 110.362 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 83.2 m -84.2 -25.48 29.48 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 121.614 0.721 . . . . 73.33 109.801 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.26 -12.51 60.31 Favored Glycine 0 N--CA 1.425 -2.08 0 CA-C-N 114.455 -1.248 . . . . 74.33 112.814 176.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -104.69 178.1 4.66 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.823 0.82 . . . . 73.1 111.09 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.7 p -132.99 154.64 50.31 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 114.65 -1.159 . . . . 74.45 109.764 -177.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.9 p -110.98 89.9 3.18 Favored 'General case' 0 N--CA 1.41 -2.461 0 N-CA-C 108.416 -0.957 . . . . 64.31 108.416 177.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.1 t -80.18 -33.61 14.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 73.44 108.312 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.08 -16.76 57.26 Favored Glycine 0 N--CA 1.44 -1.089 0 N-CA-C 110.761 -0.936 . . . . 72.14 110.761 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.31 13.3 31.21 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.872 -0.68 . . . . 74.14 113.254 176.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -136.2 128.4 29.9 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.009 -1.108 . . . . 72.1 108.009 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.9 m -92.14 148.67 21.99 Favored 'General case' 0 C--N 1.271 -2.828 0 CA-C-N 116.255 -0.429 . . . . 74.22 110.657 -178.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 46.3 t30 -84.82 -55.89 3.86 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.847 -0.615 . . . . 71.51 110.371 -178.045 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.7 m -51.27 114.62 5.14 Favored Pre-proline 0 CA--C 1.554 1.106 0 O-C-N 124.148 0.905 . . . . 65.33 111.89 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.69 116.07 3.31 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 122.398 2.066 . . . . 74.32 110.183 178.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 118.14 -4.95 15.84 Favored Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 110.64 -0.984 . . . . 74.01 110.64 -176.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -112.76 150.6 31.37 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.483 0.658 . . . . 64.21 110.695 176.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.3 p -134.23 150.93 51.07 Favored 'General case' 0 C--N 1.275 -2.635 0 CA-C-N 114.81 -1.086 . . . . 75.12 110.044 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.6 t -91.07 85.59 5.97 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.751 -1.203 . . . . 63.44 107.751 177.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.1 t -77.76 -51.71 10.1 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.413 -0.812 . . . . 73.22 109.7 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 8.9 p-90 -125.49 102.11 7.24 Favored 'General case' 0 N--CA 1.427 -1.598 0 CA-C-O 122.12 0.962 . . . . 74.23 110.652 177.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 76.4 t90 -58.82 140.18 86.23 Favored Pre-proline 0 C--N 1.302 -1.463 0 CA-C-N 113.678 -1.601 . . . . 73.43 109.255 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -102.15 36.44 5.95 Favored 'Cis proline' 0 CA--C 1.543 0.941 0 C-N-CA 124.703 -0.957 . . . . 74.4 114.189 3.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -118.41 143.91 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.235 -0.915 . . . . 74.14 110.787 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.6 m -89.12 162.33 16.02 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 121.878 0.847 . . . . 75.24 110.774 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.8 p -136.93 160.43 38.93 Favored 'General case' 0 C--N 1.276 -2.605 0 CA-C-N 114.49 -1.232 . . . . 74.31 109.072 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 25.8 tpt180 -89.1 -69.2 0.72 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-O 121.819 0.819 . . . . 72.32 109.743 -178.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 N--CA 1.41 -2.455 0 N-CA-C 105.177 -2.156 . . . . 72.11 105.177 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.399 -3.808 0 N-CA-C 109.49 -1.444 . . . . 71.41 109.49 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 34.9 tp -124.38 117.8 26.54 Favored Pre-proline 0 N--CA 1.443 -0.823 0 N-CA-C 109.162 -0.681 . . . . 75.42 109.162 -177.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -72.17 83.5 1.21 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 122.07 1.847 . . . . 73.12 111.863 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.1 m -132.4 20.41 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.12 -0.946 . . . . 70.32 109.891 178.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 81.0 m -90.05 -22.87 21.63 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.076 -0.966 . . . . 73.31 110.595 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 78.95 -4.92 59.98 Favored Glycine 0 C--N 1.3 -1.47 0 CA-C-N 114.881 -1.054 . . . . 63.33 113.71 176.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -116.57 175.54 5.52 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 120.214 -0.595 . . . . 65.3 110.484 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -127.43 148.14 50.29 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.488 -0.778 . . . . 72.4 110.475 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.464 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 6.2 p -113.23 87.94 2.72 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 109.482 -0.562 . . . . 64.51 109.482 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.3 t -79.74 -30.18 13.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.661 -0.866 . . . . 70.14 108.661 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.49 -15.75 58.03 Favored Glycine 0 N--CA 1.435 -1.375 0 CA-C-N 115.213 -0.903 . . . . 74.51 110.996 177.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.98 15.89 34.86 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.449 -0.882 . . . . 64.14 112.827 177.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.7 m -143.18 125.79 15.89 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.334 -0.987 . . . . 75.44 108.334 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 33.3 m -96.79 154.44 17.29 Favored 'General case' 0 C--N 1.274 -2.678 0 CA-C-N 115.755 -0.657 . . . . 63.14 110.846 -176.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -77.56 -53.2 7.88 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.901 -0.59 . . . . 73.51 110.451 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 33.5 m -50.99 113.09 3.44 Favored Pre-proline 0 C--O 1.253 1.268 0 C-N-CA 124.049 0.939 . . . . 72.23 112.945 -177.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.72 119.43 6.65 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.565 2.177 . . . . 73.43 109.614 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.55 -3.77 27.84 Favored Glycine 0 N--CA 1.426 -1.978 0 C-N-CA 120.622 -0.799 . . . . 73.51 111.505 -179.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.3 m -111.01 154.77 23.71 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.683 0.754 . . . . 74.45 110.639 175.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -137.83 161.02 37.7 Favored 'General case' 0 C--N 1.274 -2.676 0 CA-C-N 114.683 -1.144 . . . . 74.21 109.754 -178.304 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 17.6 t -95.68 83.23 3.71 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 121.178 0.514 . . . . 74.11 109.694 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 t -89.15 -51.48 5.56 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.242 -0.435 . . . . 74.03 109.976 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.1 t-105 -105.47 80.86 1.62 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 109.527 -0.546 . . . . 73.44 109.527 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.6 t90 -57.03 136.57 80.25 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.432 -0.804 . . . . 71.3 109.984 -177.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -100.09 35.31 7.41 Favored 'Cis proline' 0 CA--C 1.544 1.017 0 C-N-CA 124.686 -0.964 . . . . 75.31 113.715 1.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.1 142.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 108.824 -0.806 . . . . 75.25 108.824 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.1 m -88.3 153.18 21.41 Favored 'General case' 0 N--CA 1.424 -1.737 0 C-N-CA 119.422 -0.911 . . . . 74.1 110.236 179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -132.02 155.42 48.06 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.106 -1.406 . . . . 61.52 110.291 -177.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -91.99 -68.79 0.77 Allowed 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.993 0.901 . . . . 75.31 111.153 -176.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p30 . . . . . 0 C--N 1.299 -1.596 0 N-CA-C 105.505 -2.035 . . . . 73.31 105.505 179.944 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.564 0 N-CA-C 111.219 -0.752 . . . . 73.53 111.219 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.1 tp -109.1 113.48 59.01 Favored Pre-proline 0 C--N 1.328 -0.362 0 C-N-CA 120.108 -0.637 . . . . 74.03 110.529 -175.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -73.52 81.01 1.88 Allowed 'Trans proline' 0 N--CA 1.444 -1.427 0 C-N-CA 121.497 1.465 . . . . 75.21 112.674 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.5 m -126.78 24.18 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 122.326 1.06 . . . . 74.3 109.877 175.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 37.2 m -84.57 -27.59 27.18 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 114.554 -1.203 . . . . 63.12 108.051 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.54 -7.77 64.01 Favored Glycine 0 N--CA 1.438 -1.211 0 CA-C-N 113.507 -1.679 . . . . 73.53 112.702 177.518 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -107.52 -177.2 3.28 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.225 0.536 . . . . 73.21 110.893 -177.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 p -135.36 164.2 28.3 Favored 'General case' 0 N--CA 1.421 -1.915 0 CA-C-N 114.465 -1.243 . . . . 72.34 108.781 -179.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -126.73 80.2 1.92 Allowed 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 116.538 -0.301 . . . . 61.01 110.677 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.1 t -77.56 -26.51 15.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 108.423 -0.955 . . . . 74.24 108.423 178.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.74 -7.64 68.51 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 110.447 -1.061 . . . . 74.04 110.447 176.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.99 10.54 69.06 Favored Glycine 0 C--O 1.218 -0.861 0 C-N-CA 121.375 -0.441 . . . . 73.44 112.212 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -127.72 123.77 36.2 Favored 'General case' 0 N--CA 1.419 -2.01 0 N-CA-C 108.243 -1.021 . . . . 74.3 108.243 -176.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.1 m -95.65 149.7 21.17 Favored 'General case' 0 C--N 1.277 -2.564 0 N-CA-C 109.483 -0.562 . . . . 73.53 109.483 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -90.19 -54.56 3.97 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 123.12 0.568 . . . . 65.44 111.698 -177.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.454 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.1 m -51.22 119.39 12.36 Favored Pre-proline 0 CA--C 1.562 1.441 0 O-C-N 123.838 0.711 . . . . 74.42 112.75 -178.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.27 118.57 5.46 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 123.089 2.526 . . . . 70.22 111.174 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.42 5.13 37.28 Favored Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 120.728 -0.749 . . . . 60.21 111.389 -179.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.454 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.5 m -103.88 159.64 15.48 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-O 121.528 0.68 . . . . 74.22 111.057 175.139 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 p -140.34 146.34 38.34 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 114.76 -1.109 . . . . 75.44 109.627 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.1 t -92.68 87.35 5.86 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.218 -1.401 . . . . 75.24 107.218 176.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 19.6 t -88.16 -70.23 0.65 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 109.262 -0.644 . . . . 74.11 109.262 -177.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.8 m-90 -91.0 87.36 6.58 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 108.301 -1.0 . . . . 75.2 108.301 177.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 90.3 t90 -54.82 135.6 65.5 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.378 -0.601 . . . . 74.4 109.378 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -102.13 39.93 4.14 Favored 'Cis proline' 0 CA--C 1.545 1.072 0 CA-C-N 119.365 0.809 . . . . 74.32 113.212 2.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.0 t -107.02 130.43 59.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.92 -0.487 . . . . 65.42 109.829 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -88.9 152.26 21.84 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-O 121.998 0.904 . . . . 73.54 110.177 178.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.5 p -134.01 171.0 14.81 Favored 'General case' 0 C--N 1.266 -3.03 0 CA-C-N 113.946 -1.479 . . . . 71.35 108.236 -178.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.438 ' C ' HD21 ' A' ' 30' ' ' ASN . 28.1 mmm180 -87.94 -78.96 0.3 Allowed 'General case' 0 N--CA 1.4 -2.935 0 N-CA-C 107.926 -1.138 . . . . 73.35 107.926 175.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.438 HD21 ' C ' ' A' ' 29' ' ' ARG . 0.9 OUTLIER . . . . . 0 C--N 1.292 -1.906 0 N-CA-C 105.136 -2.172 . . . . 75.24 105.136 174.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.926 0 N-CA-C 108.772 -1.731 . . . . 61.23 108.772 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.0 tp -123.24 119.0 27.65 Favored Pre-proline 0 C--O 1.247 0.945 0 CA-C-N 115.043 -0.578 . . . . 73.52 109.837 -178.024 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -73.73 81.28 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.432 2.088 . . . . 74.22 112.552 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.88 20.4 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.204 -0.907 . . . . 75.52 109.405 177.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.5 m -89.48 -30.09 18.53 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.211 -0.904 . . . . 74.14 109.753 178.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.94 -1.56 88.34 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-N 114.739 -1.119 . . . . 62.53 112.724 178.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -119.84 179.79 4.14 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.339 0.59 . . . . 72.52 111.436 -178.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 p -128.18 168.2 15.75 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.908 -1.042 . . . . 70.32 110.318 -177.042 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.1 p -135.28 86.89 2.28 Favored 'General case' 0 N--CA 1.419 -1.977 0 N-CA-C 109.315 -0.624 . . . . 64.04 109.315 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -77.0 -33.06 20.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 108.649 -0.871 . . . . 75.4 108.649 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.64 -28.23 17.11 Favored Glycine 0 N--CA 1.436 -1.362 0 N-CA-C 110.456 -1.058 . . . . 73.01 110.456 175.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.68 12.51 11.44 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.558 -0.829 . . . . 73.42 112.552 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -118.93 116.56 26.72 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.663 -0.866 . . . . 74.01 108.663 -176.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 40.7 m -95.13 137.21 34.48 Favored 'General case' 0 C--N 1.274 -2.684 0 N-CA-C 109.393 -0.595 . . . . 71.45 109.393 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -76.99 -51.4 11.19 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.47 -0.332 . . . . 73.43 110.462 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 61.9 m -51.77 116.59 8.25 Favored Pre-proline 0 C--O 1.259 1.584 0 O-C-N 124.011 0.82 . . . . 73.53 112.326 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.1 118.41 5.31 Favored 'Trans proline' 0 N--CA 1.446 -1.311 0 C-N-CA 122.227 1.952 . . . . 74.31 109.686 177.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.34 -4.13 23.51 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 120.256 -0.973 . . . . 25.41 111.092 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 58.4 m -109.37 148.13 31.6 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 119.353 -0.939 . . . . 74.44 110.363 175.569 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.5 p -134.53 148.52 50.52 Favored 'General case' 0 C--N 1.257 -3.448 0 CA-C-N 114.12 -1.4 . . . . 74.34 109.259 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.1 t -85.31 75.35 10.27 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.159 -1.052 . . . . 72.15 108.159 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 16.8 m -73.23 -44.01 60.25 Favored 'General case' 0 N--CA 1.407 -2.59 0 CA-C-N 115.437 -0.801 . . . . 73.13 110.633 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 62.0 t90 -125.36 97.2 5.11 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.771 -0.826 . . . . 73.43 108.771 178.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 83.4 t90 -58.56 138.97 85.77 Favored Pre-proline 0 C--N 1.303 -1.449 0 CA-C-N 114.913 -1.039 . . . . 74.52 109.597 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -102.49 36.75 5.63 Favored 'Cis proline' 0 CA--C 1.54 0.813 0 C-N-CA 124.948 -0.855 . . . . 71.23 113.41 1.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.4 t -113.25 138.96 40.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 121.9 -0.5 . . . . 73.3 110.104 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -88.35 151.51 22.55 Favored 'General case' 0 N--CA 1.417 -2.098 0 N-CA-C 108.735 -0.839 . . . . 64.42 108.735 177.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.2 p -137.64 160.89 37.94 Favored 'General case' 0 C--N 1.252 -3.665 0 CA-C-N 114.539 -1.209 . . . . 74.24 109.582 -177.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -90.93 -60.8 1.82 Allowed 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 121.46 0.647 . . . . 73.53 111.106 -177.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 N--CA 1.424 -1.749 0 N-CA-C 105.58 -2.007 . . . . 64.33 105.58 178.556 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.405 -3.4 0 N-CA-C 110.326 -1.11 . . . . 74.4 110.326 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 47.5 tp -110.46 116.64 52.47 Favored Pre-proline 0 C--O 1.24 0.591 0 N-CA-C 109.437 -0.579 . . . . 64.21 109.437 -177.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -73.2 81.32 1.74 Allowed 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.227 1.951 . . . . 75.02 112.122 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -131.66 12.45 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.293 -0.867 . . . . 75.24 110.731 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 64.7 m -80.89 -35.88 32.0 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.848 0.833 . . . . 75.45 109.105 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.26 -0.64 88.73 Favored Glycine 0 N--CA 1.426 -1.987 0 CA-C-N 114.84 -1.073 . . . . 70.12 112.032 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.57 177.21 4.73 Favored 'General case' 0 C--O 1.255 1.377 0 CA-C-O 121.399 0.618 . . . . 64.42 110.848 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 p -130.8 168.2 17.63 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 114.596 -1.184 . . . . 70.13 110.945 -175.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -135.81 87.36 2.31 Favored 'General case' 0 N--CA 1.417 -2.124 0 CA-C-N 115.577 -0.738 . . . . 74.21 109.782 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.13 -30.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 N-CA-C 108.082 -1.081 . . . . 74.11 108.082 177.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.66 -6.65 69.98 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.117 -0.947 . . . . 64.5 111.421 177.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.02 24.72 40.07 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 120.679 -0.772 . . . . 50.13 112.921 176.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 31.7 m -147.06 127.56 14.09 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.942 -0.762 . . . . 73.14 108.942 177.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.58 152.39 18.57 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.826 -0.624 . . . . 75.53 110.463 -178.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -83.8 -57.71 3.1 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.114 -0.494 . . . . 74.31 111.241 -176.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 49.8 m -51.96 117.78 10.62 Favored Pre-proline 0 C--O 1.248 0.999 0 O-C-N 123.735 0.647 . . . . 71.23 112.312 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -62.76 111.45 1.36 Allowed 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.446 2.097 . . . . 71.11 109.557 176.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 126.11 -10.62 7.37 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 111.089 -0.804 . . . . 63.01 111.089 -176.608 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 67.5 m -100.44 154.94 18.12 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-O 121.576 0.703 . . . . 74.25 109.85 175.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 p -136.19 143.49 44.43 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-N 114.759 -1.109 . . . . 74.24 109.15 -178.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.0 t -90.96 84.39 5.76 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 106.665 -1.606 . . . . 74.22 106.665 176.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 17.9 t -104.73 -16.28 15.0 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.802 -0.635 . . . . 75.5 110.642 -175.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 84.6 m95 -133.99 72.0 1.46 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.12 -1.066 . . . . 71.35 108.12 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.2 t90 -54.95 135.47 66.77 Favored Pre-proline 0 C--O 1.244 0.787 0 CA-C-N 114.41 -1.268 . . . . 73.12 110.331 -174.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -99.43 34.54 8.22 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 C-N-CA 124.662 -0.974 . . . . 75.42 113.756 3.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.9 t -107.23 139.21 29.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 121.905 -0.497 . . . . 70.32 109.808 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 94.8 m -88.83 154.62 20.11 Favored 'General case' 0 N--CA 1.416 -2.155 0 CA-C-O 122.137 0.97 . . . . 73.03 109.758 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.2 p -138.93 166.02 25.57 Favored 'General case' 0 C--N 1.257 -3.414 0 CA-C-N 114.129 -1.396 . . . . 73.44 107.957 -178.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -88.93 -70.59 0.64 Allowed 'General case' 0 N--CA 1.419 -2.005 0 C-N-CA 119.001 -1.08 . . . . 74.35 108.93 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 C--N 1.303 -1.455 0 N-CA-C 104.797 -2.297 . . . . 63.44 104.797 179.513 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -2.138 0 N-CA-C 109.503 -1.439 . . . . 64.14 109.503 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.8 tp -110.37 109.78 58.3 Favored Pre-proline 0 C--O 1.246 0.897 0 CA-C-N 114.868 -0.666 . . . . 71.44 109.224 -177.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -75.46 83.7 1.85 Allowed 'Trans proline' 0 N--CA 1.434 -1.977 0 C-N-CA 121.945 1.763 . . . . 75.0 111.179 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.4 m -123.01 19.96 4.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.39 -0.823 . . . . 75.42 110.044 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 57.4 m -108.1 -24.25 11.64 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-N 115.611 -0.722 . . . . 61.24 111.86 177.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.76 -15.52 14.37 Favored Glycine 0 C--O 1.246 0.869 0 CA-C-N 115.421 -0.809 . . . . 72.42 114.361 176.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.43 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 15.7 pt-20 -94.98 174.27 7.17 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.635 0.731 . . . . 72.54 111.531 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.0 p -125.9 161.32 27.72 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 114.765 -1.107 . . . . 74.4 109.95 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -122.2 90.73 3.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.804 -0.813 . . . . 74.35 108.804 178.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.53 -37.08 18.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.841 -0.8 . . . . 72.43 108.841 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.43 -14.88 59.43 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.555 -0.748 . . . . 64.12 111.348 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.03 20.25 16.79 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.447 -0.882 . . . . 71.1 113.453 176.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 59.0 m -141.95 127.54 19.04 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.981 -0.748 . . . . 75.53 108.981 177.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 33.9 m -100.17 162.68 12.81 Favored 'General case' 0 C--N 1.278 -2.528 0 CA-C-N 115.541 -0.754 . . . . 64.23 109.887 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -94.96 -49.57 5.49 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.559 -0.291 . . . . 74.11 110.446 -177.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.5 m -52.47 120.37 17.8 Favored Pre-proline 0 C--O 1.264 1.86 0 O-C-N 123.96 0.787 . . . . 72.04 112.347 -176.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -62.78 114.23 2.32 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.136 1.891 . . . . 71.34 109.664 177.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.84 -21.87 6.96 Favored Glycine 0 N--CA 1.428 -1.843 0 C-N-CA 120.456 -0.878 . . . . 72.13 112.112 -177.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -107.1 154.26 21.42 Favored 'General case' 0 CA--C 1.481 -1.69 0 CA-C-O 122.246 1.022 . . . . 70.14 112.812 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 p -139.39 167.58 21.76 Favored 'General case' 0 C--N 1.274 -2.688 0 CA-C-N 113.274 -1.785 . . . . 73.22 108.848 -178.314 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 9.6 t -90.64 64.71 5.78 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.882 -1.155 . . . . 62.55 107.882 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.2 m -65.07 -26.58 68.3 Favored 'General case' 0 N--CA 1.423 -1.798 0 CA-C-N 115.174 -0.921 . . . . 55.23 111.024 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -145.87 106.96 4.15 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.726 -1.213 . . . . 75.11 107.726 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 83.5 t90 -67.35 139.31 94.58 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 108.962 -0.755 . . . . 74.34 108.962 -177.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -104.9 36.7 4.76 Favored 'Cis proline' 0 CA--C 1.537 0.656 0 C-N-CA 125.107 -0.789 . . . . 75.51 113.03 1.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.5 p -112.6 136.54 48.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-O 121.618 0.723 . . . . 72.44 111.404 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.43 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 65.1 m -88.59 138.44 31.43 Favored 'General case' 0 N--CA 1.409 -2.515 0 CA-C-O 122.482 1.134 . . . . 62.11 109.19 179.034 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -139.92 164.51 29.81 Favored 'General case' 1 C--N 1.243 -4.045 0 CA-C-N 113.2 -1.818 . . . . 74.04 109.304 -175.105 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -87.48 -66.36 0.92 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.59 -0.892 . . . . 74.31 108.59 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.8 p30 . . . . . 0 N--CA 1.426 -1.663 0 N-CA-C 105.139 -2.171 . . . . 74.23 105.139 175.87 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.938 0 N-CA-C 109.083 -1.607 . . . . 74.51 109.083 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.5 tp -104.28 115.11 63.58 Favored Pre-proline 0 C--O 1.245 0.844 0 N-CA-C 109.038 -0.727 . . . . 74.3 109.038 -178.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -73.5 80.27 2.01 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.268 1.979 . . . . 75.31 112.606 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -131.66 8.96 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 115.744 -0.662 . . . . 74.14 110.781 178.366 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.1 m -91.84 -30.29 16.27 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-O 121.784 0.802 . . . . 75.44 109.461 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.71 -12.61 46.8 Favored Glycine 0 N--CA 1.427 -1.934 0 CA-C-N 114.521 -1.218 . . . . 64.02 113.953 176.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -100.49 172.4 7.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.094 -1.042 . . . . 64.54 111.802 -176.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 p -126.51 154.75 43.37 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 114.337 -1.301 . . . . 74.33 109.802 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.427 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 5.5 p -120.57 86.06 2.5 Favored 'General case' 0 N--CA 1.408 -2.54 0 N-CA-C 107.818 -1.178 . . . . 75.31 107.818 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 44.5 t -69.89 -33.6 56.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 N-CA-C 108.655 -0.868 . . . . 74.32 108.655 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.32 -32.15 7.56 Favored Glycine 0 N--CA 1.429 -1.792 0 CA-C-N 115.403 -0.817 . . . . 74.52 111.41 176.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.407 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 118.45 13.89 6.64 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.042 -1.075 . . . . 62.2 112.436 -178.276 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.0 m -126.08 112.04 15.38 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.213 -0.662 . . . . 65.52 109.213 -177.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.0 m -95.28 150.11 20.61 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.261 -0.881 . . . . 73.04 110.766 -176.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -90.84 -54.93 3.76 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 123.203 0.601 . . . . 72.15 111.065 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 57.5 m -50.19 117.97 8.5 Favored Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 113.169 0.803 . . . . 74.24 113.169 -176.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.9 123.01 12.71 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 123.249 2.633 . . . . 74.02 111.028 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.06 57.08 Favored Glycine 0 N--CA 1.427 -1.931 0 C-N-CA 120.733 -0.746 . . . . 70.5 112.148 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.9 m -100.77 155.26 18.01 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.291 -0.564 . . . . 75.04 109.644 177.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -140.85 155.43 46.34 Favored 'General case' 0 C--N 1.277 -2.575 0 CA-C-N 115.111 -0.95 . . . . 63.1 109.528 -174.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.407 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 24.5 t -84.78 79.6 9.56 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.409 -1.7 . . . . 71.44 106.409 175.168 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.431 ' HB3' ' OG1' ' A' ' 28' ' ' THR . 23.1 t -87.03 -28.36 22.65 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 115.036 -0.984 . . . . 72.03 110.389 -175.416 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.0 t-105 -135.94 85.46 2.16 Favored 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 107.95 -1.13 . . . . 75.44 107.95 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.406 ' CD1' ' HA ' ' A' ' 25' ' ' PRO . 76.1 t90 -58.45 135.84 85.58 Favored Pre-proline 0 C--N 1.307 -1.252 0 N-CA-C 109.396 -0.594 . . . . 73.1 109.396 -179.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.406 ' HA ' ' CD1' ' A' ' 24' ' ' TRP . 17.9 Cg_endo -99.09 35.64 7.47 Favored 'Cis proline' 0 CA--C 1.553 1.445 0 N-CA-C 114.888 1.072 . . . . 71.31 114.888 5.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.6 t -112.81 135.51 52.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.607 -0.683 . . . . 75.23 109.669 179.166 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.427 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 63.4 m -88.96 146.7 24.73 Favored 'General case' 0 N--CA 1.415 -2.182 0 N-CA-C 106.721 -1.585 . . . . 72.32 106.721 174.719 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.431 ' OG1' ' HB3' ' A' ' 22' ' ' SER . 15.0 p -139.59 179.04 6.8 Favored 'General case' 0 C--N 1.248 -3.809 0 N-CA-C 108.286 -1.005 . . . . 64.13 108.286 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 20.0 tpt180 -88.49 -73.86 0.48 Allowed 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.77 -0.772 . . . . 70.35 109.513 -177.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.427 -1.583 0 N-CA-C 104.972 -2.233 . . . . 71.25 104.972 176.68 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.398 -3.885 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 24.8 tp -120.93 120.91 29.12 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -177.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -70.89 83.26 0.91 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.295 1.997 . . . . 0.0 111.804 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.0 m -130.61 11.02 2.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.483 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.1 m -80.56 -28.4 37.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.443 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.24 4.69 90.43 Favored Glycine 0 N--CA 1.427 -1.95 0 CA-C-N 114.93 -1.032 . . . . 0.0 112.009 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.28 -176.65 3.56 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.237 0.541 . . . . 0.0 110.204 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.7 p -133.23 160.33 37.57 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.124 -177.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.5 p -126.49 84.84 2.31 Favored 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.461 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.65 -31.3 41.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.18 5.09 55.61 Favored Glycine 0 N--CA 1.44 -1.081 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.795 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 81.44 11.93 82.6 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.198 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 m -116.64 110.72 18.87 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -178.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.7 m -89.54 146.5 24.55 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-O 120.981 0.42 . . . . 0.0 110.479 177.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -81.38 -62.14 1.74 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.255 -177.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.414 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.5 m -51.19 118.18 10.19 Favored Pre-proline 0 C--O 1.251 1.133 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -59.45 118.49 5.39 Favored 'Trans proline' 0 C--N 1.354 0.858 0 C-N-CA 122.887 2.391 . . . . 0.0 109.936 175.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.23 -12.12 14.32 Favored Glycine 0 C--N 1.293 -1.857 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.414 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 78.8 m -99.13 154.98 17.7 Favored 'General case' 0 N--CA 1.433 -1.314 0 CA-C-O 121.633 0.73 . . . . 0.0 110.082 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -141.55 153.26 44.74 Favored 'General case' 0 C--N 1.268 -2.958 0 C-N-CA 125.465 1.506 . . . . 0.0 107.697 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.473 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 31.0 t -96.69 83.91 3.54 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-O 121.38 0.61 . . . . 0.0 110.06 -179.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.4 m -88.11 -51.78 5.6 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.017 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.5 m95 -102.03 75.27 1.51 Allowed 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.064 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -55.6 136.43 70.91 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.13 -178.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -99.42 36.22 6.95 Favored 'Cis proline' 0 CA--C 1.541 0.85 0 C-N-CA 124.874 -0.886 . . . . 0.0 113.918 4.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.6 t -110.58 143.06 21.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.2 m -87.76 155.32 19.96 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-O 122.201 1.0 . . . . 0.0 110.5 -178.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.8 p -138.79 153.66 48.43 Favored 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.814 -1.539 . . . . 0.0 109.329 -174.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.9 tpp180 -89.82 -67.37 0.85 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.873 -0.731 . . . . 0.0 109.91 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 -177.026 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -3.001 0 N-CA-C 108.918 -1.673 . . . . 73.03 108.918 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -120.94 111.49 34.12 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.517 -1.29 . . . . 73.03 107.517 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.61 78.63 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 122.093 1.862 . . . . 74.31 113.604 -177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.01 27.84 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 122.381 1.086 . . . . 72.05 108.645 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.4 m -90.2 -21.79 22.0 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 114.129 -1.396 . . . . 61.01 110.468 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.87 -4.29 53.57 Favored Glycine 0 C--N 1.303 -1.298 0 CA-C-N 114.42 -1.263 . . . . 72.34 113.983 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.407 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.6 pt-20 -117.11 179.33 4.06 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 122.24 -0.565 . . . . 75.02 111.438 -178.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.3 p -124.21 157.36 34.98 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.359 -0.837 . . . . 75.52 110.979 -175.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -127.89 83.66 2.18 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.718 -0.475 . . . . 73.42 109.718 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.36 -35.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.481 -0.933 . . . . 64.22 108.481 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.8 -14.57 59.35 Favored Glycine 0 N--CA 1.435 -1.368 0 CA-C-N 115.237 -0.892 . . . . 61.44 110.977 177.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.27 32.9 7.97 Favored Glycine 0 N--CA 1.432 -1.594 0 C-N-CA 120.131 -1.033 . . . . 74.11 111.537 179.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -142.84 122.45 13.3 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-O 121.274 0.559 . . . . 73.11 109.777 177.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.3 m -104.06 145.38 30.26 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 115.057 -0.974 . . . . 61.42 110.572 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 38.3 m-80 -86.57 -49.87 7.23 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.522 0.729 . . . . 71.32 111.527 -176.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 65.4 m -50.27 116.2 6.33 Favored Pre-proline 0 C--O 1.249 1.072 0 O-C-N 124.039 0.837 . . . . 73.25 112.101 -178.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.81 118.87 5.71 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 123.365 2.71 . . . . 75.23 111.611 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.13 -3.23 33.33 Favored Glycine 0 N--CA 1.426 -1.977 0 CA-C-N 115.699 -0.682 . . . . 71.01 111.552 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.467 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 84.9 m -102.44 155.53 18.2 Favored 'General case' 0 N--CA 1.432 -1.351 0 CA-C-O 122.043 0.925 . . . . 73.32 111.582 178.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -140.5 156.8 46.22 Favored 'General case' 0 C--N 1.27 -2.863 0 CA-C-N 113.715 -1.584 . . . . 74.51 107.903 179.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.4 t -92.64 80.93 4.76 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.901 -0.778 . . . . 73.24 108.901 175.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.2 m -83.66 -39.92 19.61 Favored 'General case' 0 N--CA 1.405 -2.69 0 CA-C-N 115.779 -0.646 . . . . 65.55 111.221 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.507 ' CD1' HG21 ' A' ' 28' ' ' THR . 23.3 m95 -118.08 82.4 1.83 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.014 -0.735 . . . . 75.22 109.014 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 84.0 t90 -57.99 132.71 83.61 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.517 0.727 . . . . 75.14 110.752 -175.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -104.97 41.73 2.95 Favored 'Cis proline' 0 CA--C 1.545 1.037 0 CA-C-N 119.157 0.735 . . . . 74.42 113.797 4.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.95 139.86 31.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.178 -1.045 . . . . 71.32 108.178 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.407 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 88.6 m -87.97 146.89 25.29 Favored 'General case' 0 CA--C 1.474 -1.948 0 CA-C-O 122.562 1.172 . . . . 63.02 110.55 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.507 HG21 ' CD1' ' A' ' 23' ' ' TRP . 15.5 p -135.19 157.69 46.26 Favored 'General case' 0 C--N 1.256 -3.487 0 CA-C-N 113.0 -1.909 . . . . 75.33 110.325 -171.044 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.467 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 27.0 mmm180 -88.87 -65.42 1.02 Allowed 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.866 0.841 . . . . 74.04 110.61 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 C--N 1.284 -2.251 0 N-CA-C 105.415 -2.068 . . . . 75.41 105.415 -177.976 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.397 -3.922 0 N-CA-C 108.749 -1.74 . . . . 43.22 108.749 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 tp -120.23 115.32 32.96 Favored Pre-proline 0 N--CA 1.442 -0.871 0 N-CA-C 107.844 -1.169 . . . . 74.13 107.844 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.34 81.38 1.5 Allowed 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.309 2.006 . . . . 73.2 112.442 -177.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 m -132.62 9.63 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 115.038 -0.983 . . . . 65.44 110.64 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.7 m -76.66 -22.7 53.67 Favored 'General case' 0 CA--C 1.491 -1.307 0 CA-C-O 121.473 0.654 . . . . 73.44 111.295 -177.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.96 -2.01 82.27 Favored Glycine 0 N--CA 1.422 -2.249 0 CA-C-N 114.713 -1.13 . . . . 63.44 112.939 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -122.51 177.71 5.3 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.548 -0.861 . . . . 74.32 111.121 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.1 p -124.76 154.36 41.02 Favored 'General case' 0 N--CA 1.422 -1.858 0 CA-C-N 114.513 -1.222 . . . . 61.54 110.656 -178.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -122.14 85.52 2.43 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 123.549 0.74 . . . . 55.43 109.162 178.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -72.12 -33.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-O 121.566 0.698 . . . . 74.23 109.338 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.28 -16.77 56.89 Favored Glycine 0 N--CA 1.438 -1.227 0 CA-C-N 115.384 -0.826 . . . . 72.23 111.636 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.436 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.31 15.27 23.83 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.075 -1.059 . . . . 74.21 112.907 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.4 m -137.31 124.46 21.68 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.938 -1.134 . . . . 72.4 107.938 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.98 149.35 21.89 Favored 'General case' 0 C--N 1.273 -2.717 0 CA-C-N 115.953 -0.567 . . . . 61.32 111.44 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -75.06 -54.04 7.85 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.596 -0.729 . . . . 64.15 109.646 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -51.71 111.52 2.49 Favored Pre-proline 0 C--O 1.256 1.41 0 C-N-CA 124.144 0.978 . . . . 75.52 112.241 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -62.87 118.06 4.96 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.385 2.057 . . . . 74.14 109.556 176.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.9 -11.31 13.52 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 111.363 -0.695 . . . . 72.53 111.363 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.5 m -102.39 155.64 18.12 Favored 'General case' 0 CA--C 1.499 -0.996 0 CA-C-O 122.244 1.021 . . . . 64.32 111.802 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.5 p -132.16 151.69 51.66 Favored 'General case' 0 N--CA 1.401 -2.905 0 CA-C-N 113.797 -1.547 . . . . 73.4 108.858 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.436 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 20.8 t -93.18 53.08 1.88 Allowed 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.858 0.837 . . . . 73.11 108.989 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 m -70.53 -22.81 62.57 Favored 'General case' 0 N--CA 1.414 -2.244 0 CA-C-N 115.587 -0.733 . . . . 73.44 111.938 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.9 t-105 -128.99 80.43 1.97 Allowed 'General case' 0 C--O 1.205 -1.278 0 N-CA-C 108.237 -1.023 . . . . 71.43 108.237 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -62.88 135.32 95.98 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 116.094 -0.503 . . . . 74.44 110.898 -173.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -102.31 36.4 5.91 Favored 'Cis proline' 0 C--N 1.354 0.851 0 C-N-CA 125.008 -0.83 . . . . 74.54 113.304 2.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.8 t -105.35 141.44 20.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 109.275 -0.639 . . . . 73.0 109.275 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 74.7 m -88.92 144.58 26.09 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-O 122.794 1.283 . . . . 75.32 111.029 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 p -129.74 155.05 46.55 Favored 'General case' 0 C--N 1.258 -3.371 0 CA-C-N 112.867 -1.97 . . . . 74.14 110.037 -173.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 -89.55 -66.42 0.92 Allowed 'General case' 0 N--CA 1.425 -1.706 0 CA-C-O 121.763 0.792 . . . . 74.11 109.878 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 105.388 -2.079 . . . . 74.54 105.388 -178.708 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.971 0 N-CA-C 109.961 -1.255 . . . . 72.14 109.961 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.0 tp -118.24 111.53 38.45 Favored Pre-proline 0 N--CA 1.439 -0.998 0 N-CA-C 108.279 -1.008 . . . . 73.0 108.279 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -74.96 79.11 2.73 Favored 'Trans proline' 0 N--CA 1.444 -1.41 0 C-N-CA 121.879 1.719 . . . . 64.24 112.675 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.88 22.65 2.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 CA-C-O 121.821 0.819 . . . . 74.33 109.662 176.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 52.2 m -85.12 -32.65 22.66 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.906 -1.146 . . . . 62.32 107.906 176.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.51 -2.58 87.04 Favored Glycine 0 N--CA 1.43 -1.759 0 CA-C-N 114.055 -1.43 . . . . 75.43 112.694 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -112.12 175.83 5.27 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.647 0.737 . . . . 64.23 111.624 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -127.32 158.64 36.7 Favored 'General case' 0 C--N 1.284 -2.273 0 CA-C-N 114.465 -1.243 . . . . 72.4 109.732 -177.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.1 p -119.64 96.6 5.26 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.37 -0.974 . . . . 65.32 108.37 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.8 t -80.0 -38.87 19.09 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 109.084 -0.71 . . . . 73.23 109.084 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.88 -10.69 61.15 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.402 -0.817 . . . . 65.43 111.149 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.482 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 99.56 13.73 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.522 -0.847 . . . . 72.23 112.573 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.6 m -127.66 128.78 46.07 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 107.925 -1.139 . . . . 75.51 107.925 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 36.1 m -104.48 159.38 15.79 Favored 'General case' 0 C--N 1.272 -2.779 0 CA-C-N 115.741 -0.663 . . . . 75.12 109.578 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -91.62 -58.07 2.55 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.386 -0.37 . . . . 74.14 110.519 -179.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.443 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 35.6 m -46.65 116.95 4.1 Favored Pre-proline 0 CA--C 1.545 0.771 0 O-C-N 124.374 1.046 . . . . 71.41 112.219 -175.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.93 117.09 3.73 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 123.257 2.638 . . . . 72.2 110.941 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.09 -2.51 31.46 Favored Glycine 0 N--CA 1.427 -1.936 0 CA-C-N 115.554 -0.748 . . . . 72.31 111.543 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.464 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 63.2 m -106.25 150.21 26.14 Favored 'General case' 0 CA--C 1.488 -1.435 0 CA-C-O 121.789 0.804 . . . . 74.34 110.113 176.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 p -136.72 152.46 50.38 Favored 'General case' 0 C--N 1.268 -2.973 0 CA-C-N 114.165 -1.38 . . . . 73.4 109.927 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.482 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 38.8 t -88.58 65.17 7.72 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.855 -1.165 . . . . 74.24 107.855 176.362 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.6 m -72.7 -29.39 63.34 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-N 114.489 -1.232 . . . . 72.23 110.798 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.3 t-105 -134.29 82.77 1.99 Allowed 'General case' 0 N--CA 1.433 -1.322 0 CA-C-O 121.179 0.514 . . . . 72.32 110.135 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.1 t90 -56.1 139.12 72.38 Favored Pre-proline 0 C--O 1.244 0.799 0 CA-C-N 115.245 -0.889 . . . . 72.23 109.875 -177.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -97.87 30.19 13.62 Favored 'Cis proline' 0 CA--C 1.538 0.711 0 C-N-CA 125.033 -0.82 . . . . 74.02 113.483 1.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 44.5 t -107.64 136.73 41.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 N-CA-C 109.558 -0.534 . . . . 71.31 109.558 -178.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.7 m -88.46 152.49 21.85 Favored 'General case' 0 N--CA 1.419 -1.996 0 C-N-CA 119.268 -0.973 . . . . 74.32 109.113 177.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -139.25 164.32 30.13 Favored 'General case' 0 C--N 1.264 -3.149 0 CA-C-N 114.742 -1.117 . . . . 74.12 109.016 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.464 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 24.3 mmm180 -88.14 -74.14 0.46 Allowed 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.775 0.798 . . . . 74.13 110.463 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 . . . . . 0 C--N 1.275 -2.631 0 N-CA-C 104.647 -2.353 . . . . 73.31 104.647 -179.42 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.415 -2.713 0 N-CA-C 109.68 -1.368 . . . . 74.32 109.68 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -121.06 112.92 33.04 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.514 -0.55 . . . . 75.13 109.514 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -71.79 81.56 1.33 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.3 2.0 . . . . 74.14 112.981 -179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m -133.24 15.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 114.982 -1.008 . . . . 75.21 110.187 177.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.2 m -88.73 -26.75 21.61 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.725 -0.67 . . . . 74.22 111.05 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.32 6.09 86.09 Favored Glycine 0 N--CA 1.427 -1.914 0 CA-C-N 114.875 -1.057 . . . . 74.33 112.987 177.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.413 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.3 pt-20 -120.09 173.97 6.77 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.249 -0.98 . . . . 73.02 111.557 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.8 p -124.45 153.71 41.56 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-N 114.191 -1.368 . . . . 72.24 110.001 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -123.26 85.12 2.37 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 123.54 0.736 . . . . 64.25 110.389 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.0 t -80.75 -23.87 11.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.89 0.852 . . . . 74.5 108.838 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -13.7 60.22 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.594 -1.002 . . . . 55.23 110.594 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.33 17.37 46.53 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.508 -0.853 . . . . 74.05 112.071 177.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 m -139.36 131.16 27.54 Favored 'General case' 0 N--CA 1.419 -2.005 0 N-CA-C 108.368 -0.975 . . . . 73.53 108.368 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.76 156.79 16.18 Favored 'General case' 0 C--N 1.275 -2.636 0 CA-C-N 115.853 -0.612 . . . . 72.41 109.5 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -94.42 -49.71 5.56 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 116.235 -0.439 . . . . 75.22 110.947 -176.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.515 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 13.2 m -51.27 118.27 10.47 Favored Pre-proline 0 C--O 1.246 0.919 0 C-N-CA 123.913 0.885 . . . . 74.42 111.169 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.99 118.18 4.99 Favored 'Trans proline' 0 C--N 1.354 0.855 0 C-N-CA 122.728 2.285 . . . . 63.44 110.529 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.32 -1.44 32.93 Favored Glycine 0 N--CA 1.427 -1.906 0 C-N-CA 120.963 -0.636 . . . . 51.52 111.993 -178.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.515 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.3 m -105.01 154.81 19.63 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.982 0.896 . . . . 63.31 112.067 178.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 p -137.8 153.52 49.65 Favored 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 125.126 1.37 . . . . 74.52 109.74 -176.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.9 t -97.13 87.22 4.14 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.316 -0.994 . . . . 74.34 108.316 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.1 t -81.65 -57.86 3.26 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.365 -0.605 . . . . 61.2 109.365 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -107.29 96.54 6.48 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 109.223 -0.658 . . . . 73.24 109.223 -178.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 75.7 t90 -63.93 138.23 97.34 Favored Pre-proline 0 C--N 1.296 -1.717 0 N-CA-C 109.233 -0.654 . . . . 74.15 109.233 -178.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -102.63 37.84 5.03 Favored 'Cis proline' 0 CA--C 1.544 0.984 0 C-N-CA 124.464 -1.057 . . . . 75.11 114.018 1.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.5 p -108.97 143.6 18.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 O-C-N 121.516 -0.74 . . . . 70.22 110.059 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.413 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.6 m -88.5 160.75 17.36 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 122.288 1.042 . . . . 64.15 111.353 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.2 p -142.14 166.17 25.43 Favored 'General case' 0 C--N 1.267 -3.002 0 CA-C-N 113.613 -1.631 . . . . 72.21 108.154 -178.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 22.1 tpt180 -89.01 -70.93 0.62 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.736 -0.838 . . . . 74.13 108.736 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.417 -2.109 0 N-CA-C 104.775 -2.305 . . . . 73.4 104.775 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.417 -2.627 0 N-CA-C 109.219 -1.552 . . . . 64.24 109.219 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.6 tp -115.08 111.69 44.81 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 114.658 -0.771 . . . . 73.44 109.023 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.93 74.67 3.37 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 122.671 2.247 . . . . 74.21 113.678 -176.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -125.32 18.49 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 115.459 -0.792 . . . . 74.14 109.908 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.7 m -88.21 -22.26 24.09 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-O 121.996 0.903 . . . . 75.43 109.562 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.08 -15.79 19.95 Favored Glycine 0 N--CA 1.438 -1.197 0 CA-C-N 114.116 -1.402 . . . . 63.23 113.549 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -99.52 175.5 5.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 121.557 0.694 . . . . 73.35 110.733 -177.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.8 p -125.38 149.0 48.55 Favored 'General case' 0 N--CA 1.409 -2.482 0 CA-C-N 114.54 -1.209 . . . . 74.11 110.28 -178.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -116.76 93.11 4.07 Favored 'General case' 0 C--N 1.284 -2.244 0 N-CA-C 108.749 -0.834 . . . . 63.14 108.749 177.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 65.7 t -80.3 -35.22 15.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.158 -0.682 . . . . 74.14 109.158 179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.52 -10.44 65.47 Favored Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.389 -1.085 . . . . 62.51 110.389 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.464 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 92.82 17.21 45.33 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.707 -0.759 . . . . 42.44 111.802 178.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 m -123.24 122.49 38.5 Favored 'General case' 0 N--CA 1.418 -2.049 0 N-CA-C 108.474 -0.935 . . . . 73.13 108.474 -178.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 67.6 m -99.38 141.2 32.48 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-N 115.836 -0.62 . . . . 71.01 111.89 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -83.07 -50.96 7.97 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.038 -0.983 . . . . 74.22 111.639 -176.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 53.4 m -52.29 118.56 12.76 Favored Pre-proline 0 C--O 1.254 1.318 0 C-N-CA 122.531 0.333 . . . . 73.22 111.74 176.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -67.38 114.0 3.1 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.163 1.908 . . . . 74.41 109.724 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 121.19 -7.28 10.7 Favored Glycine 0 N--CA 1.417 -2.618 0 C-N-CA 120.246 -0.978 . . . . 43.22 110.916 -176.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.2 m -108.77 153.27 23.71 Favored 'General case' 0 CA--C 1.495 -1.14 0 CA-C-O 121.433 0.635 . . . . 73.34 110.54 176.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.7 p -134.25 152.86 52.04 Favored 'General case' 0 N--CA 1.406 -2.634 0 CA-C-N 114.571 -1.195 . . . . 75.41 108.137 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.464 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 36.0 t -89.28 83.06 6.44 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.26 -1.015 . . . . 73.42 108.26 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.8 t -105.23 1.04 27.8 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.632 -0.713 . . . . 75.13 110.451 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.7 t-105 -147.57 63.88 1.14 Allowed 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.341 -0.985 . . . . 72.31 108.341 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 84.5 t90 -51.61 132.8 35.97 Favored Pre-proline 0 C--N 1.318 -0.797 0 CA-C-N 114.615 -1.175 . . . . 73.14 110.482 -177.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -101.24 34.22 7.75 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.662 -0.974 . . . . 73.43 113.64 4.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -109.89 142.02 23.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.866 -0.79 . . . . 74.2 108.866 179.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.9 m -88.26 147.23 24.92 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.711 1.243 . . . . 72.11 110.835 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -130.0 158.88 38.37 Favored 'General case' 0 C--N 1.26 -3.318 0 CA-C-N 112.889 -1.959 . . . . 74.43 109.733 -172.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -89.42 -66.93 0.87 Allowed 'General case' 0 N--CA 1.416 -2.149 0 C-N-CA 119.751 -0.78 . . . . 74.34 109.767 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 N--CA 1.426 -1.67 0 N-CA-C 105.541 -2.022 . . . . 72.23 105.541 -179.324 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.331 0 N-CA-C 109.937 -1.265 . . . . 73.44 109.937 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.9 tp -118.5 120.67 31.68 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.623 -0.51 . . . . 73.3 109.623 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -70.61 82.87 0.89 Allowed 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.127 1.885 . . . . 75.12 112.521 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.4 m -130.47 19.45 2.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-O 121.759 0.79 . . . . 71.41 109.391 176.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 79.4 m -93.0 -29.61 15.75 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 115.007 -0.997 . . . . 62.32 110.251 -178.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.87 3.43 73.98 Favored Glycine 0 N--CA 1.432 -1.593 0 CA-C-N 114.832 -1.076 . . . . 73.4 113.621 177.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -120.3 175.27 6.04 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.742 0.782 . . . . 75.15 111.254 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -128.88 155.45 45.24 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-N 114.427 -1.26 . . . . 72.51 109.759 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -125.64 85.81 2.45 Favored 'General case' 0 C--N 1.278 -2.529 0 CA-C-N 116.234 -0.439 . . . . 74.15 109.924 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 41.2 t -80.3 -25.25 11.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.291 -0.963 . . . . 74.32 109.005 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.95 -15.94 56.98 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 110.927 -0.869 . . . . 55.2 110.927 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.96 14.79 38.45 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.811 -0.709 . . . . 63.1 112.263 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.8 m -130.76 124.36 31.25 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.206 -0.665 . . . . 72.33 109.206 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.9 m -98.92 152.93 19.23 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 115.847 -0.615 . . . . 71.01 109.686 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -87.88 -55.96 3.54 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.595 -0.275 . . . . 72.14 111.18 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 19.9 m -50.97 112.15 2.77 Favored Pre-proline 0 CA--C 1.56 1.34 0 O-C-N 124.29 0.994 . . . . 60.44 112.728 -176.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -58.61 121.97 10.86 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 123.115 2.543 . . . . 72.42 110.512 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.75 -3.73 30.6 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 110.766 -0.934 . . . . 72.54 110.766 -177.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 86.0 m -104.81 159.17 16.0 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.539 0.685 . . . . 72.34 110.824 176.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.5 p -137.82 146.09 43.09 Favored 'General case' 0 C--N 1.28 -2.442 0 C-N-CA 124.924 1.289 . . . . 72.41 109.233 -176.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 49.2 t -91.44 77.2 5.81 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.26 -1.385 . . . . 75.11 107.26 174.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -90.28 -36.29 14.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.689 -0.687 . . . . 75.41 110.96 -175.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 92.6 m95 -120.34 76.03 1.15 Allowed 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.209 -0.663 . . . . 73.41 109.209 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 79.9 t90 -53.75 136.91 54.51 Favored Pre-proline 0 C--N 1.313 -1.008 0 CA-C-N 114.895 -1.048 . . . . 73.15 110.372 -175.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -97.24 32.85 10.39 Favored 'Cis proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.523 -1.032 . . . . 74.12 113.295 2.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.0 t -106.15 138.18 32.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 109.549 -0.537 . . . . 75.25 109.549 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.95 153.51 20.97 Favored 'General case' 0 N--CA 1.41 -2.438 0 CA-C-O 122.104 0.954 . . . . 73.55 109.225 177.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 5.2 p -133.08 165.5 24.6 Favored 'General case' 0 C--N 1.252 -3.633 0 CA-C-N 114.408 -1.269 . . . . 64.42 108.572 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpt180 -88.95 -76.63 0.4 Allowed 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 108.678 -0.86 . . . . 73.31 108.678 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.42 -1.928 0 N-CA-C 104.852 -2.277 . . . . 74.33 104.852 179.471 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.407 -3.244 0 N-CA-C 109.27 -1.532 . . . . 74.11 109.27 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 35.0 tp -123.86 121.35 26.48 Favored Pre-proline 0 N--CA 1.44 -0.942 0 N-CA-C 108.94 -0.763 . . . . 73.32 108.94 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.83 84.52 0.41 Allowed 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.624 2.216 . . . . 74.31 111.97 178.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 m -136.42 30.53 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 CA-C-N 114.997 -1.001 . . . . 75.05 108.48 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.2 m -101.19 -24.69 14.22 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 114.836 -1.075 . . . . 65.23 110.492 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.84 -14.06 33.58 Favored Glycine 0 C--N 1.305 -1.193 0 CA-C-N 114.959 -1.019 . . . . 71.13 113.754 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -110.68 -178.05 3.38 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 121.154 0.502 . . . . 74.34 110.887 -177.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 p -131.2 154.86 47.96 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.987 -1.006 . . . . 63.42 111.386 -176.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -121.66 88.25 2.9 Favored 'General case' 0 N--CA 1.416 -2.129 0 N-CA-C 108.874 -0.787 . . . . 74.54 108.874 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -74.43 -36.25 41.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.046 -0.724 . . . . 72.05 109.046 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 -22.72 35.55 Favored Glycine 0 N--CA 1.436 -1.35 0 CA-C-N 115.392 -0.822 . . . . 73.1 111.08 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.07 12.79 13.26 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.017 -1.087 . . . . 72.44 113.325 178.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 46.7 m -136.99 124.98 22.76 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.652 -0.87 . . . . 73.35 108.652 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 38.3 m -91.97 169.86 10.32 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 115.352 -0.84 . . . . 75.41 110.874 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -92.77 -52.56 4.56 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 123.315 0.646 . . . . 74.31 110.468 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.7 m -51.13 113.94 4.36 Favored Pre-proline 0 C--O 1.25 1.117 0 C-N-CA 123.947 0.899 . . . . 71.52 113.095 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -65.48 105.98 0.81 Allowed 'Trans proline' 0 C--N 1.359 1.1 0 C-N-CA 122.53 2.153 . . . . 72.32 109.629 176.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.95 5.33 Favored Glycine 0 N--CA 1.427 -1.913 0 N-CA-C 110.782 -0.927 . . . . 70.33 110.782 -177.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.3 m -102.13 162.01 13.24 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 121.609 0.719 . . . . 60.32 111.146 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -141.0 153.13 45.42 Favored 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 114.252 -1.34 . . . . 71.04 108.325 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.88 83.17 4.33 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.018 -1.105 . . . . 73.13 108.018 175.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 21.4 t -89.77 -49.26 6.74 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.911 -0.774 . . . . 73.43 108.911 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -107.5 80.7 1.43 Allowed 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.39 -0.596 . . . . 75.5 109.39 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 92.4 t90 -55.79 139.73 69.07 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.413 -0.812 . . . . 74.41 110.033 -178.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -99.95 32.32 9.91 Favored 'Cis proline' 0 CA--C 1.534 0.493 0 C-N-CA 124.935 -0.86 . . . . 73.33 113.121 1.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 55.8 t -104.91 142.54 17.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.993 -0.743 . . . . 72.52 108.993 -179.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.3 m -87.89 144.93 26.3 Favored 'General case' 0 N--CA 1.415 -2.2 0 CA-C-O 122.707 1.241 . . . . 73.43 110.417 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -128.28 152.04 48.59 Favored 'General case' 0 C--N 1.259 -3.365 0 CA-C-N 113.104 -1.862 . . . . 71.12 111.101 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -94.82 -55.86 2.97 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-O 121.765 0.793 . . . . 74.1 111.237 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.414 -2.225 0 N-CA-C 105.01 -2.218 . . . . 73.31 105.01 -179.161 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.409 -3.134 0 N-CA-C 109.744 -1.342 . . . . 74.51 109.744 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.0 tp -103.79 116.27 62.04 Favored Pre-proline 0 C--O 1.241 0.614 0 N-CA-C 108.808 -0.812 . . . . 75.31 108.808 179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -78.37 76.69 4.31 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.179 1.919 . . . . 70.4 112.304 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -128.1 18.54 2.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.905 -1.043 . . . . 73.12 109.775 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.1 m -87.82 -26.35 22.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 CA-C-N 115.236 -0.893 . . . . 72.32 109.951 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.93 -0.88 64.78 Favored Glycine 0 N--CA 1.438 -1.17 0 CA-C-N 114.619 -1.173 . . . . 54.0 113.557 176.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.461 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 11.3 pt-20 -112.93 175.52 5.4 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.242 -0.583 . . . . 72.14 110.27 178.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 p -128.41 154.71 45.75 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 115.055 -0.975 . . . . 74.42 110.752 -174.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.415 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 7.6 p -129.86 89.68 2.85 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 109.622 -0.51 . . . . 74.13 109.622 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -80.18 -31.25 13.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 108.707 -0.849 . . . . 73.52 108.707 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.4 -12.21 61.6 Favored Glycine 0 N--CA 1.439 -1.167 0 CA-C-N 115.424 -0.807 . . . . 64.22 111.315 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.471 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 93.14 19.48 36.02 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.478 -0.868 . . . . 63.34 112.609 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.9 m -135.85 119.66 17.32 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.1 -0.704 . . . . 61.3 109.1 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 56.4 m -99.13 167.51 10.65 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.312 -0.858 . . . . 72.12 110.955 -176.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -103.83 -49.28 3.69 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.648 0.379 . . . . 73.43 111.875 -178.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.8 m -51.29 114.17 4.68 Favored Pre-proline 0 C--O 1.257 1.465 0 N-CA-C 113.081 0.771 . . . . 65.52 113.081 -179.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -62.93 115.67 3.08 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.883 2.389 . . . . 73.35 109.571 175.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -10.42 11.5 Favored Glycine 0 C--N 1.298 -1.568 0 N-CA-C 110.94 -0.864 . . . . 73.54 110.94 -176.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.4 m -112.95 162.37 15.93 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.235 0.54 . . . . 62.3 110.545 176.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 p -145.35 160.93 40.79 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 124.933 1.293 . . . . 74.02 108.337 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.471 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 46.2 t -92.27 85.24 5.36 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.536 -0.913 . . . . 70.24 108.536 177.483 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -103.36 -31.17 10.17 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.828 -0.623 . . . . 70.31 110.124 -178.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.1 m95 -112.66 64.84 0.63 Allowed 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.186 0.517 . . . . 74.13 109.701 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 89.1 t90 -52.88 135.32 47.18 Favored Pre-proline 0 C--O 1.247 0.971 0 CA-C-N 114.567 -1.197 . . . . 72.44 110.498 -176.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -96.3 33.35 9.94 Favored 'Cis proline' 0 CA--C 1.549 1.261 0 N-CA-C 114.518 0.93 . . . . 75.45 114.518 3.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 69.1 t -111.09 143.69 20.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 108.861 -0.792 . . . . 63.24 108.861 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.461 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 63.0 m -88.69 145.49 25.62 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-O 122.301 1.048 . . . . 74.43 109.345 178.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.4 p -129.5 165.03 22.47 Favored 'General case' 0 C--N 1.254 -3.546 0 CA-C-N 113.786 -1.552 . . . . 71.1 110.688 -174.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -88.22 -67.43 0.83 Allowed 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.897 -0.779 . . . . 74.43 108.897 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 . . . . . 0 N--CA 1.423 -1.816 0 N-CA-C 105.906 -1.887 . . . . 64.33 105.906 176.068 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.654 0 N-CA-C 110.596 -1.002 . . . . 75.22 110.596 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.5 tp -112.59 110.04 52.9 Favored Pre-proline 0 C--O 1.239 0.516 0 N-CA-C 109.704 -0.48 . . . . 70.21 109.704 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -72.86 79.32 1.98 Allowed 'Trans proline' 0 C--O 1.24 0.586 0 C-N-CA 122.421 2.081 . . . . 65.1 112.528 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.8 m -137.09 23.37 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.93 -1.032 . . . . 75.52 109.737 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.3 m -84.99 -21.68 29.39 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.56 -0.745 . . . . 74.33 110.839 -178.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.07 -0.24 79.94 Favored Glycine 0 C--N 1.294 -1.781 0 CA-C-N 114.794 -1.094 . . . . 75.33 113.678 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -121.62 177.92 5.04 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.278 -0.569 . . . . 74.21 109.639 177.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.3 p -130.91 158.85 39.1 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 116.051 -0.522 . . . . 73.11 110.675 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -129.72 88.77 2.72 Favored 'General case' 0 C--N 1.282 -2.351 0 C-N-CA 123.041 0.536 . . . . 74.41 109.665 -179.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.7 t -76.76 -31.74 19.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 119.955 -0.698 . . . . 73.31 109.351 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.68 -19.71 47.11 Favored Glycine 0 C--N 1.306 -1.084 0 N-CA-C 111.068 -0.813 . . . . 73.12 111.068 176.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.21 17.08 19.09 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.806 -0.711 . . . . 74.24 112.136 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.6 m -122.73 122.19 38.16 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 108.706 -0.85 . . . . 75.53 108.706 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 60.5 m -102.47 147.59 26.56 Favored 'General case' 0 C--N 1.274 -2.704 0 CA-C-N 115.746 -0.661 . . . . 62.42 110.198 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -90.99 -49.83 6.2 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.921 -0.581 . . . . 75.04 110.909 -178.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.2 m -50.73 113.26 3.52 Favored Pre-proline 0 C--O 1.25 1.119 0 O-C-N 123.987 0.804 . . . . 74.15 112.194 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.45 116.77 3.48 Favored 'Trans proline' 0 C--N 1.358 1.047 0 C-N-CA 123.19 2.593 . . . . 75.44 110.831 179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.86 -10.85 20.89 Favored Glycine 0 N--CA 1.424 -2.121 0 C-N-CA 120.3 -0.952 . . . . 74.51 112.214 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 80.4 m -103.97 156.82 17.55 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 121.636 0.731 . . . . 75.34 111.31 178.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.79 154.94 47.51 Favored 'General case' 0 C--N 1.271 -2.811 0 CA-C-N 114.465 -1.243 . . . . 74.22 108.89 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.48 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 t -91.47 87.45 6.41 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.923 -0.769 . . . . 72.54 108.923 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.3 t -96.84 -59.87 1.71 Allowed 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 116.137 -0.483 . . . . 73.13 109.711 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 64.2 t-105 -92.07 77.74 5.32 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.678 -0.86 . . . . 73.04 108.678 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -54.98 139.53 63.24 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 114.818 -1.083 . . . . 74.22 110.553 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -98.18 36.94 6.53 Favored 'Cis proline' 0 C--N 1.353 0.793 0 C-N-CA 124.663 -0.974 . . . . 71.01 112.56 1.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -109.47 142.32 22.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 108.588 -0.893 . . . . 74.45 108.588 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.0 m -87.96 150.4 23.48 Favored 'General case' 0 N--CA 1.416 -2.155 0 C-N-CA 119.355 -0.938 . . . . 53.25 109.34 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.1 p -128.66 160.72 31.58 Favored 'General case' 0 C--N 1.254 -3.548 0 CA-C-N 113.735 -1.575 . . . . 65.34 109.472 -176.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -88.73 -67.75 0.81 Allowed 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 121.872 0.844 . . . . 72.45 110.083 -177.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 104.726 -2.324 . . . . 72.55 104.726 178.548 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.345 0 N-CA-C 109.39 -1.484 . . . . 73.24 109.39 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 39.4 tp -104.69 120.68 49.48 Favored Pre-proline 0 C--O 1.248 1.023 0 N-CA-C 108.932 -0.766 . . . . 74.41 108.932 -177.171 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.71 80.76 2.28 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.255 1.97 . . . . 75.34 112.741 -178.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.04 22.37 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.803 -1.09 . . . . 73.21 109.029 177.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 78.5 m -100.46 -27.91 13.2 Favored 'General case' 0 N--CA 1.431 -1.375 0 CA-C-N 115.303 -0.862 . . . . 73.32 110.381 -178.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.83 -10.99 43.5 Favored Glycine 0 C--N 1.303 -1.3 0 CA-C-N 114.977 -1.01 . . . . 64.15 113.484 177.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -109.9 176.64 4.99 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.768 0.794 . . . . 75.22 110.942 -177.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.3 p -128.05 163.22 25.05 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 114.315 -1.311 . . . . 71.24 109.747 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 6.7 p -128.82 87.38 2.57 Favored 'General case' 0 N--CA 1.408 -2.568 0 N-CA-C 108.894 -0.78 . . . . 74.33 108.894 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 25.7 t -77.96 -33.62 18.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 108.171 -1.048 . . . . 75.32 108.171 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.01 -20.05 44.46 Favored Glycine 0 N--CA 1.439 -1.106 0 CA-C-N 114.982 -1.008 . . . . 74.14 111.325 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.414 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 100.06 18.66 21.53 Favored Glycine 0 C--O 1.221 -0.674 0 C-N-CA 120.611 -0.804 . . . . 53.33 112.342 178.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.1 m -131.04 117.54 19.29 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 108.802 -0.814 . . . . 72.51 108.802 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 59.8 m -96.38 152.68 18.37 Favored 'General case' 0 C--N 1.281 -2.405 0 CA-C-N 115.94 -0.573 . . . . 63.2 111.838 -177.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -91.71 -54.1 4.02 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.689 -0.687 . . . . 74.14 111.194 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.1 m -51.47 112.29 3.0 Favored Pre-proline 0 C--O 1.249 1.04 0 O-C-N 123.952 0.783 . . . . 65.31 111.329 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.39 113.57 2.32 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.172 1.915 . . . . 72.4 110.981 -178.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.84 -10.63 8.93 Favored Glycine 0 N--CA 1.42 -2.431 0 N-CA-C 110.738 -0.945 . . . . 62.52 110.738 -177.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.6 m -104.25 155.31 18.84 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.314 0.578 . . . . 72.53 109.911 176.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 p -137.55 160.21 39.79 Favored 'General case' 0 C--N 1.275 -2.647 0 CA-C-N 115.043 -0.98 . . . . 75.0 108.835 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.414 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 12.3 t -85.63 63.54 8.12 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.948 -1.131 . . . . 64.43 107.948 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.4 t -69.09 -36.33 77.46 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.432 -0.804 . . . . 62.14 110.573 -177.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -129.91 87.81 2.58 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 108.713 -0.847 . . . . 74.24 108.713 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -58.17 138.56 84.24 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 123.34 0.656 . . . . 75.33 109.742 -177.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -99.54 40.19 4.49 Favored 'Cis proline' 0 CA--C 1.54 0.792 0 C-N-CA 125.129 -0.78 . . . . 72.04 112.956 1.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.1 t -112.53 136.17 49.62 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.794 -0.566 . . . . 73.53 110.303 -179.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 72.0 m -88.03 139.85 30.1 Favored 'General case' 0 N--CA 1.408 -2.531 0 N-CA-C 107.558 -1.275 . . . . 65.4 107.558 174.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -138.34 165.18 27.39 Favored 'General case' 1 C--N 1.238 -4.272 0 CA-C-N 113.514 -1.676 . . . . 74.11 109.582 -171.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.409 ' HA ' ' HD3' ' A' ' 29' ' ' ARG . 7.4 tpp180 -88.53 -68.1 0.79 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.598 -0.841 . . . . 74.41 110.232 -175.242 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 C--N 1.289 -2.062 0 N-CA-C 104.925 -2.25 . . . . 72.55 104.925 177.496 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.512 0 N-CA-C 111.109 -0.796 . . . . 70.55 111.109 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 24.2 tp -132.07 117.09 15.81 Favored Pre-proline 0 N--CA 1.45 -0.445 0 N-CA-C 108.866 -0.79 . . . . 74.14 108.866 177.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -72.34 78.45 1.93 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.583 2.189 . . . . 64.21 112.482 -178.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.3 m -128.77 17.87 2.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 115.456 -0.793 . . . . 74.2 110.413 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.4 m -85.36 -25.43 27.09 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.433 -0.803 . . . . 73.15 110.371 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.29 2.73 89.49 Favored Glycine 0 N--CA 1.428 -1.849 0 CA-C-N 114.686 -1.143 . . . . 71.41 111.945 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -119.53 179.37 4.23 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-O 121.632 0.729 . . . . 74.34 111.707 -179.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.1 p -129.58 162.13 28.95 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.397 -1.274 . . . . 75.22 110.513 -175.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -131.91 88.04 2.51 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.567 -0.742 . . . . 64.44 109.208 179.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.7 t -74.21 -35.36 40.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.834 0.826 . . . . 75.23 109.293 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.04 -17.97 48.88 Favored Glycine 0 C--N 1.311 -0.846 0 CA-C-N 115.289 -0.869 . . . . 65.44 111.139 176.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.9 14.54 20.81 Favored Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.423 -0.894 . . . . 65.5 112.385 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.9 m -126.11 132.54 51.86 Favored 'General case' 0 N--CA 1.416 -2.147 0 N-CA-C 109.051 -0.722 . . . . 75.13 109.051 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.0 m -109.7 149.39 29.82 Favored 'General case' 0 C--N 1.273 -2.753 0 CA-C-N 114.924 -1.035 . . . . 70.31 109.581 178.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -89.83 -50.29 6.13 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.474 0.484 . . . . 75.01 112.137 -176.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 84.8 m -50.73 123.37 18.02 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 113.184 0.809 . . . . 75.43 113.184 -176.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -59.72 113.76 1.77 Allowed 'Trans proline' 0 C--N 1.357 0.997 0 C-N-CA 123.096 2.53 . . . . 71.14 111.462 178.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.88 -1.46 24.4 Favored Glycine 0 N--CA 1.424 -2.133 0 CA-C-N 115.596 -0.729 . . . . 74.31 111.524 -178.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.89 156.09 20.85 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-O 121.58 0.705 . . . . 74.1 111.119 178.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.39 160.88 42.05 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 113.889 -1.505 . . . . 75.31 108.207 178.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.2 t -97.86 84.87 3.41 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.411 -0.588 . . . . 74.22 109.411 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 20.4 m -93.08 -26.69 17.36 Favored 'General case' 0 N--CA 1.408 -2.573 0 CA-C-N 116.001 -0.545 . . . . 71.53 111.131 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -123.21 70.93 1.04 Allowed 'General case' 0 CA--C 1.503 -0.831 0 CA-C-O 120.713 0.292 . . . . 74.11 110.293 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.8 t90 -52.47 134.34 43.77 Favored Pre-proline 0 C--N 1.318 -0.77 0 CA-C-N 115.319 -0.855 . . . . 74.35 110.407 -178.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -99.38 34.2 8.53 Favored 'Cis proline' 0 CA--C 1.543 0.935 0 CA-C-N 119.259 0.771 . . . . 71.14 113.824 3.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.51 142.07 23.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 108.744 -0.836 . . . . 65.13 108.744 178.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 90.5 m -88.03 154.82 20.18 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.322 1.058 . . . . 72.43 110.585 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.62 161.83 31.78 Favored 'General case' 0 C--N 1.247 -3.854 0 CA-C-N 113.468 -1.697 . . . . 75.51 108.777 -176.727 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -88.44 -66.76 0.89 Allowed 'General case' 0 N--CA 1.409 -2.477 0 N-CA-C 107.963 -1.125 . . . . 75.32 107.963 177.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 . . . . . 0 N--CA 1.416 -2.167 0 N-CA-C 105.469 -2.048 . . . . 71.44 105.469 179.016 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.318 0 N-CA-C 109.774 -1.331 . . . . 55.02 109.774 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.2 tp -113.23 116.69 46.48 Favored Pre-proline 0 C--O 1.24 0.577 0 N-CA-C 109.091 -0.707 . . . . 72.35 109.091 -178.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.97 81.48 1.66 Allowed 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.089 1.859 . . . . 74.2 112.542 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.9 m -133.08 22.56 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 114.913 -1.04 . . . . 72.43 109.412 177.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 72.1 m -92.02 -18.3 23.84 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 122.017 0.913 . . . . 75.53 109.963 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.43 -19.7 17.73 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-N 114.15 -1.386 . . . . 74.24 113.599 174.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -102.83 177.15 4.93 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-O 121.505 0.669 . . . . 73.35 111.767 -174.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -124.14 154.75 39.59 Favored 'General case' 0 N--CA 1.414 -2.253 0 CA-C-N 114.555 -1.202 . . . . 75.1 110.597 -177.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.2 p -123.77 87.32 2.72 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 123.776 0.83 . . . . 74.3 108.826 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.1 t -73.19 -35.21 46.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 109.108 -0.701 . . . . 75.13 109.108 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.45 -5.18 63.6 Favored Glycine 0 C--N 1.312 -0.801 0 N-CA-C 111.35 -0.7 . . . . 65.31 111.35 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.05 9.67 61.99 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.903 -0.665 . . . . 63.43 112.731 178.152 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.2 m -122.53 120.32 33.49 Favored 'General case' 0 N--CA 1.427 -1.598 0 N-CA-C 107.987 -1.116 . . . . 74.54 107.987 -176.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 66.1 m -92.7 151.83 19.85 Favored 'General case' 0 C--N 1.274 -2.715 0 CA-C-N 115.838 -0.619 . . . . 72.12 111.808 -177.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -80.69 -55.8 4.59 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.52 -0.764 . . . . 74.31 109.716 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.4 m -51.26 111.13 2.13 Favored Pre-proline 0 C--O 1.251 1.179 0 C-N-CA 124.215 1.006 . . . . 72.32 111.791 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -65.58 110.73 1.69 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 122.266 1.977 . . . . 74.3 109.474 177.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.87 -20.75 5.38 Favored Glycine 0 C--N 1.293 -1.855 0 N-CA-C 110.892 -0.883 . . . . 71.21 110.892 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.1 m -100.76 157.37 16.75 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 121.332 0.587 . . . . 61.25 109.894 177.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -139.0 161.76 36.58 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 114.822 -1.081 . . . . 73.3 109.339 -178.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.1 t -95.18 82.58 3.77 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.523 -0.547 . . . . 75.24 109.523 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.0 t -96.31 -13.73 23.1 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 116.377 -0.374 . . . . 74.41 110.463 -178.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 55.6 t-105 -136.2 79.04 1.75 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 108.621 -0.881 . . . . 71.33 108.621 177.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.1 t90 -58.25 136.89 84.91 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 115.322 -0.854 . . . . 71.33 110.375 -176.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -100.53 36.05 6.78 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.717 -0.951 . . . . 65.34 113.529 2.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -110.31 144.4 18.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 109.124 -0.695 . . . . 74.11 109.124 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.5 m -88.62 147.62 24.47 Favored 'General case' 0 N--CA 1.418 -2.07 0 CA-C-O 122.592 1.187 . . . . 65.14 111.168 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.6 p -127.4 156.19 42.45 Favored 'General case' 0 C--N 1.256 -3.474 0 CA-C-N 113.258 -1.792 . . . . 75.53 110.789 -173.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 21.1 tpt180 -89.75 -67.1 0.86 Allowed 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.824 0.821 . . . . 72.25 111.154 -176.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 N--CA 1.42 -1.954 0 N-CA-C 104.978 -2.231 . . . . 74.23 104.978 179.377 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.408 -3.172 0 N-CA-C 109.997 -1.241 . . . . 73.14 109.997 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.8 tp -127.0 118.68 22.17 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.065 -0.717 . . . . 61.23 109.065 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -74.59 78.47 2.74 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 122.198 1.932 . . . . 75.34 112.998 -178.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 m -129.86 16.21 2.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 CA-C-N 114.897 -1.047 . . . . 72.4 110.362 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 83.2 m -84.2 -25.48 29.48 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 121.614 0.721 . . . . 73.33 109.801 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.26 -12.51 60.31 Favored Glycine 0 N--CA 1.425 -2.08 0 CA-C-N 114.455 -1.248 . . . . 74.33 112.814 176.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -104.69 178.1 4.66 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.823 0.82 . . . . 73.1 111.09 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.7 p -132.99 154.64 50.31 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 114.65 -1.159 . . . . 74.45 109.764 -177.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.9 p -110.98 89.9 3.18 Favored 'General case' 0 N--CA 1.41 -2.461 0 N-CA-C 108.416 -0.957 . . . . 64.31 108.416 177.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.1 t -80.18 -33.61 14.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 73.44 108.312 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.08 -16.76 57.26 Favored Glycine 0 N--CA 1.44 -1.089 0 N-CA-C 110.761 -0.936 . . . . 72.14 110.761 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.31 13.3 31.21 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.872 -0.68 . . . . 74.14 113.254 176.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -136.2 128.4 29.9 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.009 -1.108 . . . . 72.1 108.009 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.9 m -92.14 148.67 21.99 Favored 'General case' 0 C--N 1.271 -2.828 0 CA-C-N 116.255 -0.429 . . . . 74.22 110.657 -178.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 46.3 t30 -84.82 -55.89 3.86 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.847 -0.615 . . . . 71.51 110.371 -178.045 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.7 m -51.27 114.62 5.14 Favored Pre-proline 0 CA--C 1.554 1.106 0 O-C-N 124.148 0.905 . . . . 65.33 111.89 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.69 116.07 3.31 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 122.398 2.066 . . . . 74.32 110.183 178.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 118.14 -4.95 15.84 Favored Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 110.64 -0.984 . . . . 74.01 110.64 -176.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -112.76 150.6 31.37 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.483 0.658 . . . . 64.21 110.695 176.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.3 p -134.23 150.93 51.07 Favored 'General case' 0 C--N 1.275 -2.635 0 CA-C-N 114.81 -1.086 . . . . 75.12 110.044 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.6 t -91.07 85.59 5.97 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.751 -1.203 . . . . 63.44 107.751 177.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.1 t -77.76 -51.71 10.1 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.413 -0.812 . . . . 73.22 109.7 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 8.9 p-90 -125.49 102.11 7.24 Favored 'General case' 0 N--CA 1.427 -1.598 0 CA-C-O 122.12 0.962 . . . . 74.23 110.652 177.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 76.4 t90 -58.82 140.18 86.23 Favored Pre-proline 0 C--N 1.302 -1.463 0 CA-C-N 113.678 -1.601 . . . . 73.43 109.255 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -102.15 36.44 5.95 Favored 'Cis proline' 0 CA--C 1.543 0.941 0 C-N-CA 124.703 -0.957 . . . . 74.4 114.189 3.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -118.41 143.91 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.235 -0.915 . . . . 74.14 110.787 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.6 m -89.12 162.33 16.02 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 121.878 0.847 . . . . 75.24 110.774 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.8 p -136.93 160.43 38.93 Favored 'General case' 0 C--N 1.276 -2.605 0 CA-C-N 114.49 -1.232 . . . . 74.31 109.072 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 25.8 tpt180 -89.1 -69.2 0.72 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-O 121.819 0.819 . . . . 72.32 109.743 -178.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 N--CA 1.41 -2.455 0 N-CA-C 105.177 -2.156 . . . . 72.11 105.177 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.399 -3.808 0 N-CA-C 109.49 -1.444 . . . . 71.41 109.49 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 34.9 tp -124.38 117.8 26.54 Favored Pre-proline 0 N--CA 1.443 -0.823 0 N-CA-C 109.162 -0.681 . . . . 75.42 109.162 -177.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -72.17 83.5 1.21 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 122.07 1.847 . . . . 73.12 111.863 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.1 m -132.4 20.41 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.12 -0.946 . . . . 70.32 109.891 178.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 81.0 m -90.05 -22.87 21.63 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.076 -0.966 . . . . 73.31 110.595 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 78.95 -4.92 59.98 Favored Glycine 0 C--N 1.3 -1.47 0 CA-C-N 114.881 -1.054 . . . . 63.33 113.71 176.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -116.57 175.54 5.52 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 120.214 -0.595 . . . . 65.3 110.484 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -127.43 148.14 50.29 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.488 -0.778 . . . . 72.4 110.475 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.464 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 6.2 p -113.23 87.94 2.72 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 109.482 -0.562 . . . . 64.51 109.482 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.3 t -79.74 -30.18 13.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.661 -0.866 . . . . 70.14 108.661 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.49 -15.75 58.03 Favored Glycine 0 N--CA 1.435 -1.375 0 CA-C-N 115.213 -0.903 . . . . 74.51 110.996 177.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.98 15.89 34.86 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.449 -0.882 . . . . 64.14 112.827 177.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.7 m -143.18 125.79 15.89 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.334 -0.987 . . . . 75.44 108.334 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.464 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 33.3 m -96.79 154.44 17.29 Favored 'General case' 0 C--N 1.274 -2.678 0 CA-C-N 115.755 -0.657 . . . . 63.14 110.846 -176.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -77.56 -53.2 7.88 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.901 -0.59 . . . . 73.51 110.451 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 33.5 m -50.99 113.09 3.44 Favored Pre-proline 0 C--O 1.253 1.268 0 C-N-CA 124.049 0.939 . . . . 72.23 112.945 -177.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.72 119.43 6.65 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.565 2.177 . . . . 73.43 109.614 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.55 -3.77 27.84 Favored Glycine 0 N--CA 1.426 -1.978 0 C-N-CA 120.622 -0.799 . . . . 73.51 111.505 -179.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.3 m -111.01 154.77 23.71 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.683 0.754 . . . . 74.45 110.639 175.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -137.83 161.02 37.7 Favored 'General case' 0 C--N 1.274 -2.676 0 CA-C-N 114.683 -1.144 . . . . 74.21 109.754 -178.304 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 17.6 t -95.68 83.23 3.71 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 121.178 0.514 . . . . 74.11 109.694 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 t -89.15 -51.48 5.56 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.242 -0.435 . . . . 74.03 109.976 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.1 t-105 -105.47 80.86 1.62 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 109.527 -0.546 . . . . 73.44 109.527 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.6 t90 -57.03 136.57 80.25 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.432 -0.804 . . . . 71.3 109.984 -177.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -100.09 35.31 7.41 Favored 'Cis proline' 0 CA--C 1.544 1.017 0 C-N-CA 124.686 -0.964 . . . . 75.31 113.715 1.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.1 142.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 108.824 -0.806 . . . . 75.25 108.824 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.1 m -88.3 153.18 21.41 Favored 'General case' 0 N--CA 1.424 -1.737 0 C-N-CA 119.422 -0.911 . . . . 74.1 110.236 179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -132.02 155.42 48.06 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.106 -1.406 . . . . 61.52 110.291 -177.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -91.99 -68.79 0.77 Allowed 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.993 0.901 . . . . 75.31 111.153 -176.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p30 . . . . . 0 C--N 1.299 -1.596 0 N-CA-C 105.505 -2.035 . . . . 73.31 105.505 179.944 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.564 0 N-CA-C 111.219 -0.752 . . . . 73.53 111.219 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.1 tp -109.1 113.48 59.01 Favored Pre-proline 0 C--N 1.328 -0.362 0 C-N-CA 120.108 -0.637 . . . . 74.03 110.529 -175.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -73.52 81.01 1.88 Allowed 'Trans proline' 0 N--CA 1.444 -1.427 0 C-N-CA 121.497 1.465 . . . . 75.21 112.674 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.5 m -126.78 24.18 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 122.326 1.06 . . . . 74.3 109.877 175.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 37.2 m -84.57 -27.59 27.18 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 114.554 -1.203 . . . . 63.12 108.051 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.54 -7.77 64.01 Favored Glycine 0 N--CA 1.438 -1.211 0 CA-C-N 113.507 -1.679 . . . . 73.53 112.702 177.518 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -107.52 -177.2 3.28 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.225 0.536 . . . . 73.21 110.893 -177.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 p -135.36 164.2 28.3 Favored 'General case' 0 N--CA 1.421 -1.915 0 CA-C-N 114.465 -1.243 . . . . 72.34 108.781 -179.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -126.73 80.2 1.92 Allowed 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 116.538 -0.301 . . . . 61.01 110.677 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.1 t -77.56 -26.51 15.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 108.423 -0.955 . . . . 74.24 108.423 178.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.74 -7.64 68.51 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 110.447 -1.061 . . . . 74.04 110.447 176.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.99 10.54 69.06 Favored Glycine 0 C--O 1.218 -0.861 0 C-N-CA 121.375 -0.441 . . . . 73.44 112.212 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -127.72 123.77 36.2 Favored 'General case' 0 N--CA 1.419 -2.01 0 N-CA-C 108.243 -1.021 . . . . 74.3 108.243 -176.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.1 m -95.65 149.7 21.17 Favored 'General case' 0 C--N 1.277 -2.564 0 N-CA-C 109.483 -0.562 . . . . 73.53 109.483 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -90.19 -54.56 3.97 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 123.12 0.568 . . . . 65.44 111.698 -177.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.454 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.1 m -51.22 119.39 12.36 Favored Pre-proline 0 CA--C 1.562 1.441 0 O-C-N 123.838 0.711 . . . . 74.42 112.75 -178.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.27 118.57 5.46 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 123.089 2.526 . . . . 70.22 111.174 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.42 5.13 37.28 Favored Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 120.728 -0.749 . . . . 60.21 111.389 -179.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.454 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.5 m -103.88 159.64 15.48 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-O 121.528 0.68 . . . . 74.22 111.057 175.139 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 p -140.34 146.34 38.34 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 114.76 -1.109 . . . . 75.44 109.627 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.1 t -92.68 87.35 5.86 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.218 -1.401 . . . . 75.24 107.218 176.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 19.6 t -88.16 -70.23 0.65 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 109.262 -0.644 . . . . 74.11 109.262 -177.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.8 m-90 -91.0 87.36 6.58 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 108.301 -1.0 . . . . 75.2 108.301 177.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 90.3 t90 -54.82 135.6 65.5 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.378 -0.601 . . . . 74.4 109.378 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -102.13 39.93 4.14 Favored 'Cis proline' 0 CA--C 1.545 1.072 0 CA-C-N 119.365 0.809 . . . . 74.32 113.212 2.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.0 t -107.02 130.43 59.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.92 -0.487 . . . . 65.42 109.829 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -88.9 152.26 21.84 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-O 121.998 0.904 . . . . 73.54 110.177 178.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.5 p -134.01 171.0 14.81 Favored 'General case' 0 C--N 1.266 -3.03 0 CA-C-N 113.946 -1.479 . . . . 71.35 108.236 -178.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.438 ' C ' HD21 ' A' ' 30' ' ' ASN . 28.1 mmm180 -87.94 -78.96 0.3 Allowed 'General case' 0 N--CA 1.4 -2.935 0 N-CA-C 107.926 -1.138 . . . . 73.35 107.926 175.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.438 HD21 ' C ' ' A' ' 29' ' ' ARG . 0.9 OUTLIER . . . . . 0 C--N 1.292 -1.906 0 N-CA-C 105.136 -2.172 . . . . 75.24 105.136 174.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.926 0 N-CA-C 108.772 -1.731 . . . . 61.23 108.772 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.0 tp -123.24 119.0 27.65 Favored Pre-proline 0 C--O 1.247 0.945 0 CA-C-N 115.043 -0.578 . . . . 73.52 109.837 -178.024 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -73.73 81.28 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.432 2.088 . . . . 74.22 112.552 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.88 20.4 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.204 -0.907 . . . . 75.52 109.405 177.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.5 m -89.48 -30.09 18.53 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.211 -0.904 . . . . 74.14 109.753 178.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.94 -1.56 88.34 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-N 114.739 -1.119 . . . . 62.53 112.724 178.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -119.84 179.79 4.14 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.339 0.59 . . . . 72.52 111.436 -178.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 p -128.18 168.2 15.75 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.908 -1.042 . . . . 70.32 110.318 -177.042 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.1 p -135.28 86.89 2.28 Favored 'General case' 0 N--CA 1.419 -1.977 0 N-CA-C 109.315 -0.624 . . . . 64.04 109.315 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -77.0 -33.06 20.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 108.649 -0.871 . . . . 75.4 108.649 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.64 -28.23 17.11 Favored Glycine 0 N--CA 1.436 -1.362 0 N-CA-C 110.456 -1.058 . . . . 73.01 110.456 175.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.68 12.51 11.44 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.558 -0.829 . . . . 73.42 112.552 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -118.93 116.56 26.72 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.663 -0.866 . . . . 74.01 108.663 -176.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 40.7 m -95.13 137.21 34.48 Favored 'General case' 0 C--N 1.274 -2.684 0 N-CA-C 109.393 -0.595 . . . . 71.45 109.393 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -76.99 -51.4 11.19 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.47 -0.332 . . . . 73.43 110.462 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 61.9 m -51.77 116.59 8.25 Favored Pre-proline 0 C--O 1.259 1.584 0 O-C-N 124.011 0.82 . . . . 73.53 112.326 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.1 118.41 5.31 Favored 'Trans proline' 0 N--CA 1.446 -1.311 0 C-N-CA 122.227 1.952 . . . . 74.31 109.686 177.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.34 -4.13 23.51 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 120.256 -0.973 . . . . 25.41 111.092 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 58.4 m -109.37 148.13 31.6 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 119.353 -0.939 . . . . 74.44 110.363 175.569 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.5 p -134.53 148.52 50.52 Favored 'General case' 0 C--N 1.257 -3.448 0 CA-C-N 114.12 -1.4 . . . . 74.34 109.259 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.1 t -85.31 75.35 10.27 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.159 -1.052 . . . . 72.15 108.159 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 16.8 m -73.23 -44.01 60.25 Favored 'General case' 0 N--CA 1.407 -2.59 0 CA-C-N 115.437 -0.801 . . . . 73.13 110.633 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 62.0 t90 -125.36 97.2 5.11 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.771 -0.826 . . . . 73.43 108.771 178.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 83.4 t90 -58.56 138.97 85.77 Favored Pre-proline 0 C--N 1.303 -1.449 0 CA-C-N 114.913 -1.039 . . . . 74.52 109.597 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -102.49 36.75 5.63 Favored 'Cis proline' 0 CA--C 1.54 0.813 0 C-N-CA 124.948 -0.855 . . . . 71.23 113.41 1.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.4 t -113.25 138.96 40.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 121.9 -0.5 . . . . 73.3 110.104 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -88.35 151.51 22.55 Favored 'General case' 0 N--CA 1.417 -2.098 0 N-CA-C 108.735 -0.839 . . . . 64.42 108.735 177.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.2 p -137.64 160.89 37.94 Favored 'General case' 0 C--N 1.252 -3.665 0 CA-C-N 114.539 -1.209 . . . . 74.24 109.582 -177.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -90.93 -60.8 1.82 Allowed 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 121.46 0.647 . . . . 73.53 111.106 -177.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 N--CA 1.424 -1.749 0 N-CA-C 105.58 -2.007 . . . . 64.33 105.58 178.556 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.405 -3.4 0 N-CA-C 110.326 -1.11 . . . . 74.4 110.326 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 47.5 tp -110.46 116.64 52.47 Favored Pre-proline 0 C--O 1.24 0.591 0 N-CA-C 109.437 -0.579 . . . . 64.21 109.437 -177.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -73.2 81.32 1.74 Allowed 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.227 1.951 . . . . 75.02 112.122 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -131.66 12.45 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.293 -0.867 . . . . 75.24 110.731 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 64.7 m -80.89 -35.88 32.0 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.848 0.833 . . . . 75.45 109.105 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.26 -0.64 88.73 Favored Glycine 0 N--CA 1.426 -1.987 0 CA-C-N 114.84 -1.073 . . . . 70.12 112.032 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.57 177.21 4.73 Favored 'General case' 0 C--O 1.255 1.377 0 CA-C-O 121.399 0.618 . . . . 64.42 110.848 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 p -130.8 168.2 17.63 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 114.596 -1.184 . . . . 70.13 110.945 -175.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -135.81 87.36 2.31 Favored 'General case' 0 N--CA 1.417 -2.124 0 CA-C-N 115.577 -0.738 . . . . 74.21 109.782 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.13 -30.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 N-CA-C 108.082 -1.081 . . . . 74.11 108.082 177.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.66 -6.65 69.98 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.117 -0.947 . . . . 64.5 111.421 177.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.02 24.72 40.07 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 120.679 -0.772 . . . . 50.13 112.921 176.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 31.7 m -147.06 127.56 14.09 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.942 -0.762 . . . . 73.14 108.942 177.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.58 152.39 18.57 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.826 -0.624 . . . . 75.53 110.463 -178.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -83.8 -57.71 3.1 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.114 -0.494 . . . . 74.31 111.241 -176.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 49.8 m -51.96 117.78 10.62 Favored Pre-proline 0 C--O 1.248 0.999 0 O-C-N 123.735 0.647 . . . . 71.23 112.312 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -62.76 111.45 1.36 Allowed 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.446 2.097 . . . . 71.11 109.557 176.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 126.11 -10.62 7.37 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 111.089 -0.804 . . . . 63.01 111.089 -176.608 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 67.5 m -100.44 154.94 18.12 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-O 121.576 0.703 . . . . 74.25 109.85 175.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 p -136.19 143.49 44.43 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-N 114.759 -1.109 . . . . 74.24 109.15 -178.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.0 t -90.96 84.39 5.76 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 106.665 -1.606 . . . . 74.22 106.665 176.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 17.9 t -104.73 -16.28 15.0 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.802 -0.635 . . . . 75.5 110.642 -175.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 84.6 m95 -133.99 72.0 1.46 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.12 -1.066 . . . . 71.35 108.12 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.2 t90 -54.95 135.47 66.77 Favored Pre-proline 0 C--O 1.244 0.787 0 CA-C-N 114.41 -1.268 . . . . 73.12 110.331 -174.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -99.43 34.54 8.22 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 C-N-CA 124.662 -0.974 . . . . 75.42 113.756 3.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.9 t -107.23 139.21 29.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 121.905 -0.497 . . . . 70.32 109.808 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 94.8 m -88.83 154.62 20.11 Favored 'General case' 0 N--CA 1.416 -2.155 0 CA-C-O 122.137 0.97 . . . . 73.03 109.758 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.2 p -138.93 166.02 25.57 Favored 'General case' 0 C--N 1.257 -3.414 0 CA-C-N 114.129 -1.396 . . . . 73.44 107.957 -178.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -88.93 -70.59 0.64 Allowed 'General case' 0 N--CA 1.419 -2.005 0 C-N-CA 119.001 -1.08 . . . . 74.35 108.93 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 C--N 1.303 -1.455 0 N-CA-C 104.797 -2.297 . . . . 63.44 104.797 179.513 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -2.138 0 N-CA-C 109.503 -1.439 . . . . 64.14 109.503 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.8 tp -110.37 109.78 58.3 Favored Pre-proline 0 C--O 1.246 0.897 0 CA-C-N 114.868 -0.666 . . . . 71.44 109.224 -177.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -75.46 83.7 1.85 Allowed 'Trans proline' 0 N--CA 1.434 -1.977 0 C-N-CA 121.945 1.763 . . . . 75.0 111.179 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.4 m -123.01 19.96 4.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.39 -0.823 . . . . 75.42 110.044 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 57.4 m -108.1 -24.25 11.64 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-N 115.611 -0.722 . . . . 61.24 111.86 177.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.76 -15.52 14.37 Favored Glycine 0 C--O 1.246 0.869 0 CA-C-N 115.421 -0.809 . . . . 72.42 114.361 176.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.43 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 15.7 pt-20 -94.98 174.27 7.17 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.635 0.731 . . . . 72.54 111.531 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.0 p -125.9 161.32 27.72 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 114.765 -1.107 . . . . 74.4 109.95 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -122.2 90.73 3.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.804 -0.813 . . . . 74.35 108.804 178.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.53 -37.08 18.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.841 -0.8 . . . . 72.43 108.841 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.43 -14.88 59.43 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.555 -0.748 . . . . 64.12 111.348 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.03 20.25 16.79 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.447 -0.882 . . . . 71.1 113.453 176.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 59.0 m -141.95 127.54 19.04 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.981 -0.748 . . . . 75.53 108.981 177.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 33.9 m -100.17 162.68 12.81 Favored 'General case' 0 C--N 1.278 -2.528 0 CA-C-N 115.541 -0.754 . . . . 64.23 109.887 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -94.96 -49.57 5.49 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.559 -0.291 . . . . 74.11 110.446 -177.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.5 m -52.47 120.37 17.8 Favored Pre-proline 0 C--O 1.264 1.86 0 O-C-N 123.96 0.787 . . . . 72.04 112.347 -176.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -62.78 114.23 2.32 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.136 1.891 . . . . 71.34 109.664 177.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.84 -21.87 6.96 Favored Glycine 0 N--CA 1.428 -1.843 0 C-N-CA 120.456 -0.878 . . . . 72.13 112.112 -177.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -107.1 154.26 21.42 Favored 'General case' 0 CA--C 1.481 -1.69 0 CA-C-O 122.246 1.022 . . . . 70.14 112.812 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 p -139.39 167.58 21.76 Favored 'General case' 0 C--N 1.274 -2.688 0 CA-C-N 113.274 -1.785 . . . . 73.22 108.848 -178.314 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 9.6 t -90.64 64.71 5.78 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.882 -1.155 . . . . 62.55 107.882 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.2 m -65.07 -26.58 68.3 Favored 'General case' 0 N--CA 1.423 -1.798 0 CA-C-N 115.174 -0.921 . . . . 55.23 111.024 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -145.87 106.96 4.15 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.726 -1.213 . . . . 75.11 107.726 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 83.5 t90 -67.35 139.31 94.58 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 108.962 -0.755 . . . . 74.34 108.962 -177.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -104.9 36.7 4.76 Favored 'Cis proline' 0 CA--C 1.537 0.656 0 C-N-CA 125.107 -0.789 . . . . 75.51 113.03 1.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.5 p -112.6 136.54 48.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-O 121.618 0.723 . . . . 72.44 111.404 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.43 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 65.1 m -88.59 138.44 31.43 Favored 'General case' 0 N--CA 1.409 -2.515 0 CA-C-O 122.482 1.134 . . . . 62.11 109.19 179.034 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -139.92 164.51 29.81 Favored 'General case' 1 C--N 1.243 -4.045 0 CA-C-N 113.2 -1.818 . . . . 74.04 109.304 -175.105 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -87.48 -66.36 0.92 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.59 -0.892 . . . . 74.31 108.59 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.8 p30 . . . . . 0 N--CA 1.426 -1.663 0 N-CA-C 105.139 -2.171 . . . . 74.23 105.139 175.87 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.938 0 N-CA-C 109.083 -1.607 . . . . 74.51 109.083 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.5 tp -104.28 115.11 63.58 Favored Pre-proline 0 C--O 1.245 0.844 0 N-CA-C 109.038 -0.727 . . . . 74.3 109.038 -178.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -73.5 80.27 2.01 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.268 1.979 . . . . 75.31 112.606 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -131.66 8.96 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 115.744 -0.662 . . . . 74.14 110.781 178.366 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.1 m -91.84 -30.29 16.27 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-O 121.784 0.802 . . . . 75.44 109.461 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.71 -12.61 46.8 Favored Glycine 0 N--CA 1.427 -1.934 0 CA-C-N 114.521 -1.218 . . . . 64.02 113.953 176.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -100.49 172.4 7.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.094 -1.042 . . . . 64.54 111.802 -176.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 p -126.51 154.75 43.37 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 114.337 -1.301 . . . . 74.33 109.802 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.427 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 5.5 p -120.57 86.06 2.5 Favored 'General case' 0 N--CA 1.408 -2.54 0 N-CA-C 107.818 -1.178 . . . . 75.31 107.818 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 44.5 t -69.89 -33.6 56.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 N-CA-C 108.655 -0.868 . . . . 74.32 108.655 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.32 -32.15 7.56 Favored Glycine 0 N--CA 1.429 -1.792 0 CA-C-N 115.403 -0.817 . . . . 74.52 111.41 176.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.407 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 118.45 13.89 6.64 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.042 -1.075 . . . . 62.2 112.436 -178.276 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.0 m -126.08 112.04 15.38 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.213 -0.662 . . . . 65.52 109.213 -177.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.0 m -95.28 150.11 20.61 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.261 -0.881 . . . . 73.04 110.766 -176.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -90.84 -54.93 3.76 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 123.203 0.601 . . . . 72.15 111.065 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 57.5 m -50.19 117.97 8.5 Favored Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 113.169 0.803 . . . . 74.24 113.169 -176.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.9 123.01 12.71 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 123.249 2.633 . . . . 74.02 111.028 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.06 57.08 Favored Glycine 0 N--CA 1.427 -1.931 0 C-N-CA 120.733 -0.746 . . . . 70.5 112.148 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.9 m -100.77 155.26 18.01 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.291 -0.564 . . . . 75.04 109.644 177.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -140.85 155.43 46.34 Favored 'General case' 0 C--N 1.277 -2.575 0 CA-C-N 115.111 -0.95 . . . . 63.1 109.528 -174.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.407 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 24.5 t -84.78 79.6 9.56 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.409 -1.7 . . . . 71.44 106.409 175.168 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.431 ' HB3' ' OG1' ' A' ' 28' ' ' THR . 23.1 t -87.03 -28.36 22.65 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 115.036 -0.984 . . . . 72.03 110.389 -175.416 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.0 t-105 -135.94 85.46 2.16 Favored 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 107.95 -1.13 . . . . 75.44 107.95 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.406 ' CD1' ' HA ' ' A' ' 25' ' ' PRO . 76.1 t90 -58.45 135.84 85.58 Favored Pre-proline 0 C--N 1.307 -1.252 0 N-CA-C 109.396 -0.594 . . . . 73.1 109.396 -179.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.406 ' HA ' ' CD1' ' A' ' 24' ' ' TRP . 17.9 Cg_endo -99.09 35.64 7.47 Favored 'Cis proline' 0 CA--C 1.553 1.445 0 N-CA-C 114.888 1.072 . . . . 71.31 114.888 5.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.6 t -112.81 135.51 52.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.607 -0.683 . . . . 75.23 109.669 179.166 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.427 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 63.4 m -88.96 146.7 24.73 Favored 'General case' 0 N--CA 1.415 -2.182 0 N-CA-C 106.721 -1.585 . . . . 72.32 106.721 174.719 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.431 ' OG1' ' HB3' ' A' ' 22' ' ' SER . 15.0 p -139.59 179.04 6.8 Favored 'General case' 0 C--N 1.248 -3.809 0 N-CA-C 108.286 -1.005 . . . . 64.13 108.286 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 20.0 tpt180 -88.49 -73.86 0.48 Allowed 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.77 -0.772 . . . . 70.35 109.513 -177.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.427 -1.583 0 N-CA-C 104.972 -2.233 . . . . 71.25 104.972 176.68 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.398 -3.885 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.414 ' HG ' HG13 ' A' ' 4' ' ' VAL . 24.8 tp -120.93 120.91 29.12 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -177.345 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -70.89 83.26 0.91 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.295 1.997 . . . . 0.0 111.804 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.414 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.0 m -130.61 11.02 2.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.483 179.507 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.1 m -80.56 -28.4 37.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.443 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.24 4.69 90.43 Favored Glycine 0 N--CA 1.427 -1.95 0 CA-C-N 114.93 -1.032 . . . . 0.0 112.009 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.28 -176.65 3.56 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.237 0.541 . . . . 0.0 110.204 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.7 p -133.23 160.33 37.57 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.124 -177.276 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.5 p -126.49 84.84 2.31 Favored 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.461 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.65 -31.3 41.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.18 5.09 55.61 Favored Glycine 0 N--CA 1.44 -1.081 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.795 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 81.44 11.93 82.6 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.198 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 m -116.64 110.72 18.87 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -178.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.7 m -89.54 146.5 24.55 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-O 120.981 0.42 . . . . 0.0 110.479 177.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -81.38 -62.14 1.74 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.255 -177.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.426 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.5 m -51.19 118.18 10.19 Favored Pre-proline 0 C--O 1.251 1.133 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -59.45 118.49 5.39 Favored 'Trans proline' 0 C--N 1.354 0.858 0 C-N-CA 122.887 2.391 . . . . 0.0 109.936 175.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.23 -12.12 14.32 Favored Glycine 0 C--N 1.293 -1.857 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 78.8 m -99.13 154.98 17.7 Favored 'General case' 0 N--CA 1.433 -1.314 0 CA-C-O 121.633 0.73 . . . . 0.0 110.082 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -141.55 153.26 44.74 Favored 'General case' 0 C--N 1.268 -2.958 0 C-N-CA 125.465 1.506 . . . . 0.0 107.697 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.483 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 31.0 t -96.69 83.91 3.54 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-O 121.38 0.61 . . . . 0.0 110.06 -179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.4 m -88.11 -51.78 5.6 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.017 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.5 m95 -102.03 75.27 1.51 Allowed 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.064 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 88.7 t90 -55.6 136.43 70.91 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.13 -178.188 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 18.0 Cg_endo -99.42 36.22 6.95 Favored 'Cis proline' 0 CA--C 1.541 0.85 0 C-N-CA 124.874 -0.886 . . . . 0.0 113.918 4.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.6 t -110.58 143.06 21.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.2 m -87.76 155.32 19.96 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-O 122.201 1.0 . . . . 0.0 110.5 -178.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.8 p -138.79 153.66 48.43 Favored 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.814 -1.539 . . . . 0.0 109.329 -174.395 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.9 tpp180 -89.82 -67.37 0.85 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.873 -0.731 . . . . 0.0 109.91 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 -177.026 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -3.001 0 N-CA-C 108.918 -1.673 . . . . 73.03 108.918 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -120.94 111.49 34.12 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.517 -1.29 . . . . 70.33 107.517 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.61 78.63 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 122.093 1.862 . . . . 54.32 113.604 -177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.01 27.84 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 122.381 1.086 . . . . 72.05 108.645 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.4 m -90.2 -21.79 22.0 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 114.129 -1.396 . . . . 55.54 110.468 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.87 -4.29 53.57 Favored Glycine 0 C--N 1.303 -1.298 0 CA-C-N 114.42 -1.263 . . . . 72.34 113.983 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.428 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.6 pt-20 -117.11 179.33 4.06 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 122.24 -0.565 . . . . 75.02 111.438 -178.713 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.3 p -124.21 157.36 34.98 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.359 -0.837 . . . . 63.21 110.979 -175.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -127.89 83.66 2.18 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.718 -0.475 . . . . 73.42 109.718 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.36 -35.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.481 -0.933 . . . . 54.1 108.481 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.8 -14.57 59.35 Favored Glycine 0 N--CA 1.435 -1.368 0 CA-C-N 115.237 -0.892 . . . . 54.42 110.977 177.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.27 32.9 7.97 Favored Glycine 0 N--CA 1.432 -1.594 0 C-N-CA 120.131 -1.033 . . . . 74.11 111.537 179.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -142.84 122.45 13.3 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-O 121.274 0.559 . . . . 73.11 109.777 177.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.3 m -104.06 145.38 30.26 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 115.057 -0.974 . . . . 61.42 110.572 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 38.3 m-80 -86.57 -49.87 7.23 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.522 0.729 . . . . 71.32 111.527 -176.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 65.4 m -50.27 116.2 6.33 Favored Pre-proline 0 C--O 1.249 1.072 0 O-C-N 124.039 0.837 . . . . 71.33 112.101 -178.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.81 118.87 5.71 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 123.365 2.71 . . . . 75.23 111.611 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.13 -3.23 33.33 Favored Glycine 0 N--CA 1.426 -1.977 0 CA-C-N 115.699 -0.682 . . . . 44.24 111.552 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.482 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 84.9 m -102.44 155.53 18.2 Favored 'General case' 0 N--CA 1.432 -1.351 0 CA-C-O 122.043 0.925 . . . . 73.32 111.582 178.066 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -140.5 156.8 46.22 Favored 'General case' 0 C--N 1.27 -2.863 0 CA-C-N 113.715 -1.584 . . . . 74.51 107.903 179.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.4 t -92.64 80.93 4.76 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.901 -0.778 . . . . 73.24 108.901 175.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.2 m -83.66 -39.92 19.61 Favored 'General case' 0 N--CA 1.405 -2.69 0 CA-C-N 115.779 -0.646 . . . . 65.55 111.221 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.528 ' CD1' HG21 ' A' ' 28' ' ' THR . 23.3 m95 -118.08 82.4 1.83 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.014 -0.735 . . . . 75.22 109.014 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.411 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.0 t90 -57.99 132.71 83.61 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.517 0.727 . . . . 74.43 110.752 -175.512 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 90.9 Cg_endo -104.97 41.73 2.95 Favored 'Cis proline' 0 CA--C 1.545 1.037 0 CA-C-N 119.157 0.735 . . . . 74.42 113.797 4.273 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.95 139.86 31.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.178 -1.045 . . . . 71.32 108.178 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.428 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 88.6 m -87.97 146.89 25.29 Favored 'General case' 0 CA--C 1.474 -1.948 0 CA-C-O 122.562 1.172 . . . . 62.14 110.55 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.528 HG21 ' CD1' ' A' ' 23' ' ' TRP . 15.5 p -135.19 157.69 46.26 Favored 'General case' 0 C--N 1.256 -3.487 0 CA-C-N 113.0 -1.909 . . . . 74.12 110.325 -171.044 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.482 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 27.0 mmm180 -88.87 -65.42 1.02 Allowed 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.866 0.841 . . . . 53.34 110.61 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 C--N 1.284 -2.251 0 N-CA-C 105.415 -2.068 . . . . 75.41 105.415 -177.976 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.397 -3.922 0 N-CA-C 108.749 -1.74 . . . . 43.22 108.749 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 tp -120.23 115.32 32.96 Favored Pre-proline 0 N--CA 1.442 -0.871 0 N-CA-C 107.844 -1.169 . . . . 71.32 107.844 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.34 81.38 1.5 Allowed 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.309 2.006 . . . . 65.23 112.442 -177.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 m -132.62 9.63 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 115.038 -0.983 . . . . 65.44 110.64 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.7 m -76.66 -22.7 53.67 Favored 'General case' 0 CA--C 1.491 -1.307 0 CA-C-O 121.473 0.654 . . . . 30.35 111.295 -177.442 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.96 -2.01 82.27 Favored Glycine 0 N--CA 1.422 -2.249 0 CA-C-N 114.713 -1.13 . . . . 63.44 112.939 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -122.51 177.71 5.3 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.548 -0.861 . . . . 72.41 111.121 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.1 p -124.76 154.36 41.02 Favored 'General case' 0 N--CA 1.422 -1.858 0 CA-C-N 114.513 -1.222 . . . . 60.3 110.656 -178.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -122.14 85.52 2.43 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 123.549 0.74 . . . . 43.15 109.162 178.678 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -72.12 -33.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-O 121.566 0.698 . . . . 73.42 109.338 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.28 -16.77 56.89 Favored Glycine 0 N--CA 1.438 -1.227 0 CA-C-N 115.384 -0.826 . . . . 61.42 111.636 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.444 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.31 15.27 23.83 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.075 -1.059 . . . . 74.21 112.907 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.4 m -137.31 124.46 21.68 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.938 -1.134 . . . . 71.43 107.938 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.98 149.35 21.89 Favored 'General case' 0 C--N 1.273 -2.717 0 CA-C-N 115.953 -0.567 . . . . 51.24 111.44 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -75.06 -54.04 7.85 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.596 -0.729 . . . . 64.15 109.646 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -51.71 111.52 2.49 Favored Pre-proline 0 C--O 1.256 1.41 0 C-N-CA 124.144 0.978 . . . . 43.55 112.241 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -62.87 118.06 4.96 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.385 2.057 . . . . 74.14 109.556 176.322 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.9 -11.31 13.52 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 111.363 -0.695 . . . . 40.24 111.363 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.5 m -102.39 155.64 18.12 Favored 'General case' 0 CA--C 1.499 -0.996 0 CA-C-O 122.244 1.021 . . . . 51.42 111.802 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.5 p -132.16 151.69 51.66 Favored 'General case' 0 N--CA 1.401 -2.905 0 CA-C-N 113.797 -1.547 . . . . 71.31 108.858 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.444 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 20.8 t -93.18 53.08 1.88 Allowed 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.858 0.837 . . . . 73.11 108.989 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 m -70.53 -22.81 62.57 Favored 'General case' 0 N--CA 1.414 -2.244 0 CA-C-N 115.587 -0.733 . . . . 63.14 111.938 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.9 t-105 -128.99 80.43 1.97 Allowed 'General case' 0 C--O 1.205 -1.278 0 N-CA-C 108.237 -1.023 . . . . 71.43 108.237 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 77.2 t90 -62.88 135.32 95.98 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 116.094 -0.503 . . . . 72.34 110.898 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 52.5 Cg_endo -102.31 36.4 5.91 Favored 'Cis proline' 0 C--N 1.354 0.851 0 C-N-CA 125.008 -0.83 . . . . 74.54 113.304 2.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.8 t -105.35 141.44 20.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 109.275 -0.639 . . . . 73.0 109.275 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 74.7 m -88.92 144.58 26.09 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-O 122.794 1.283 . . . . 44.14 111.029 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 p -129.74 155.05 46.55 Favored 'General case' 0 C--N 1.258 -3.371 0 CA-C-N 112.867 -1.97 . . . . 73.04 110.037 -173.037 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 -89.55 -66.42 0.92 Allowed 'General case' 0 N--CA 1.425 -1.706 0 CA-C-O 121.763 0.792 . . . . 63.23 109.878 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 105.388 -2.079 . . . . 74.54 105.388 -178.708 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.971 0 N-CA-C 109.961 -1.255 . . . . 72.14 109.961 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.0 tp -118.24 111.53 38.45 Favored Pre-proline 0 N--CA 1.439 -0.998 0 N-CA-C 108.279 -1.008 . . . . 73.0 108.279 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -74.96 79.11 2.73 Favored 'Trans proline' 0 N--CA 1.444 -1.41 0 C-N-CA 121.879 1.719 . . . . 64.24 112.675 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.88 22.65 2.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 CA-C-O 121.821 0.819 . . . . 74.32 109.662 176.359 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 52.2 m -85.12 -32.65 22.66 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.906 -1.146 . . . . 62.32 107.906 176.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.51 -2.58 87.04 Favored Glycine 0 N--CA 1.43 -1.759 0 CA-C-N 114.055 -1.43 . . . . 75.43 112.694 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -112.12 175.83 5.27 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.647 0.737 . . . . 60.13 111.624 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -127.32 158.64 36.7 Favored 'General case' 0 C--N 1.284 -2.273 0 CA-C-N 114.465 -1.243 . . . . 64.21 109.732 -177.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.1 p -119.64 96.6 5.26 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.37 -0.974 . . . . 65.32 108.37 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.8 t -80.0 -38.87 19.09 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 109.084 -0.71 . . . . 73.23 109.084 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.88 -10.69 61.15 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.402 -0.817 . . . . 53.13 111.149 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.491 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 99.56 13.73 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.522 -0.847 . . . . 72.23 112.573 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.6 m -127.66 128.78 46.07 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 107.925 -1.139 . . . . 75.31 107.925 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 36.1 m -104.48 159.38 15.79 Favored 'General case' 0 C--N 1.272 -2.779 0 CA-C-N 115.741 -0.663 . . . . 54.51 109.578 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -91.62 -58.07 2.55 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.386 -0.37 . . . . 74.14 110.519 -179.139 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.452 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 35.6 m -46.65 116.95 4.1 Favored Pre-proline 0 CA--C 1.545 0.771 0 O-C-N 124.374 1.046 . . . . 71.41 112.219 -175.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.93 117.09 3.73 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 123.257 2.638 . . . . 53.1 110.941 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.09 -2.51 31.46 Favored Glycine 0 N--CA 1.427 -1.936 0 CA-C-N 115.554 -0.748 . . . . 72.14 111.543 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.486 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 63.2 m -106.25 150.21 26.14 Favored 'General case' 0 CA--C 1.488 -1.435 0 CA-C-O 121.789 0.804 . . . . 72.25 110.113 176.186 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 p -136.72 152.46 50.38 Favored 'General case' 0 C--N 1.268 -2.973 0 CA-C-N 114.165 -1.38 . . . . 73.35 109.927 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.491 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 38.8 t -88.58 65.17 7.72 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.855 -1.165 . . . . 51.12 107.855 176.362 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.6 m -72.7 -29.39 63.34 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-N 114.489 -1.232 . . . . 72.23 110.798 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.3 t-105 -134.29 82.77 1.99 Allowed 'General case' 0 N--CA 1.433 -1.322 0 CA-C-O 121.179 0.514 . . . . 72.32 110.135 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.1 t90 -56.1 139.12 72.38 Favored Pre-proline 0 C--O 1.244 0.799 0 CA-C-N 115.245 -0.889 . . . . 65.04 109.875 -177.651 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -97.87 30.19 13.62 Favored 'Cis proline' 0 CA--C 1.538 0.711 0 C-N-CA 125.033 -0.82 . . . . 74.02 113.483 1.089 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 44.5 t -107.64 136.73 41.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 N-CA-C 109.558 -0.534 . . . . 62.22 109.558 -178.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.7 m -88.46 152.49 21.85 Favored 'General case' 0 N--CA 1.419 -1.996 0 C-N-CA 119.268 -0.973 . . . . 72.03 109.113 177.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -139.25 164.32 30.13 Favored 'General case' 0 C--N 1.264 -3.149 0 CA-C-N 114.742 -1.117 . . . . 74.12 109.016 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 24.3 mmm180 -88.14 -74.14 0.46 Allowed 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.775 0.798 . . . . 64.12 110.463 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 . . . . . 0 C--N 1.275 -2.631 0 N-CA-C 104.647 -2.353 . . . . 73.31 104.647 -179.42 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.415 -2.713 0 N-CA-C 109.68 -1.368 . . . . 74.32 109.68 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -121.06 112.92 33.04 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.514 -0.55 . . . . 75.13 109.514 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -71.79 81.56 1.33 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.3 2.0 . . . . 74.14 112.981 -179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m -133.24 15.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 114.982 -1.008 . . . . 75.14 110.187 177.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.2 m -88.73 -26.75 21.61 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.725 -0.67 . . . . 50.52 111.05 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.32 6.09 86.09 Favored Glycine 0 N--CA 1.427 -1.914 0 CA-C-N 114.875 -1.057 . . . . 74.33 112.987 177.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.3 pt-20 -120.09 173.97 6.77 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.249 -0.98 . . . . 72.22 111.557 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.8 p -124.45 153.71 41.56 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-N 114.191 -1.368 . . . . 71.42 110.001 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -123.26 85.12 2.37 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 123.54 0.736 . . . . 64.23 110.389 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.0 t -80.75 -23.87 11.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.89 0.852 . . . . 73.34 108.838 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -13.7 60.22 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.594 -1.002 . . . . 55.23 110.594 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.33 17.37 46.53 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.508 -0.853 . . . . 74.05 112.071 177.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 m -139.36 131.16 27.54 Favored 'General case' 0 N--CA 1.419 -2.005 0 N-CA-C 108.368 -0.975 . . . . 73.53 108.368 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.76 156.79 16.18 Favored 'General case' 0 C--N 1.275 -2.636 0 CA-C-N 115.853 -0.612 . . . . 72.41 109.5 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -94.42 -49.71 5.56 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 116.235 -0.439 . . . . 75.22 110.947 -176.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.524 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 13.2 m -51.27 118.27 10.47 Favored Pre-proline 0 C--O 1.246 0.919 0 C-N-CA 123.913 0.885 . . . . 52.25 111.169 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.99 118.18 4.99 Favored 'Trans proline' 0 C--N 1.354 0.855 0 C-N-CA 122.728 2.285 . . . . 60.44 110.529 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.32 -1.44 32.93 Favored Glycine 0 N--CA 1.427 -1.906 0 C-N-CA 120.963 -0.636 . . . . 44.23 111.993 -178.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.524 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.3 m -105.01 154.81 19.63 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.982 0.896 . . . . 63.31 112.067 178.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 p -137.8 153.52 49.65 Favored 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 125.126 1.37 . . . . 74.52 109.74 -176.292 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.9 t -97.13 87.22 4.14 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.316 -0.994 . . . . 55.31 108.316 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.1 t -81.65 -57.86 3.26 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.365 -0.605 . . . . 41.32 109.365 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -107.29 96.54 6.48 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 109.223 -0.658 . . . . 65.44 109.223 -178.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 75.7 t90 -63.93 138.23 97.34 Favored Pre-proline 0 C--N 1.296 -1.717 0 N-CA-C 109.233 -0.654 . . . . 74.15 109.233 -178.067 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 61.4 Cg_endo -102.63 37.84 5.03 Favored 'Cis proline' 0 CA--C 1.544 0.984 0 C-N-CA 124.464 -1.057 . . . . 74.24 114.018 1.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.5 p -108.97 143.6 18.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 O-C-N 121.516 -0.74 . . . . 70.22 110.059 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.6 m -88.5 160.75 17.36 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 122.288 1.042 . . . . 64.15 111.353 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.2 p -142.14 166.17 25.43 Favored 'General case' 0 C--N 1.267 -3.002 0 CA-C-N 113.613 -1.631 . . . . 72.21 108.154 -178.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 22.1 tpt180 -89.01 -70.93 0.62 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.736 -0.838 . . . . 73.12 108.736 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.417 -2.109 0 N-CA-C 104.775 -2.305 . . . . 72.43 104.775 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.417 -2.627 0 N-CA-C 109.219 -1.552 . . . . 50.42 109.219 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.6 tp -115.08 111.69 44.81 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 114.658 -0.771 . . . . 73.44 109.023 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.93 74.67 3.37 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 122.671 2.247 . . . . 54.32 113.678 -176.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -125.32 18.49 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 115.459 -0.792 . . . . 74.14 109.908 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.7 m -88.21 -22.26 24.09 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-O 121.996 0.903 . . . . 75.43 109.562 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.08 -15.79 19.95 Favored Glycine 0 N--CA 1.438 -1.197 0 CA-C-N 114.116 -1.402 . . . . 63.23 113.549 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -99.52 175.5 5.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 121.557 0.694 . . . . 73.35 110.733 -177.191 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.8 p -125.38 149.0 48.55 Favored 'General case' 0 N--CA 1.409 -2.482 0 CA-C-N 114.54 -1.209 . . . . 70.42 110.28 -178.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -116.76 93.11 4.07 Favored 'General case' 0 C--N 1.284 -2.244 0 N-CA-C 108.749 -0.834 . . . . 52.13 108.749 177.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 65.7 t -80.3 -35.22 15.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.158 -0.682 . . . . 74.14 109.158 179.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.52 -10.44 65.47 Favored Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.389 -1.085 . . . . 62.51 110.389 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 92.82 17.21 45.33 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.707 -0.759 . . . . 32.52 111.802 178.573 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 m -123.24 122.49 38.5 Favored 'General case' 0 N--CA 1.418 -2.049 0 N-CA-C 108.474 -0.935 . . . . 64.33 108.474 -178.368 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 67.6 m -99.38 141.2 32.48 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-N 115.836 -0.62 . . . . 71.01 111.89 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -83.07 -50.96 7.97 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.038 -0.983 . . . . 74.22 111.639 -176.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 53.4 m -52.29 118.56 12.76 Favored Pre-proline 0 C--O 1.254 1.318 0 C-N-CA 122.531 0.333 . . . . 73.22 111.74 176.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -67.38 114.0 3.1 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.163 1.908 . . . . 74.34 109.724 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 121.19 -7.28 10.7 Favored Glycine 0 N--CA 1.417 -2.618 0 C-N-CA 120.246 -0.978 . . . . 43.22 110.916 -176.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.2 m -108.77 153.27 23.71 Favored 'General case' 0 CA--C 1.495 -1.14 0 CA-C-O 121.433 0.635 . . . . 73.34 110.54 176.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.7 p -134.25 152.86 52.04 Favored 'General case' 0 N--CA 1.406 -2.634 0 CA-C-N 114.571 -1.195 . . . . 63.41 108.137 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.473 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 36.0 t -89.28 83.06 6.44 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.26 -1.015 . . . . 73.42 108.26 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.8 t -105.23 1.04 27.8 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.632 -0.713 . . . . 71.13 110.451 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.7 t-105 -147.57 63.88 1.14 Allowed 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.341 -0.985 . . . . 72.31 108.341 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.5 t90 -51.61 132.8 35.97 Favored Pre-proline 0 C--N 1.318 -0.797 0 CA-C-N 114.615 -1.175 . . . . 73.14 110.482 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 73.1 Cg_endo -101.24 34.22 7.75 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.662 -0.974 . . . . 73.42 113.64 4.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -109.89 142.02 23.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.866 -0.79 . . . . 73.34 108.866 179.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.9 m -88.26 147.23 24.92 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.711 1.243 . . . . 72.11 110.835 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -130.0 158.88 38.37 Favored 'General case' 0 C--N 1.26 -3.318 0 CA-C-N 112.889 -1.959 . . . . 50.33 109.733 -172.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -89.42 -66.93 0.87 Allowed 'General case' 0 N--CA 1.416 -2.149 0 C-N-CA 119.751 -0.78 . . . . 74.34 109.767 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 N--CA 1.426 -1.67 0 N-CA-C 105.541 -2.022 . . . . 72.23 105.541 -179.324 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.331 0 N-CA-C 109.937 -1.265 . . . . 64.21 109.937 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.9 tp -118.5 120.67 31.68 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.623 -0.51 . . . . 63.11 109.623 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -70.61 82.87 0.89 Allowed 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.127 1.885 . . . . 75.12 112.521 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.4 m -130.47 19.45 2.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-O 121.759 0.79 . . . . 63.23 109.391 176.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 79.4 m -93.0 -29.61 15.75 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 115.007 -0.997 . . . . 53.52 110.251 -178.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.87 3.43 73.98 Favored Glycine 0 N--CA 1.432 -1.593 0 CA-C-N 114.832 -1.076 . . . . 73.4 113.621 177.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -120.3 175.27 6.04 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.742 0.782 . . . . 75.15 111.254 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -128.88 155.45 45.24 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-N 114.427 -1.26 . . . . 43.54 109.759 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -125.64 85.81 2.45 Favored 'General case' 0 C--N 1.278 -2.529 0 CA-C-N 116.234 -0.439 . . . . 74.15 109.924 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 41.2 t -80.3 -25.25 11.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.291 -0.963 . . . . 74.32 109.005 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.95 -15.94 56.98 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 110.927 -0.869 . . . . 55.2 110.927 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.96 14.79 38.45 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.811 -0.709 . . . . 63.1 112.263 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.8 m -130.76 124.36 31.25 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.206 -0.665 . . . . 70.03 109.206 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.9 m -98.92 152.93 19.23 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 115.847 -0.615 . . . . 64.15 109.686 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -87.88 -55.96 3.54 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.595 -0.275 . . . . 72.14 111.18 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.403 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 19.9 m -50.97 112.15 2.77 Favored Pre-proline 0 CA--C 1.56 1.34 0 O-C-N 124.29 0.994 . . . . 60.44 112.728 -176.788 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -58.61 121.97 10.86 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 123.115 2.543 . . . . 72.42 110.512 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.75 -3.73 30.6 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 110.766 -0.934 . . . . 72.54 110.766 -177.148 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.403 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 86.0 m -104.81 159.17 16.0 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.539 0.685 . . . . 72.02 110.824 176.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.5 p -137.82 146.09 43.09 Favored 'General case' 0 C--N 1.28 -2.442 0 C-N-CA 124.924 1.289 . . . . 72.41 109.233 -176.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 49.2 t -91.44 77.2 5.81 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.26 -1.385 . . . . 43.0 107.26 174.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -90.28 -36.29 14.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.689 -0.687 . . . . 75.41 110.96 -175.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 92.6 m95 -120.34 76.03 1.15 Allowed 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.209 -0.663 . . . . 53.3 109.209 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 79.9 t90 -53.75 136.91 54.51 Favored Pre-proline 0 C--N 1.313 -1.008 0 CA-C-N 114.895 -1.048 . . . . 73.15 110.372 -175.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -97.24 32.85 10.39 Favored 'Cis proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.523 -1.032 . . . . 74.12 113.295 2.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.0 t -106.15 138.18 32.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 109.549 -0.537 . . . . 75.25 109.549 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.95 153.51 20.97 Favored 'General case' 0 N--CA 1.41 -2.438 0 CA-C-O 122.104 0.954 . . . . 73.55 109.225 177.208 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 5.2 p -133.08 165.5 24.6 Favored 'General case' 0 C--N 1.252 -3.633 0 CA-C-N 114.408 -1.269 . . . . 64.42 108.572 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpt180 -88.95 -76.63 0.4 Allowed 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 108.678 -0.86 . . . . 73.31 108.678 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.42 -1.928 0 N-CA-C 104.852 -2.277 . . . . 65.42 104.852 179.471 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.407 -3.244 0 N-CA-C 109.27 -1.532 . . . . 73.34 109.27 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 35.0 tp -123.86 121.35 26.48 Favored Pre-proline 0 N--CA 1.44 -0.942 0 N-CA-C 108.94 -0.763 . . . . 73.32 108.94 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.83 84.52 0.41 Allowed 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.624 2.216 . . . . 53.22 111.97 178.003 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 m -136.42 30.53 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 CA-C-N 114.997 -1.001 . . . . 54.02 108.48 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.2 m -101.19 -24.69 14.22 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 114.836 -1.075 . . . . 65.23 110.492 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.84 -14.06 33.58 Favored Glycine 0 C--N 1.305 -1.193 0 CA-C-N 114.959 -1.019 . . . . 61.43 113.754 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.401 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 10.6 pt-20 -110.68 -178.05 3.38 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 121.154 0.502 . . . . 74.34 110.887 -177.265 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 p -131.2 154.86 47.96 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.987 -1.006 . . . . 50.42 111.386 -176.049 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -121.66 88.25 2.9 Favored 'General case' 0 N--CA 1.416 -2.129 0 N-CA-C 108.874 -0.787 . . . . 74.54 108.874 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -74.43 -36.25 41.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.046 -0.724 . . . . 42.04 109.046 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 -22.72 35.55 Favored Glycine 0 N--CA 1.436 -1.35 0 CA-C-N 115.392 -0.822 . . . . 70.24 111.08 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.07 12.79 13.26 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.017 -1.087 . . . . 72.44 113.325 178.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 46.7 m -136.99 124.98 22.76 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.652 -0.87 . . . . 44.33 108.652 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 38.3 m -91.97 169.86 10.32 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 115.352 -0.84 . . . . 75.41 110.874 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -92.77 -52.56 4.56 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 123.315 0.646 . . . . 74.11 110.468 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.7 m -51.13 113.94 4.36 Favored Pre-proline 0 C--O 1.25 1.117 0 C-N-CA 123.947 0.899 . . . . 71.52 113.095 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -65.48 105.98 0.81 Allowed 'Trans proline' 0 C--N 1.359 1.1 0 C-N-CA 122.53 2.153 . . . . 62.42 109.629 176.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.95 5.33 Favored Glycine 0 N--CA 1.427 -1.913 0 N-CA-C 110.782 -0.927 . . . . 64.4 110.782 -177.294 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.3 m -102.13 162.01 13.24 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 121.609 0.719 . . . . 43.13 111.146 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -141.0 153.13 45.42 Favored 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 114.252 -1.34 . . . . 71.04 108.325 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.88 83.17 4.33 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.018 -1.105 . . . . 73.13 108.018 175.241 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 21.4 t -89.77 -49.26 6.74 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.911 -0.774 . . . . 73.43 108.911 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -107.5 80.7 1.43 Allowed 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.39 -0.596 . . . . 75.5 109.39 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 92.4 t90 -55.79 139.73 69.07 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.413 -0.812 . . . . 63.35 110.033 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 17.6 Cg_endo -99.95 32.32 9.91 Favored 'Cis proline' 0 CA--C 1.534 0.493 0 C-N-CA 124.935 -0.86 . . . . 72.02 113.121 1.032 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 55.8 t -104.91 142.54 17.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.993 -0.743 . . . . 70.24 108.993 -179.691 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.401 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 71.3 m -87.89 144.93 26.3 Favored 'General case' 0 N--CA 1.415 -2.2 0 CA-C-O 122.707 1.241 . . . . 73.43 110.417 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -128.28 152.04 48.59 Favored 'General case' 0 C--N 1.259 -3.365 0 CA-C-N 113.104 -1.862 . . . . 53.3 111.101 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -94.82 -55.86 2.97 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-O 121.765 0.793 . . . . 64.33 111.237 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.414 -2.225 0 N-CA-C 105.01 -2.218 . . . . 51.13 105.01 -179.161 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.409 -3.134 0 N-CA-C 109.744 -1.342 . . . . 70.42 109.744 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.0 tp -103.79 116.27 62.04 Favored Pre-proline 0 C--O 1.241 0.614 0 N-CA-C 108.808 -0.812 . . . . 74.21 108.808 179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -78.37 76.69 4.31 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.179 1.919 . . . . 64.25 112.304 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -128.1 18.54 2.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.905 -1.043 . . . . 73.12 109.775 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.1 m -87.82 -26.35 22.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 CA-C-N 115.236 -0.893 . . . . 71.33 109.951 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.93 -0.88 64.78 Favored Glycine 0 N--CA 1.438 -1.17 0 CA-C-N 114.619 -1.173 . . . . 53.42 113.557 176.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.479 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 11.3 pt-20 -112.93 175.52 5.4 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.242 -0.583 . . . . 72.14 110.27 178.703 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 p -128.41 154.71 45.75 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 115.055 -0.975 . . . . 73.52 110.752 -174.5 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.415 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 7.6 p -129.86 89.68 2.85 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 109.622 -0.51 . . . . 74.13 109.622 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -80.18 -31.25 13.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 108.707 -0.849 . . . . 73.23 108.707 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.4 -12.21 61.6 Favored Glycine 0 N--CA 1.439 -1.167 0 CA-C-N 115.424 -0.807 . . . . 64.22 111.315 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 93.14 19.48 36.02 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.478 -0.868 . . . . 63.34 112.609 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.9 m -135.85 119.66 17.32 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.1 -0.704 . . . . 61.3 109.1 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 56.4 m -99.13 167.51 10.65 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.312 -0.858 . . . . 65.55 110.955 -176.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -103.83 -49.28 3.69 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.648 0.379 . . . . 73.43 111.875 -178.043 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.8 m -51.29 114.17 4.68 Favored Pre-proline 0 C--O 1.257 1.465 0 N-CA-C 113.081 0.771 . . . . 44.3 113.081 -179.046 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -62.93 115.67 3.08 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.883 2.389 . . . . 64.43 109.571 175.458 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -10.42 11.5 Favored Glycine 0 C--N 1.298 -1.568 0 N-CA-C 110.94 -0.864 . . . . 73.54 110.94 -176.638 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.4 m -112.95 162.37 15.93 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.235 0.54 . . . . 62.3 110.545 176.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 p -145.35 160.93 40.79 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 124.933 1.293 . . . . 71.31 108.337 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.48 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 46.2 t -92.27 85.24 5.36 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.536 -0.913 . . . . 45.54 108.536 177.483 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -103.36 -31.17 10.17 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.828 -0.623 . . . . 70.31 110.124 -178.406 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.1 m95 -112.66 64.84 0.63 Allowed 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.186 0.517 . . . . 74.13 109.701 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 89.1 t90 -52.88 135.32 47.18 Favored Pre-proline 0 C--O 1.247 0.971 0 CA-C-N 114.567 -1.197 . . . . 72.44 110.498 -176.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 9.7 Cg_endo -96.3 33.35 9.94 Favored 'Cis proline' 0 CA--C 1.549 1.261 0 N-CA-C 114.518 0.93 . . . . 75.45 114.518 3.052 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 69.1 t -111.09 143.69 20.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 108.861 -0.792 . . . . 63.12 108.861 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.479 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 63.0 m -88.69 145.49 25.62 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-O 122.301 1.048 . . . . 72.42 109.345 178.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.4 p -129.5 165.03 22.47 Favored 'General case' 0 C--N 1.254 -3.546 0 CA-C-N 113.786 -1.552 . . . . 71.1 110.688 -174.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -88.22 -67.43 0.83 Allowed 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.897 -0.779 . . . . 73.12 108.897 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 . . . . . 0 N--CA 1.423 -1.816 0 N-CA-C 105.906 -1.887 . . . . 64.33 105.906 176.068 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.654 0 N-CA-C 110.596 -1.002 . . . . 72.13 110.596 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.5 tp -112.59 110.04 52.9 Favored Pre-proline 0 C--O 1.239 0.516 0 N-CA-C 109.704 -0.48 . . . . 70.21 109.704 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -72.86 79.32 1.98 Allowed 'Trans proline' 0 C--O 1.24 0.586 0 C-N-CA 122.421 2.081 . . . . 61.44 112.528 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.8 m -137.09 23.37 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.93 -1.032 . . . . 75.52 109.737 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.3 m -84.99 -21.68 29.39 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.56 -0.745 . . . . 74.33 110.839 -178.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.07 -0.24 79.94 Favored Glycine 0 C--N 1.294 -1.781 0 CA-C-N 114.794 -1.094 . . . . 75.33 113.678 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -121.62 177.92 5.04 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.278 -0.569 . . . . 71.54 109.639 177.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.3 p -130.91 158.85 39.1 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 116.051 -0.522 . . . . 62.04 110.675 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -129.72 88.77 2.72 Favored 'General case' 0 C--N 1.282 -2.351 0 C-N-CA 123.041 0.536 . . . . 74.41 109.665 -179.04 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.7 t -76.76 -31.74 19.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 119.955 -0.698 . . . . 73.31 109.351 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.68 -19.71 47.11 Favored Glycine 0 C--N 1.306 -1.084 0 N-CA-C 111.068 -0.813 . . . . 73.12 111.068 176.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.488 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.21 17.08 19.09 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.806 -0.711 . . . . 55.5 112.136 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.6 m -122.73 122.19 38.16 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 108.706 -0.85 . . . . 55.22 108.706 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 60.5 m -102.47 147.59 26.56 Favored 'General case' 0 C--N 1.274 -2.704 0 CA-C-N 115.746 -0.661 . . . . 62.42 110.198 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -90.99 -49.83 6.2 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.921 -0.581 . . . . 73.11 110.909 -178.045 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.2 m -50.73 113.26 3.52 Favored Pre-proline 0 C--O 1.25 1.119 0 O-C-N 123.987 0.804 . . . . 74.15 112.194 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.45 116.77 3.48 Favored 'Trans proline' 0 C--N 1.358 1.047 0 C-N-CA 123.19 2.593 . . . . 75.44 110.831 179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.86 -10.85 20.89 Favored Glycine 0 N--CA 1.424 -2.121 0 C-N-CA 120.3 -0.952 . . . . 53.12 112.214 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 80.4 m -103.97 156.82 17.55 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 121.636 0.731 . . . . 75.34 111.31 178.239 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.79 154.94 47.51 Favored 'General case' 0 C--N 1.271 -2.811 0 CA-C-N 114.465 -1.243 . . . . 74.22 108.89 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.488 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 t -91.47 87.45 6.41 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.923 -0.769 . . . . 72.54 108.923 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.3 t -96.84 -59.87 1.71 Allowed 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 116.137 -0.483 . . . . 73.13 109.711 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 64.2 t-105 -92.07 77.74 5.32 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.678 -0.86 . . . . 72.2 108.678 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -54.98 139.53 63.24 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 114.818 -1.083 . . . . 74.14 110.553 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -98.18 36.94 6.53 Favored 'Cis proline' 0 C--N 1.353 0.793 0 C-N-CA 124.663 -0.974 . . . . 64.1 112.56 1.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -109.47 142.32 22.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 108.588 -0.893 . . . . 74.45 108.588 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.0 m -87.96 150.4 23.48 Favored 'General case' 0 N--CA 1.416 -2.155 0 C-N-CA 119.355 -0.938 . . . . 53.25 109.34 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.1 p -128.66 160.72 31.58 Favored 'General case' 0 C--N 1.254 -3.548 0 CA-C-N 113.735 -1.575 . . . . 55.3 109.472 -176.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -88.73 -67.75 0.81 Allowed 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 121.872 0.844 . . . . 72.45 110.083 -177.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 104.726 -2.324 . . . . 55.54 104.726 178.548 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.345 0 N-CA-C 109.39 -1.484 . . . . 73.24 109.39 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 39.4 tp -104.69 120.68 49.48 Favored Pre-proline 0 C--O 1.248 1.023 0 N-CA-C 108.932 -0.766 . . . . 74.41 108.932 -177.171 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.71 80.76 2.28 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.255 1.97 . . . . 75.34 112.741 -178.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.04 22.37 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.803 -1.09 . . . . 73.21 109.029 177.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 78.5 m -100.46 -27.91 13.2 Favored 'General case' 0 N--CA 1.431 -1.375 0 CA-C-N 115.303 -0.862 . . . . 64.2 110.381 -178.07 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.83 -10.99 43.5 Favored Glycine 0 C--N 1.303 -1.3 0 CA-C-N 114.977 -1.01 . . . . 64.15 113.484 177.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -109.9 176.64 4.99 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.768 0.794 . . . . 72.42 110.942 -177.611 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.3 p -128.05 163.22 25.05 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 114.315 -1.311 . . . . 71.23 109.747 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 6.7 p -128.82 87.38 2.57 Favored 'General case' 0 N--CA 1.408 -2.568 0 N-CA-C 108.894 -0.78 . . . . 74.33 108.894 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 25.7 t -77.96 -33.62 18.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 108.171 -1.048 . . . . 75.32 108.171 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.01 -20.05 44.46 Favored Glycine 0 N--CA 1.439 -1.106 0 CA-C-N 114.982 -1.008 . . . . 72.11 111.325 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.423 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 100.06 18.66 21.53 Favored Glycine 0 C--O 1.221 -0.674 0 C-N-CA 120.611 -0.804 . . . . 53.33 112.342 178.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.1 m -131.04 117.54 19.29 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 108.802 -0.814 . . . . 72.51 108.802 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 59.8 m -96.38 152.68 18.37 Favored 'General case' 0 C--N 1.281 -2.405 0 CA-C-N 115.94 -0.573 . . . . 63.2 111.838 -177.211 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -91.71 -54.1 4.02 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.689 -0.687 . . . . 74.14 111.194 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.1 m -51.47 112.29 3.0 Favored Pre-proline 0 C--O 1.249 1.04 0 O-C-N 123.952 0.783 . . . . 65.31 111.329 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.39 113.57 2.32 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.172 1.915 . . . . 60.35 110.981 -178.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.84 -10.63 8.93 Favored Glycine 0 N--CA 1.42 -2.431 0 N-CA-C 110.738 -0.945 . . . . 62.52 110.738 -177.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.6 m -104.25 155.31 18.84 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.314 0.578 . . . . 72.53 109.911 176.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 p -137.55 160.21 39.79 Favored 'General case' 0 C--N 1.275 -2.647 0 CA-C-N 115.043 -0.98 . . . . 74.54 108.835 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.423 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 12.3 t -85.63 63.54 8.12 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.948 -1.131 . . . . 64.43 107.948 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.4 t -69.09 -36.33 77.46 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.432 -0.804 . . . . 54.42 110.573 -177.272 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -129.91 87.81 2.58 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 108.713 -0.847 . . . . 74.24 108.713 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -58.17 138.56 84.24 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 123.34 0.656 . . . . 75.33 109.742 -177.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -99.54 40.19 4.49 Favored 'Cis proline' 0 CA--C 1.54 0.792 0 C-N-CA 125.129 -0.78 . . . . 63.12 112.956 1.401 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.1 t -112.53 136.17 49.62 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.794 -0.566 . . . . 73.53 110.303 -179.145 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.496 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 72.0 m -88.03 139.85 30.1 Favored 'General case' 0 N--CA 1.408 -2.531 0 N-CA-C 107.558 -1.275 . . . . 65.4 107.558 174.858 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -138.34 165.18 27.39 Favored 'General case' 1 C--N 1.238 -4.272 0 CA-C-N 113.514 -1.676 . . . . 74.11 109.582 -171.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -88.53 -68.1 0.79 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.598 -0.841 . . . . 74.41 110.232 -175.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 C--N 1.289 -2.062 0 N-CA-C 104.925 -2.25 . . . . 72.55 104.925 177.496 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.512 0 N-CA-C 111.109 -0.796 . . . . 70.55 111.109 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 24.2 tp -132.07 117.09 15.81 Favored Pre-proline 0 N--CA 1.45 -0.445 0 N-CA-C 108.866 -0.79 . . . . 65.02 108.866 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 5.6 Cg_exo -72.34 78.45 1.93 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.583 2.189 . . . . 51.23 112.482 -178.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.3 m -128.77 17.87 2.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 115.456 -0.793 . . . . 61.35 110.413 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.4 m -85.36 -25.43 27.09 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.433 -0.803 . . . . 64.25 110.371 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.29 2.73 89.49 Favored Glycine 0 N--CA 1.428 -1.849 0 CA-C-N 114.686 -1.143 . . . . 71.41 111.945 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.1 pt-20 -119.53 179.37 4.23 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-O 121.632 0.729 . . . . 74.34 111.707 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.1 p -129.58 162.13 28.95 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.397 -1.274 . . . . 75.22 110.513 -175.123 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -131.91 88.04 2.51 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.567 -0.742 . . . . 54.42 109.208 179.416 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.7 t -74.21 -35.36 40.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.834 0.826 . . . . 75.23 109.293 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.04 -17.97 48.88 Favored Glycine 0 C--N 1.311 -0.846 0 CA-C-N 115.289 -0.869 . . . . 64.1 111.139 176.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.9 14.54 20.81 Favored Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.423 -0.894 . . . . 51.1 112.385 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.9 m -126.11 132.54 51.86 Favored 'General case' 0 N--CA 1.416 -2.147 0 N-CA-C 109.051 -0.722 . . . . 75.13 109.051 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.0 m -109.7 149.39 29.82 Favored 'General case' 0 C--N 1.273 -2.753 0 CA-C-N 114.924 -1.035 . . . . 70.31 109.581 178.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -89.83 -50.29 6.13 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.474 0.484 . . . . 75.01 112.137 -176.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.421 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 84.8 m -50.73 123.37 18.02 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 113.184 0.809 . . . . 60.22 113.184 -176.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.421 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.6 Cg_endo -59.72 113.76 1.77 Allowed 'Trans proline' 0 C--N 1.357 0.997 0 C-N-CA 123.096 2.53 . . . . 65.0 111.462 178.738 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.88 -1.46 24.4 Favored Glycine 0 N--CA 1.424 -2.133 0 CA-C-N 115.596 -0.729 . . . . 70.12 111.524 -178.129 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.89 156.09 20.85 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-O 121.58 0.705 . . . . 52.41 111.119 178.216 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.39 160.88 42.05 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 113.889 -1.505 . . . . 71.22 108.207 178.335 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.2 t -97.86 84.87 3.41 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.411 -0.588 . . . . 74.22 109.411 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 20.4 m -93.08 -26.69 17.36 Favored 'General case' 0 N--CA 1.408 -2.573 0 CA-C-N 116.001 -0.545 . . . . 71.53 111.131 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -123.21 70.93 1.04 Allowed 'General case' 0 CA--C 1.503 -0.831 0 CA-C-O 120.713 0.292 . . . . 71.2 110.293 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 87.8 t90 -52.47 134.34 43.77 Favored Pre-proline 0 C--N 1.318 -0.77 0 CA-C-N 115.319 -0.855 . . . . 73.24 110.407 -178.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 40.0 Cg_endo -99.38 34.2 8.53 Favored 'Cis proline' 0 CA--C 1.543 0.935 0 CA-C-N 119.259 0.771 . . . . 51.11 113.824 3.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.51 142.07 23.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 108.744 -0.836 . . . . 65.13 108.744 178.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.414 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.5 m -88.03 154.82 20.18 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.322 1.058 . . . . 72.43 110.585 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.62 161.83 31.78 Favored 'General case' 0 C--N 1.247 -3.854 0 CA-C-N 113.468 -1.697 . . . . 74.31 108.777 -176.727 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -88.44 -66.76 0.89 Allowed 'General case' 0 N--CA 1.409 -2.477 0 N-CA-C 107.963 -1.125 . . . . 75.32 107.963 177.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.4 t30 . . . . . 0 N--CA 1.416 -2.167 0 N-CA-C 105.469 -2.048 . . . . 63.23 105.469 179.016 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.318 0 N-CA-C 109.774 -1.331 . . . . 54.32 109.774 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.2 tp -113.23 116.69 46.48 Favored Pre-proline 0 C--O 1.24 0.577 0 N-CA-C 109.091 -0.707 . . . . 70.42 109.091 -178.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.97 81.48 1.66 Allowed 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.089 1.859 . . . . 63.2 112.542 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.9 m -133.08 22.56 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 114.913 -1.04 . . . . 72.43 109.412 177.684 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 72.1 m -92.02 -18.3 23.84 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 122.017 0.913 . . . . 75.53 109.963 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.43 -19.7 17.73 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-N 114.15 -1.386 . . . . 74.1 113.599 174.353 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -102.83 177.15 4.93 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-O 121.505 0.669 . . . . 63.5 111.767 -174.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -124.14 154.75 39.59 Favored 'General case' 0 N--CA 1.414 -2.253 0 CA-C-N 114.555 -1.202 . . . . 75.1 110.597 -177.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.2 p -123.77 87.32 2.72 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 123.776 0.83 . . . . 61.53 108.826 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.1 t -73.19 -35.21 46.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 109.108 -0.701 . . . . 75.13 109.108 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.45 -5.18 63.6 Favored Glycine 0 C--N 1.312 -0.801 0 N-CA-C 111.35 -0.7 . . . . 31.33 111.35 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.05 9.67 61.99 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.903 -0.665 . . . . 53.32 112.731 178.152 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.2 m -122.53 120.32 33.49 Favored 'General case' 0 N--CA 1.427 -1.598 0 N-CA-C 107.987 -1.116 . . . . 62.4 107.987 -176.418 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 66.1 m -92.7 151.83 19.85 Favored 'General case' 0 C--N 1.274 -2.715 0 CA-C-N 115.838 -0.619 . . . . 72.11 111.808 -177.532 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -80.69 -55.8 4.59 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.52 -0.764 . . . . 74.31 109.716 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.4 m -51.26 111.13 2.13 Favored Pre-proline 0 C--O 1.251 1.179 0 C-N-CA 124.215 1.006 . . . . 72.32 111.791 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -65.58 110.73 1.69 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 122.266 1.977 . . . . 74.3 109.474 177.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.87 -20.75 5.38 Favored Glycine 0 C--N 1.293 -1.855 0 N-CA-C 110.892 -0.883 . . . . 71.21 110.892 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.1 m -100.76 157.37 16.75 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 121.332 0.587 . . . . 54.44 109.894 177.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -139.0 161.76 36.58 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 114.822 -1.081 . . . . 73.3 109.339 -178.482 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.1 t -95.18 82.58 3.77 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.523 -0.547 . . . . 70.15 109.523 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.0 t -96.31 -13.73 23.1 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 116.377 -0.374 . . . . 73.42 110.463 -178.808 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 55.6 t-105 -136.2 79.04 1.75 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 108.621 -0.881 . . . . 71.33 108.621 177.285 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.1 t90 -58.25 136.89 84.91 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 115.322 -0.854 . . . . 71.33 110.375 -176.564 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -100.53 36.05 6.78 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.717 -0.951 . . . . 52.25 113.529 2.103 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -110.31 144.4 18.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 109.124 -0.695 . . . . 61.42 109.124 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.5 m -88.62 147.62 24.47 Favored 'General case' 0 N--CA 1.418 -2.07 0 CA-C-O 122.592 1.187 . . . . 65.14 111.168 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.6 p -127.4 156.19 42.45 Favored 'General case' 0 C--N 1.256 -3.474 0 CA-C-N 113.258 -1.792 . . . . 75.53 110.789 -173.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 21.1 tpt180 -89.75 -67.1 0.86 Allowed 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.824 0.821 . . . . 72.22 111.154 -176.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 N--CA 1.42 -1.954 0 N-CA-C 104.978 -2.231 . . . . 74.23 104.978 179.377 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.408 -3.172 0 N-CA-C 109.997 -1.241 . . . . 73.14 109.997 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.8 tp -127.0 118.68 22.17 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.065 -0.717 . . . . 61.23 109.065 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -74.59 78.47 2.74 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 122.198 1.932 . . . . 74.33 112.998 -178.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 m -129.86 16.21 2.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 CA-C-N 114.897 -1.047 . . . . 72.4 110.362 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 83.2 m -84.2 -25.48 29.48 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 121.614 0.721 . . . . 64.41 109.801 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.26 -12.51 60.31 Favored Glycine 0 N--CA 1.425 -2.08 0 CA-C-N 114.455 -1.248 . . . . 74.33 112.814 176.498 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -104.69 178.1 4.66 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.823 0.82 . . . . 64.24 111.09 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.7 p -132.99 154.64 50.31 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 114.65 -1.159 . . . . 74.45 109.764 -177.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.9 p -110.98 89.9 3.18 Favored 'General case' 0 N--CA 1.41 -2.461 0 N-CA-C 108.416 -0.957 . . . . 64.31 108.416 177.334 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.1 t -80.18 -33.61 14.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 70.51 108.312 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.08 -16.76 57.26 Favored Glycine 0 N--CA 1.44 -1.089 0 N-CA-C 110.761 -0.936 . . . . 64.11 110.761 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.31 13.3 31.21 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.872 -0.68 . . . . 42.23 113.254 176.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -136.2 128.4 29.9 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.009 -1.108 . . . . 72.1 108.009 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.9 m -92.14 148.67 21.99 Favored 'General case' 0 C--N 1.271 -2.828 0 CA-C-N 116.255 -0.429 . . . . 74.22 110.657 -178.619 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 46.3 t30 -84.82 -55.89 3.86 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.847 -0.615 . . . . 70.5 110.371 -178.045 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.7 m -51.27 114.62 5.14 Favored Pre-proline 0 CA--C 1.554 1.106 0 O-C-N 124.148 0.905 . . . . 65.33 111.89 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.69 116.07 3.31 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 122.398 2.066 . . . . 74.11 110.183 178.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 118.14 -4.95 15.84 Favored Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 110.64 -0.984 . . . . 62.34 110.64 -176.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -112.76 150.6 31.37 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.483 0.658 . . . . 62.13 110.695 176.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.3 p -134.23 150.93 51.07 Favored 'General case' 0 C--N 1.275 -2.635 0 CA-C-N 114.81 -1.086 . . . . 75.12 110.044 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.6 t -91.07 85.59 5.97 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.751 -1.203 . . . . 63.44 107.751 177.66 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.1 t -77.76 -51.71 10.1 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.413 -0.812 . . . . 65.43 109.7 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 8.9 p-90 -125.49 102.11 7.24 Favored 'General case' 0 N--CA 1.427 -1.598 0 CA-C-O 122.12 0.962 . . . . 74.23 110.652 177.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 76.4 t90 -58.82 140.18 86.23 Favored Pre-proline 0 C--N 1.302 -1.463 0 CA-C-N 113.678 -1.601 . . . . 72.51 109.255 -178.035 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.3 Cg_endo -102.15 36.44 5.95 Favored 'Cis proline' 0 CA--C 1.543 0.941 0 C-N-CA 124.703 -0.957 . . . . 71.34 114.189 3.299 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -118.41 143.91 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.235 -0.915 . . . . 74.14 110.787 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.6 m -89.12 162.33 16.02 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 121.878 0.847 . . . . 75.24 110.774 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.8 p -136.93 160.43 38.93 Favored 'General case' 0 C--N 1.276 -2.605 0 CA-C-N 114.49 -1.232 . . . . 74.31 109.072 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 25.8 tpt180 -89.1 -69.2 0.72 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-O 121.819 0.819 . . . . 63.14 109.743 -178.554 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 N--CA 1.41 -2.455 0 N-CA-C 105.177 -2.156 . . . . 72.11 105.177 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.399 -3.808 0 N-CA-C 109.49 -1.444 . . . . 71.41 109.49 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.468 ' HG ' HG13 ' A' ' 4' ' ' VAL . 34.9 tp -124.38 117.8 26.54 Favored Pre-proline 0 N--CA 1.443 -0.823 0 N-CA-C 109.162 -0.681 . . . . 75.42 109.162 -177.502 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -72.17 83.5 1.21 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 122.07 1.847 . . . . 73.12 111.863 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.468 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.1 m -132.4 20.41 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.12 -0.946 . . . . 70.32 109.891 178.406 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 81.0 m -90.05 -22.87 21.63 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.076 -0.966 . . . . 73.31 110.595 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 78.95 -4.92 59.98 Favored Glycine 0 C--N 1.3 -1.47 0 CA-C-N 114.881 -1.054 . . . . 63.33 113.71 176.634 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -116.57 175.54 5.52 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 120.214 -0.595 . . . . 65.3 110.484 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -127.43 148.14 50.29 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.488 -0.778 . . . . 53.2 110.475 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.468 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 6.2 p -113.23 87.94 2.72 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 109.482 -0.562 . . . . 63.21 109.482 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.3 t -79.74 -30.18 13.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.661 -0.866 . . . . 70.14 108.661 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.49 -15.75 58.03 Favored Glycine 0 N--CA 1.435 -1.375 0 CA-C-N 115.213 -0.903 . . . . 72.03 110.996 177.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.98 15.89 34.86 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.449 -0.882 . . . . 51.31 112.827 177.518 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.7 m -143.18 125.79 15.89 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.334 -0.987 . . . . 55.32 108.334 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 33.3 m -96.79 154.44 17.29 Favored 'General case' 0 C--N 1.274 -2.678 0 CA-C-N 115.755 -0.657 . . . . 52.13 110.846 -176.638 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -77.56 -53.2 7.88 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.901 -0.59 . . . . 73.51 110.451 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 33.5 m -50.99 113.09 3.44 Favored Pre-proline 0 C--O 1.253 1.268 0 C-N-CA 124.049 0.939 . . . . 72.23 112.945 -177.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.72 119.43 6.65 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.565 2.177 . . . . 73.15 109.614 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.55 -3.77 27.84 Favored Glycine 0 N--CA 1.426 -1.978 0 C-N-CA 120.622 -0.799 . . . . 61.24 111.505 -179.152 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.3 m -111.01 154.77 23.71 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.683 0.754 . . . . 74.45 110.639 175.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -137.83 161.02 37.7 Favored 'General case' 0 C--N 1.274 -2.676 0 CA-C-N 114.683 -1.144 . . . . 70.43 109.754 -178.304 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 17.6 t -95.68 83.23 3.71 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 121.178 0.514 . . . . 70.4 109.694 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 t -89.15 -51.48 5.56 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.242 -0.435 . . . . 74.03 109.976 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.1 t-105 -105.47 80.86 1.62 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 109.527 -0.546 . . . . 73.44 109.527 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.6 t90 -57.03 136.57 80.25 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.432 -0.804 . . . . 71.3 109.984 -177.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -100.09 35.31 7.41 Favored 'Cis proline' 0 CA--C 1.544 1.017 0 C-N-CA 124.686 -0.964 . . . . 75.31 113.715 1.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.1 142.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 108.824 -0.806 . . . . 62.03 108.824 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.1 m -88.3 153.18 21.41 Favored 'General case' 0 N--CA 1.424 -1.737 0 C-N-CA 119.422 -0.911 . . . . 74.1 110.236 179.488 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -132.02 155.42 48.06 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.106 -1.406 . . . . 61.52 110.291 -177.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -91.99 -68.79 0.77 Allowed 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.993 0.901 . . . . 72.0 111.153 -176.43 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p30 . . . . . 0 C--N 1.299 -1.596 0 N-CA-C 105.505 -2.035 . . . . 61.15 105.505 179.944 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.564 0 N-CA-C 111.219 -0.752 . . . . 73.53 111.219 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.1 tp -109.1 113.48 59.01 Favored Pre-proline 0 C--N 1.328 -0.362 0 C-N-CA 120.108 -0.637 . . . . 60.03 110.529 -175.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -73.52 81.01 1.88 Allowed 'Trans proline' 0 N--CA 1.444 -1.427 0 C-N-CA 121.497 1.465 . . . . 73.23 112.674 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.5 m -126.78 24.18 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 122.326 1.06 . . . . 74.3 109.877 175.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 37.2 m -84.57 -27.59 27.18 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 114.554 -1.203 . . . . 63.04 108.051 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.54 -7.77 64.01 Favored Glycine 0 N--CA 1.438 -1.211 0 CA-C-N 113.507 -1.679 . . . . 73.53 112.702 177.518 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -107.52 -177.2 3.28 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.225 0.536 . . . . 52.34 110.893 -177.353 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 p -135.36 164.2 28.3 Favored 'General case' 0 N--CA 1.421 -1.915 0 CA-C-N 114.465 -1.243 . . . . 72.34 108.781 -179.088 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -126.73 80.2 1.92 Allowed 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 116.538 -0.301 . . . . 61.01 110.677 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.1 t -77.56 -26.51 15.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 108.423 -0.955 . . . . 74.24 108.423 178.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.74 -7.64 68.51 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 110.447 -1.061 . . . . 74.04 110.447 176.298 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.99 10.54 69.06 Favored Glycine 0 C--O 1.218 -0.861 0 C-N-CA 121.375 -0.441 . . . . 73.44 112.212 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -127.72 123.77 36.2 Favored 'General case' 0 N--CA 1.419 -2.01 0 N-CA-C 108.243 -1.021 . . . . 74.3 108.243 -176.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.1 m -95.65 149.7 21.17 Favored 'General case' 0 C--N 1.277 -2.564 0 N-CA-C 109.483 -0.562 . . . . 73.43 109.483 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -90.19 -54.56 3.97 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 123.12 0.568 . . . . 65.44 111.698 -177.387 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.478 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.1 m -51.22 119.39 12.36 Favored Pre-proline 0 CA--C 1.562 1.441 0 O-C-N 123.838 0.711 . . . . 74.42 112.75 -178.386 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.27 118.57 5.46 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 123.089 2.526 . . . . 70.22 111.174 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.42 5.13 37.28 Favored Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 120.728 -0.749 . . . . 60.21 111.389 -179.06 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.478 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.5 m -103.88 159.64 15.48 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-O 121.528 0.68 . . . . 74.22 111.057 175.139 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 p -140.34 146.34 38.34 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 114.76 -1.109 . . . . 75.44 109.627 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.1 t -92.68 87.35 5.86 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.218 -1.401 . . . . 61.12 107.218 176.281 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 19.6 t -88.16 -70.23 0.65 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 109.262 -0.644 . . . . 74.11 109.262 -177.658 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.8 m-90 -91.0 87.36 6.58 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 108.301 -1.0 . . . . 75.2 108.301 177.463 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 90.3 t90 -54.82 135.6 65.5 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.378 -0.601 . . . . 64.03 109.378 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.4 Cg_endo -102.13 39.93 4.14 Favored 'Cis proline' 0 CA--C 1.545 1.072 0 CA-C-N 119.365 0.809 . . . . 61.32 113.212 2.69 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.0 t -107.02 130.43 59.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.92 -0.487 . . . . 65.42 109.829 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -88.9 152.26 21.84 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-O 121.998 0.904 . . . . 62.32 110.177 178.044 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.5 p -134.01 171.0 14.81 Favored 'General case' 0 C--N 1.266 -3.03 0 CA-C-N 113.946 -1.479 . . . . 64.03 108.236 -178.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 28.1 mmm180 -87.94 -78.96 0.3 Allowed 'General case' 0 N--CA 1.4 -2.935 0 N-CA-C 107.926 -1.138 . . . . 65.54 107.926 175.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 C--N 1.292 -1.906 0 N-CA-C 105.136 -2.172 . . . . 74.13 105.136 174.514 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.926 0 N-CA-C 108.772 -1.731 . . . . 61.23 108.772 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.0 tp -123.24 119.0 27.65 Favored Pre-proline 0 C--O 1.247 0.945 0 CA-C-N 115.043 -0.578 . . . . 73.52 109.837 -178.024 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -73.73 81.28 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.432 2.088 . . . . 74.22 112.552 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.88 20.4 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.204 -0.907 . . . . 75.52 109.405 177.518 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.5 m -89.48 -30.09 18.53 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.211 -0.904 . . . . 74.14 109.753 178.427 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.94 -1.56 88.34 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-N 114.739 -1.119 . . . . 42.34 112.724 178.062 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -119.84 179.79 4.14 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.339 0.59 . . . . 64.53 111.436 -178.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 p -128.18 168.2 15.75 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.908 -1.042 . . . . 62.22 110.318 -177.042 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.1 p -135.28 86.89 2.28 Favored 'General case' 0 N--CA 1.419 -1.977 0 N-CA-C 109.315 -0.624 . . . . 64.04 109.315 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -77.0 -33.06 20.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 108.649 -0.871 . . . . 75.4 108.649 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.64 -28.23 17.11 Favored Glycine 0 N--CA 1.436 -1.362 0 N-CA-C 110.456 -1.058 . . . . 73.01 110.456 175.188 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.68 12.51 11.44 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.558 -0.829 . . . . 65.24 112.552 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -118.93 116.56 26.72 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.663 -0.866 . . . . 72.34 108.663 -176.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 40.7 m -95.13 137.21 34.48 Favored 'General case' 0 C--N 1.274 -2.684 0 N-CA-C 109.393 -0.595 . . . . 61.21 109.393 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -76.99 -51.4 11.19 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.47 -0.332 . . . . 55.31 110.462 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 61.9 m -51.77 116.59 8.25 Favored Pre-proline 0 C--O 1.259 1.584 0 O-C-N 124.011 0.82 . . . . 73.53 112.326 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.1 118.41 5.31 Favored 'Trans proline' 0 N--CA 1.446 -1.311 0 C-N-CA 122.227 1.952 . . . . 62.44 109.686 177.303 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.34 -4.13 23.51 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 120.256 -0.973 . . . . 20.14 111.092 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 58.4 m -109.37 148.13 31.6 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 119.353 -0.939 . . . . 62.33 110.363 175.569 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.5 p -134.53 148.52 50.52 Favored 'General case' 0 C--N 1.257 -3.448 0 CA-C-N 114.12 -1.4 . . . . 74.34 109.259 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.1 t -85.31 75.35 10.27 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.159 -1.052 . . . . 72.15 108.159 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 16.8 m -73.23 -44.01 60.25 Favored 'General case' 0 N--CA 1.407 -2.59 0 CA-C-N 115.437 -0.801 . . . . 71.03 110.633 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 62.0 t90 -125.36 97.2 5.11 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.771 -0.826 . . . . 73.43 108.771 178.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.405 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.4 t90 -58.56 138.97 85.77 Favored Pre-proline 0 C--N 1.303 -1.449 0 CA-C-N 114.913 -1.039 . . . . 72.12 109.597 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 86.0 Cg_endo -102.49 36.75 5.63 Favored 'Cis proline' 0 CA--C 1.54 0.813 0 C-N-CA 124.948 -0.855 . . . . 71.23 113.41 1.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.4 t -113.25 138.96 40.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 121.9 -0.5 . . . . 63.52 110.104 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -88.35 151.51 22.55 Favored 'General case' 0 N--CA 1.417 -2.098 0 N-CA-C 108.735 -0.839 . . . . 64.42 108.735 177.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.2 p -137.64 160.89 37.94 Favored 'General case' 0 C--N 1.252 -3.665 0 CA-C-N 114.539 -1.209 . . . . 64.11 109.582 -177.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -90.93 -60.8 1.82 Allowed 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 121.46 0.647 . . . . 73.4 111.106 -177.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 N--CA 1.424 -1.749 0 N-CA-C 105.58 -2.007 . . . . 64.33 105.58 178.556 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.405 -3.4 0 N-CA-C 110.326 -1.11 . . . . 74.4 110.326 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HG ' HG13 ' A' ' 4' ' ' VAL . 47.5 tp -110.46 116.64 52.47 Favored Pre-proline 0 C--O 1.24 0.591 0 N-CA-C 109.437 -0.579 . . . . 62.11 109.437 -177.565 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -73.2 81.32 1.74 Allowed 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.227 1.951 . . . . 51.33 112.122 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.432 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.5 m -131.66 12.45 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.293 -0.867 . . . . 75.24 110.731 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 64.7 m -80.89 -35.88 32.0 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.848 0.833 . . . . 75.45 109.105 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.26 -0.64 88.73 Favored Glycine 0 N--CA 1.426 -1.987 0 CA-C-N 114.84 -1.073 . . . . 52.33 112.032 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.57 177.21 4.73 Favored 'General case' 0 C--O 1.255 1.377 0 CA-C-O 121.399 0.618 . . . . 63.04 110.848 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 p -130.8 168.2 17.63 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 114.596 -1.184 . . . . 70.13 110.945 -175.46 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -135.81 87.36 2.31 Favored 'General case' 0 N--CA 1.417 -2.124 0 CA-C-N 115.577 -0.738 . . . . 74.13 109.782 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.13 -30.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 N-CA-C 108.082 -1.081 . . . . 74.11 108.082 177.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.66 -6.65 69.98 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.117 -0.947 . . . . 64.5 111.421 177.853 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.02 24.72 40.07 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 120.679 -0.772 . . . . 50.13 112.921 176.251 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 31.7 m -147.06 127.56 14.09 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.942 -0.762 . . . . 73.14 108.942 177.481 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.58 152.39 18.57 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.826 -0.624 . . . . 75.53 110.463 -178.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -83.8 -57.71 3.1 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.114 -0.494 . . . . 74.31 111.241 -176.413 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.402 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 49.8 m -51.96 117.78 10.62 Favored Pre-proline 0 C--O 1.248 0.999 0 O-C-N 123.735 0.647 . . . . 62.54 112.312 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -62.76 111.45 1.36 Allowed 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.446 2.097 . . . . 71.11 109.557 176.725 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 126.11 -10.62 7.37 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 111.089 -0.804 . . . . 63.01 111.089 -176.608 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.402 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 67.5 m -100.44 154.94 18.12 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-O 121.576 0.703 . . . . 74.25 109.85 175.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 p -136.19 143.49 44.43 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-N 114.759 -1.109 . . . . 71.12 109.15 -178.316 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.0 t -90.96 84.39 5.76 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 106.665 -1.606 . . . . 74.0 106.665 176.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 17.9 t -104.73 -16.28 15.0 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.802 -0.635 . . . . 75.5 110.642 -175.523 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 84.6 m95 -133.99 72.0 1.46 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.12 -1.066 . . . . 65.34 108.12 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 82.2 t90 -54.95 135.47 66.77 Favored Pre-proline 0 C--O 1.244 0.787 0 CA-C-N 114.41 -1.268 . . . . 73.12 110.331 -174.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 45.0 Cg_endo -99.43 34.54 8.22 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 C-N-CA 124.662 -0.974 . . . . 71.43 113.756 3.389 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.9 t -107.23 139.21 29.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 121.905 -0.497 . . . . 70.32 109.808 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 94.8 m -88.83 154.62 20.11 Favored 'General case' 0 N--CA 1.416 -2.155 0 CA-C-O 122.137 0.97 . . . . 62.23 109.758 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.2 p -138.93 166.02 25.57 Favored 'General case' 0 C--N 1.257 -3.414 0 CA-C-N 114.129 -1.396 . . . . 73.44 107.957 -178.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -88.93 -70.59 0.64 Allowed 'General case' 0 N--CA 1.419 -2.005 0 C-N-CA 119.001 -1.08 . . . . 74.35 108.93 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 C--N 1.303 -1.455 0 N-CA-C 104.797 -2.297 . . . . 52.13 104.797 179.513 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -2.138 0 N-CA-C 109.503 -1.439 . . . . 64.14 109.503 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.528 ' HG ' HG13 ' A' ' 4' ' ' VAL . 55.8 tp -110.37 109.78 58.3 Favored Pre-proline 0 C--O 1.246 0.897 0 CA-C-N 114.868 -0.666 . . . . 71.44 109.224 -177.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -75.46 83.7 1.85 Allowed 'Trans proline' 0 N--CA 1.434 -1.977 0 C-N-CA 121.945 1.763 . . . . 75.0 111.179 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.528 HG13 ' HG ' ' A' ' 2' ' ' LEU . 8.4 m -123.01 19.96 4.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.39 -0.823 . . . . 75.42 110.044 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 57.4 m -108.1 -24.25 11.64 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-N 115.611 -0.722 . . . . 61.24 111.86 177.798 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.76 -15.52 14.37 Favored Glycine 0 C--O 1.246 0.869 0 CA-C-N 115.421 -0.809 . . . . 64.31 114.361 176.439 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.45 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 15.7 pt-20 -94.98 174.27 7.17 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.635 0.731 . . . . 63.43 111.531 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.0 p -125.9 161.32 27.72 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 114.765 -1.107 . . . . 74.4 109.95 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -122.2 90.73 3.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.804 -0.813 . . . . 71.22 108.804 178.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.53 -37.08 18.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.841 -0.8 . . . . 72.43 108.841 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.43 -14.88 59.43 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.555 -0.748 . . . . 50.14 111.348 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.03 20.25 16.79 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.447 -0.882 . . . . 70.43 113.453 176.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 59.0 m -141.95 127.54 19.04 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.981 -0.748 . . . . 75.53 108.981 177.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 33.9 m -100.17 162.68 12.81 Favored 'General case' 0 C--N 1.278 -2.528 0 CA-C-N 115.541 -0.754 . . . . 64.23 109.887 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -94.96 -49.57 5.49 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.559 -0.291 . . . . 72.11 110.446 -177.371 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.5 m -52.47 120.37 17.8 Favored Pre-proline 0 C--O 1.264 1.86 0 O-C-N 123.96 0.787 . . . . 65.43 112.347 -176.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -62.78 114.23 2.32 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.136 1.891 . . . . 65.01 109.664 177.019 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.84 -21.87 6.96 Favored Glycine 0 N--CA 1.428 -1.843 0 C-N-CA 120.456 -0.878 . . . . 72.13 112.112 -177.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -107.1 154.26 21.42 Favored 'General case' 0 CA--C 1.481 -1.69 0 CA-C-O 122.246 1.022 . . . . 70.14 112.812 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 p -139.39 167.58 21.76 Favored 'General case' 0 C--N 1.274 -2.688 0 CA-C-N 113.274 -1.785 . . . . 71.41 108.848 -178.314 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 9.6 t -90.64 64.71 5.78 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.882 -1.155 . . . . 62.34 107.882 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.2 m -65.07 -26.58 68.3 Favored 'General case' 0 N--CA 1.423 -1.798 0 CA-C-N 115.174 -0.921 . . . . 53.14 111.024 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -145.87 106.96 4.15 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.726 -1.213 . . . . 75.11 107.726 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.5 t90 -67.35 139.31 94.58 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 108.962 -0.755 . . . . 74.34 108.962 -177.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 43.2 Cg_endo -104.9 36.7 4.76 Favored 'Cis proline' 0 CA--C 1.537 0.656 0 C-N-CA 125.107 -0.789 . . . . 75.51 113.03 1.004 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.5 p -112.6 136.54 48.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-O 121.618 0.723 . . . . 72.44 111.404 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 65.1 m -88.59 138.44 31.43 Favored 'General case' 0 N--CA 1.409 -2.515 0 CA-C-O 122.482 1.134 . . . . 61.12 109.19 179.034 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -139.92 164.51 29.81 Favored 'General case' 1 C--N 1.243 -4.045 0 CA-C-N 113.2 -1.818 . . . . 63.51 109.304 -175.105 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -87.48 -66.36 0.92 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.59 -0.892 . . . . 74.31 108.59 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.8 p30 . . . . . 0 N--CA 1.426 -1.663 0 N-CA-C 105.139 -2.171 . . . . 62.03 105.139 175.87 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.938 0 N-CA-C 109.083 -1.607 . . . . 74.51 109.083 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.402 ' HG ' HG13 ' A' ' 4' ' ' VAL . 46.5 tp -104.28 115.11 63.58 Favored Pre-proline 0 C--O 1.245 0.844 0 N-CA-C 109.038 -0.727 . . . . 74.3 109.038 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -73.5 80.27 2.01 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.268 1.979 . . . . 75.31 112.606 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.402 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.0 m -131.66 8.96 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 115.744 -0.662 . . . . 55.13 110.781 178.366 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.1 m -91.84 -30.29 16.27 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-O 121.784 0.802 . . . . 75.44 109.461 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.71 -12.61 46.8 Favored Glycine 0 N--CA 1.427 -1.934 0 CA-C-N 114.521 -1.218 . . . . 54.34 113.953 176.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -100.49 172.4 7.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.094 -1.042 . . . . 63.02 111.802 -176.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 p -126.51 154.75 43.37 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 114.337 -1.301 . . . . 74.33 109.802 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.45 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 5.5 p -120.57 86.06 2.5 Favored 'General case' 0 N--CA 1.408 -2.54 0 N-CA-C 107.818 -1.178 . . . . 75.31 107.818 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 44.5 t -69.89 -33.6 56.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 N-CA-C 108.655 -0.868 . . . . 61.22 108.655 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.32 -32.15 7.56 Favored Glycine 0 N--CA 1.429 -1.792 0 CA-C-N 115.403 -0.817 . . . . 71.43 111.41 176.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 118.45 13.89 6.64 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.042 -1.075 . . . . 62.2 112.436 -178.276 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.0 m -126.08 112.04 15.38 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.213 -0.662 . . . . 64.04 109.213 -177.823 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.0 m -95.28 150.11 20.61 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.261 -0.881 . . . . 73.04 110.766 -176.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -90.84 -54.93 3.76 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 123.203 0.601 . . . . 72.15 111.065 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 57.5 m -50.19 117.97 8.5 Favored Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 113.169 0.803 . . . . 74.24 113.169 -176.042 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.9 123.01 12.71 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 123.249 2.633 . . . . 54.52 111.028 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.06 57.08 Favored Glycine 0 N--CA 1.427 -1.931 0 C-N-CA 120.733 -0.746 . . . . 42.51 112.148 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.9 m -100.77 155.26 18.01 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.291 -0.564 . . . . 62.45 109.644 177.77 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -140.85 155.43 46.34 Favored 'General case' 0 C--N 1.277 -2.575 0 CA-C-N 115.111 -0.95 . . . . 55.31 109.528 -174.529 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.415 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 24.5 t -84.78 79.6 9.56 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.409 -1.7 . . . . 71.44 106.409 175.168 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.449 ' HB3' ' OG1' ' A' ' 28' ' ' THR . 23.1 t -87.03 -28.36 22.65 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 115.036 -0.984 . . . . 42.43 110.389 -175.416 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.0 t-105 -135.94 85.46 2.16 Favored 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 107.95 -1.13 . . . . 75.44 107.95 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -58.45 135.84 85.58 Favored Pre-proline 0 C--N 1.307 -1.252 0 N-CA-C 109.396 -0.594 . . . . 73.1 109.396 -179.177 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -99.09 35.64 7.47 Favored 'Cis proline' 0 CA--C 1.553 1.445 0 N-CA-C 114.888 1.072 . . . . 71.31 114.888 5.132 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.6 t -112.81 135.51 52.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.607 -0.683 . . . . 75.23 109.669 179.166 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 63.4 m -88.96 146.7 24.73 Favored 'General case' 0 N--CA 1.415 -2.182 0 N-CA-C 106.721 -1.585 . . . . 63.11 106.721 174.719 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.449 ' OG1' ' HB3' ' A' ' 22' ' ' SER . 15.0 p -139.59 179.04 6.8 Favored 'General case' 0 C--N 1.248 -3.809 0 N-CA-C 108.286 -1.005 . . . . 64.13 108.286 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 20.0 tpt180 -88.49 -73.86 0.48 Allowed 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.77 -0.772 . . . . 70.24 109.513 -177.399 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.427 -1.583 0 N-CA-C 104.972 -2.233 . . . . 71.25 104.972 176.68 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.398 -3.885 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.414 ' HG ' HG13 ' A' ' 4' ' ' VAL . 24.8 tp -120.93 120.91 29.12 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -177.345 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -70.89 83.26 0.91 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.295 1.997 . . . . 0.0 111.804 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.414 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.0 m -130.61 11.02 2.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.483 179.507 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.1 m -80.56 -28.4 37.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.443 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.24 4.69 90.43 Favored Glycine 0 N--CA 1.427 -1.95 0 CA-C-N 114.93 -1.032 . . . . 0.0 112.009 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.28 -176.65 3.56 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.237 0.541 . . . . 0.0 110.204 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.7 p -133.23 160.33 37.57 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.124 -177.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.5 p -126.49 84.84 2.31 Favored 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.461 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.65 -31.3 41.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.18 5.09 55.61 Favored Glycine 0 N--CA 1.44 -1.081 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.795 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 81.44 11.93 82.6 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.198 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 m -116.64 110.72 18.87 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -178.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.7 m -89.54 146.5 24.55 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-O 120.981 0.42 . . . . 0.0 110.479 177.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -81.38 -62.14 1.74 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.255 -177.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.426 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.5 m -51.19 118.18 10.19 Favored Pre-proline 0 C--O 1.251 1.133 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -59.45 118.49 5.39 Favored 'Trans proline' 0 C--N 1.354 0.858 0 C-N-CA 122.887 2.391 . . . . 0.0 109.936 175.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.23 -12.12 14.32 Favored Glycine 0 C--N 1.293 -1.857 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 78.8 m -99.13 154.98 17.7 Favored 'General case' 0 N--CA 1.433 -1.314 0 CA-C-O 121.633 0.73 . . . . 0.0 110.082 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -141.55 153.26 44.74 Favored 'General case' 0 C--N 1.268 -2.958 0 C-N-CA 125.465 1.506 . . . . 0.0 107.697 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.483 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 31.0 t -96.69 83.91 3.54 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-O 121.38 0.61 . . . . 0.0 110.06 -179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.4 m -88.11 -51.78 5.6 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.017 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.5 m95 -102.03 75.27 1.51 Allowed 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.064 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 88.7 t90 -55.6 136.43 70.91 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.13 -178.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 18.0 Cg_endo -99.42 36.22 6.95 Favored 'Cis proline' 0 CA--C 1.541 0.85 0 C-N-CA 124.874 -0.886 . . . . 0.0 113.918 4.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.6 t -110.58 143.06 21.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.2 m -87.76 155.32 19.96 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-O 122.201 1.0 . . . . 0.0 110.5 -178.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.8 p -138.79 153.66 48.43 Favored 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.814 -1.539 . . . . 0.0 109.329 -174.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.9 tpp180 -89.82 -67.37 0.85 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.873 -0.731 . . . . 0.0 109.91 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 -177.026 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -3.001 0 N-CA-C 108.918 -1.673 . . . . 73.03 108.918 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -120.94 111.49 34.12 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.517 -1.29 . . . . 70.33 107.517 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.61 78.63 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 122.093 1.862 . . . . 54.32 113.604 -177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.01 27.84 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 122.381 1.086 . . . . 72.05 108.645 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.4 m -90.2 -21.79 22.0 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 114.129 -1.396 . . . . 55.54 110.468 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.87 -4.29 53.57 Favored Glycine 0 C--N 1.303 -1.298 0 CA-C-N 114.42 -1.263 . . . . 72.34 113.983 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.428 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.6 pt-20 -117.11 179.33 4.06 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 122.24 -0.565 . . . . 75.02 111.438 -178.713 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.3 p -124.21 157.36 34.98 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.359 -0.837 . . . . 63.21 110.979 -175.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -127.89 83.66 2.18 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.718 -0.475 . . . . 73.42 109.718 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.36 -35.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.481 -0.933 . . . . 54.1 108.481 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.8 -14.57 59.35 Favored Glycine 0 N--CA 1.435 -1.368 0 CA-C-N 115.237 -0.892 . . . . 54.42 110.977 177.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.27 32.9 7.97 Favored Glycine 0 N--CA 1.432 -1.594 0 C-N-CA 120.131 -1.033 . . . . 74.11 111.537 179.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -142.84 122.45 13.3 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-O 121.274 0.559 . . . . 73.11 109.777 177.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.3 m -104.06 145.38 30.26 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 115.057 -0.974 . . . . 61.42 110.572 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 38.3 m-80 -86.57 -49.87 7.23 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.522 0.729 . . . . 71.32 111.527 -176.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 65.4 m -50.27 116.2 6.33 Favored Pre-proline 0 C--O 1.249 1.072 0 O-C-N 124.039 0.837 . . . . 71.33 112.101 -178.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.81 118.87 5.71 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 123.365 2.71 . . . . 75.23 111.611 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.13 -3.23 33.33 Favored Glycine 0 N--CA 1.426 -1.977 0 CA-C-N 115.699 -0.682 . . . . 44.24 111.552 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.482 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 84.9 m -102.44 155.53 18.2 Favored 'General case' 0 N--CA 1.432 -1.351 0 CA-C-O 122.043 0.925 . . . . 73.32 111.582 178.066 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -140.5 156.8 46.22 Favored 'General case' 0 C--N 1.27 -2.863 0 CA-C-N 113.715 -1.584 . . . . 74.51 107.903 179.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.4 t -92.64 80.93 4.76 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.901 -0.778 . . . . 73.24 108.901 175.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.2 m -83.66 -39.92 19.61 Favored 'General case' 0 N--CA 1.405 -2.69 0 CA-C-N 115.779 -0.646 . . . . 65.55 111.221 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.528 ' CD1' HG21 ' A' ' 28' ' ' THR . 23.3 m95 -118.08 82.4 1.83 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.014 -0.735 . . . . 75.22 109.014 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.411 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.0 t90 -57.99 132.71 83.61 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.517 0.727 . . . . 74.43 110.752 -175.512 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 90.9 Cg_endo -104.97 41.73 2.95 Favored 'Cis proline' 0 CA--C 1.545 1.037 0 CA-C-N 119.157 0.735 . . . . 74.42 113.797 4.273 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.95 139.86 31.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.178 -1.045 . . . . 71.32 108.178 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.428 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 88.6 m -87.97 146.89 25.29 Favored 'General case' 0 CA--C 1.474 -1.948 0 CA-C-O 122.562 1.172 . . . . 62.14 110.55 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.528 HG21 ' CD1' ' A' ' 23' ' ' TRP . 15.5 p -135.19 157.69 46.26 Favored 'General case' 0 C--N 1.256 -3.487 0 CA-C-N 113.0 -1.909 . . . . 74.12 110.325 -171.044 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.482 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 27.0 mmm180 -88.87 -65.42 1.02 Allowed 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.866 0.841 . . . . 53.34 110.61 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 C--N 1.284 -2.251 0 N-CA-C 105.415 -2.068 . . . . 75.41 105.415 -177.976 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.397 -3.922 0 N-CA-C 108.749 -1.74 . . . . 43.22 108.749 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 tp -120.23 115.32 32.96 Favored Pre-proline 0 N--CA 1.442 -0.871 0 N-CA-C 107.844 -1.169 . . . . 71.32 107.844 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.34 81.38 1.5 Allowed 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.309 2.006 . . . . 65.23 112.442 -177.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 m -132.62 9.63 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 115.038 -0.983 . . . . 65.44 110.64 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.7 m -76.66 -22.7 53.67 Favored 'General case' 0 CA--C 1.491 -1.307 0 CA-C-O 121.473 0.654 . . . . 30.35 111.295 -177.442 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.96 -2.01 82.27 Favored Glycine 0 N--CA 1.422 -2.249 0 CA-C-N 114.713 -1.13 . . . . 63.44 112.939 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -122.51 177.71 5.3 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.548 -0.861 . . . . 72.41 111.121 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.1 p -124.76 154.36 41.02 Favored 'General case' 0 N--CA 1.422 -1.858 0 CA-C-N 114.513 -1.222 . . . . 60.3 110.656 -178.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -122.14 85.52 2.43 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 123.549 0.74 . . . . 43.15 109.162 178.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -72.12 -33.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-O 121.566 0.698 . . . . 73.42 109.338 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.28 -16.77 56.89 Favored Glycine 0 N--CA 1.438 -1.227 0 CA-C-N 115.384 -0.826 . . . . 61.42 111.636 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.444 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.31 15.27 23.83 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.075 -1.059 . . . . 74.21 112.907 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.4 m -137.31 124.46 21.68 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.938 -1.134 . . . . 71.43 107.938 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.98 149.35 21.89 Favored 'General case' 0 C--N 1.273 -2.717 0 CA-C-N 115.953 -0.567 . . . . 51.24 111.44 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -75.06 -54.04 7.85 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.596 -0.729 . . . . 64.15 109.646 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -51.71 111.52 2.49 Favored Pre-proline 0 C--O 1.256 1.41 0 C-N-CA 124.144 0.978 . . . . 43.55 112.241 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -62.87 118.06 4.96 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.385 2.057 . . . . 74.14 109.556 176.322 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.9 -11.31 13.52 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 111.363 -0.695 . . . . 40.24 111.363 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.5 m -102.39 155.64 18.12 Favored 'General case' 0 CA--C 1.499 -0.996 0 CA-C-O 122.244 1.021 . . . . 51.42 111.802 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.5 p -132.16 151.69 51.66 Favored 'General case' 0 N--CA 1.401 -2.905 0 CA-C-N 113.797 -1.547 . . . . 71.31 108.858 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.444 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 20.8 t -93.18 53.08 1.88 Allowed 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.858 0.837 . . . . 73.11 108.989 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 m -70.53 -22.81 62.57 Favored 'General case' 0 N--CA 1.414 -2.244 0 CA-C-N 115.587 -0.733 . . . . 63.14 111.938 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.9 t-105 -128.99 80.43 1.97 Allowed 'General case' 0 C--O 1.205 -1.278 0 N-CA-C 108.237 -1.023 . . . . 71.43 108.237 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 77.2 t90 -62.88 135.32 95.98 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 116.094 -0.503 . . . . 72.34 110.898 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 52.5 Cg_endo -102.31 36.4 5.91 Favored 'Cis proline' 0 C--N 1.354 0.851 0 C-N-CA 125.008 -0.83 . . . . 74.54 113.304 2.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.8 t -105.35 141.44 20.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 109.275 -0.639 . . . . 73.0 109.275 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 74.7 m -88.92 144.58 26.09 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-O 122.794 1.283 . . . . 44.14 111.029 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 p -129.74 155.05 46.55 Favored 'General case' 0 C--N 1.258 -3.371 0 CA-C-N 112.867 -1.97 . . . . 73.04 110.037 -173.037 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 -89.55 -66.42 0.92 Allowed 'General case' 0 N--CA 1.425 -1.706 0 CA-C-O 121.763 0.792 . . . . 63.23 109.878 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 105.388 -2.079 . . . . 74.54 105.388 -178.708 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.971 0 N-CA-C 109.961 -1.255 . . . . 72.14 109.961 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.0 tp -118.24 111.53 38.45 Favored Pre-proline 0 N--CA 1.439 -0.998 0 N-CA-C 108.279 -1.008 . . . . 73.0 108.279 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -74.96 79.11 2.73 Favored 'Trans proline' 0 N--CA 1.444 -1.41 0 C-N-CA 121.879 1.719 . . . . 64.24 112.675 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.88 22.65 2.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 CA-C-O 121.821 0.819 . . . . 74.32 109.662 176.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 52.2 m -85.12 -32.65 22.66 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.906 -1.146 . . . . 62.32 107.906 176.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.51 -2.58 87.04 Favored Glycine 0 N--CA 1.43 -1.759 0 CA-C-N 114.055 -1.43 . . . . 75.43 112.694 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -112.12 175.83 5.27 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.647 0.737 . . . . 60.13 111.624 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -127.32 158.64 36.7 Favored 'General case' 0 C--N 1.284 -2.273 0 CA-C-N 114.465 -1.243 . . . . 64.21 109.732 -177.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.1 p -119.64 96.6 5.26 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.37 -0.974 . . . . 65.32 108.37 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.8 t -80.0 -38.87 19.09 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 109.084 -0.71 . . . . 73.23 109.084 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.88 -10.69 61.15 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.402 -0.817 . . . . 53.13 111.149 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.491 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 99.56 13.73 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.522 -0.847 . . . . 72.23 112.573 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.6 m -127.66 128.78 46.07 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 107.925 -1.139 . . . . 75.31 107.925 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 36.1 m -104.48 159.38 15.79 Favored 'General case' 0 C--N 1.272 -2.779 0 CA-C-N 115.741 -0.663 . . . . 54.51 109.578 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -91.62 -58.07 2.55 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.386 -0.37 . . . . 74.14 110.519 -179.139 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.452 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 35.6 m -46.65 116.95 4.1 Favored Pre-proline 0 CA--C 1.545 0.771 0 O-C-N 124.374 1.046 . . . . 71.41 112.219 -175.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.93 117.09 3.73 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 123.257 2.638 . . . . 53.1 110.941 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.09 -2.51 31.46 Favored Glycine 0 N--CA 1.427 -1.936 0 CA-C-N 115.554 -0.748 . . . . 72.14 111.543 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.486 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 63.2 m -106.25 150.21 26.14 Favored 'General case' 0 CA--C 1.488 -1.435 0 CA-C-O 121.789 0.804 . . . . 72.25 110.113 176.186 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 p -136.72 152.46 50.38 Favored 'General case' 0 C--N 1.268 -2.973 0 CA-C-N 114.165 -1.38 . . . . 73.35 109.927 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.491 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 38.8 t -88.58 65.17 7.72 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.855 -1.165 . . . . 51.12 107.855 176.362 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.6 m -72.7 -29.39 63.34 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-N 114.489 -1.232 . . . . 72.23 110.798 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.3 t-105 -134.29 82.77 1.99 Allowed 'General case' 0 N--CA 1.433 -1.322 0 CA-C-O 121.179 0.514 . . . . 72.32 110.135 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.1 t90 -56.1 139.12 72.38 Favored Pre-proline 0 C--O 1.244 0.799 0 CA-C-N 115.245 -0.889 . . . . 65.04 109.875 -177.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -97.87 30.19 13.62 Favored 'Cis proline' 0 CA--C 1.538 0.711 0 C-N-CA 125.033 -0.82 . . . . 74.02 113.483 1.089 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 44.5 t -107.64 136.73 41.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 N-CA-C 109.558 -0.534 . . . . 62.22 109.558 -178.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.7 m -88.46 152.49 21.85 Favored 'General case' 0 N--CA 1.419 -1.996 0 C-N-CA 119.268 -0.973 . . . . 72.03 109.113 177.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -139.25 164.32 30.13 Favored 'General case' 0 C--N 1.264 -3.149 0 CA-C-N 114.742 -1.117 . . . . 74.12 109.016 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 24.3 mmm180 -88.14 -74.14 0.46 Allowed 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.775 0.798 . . . . 64.12 110.463 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 . . . . . 0 C--N 1.275 -2.631 0 N-CA-C 104.647 -2.353 . . . . 73.31 104.647 -179.42 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.415 -2.713 0 N-CA-C 109.68 -1.368 . . . . 74.32 109.68 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -121.06 112.92 33.04 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.514 -0.55 . . . . 75.13 109.514 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -71.79 81.56 1.33 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.3 2.0 . . . . 74.14 112.981 -179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m -133.24 15.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 114.982 -1.008 . . . . 75.14 110.187 177.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.2 m -88.73 -26.75 21.61 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.725 -0.67 . . . . 50.52 111.05 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.32 6.09 86.09 Favored Glycine 0 N--CA 1.427 -1.914 0 CA-C-N 114.875 -1.057 . . . . 74.33 112.987 177.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.3 pt-20 -120.09 173.97 6.77 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.249 -0.98 . . . . 72.22 111.557 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.8 p -124.45 153.71 41.56 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-N 114.191 -1.368 . . . . 71.42 110.001 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -123.26 85.12 2.37 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 123.54 0.736 . . . . 64.23 110.389 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.0 t -80.75 -23.87 11.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.89 0.852 . . . . 73.34 108.838 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -13.7 60.22 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.594 -1.002 . . . . 55.23 110.594 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.33 17.37 46.53 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.508 -0.853 . . . . 74.05 112.071 177.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 m -139.36 131.16 27.54 Favored 'General case' 0 N--CA 1.419 -2.005 0 N-CA-C 108.368 -0.975 . . . . 73.53 108.368 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.76 156.79 16.18 Favored 'General case' 0 C--N 1.275 -2.636 0 CA-C-N 115.853 -0.612 . . . . 72.41 109.5 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -94.42 -49.71 5.56 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 116.235 -0.439 . . . . 75.22 110.947 -176.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.524 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 13.2 m -51.27 118.27 10.47 Favored Pre-proline 0 C--O 1.246 0.919 0 C-N-CA 123.913 0.885 . . . . 52.25 111.169 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.99 118.18 4.99 Favored 'Trans proline' 0 C--N 1.354 0.855 0 C-N-CA 122.728 2.285 . . . . 60.44 110.529 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.32 -1.44 32.93 Favored Glycine 0 N--CA 1.427 -1.906 0 C-N-CA 120.963 -0.636 . . . . 44.23 111.993 -178.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.524 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.3 m -105.01 154.81 19.63 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.982 0.896 . . . . 63.31 112.067 178.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 p -137.8 153.52 49.65 Favored 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 125.126 1.37 . . . . 74.52 109.74 -176.292 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.9 t -97.13 87.22 4.14 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.316 -0.994 . . . . 55.31 108.316 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.1 t -81.65 -57.86 3.26 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.365 -0.605 . . . . 41.32 109.365 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -107.29 96.54 6.48 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 109.223 -0.658 . . . . 65.44 109.223 -178.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 75.7 t90 -63.93 138.23 97.34 Favored Pre-proline 0 C--N 1.296 -1.717 0 N-CA-C 109.233 -0.654 . . . . 74.15 109.233 -178.067 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 61.4 Cg_endo -102.63 37.84 5.03 Favored 'Cis proline' 0 CA--C 1.544 0.984 0 C-N-CA 124.464 -1.057 . . . . 74.24 114.018 1.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.5 p -108.97 143.6 18.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 O-C-N 121.516 -0.74 . . . . 70.22 110.059 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.6 m -88.5 160.75 17.36 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 122.288 1.042 . . . . 64.15 111.353 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.2 p -142.14 166.17 25.43 Favored 'General case' 0 C--N 1.267 -3.002 0 CA-C-N 113.613 -1.631 . . . . 72.21 108.154 -178.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 22.1 tpt180 -89.01 -70.93 0.62 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.736 -0.838 . . . . 73.12 108.736 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.417 -2.109 0 N-CA-C 104.775 -2.305 . . . . 72.43 104.775 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.417 -2.627 0 N-CA-C 109.219 -1.552 . . . . 50.42 109.219 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.6 tp -115.08 111.69 44.81 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 114.658 -0.771 . . . . 73.44 109.023 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.93 74.67 3.37 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 122.671 2.247 . . . . 54.32 113.678 -176.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -125.32 18.49 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 115.459 -0.792 . . . . 74.14 109.908 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.7 m -88.21 -22.26 24.09 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-O 121.996 0.903 . . . . 75.43 109.562 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.08 -15.79 19.95 Favored Glycine 0 N--CA 1.438 -1.197 0 CA-C-N 114.116 -1.402 . . . . 63.23 113.549 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -99.52 175.5 5.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 121.557 0.694 . . . . 73.35 110.733 -177.191 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.8 p -125.38 149.0 48.55 Favored 'General case' 0 N--CA 1.409 -2.482 0 CA-C-N 114.54 -1.209 . . . . 70.42 110.28 -178.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -116.76 93.11 4.07 Favored 'General case' 0 C--N 1.284 -2.244 0 N-CA-C 108.749 -0.834 . . . . 52.13 108.749 177.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 65.7 t -80.3 -35.22 15.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.158 -0.682 . . . . 74.14 109.158 179.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.52 -10.44 65.47 Favored Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.389 -1.085 . . . . 62.51 110.389 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 92.82 17.21 45.33 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.707 -0.759 . . . . 32.52 111.802 178.573 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 m -123.24 122.49 38.5 Favored 'General case' 0 N--CA 1.418 -2.049 0 N-CA-C 108.474 -0.935 . . . . 64.33 108.474 -178.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 67.6 m -99.38 141.2 32.48 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-N 115.836 -0.62 . . . . 71.01 111.89 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -83.07 -50.96 7.97 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.038 -0.983 . . . . 74.22 111.639 -176.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 53.4 m -52.29 118.56 12.76 Favored Pre-proline 0 C--O 1.254 1.318 0 C-N-CA 122.531 0.333 . . . . 73.22 111.74 176.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -67.38 114.0 3.1 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.163 1.908 . . . . 74.34 109.724 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 121.19 -7.28 10.7 Favored Glycine 0 N--CA 1.417 -2.618 0 C-N-CA 120.246 -0.978 . . . . 43.22 110.916 -176.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.2 m -108.77 153.27 23.71 Favored 'General case' 0 CA--C 1.495 -1.14 0 CA-C-O 121.433 0.635 . . . . 73.34 110.54 176.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.7 p -134.25 152.86 52.04 Favored 'General case' 0 N--CA 1.406 -2.634 0 CA-C-N 114.571 -1.195 . . . . 63.41 108.137 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.473 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 36.0 t -89.28 83.06 6.44 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.26 -1.015 . . . . 73.42 108.26 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.8 t -105.23 1.04 27.8 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.632 -0.713 . . . . 71.13 110.451 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.7 t-105 -147.57 63.88 1.14 Allowed 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.341 -0.985 . . . . 72.31 108.341 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.5 t90 -51.61 132.8 35.97 Favored Pre-proline 0 C--N 1.318 -0.797 0 CA-C-N 114.615 -1.175 . . . . 73.14 110.482 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 73.1 Cg_endo -101.24 34.22 7.75 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.662 -0.974 . . . . 73.42 113.64 4.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -109.89 142.02 23.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.866 -0.79 . . . . 73.34 108.866 179.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.9 m -88.26 147.23 24.92 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.711 1.243 . . . . 72.11 110.835 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -130.0 158.88 38.37 Favored 'General case' 0 C--N 1.26 -3.318 0 CA-C-N 112.889 -1.959 . . . . 50.33 109.733 -172.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -89.42 -66.93 0.87 Allowed 'General case' 0 N--CA 1.416 -2.149 0 C-N-CA 119.751 -0.78 . . . . 74.34 109.767 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 N--CA 1.426 -1.67 0 N-CA-C 105.541 -2.022 . . . . 72.23 105.541 -179.324 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.331 0 N-CA-C 109.937 -1.265 . . . . 64.21 109.937 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.9 tp -118.5 120.67 31.68 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.623 -0.51 . . . . 63.11 109.623 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -70.61 82.87 0.89 Allowed 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.127 1.885 . . . . 75.12 112.521 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.4 m -130.47 19.45 2.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-O 121.759 0.79 . . . . 63.23 109.391 176.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 79.4 m -93.0 -29.61 15.75 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 115.007 -0.997 . . . . 53.52 110.251 -178.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.87 3.43 73.98 Favored Glycine 0 N--CA 1.432 -1.593 0 CA-C-N 114.832 -1.076 . . . . 73.4 113.621 177.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -120.3 175.27 6.04 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.742 0.782 . . . . 75.15 111.254 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -128.88 155.45 45.24 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-N 114.427 -1.26 . . . . 43.54 109.759 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -125.64 85.81 2.45 Favored 'General case' 0 C--N 1.278 -2.529 0 CA-C-N 116.234 -0.439 . . . . 74.15 109.924 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 41.2 t -80.3 -25.25 11.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.291 -0.963 . . . . 74.32 109.005 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.95 -15.94 56.98 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 110.927 -0.869 . . . . 55.2 110.927 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.96 14.79 38.45 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.811 -0.709 . . . . 63.1 112.263 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.8 m -130.76 124.36 31.25 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.206 -0.665 . . . . 70.03 109.206 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.9 m -98.92 152.93 19.23 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 115.847 -0.615 . . . . 64.15 109.686 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -87.88 -55.96 3.54 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.595 -0.275 . . . . 72.14 111.18 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.403 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 19.9 m -50.97 112.15 2.77 Favored Pre-proline 0 CA--C 1.56 1.34 0 O-C-N 124.29 0.994 . . . . 60.44 112.728 -176.788 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -58.61 121.97 10.86 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 123.115 2.543 . . . . 72.42 110.512 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.75 -3.73 30.6 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 110.766 -0.934 . . . . 72.54 110.766 -177.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.403 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 86.0 m -104.81 159.17 16.0 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.539 0.685 . . . . 72.02 110.824 176.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.5 p -137.82 146.09 43.09 Favored 'General case' 0 C--N 1.28 -2.442 0 C-N-CA 124.924 1.289 . . . . 72.41 109.233 -176.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 49.2 t -91.44 77.2 5.81 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.26 -1.385 . . . . 43.0 107.26 174.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -90.28 -36.29 14.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.689 -0.687 . . . . 75.41 110.96 -175.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 92.6 m95 -120.34 76.03 1.15 Allowed 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.209 -0.663 . . . . 53.3 109.209 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 79.9 t90 -53.75 136.91 54.51 Favored Pre-proline 0 C--N 1.313 -1.008 0 CA-C-N 114.895 -1.048 . . . . 73.15 110.372 -175.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -97.24 32.85 10.39 Favored 'Cis proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.523 -1.032 . . . . 74.12 113.295 2.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.0 t -106.15 138.18 32.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 109.549 -0.537 . . . . 75.25 109.549 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.95 153.51 20.97 Favored 'General case' 0 N--CA 1.41 -2.438 0 CA-C-O 122.104 0.954 . . . . 73.55 109.225 177.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 5.2 p -133.08 165.5 24.6 Favored 'General case' 0 C--N 1.252 -3.633 0 CA-C-N 114.408 -1.269 . . . . 64.42 108.572 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpt180 -88.95 -76.63 0.4 Allowed 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 108.678 -0.86 . . . . 73.31 108.678 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.42 -1.928 0 N-CA-C 104.852 -2.277 . . . . 65.42 104.852 179.471 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.407 -3.244 0 N-CA-C 109.27 -1.532 . . . . 73.34 109.27 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 35.0 tp -123.86 121.35 26.48 Favored Pre-proline 0 N--CA 1.44 -0.942 0 N-CA-C 108.94 -0.763 . . . . 73.32 108.94 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.83 84.52 0.41 Allowed 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.624 2.216 . . . . 53.22 111.97 178.003 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 m -136.42 30.53 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 CA-C-N 114.997 -1.001 . . . . 54.02 108.48 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.2 m -101.19 -24.69 14.22 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 114.836 -1.075 . . . . 65.23 110.492 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.84 -14.06 33.58 Favored Glycine 0 C--N 1.305 -1.193 0 CA-C-N 114.959 -1.019 . . . . 61.43 113.754 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.401 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 10.6 pt-20 -110.68 -178.05 3.38 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 121.154 0.502 . . . . 74.34 110.887 -177.265 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 p -131.2 154.86 47.96 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.987 -1.006 . . . . 50.42 111.386 -176.049 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -121.66 88.25 2.9 Favored 'General case' 0 N--CA 1.416 -2.129 0 N-CA-C 108.874 -0.787 . . . . 74.54 108.874 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -74.43 -36.25 41.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.046 -0.724 . . . . 42.04 109.046 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 -22.72 35.55 Favored Glycine 0 N--CA 1.436 -1.35 0 CA-C-N 115.392 -0.822 . . . . 70.24 111.08 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.07 12.79 13.26 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.017 -1.087 . . . . 72.44 113.325 178.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 46.7 m -136.99 124.98 22.76 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.652 -0.87 . . . . 44.33 108.652 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 38.3 m -91.97 169.86 10.32 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 115.352 -0.84 . . . . 75.41 110.874 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -92.77 -52.56 4.56 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 123.315 0.646 . . . . 74.11 110.468 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.7 m -51.13 113.94 4.36 Favored Pre-proline 0 C--O 1.25 1.117 0 C-N-CA 123.947 0.899 . . . . 71.52 113.095 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -65.48 105.98 0.81 Allowed 'Trans proline' 0 C--N 1.359 1.1 0 C-N-CA 122.53 2.153 . . . . 62.42 109.629 176.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.95 5.33 Favored Glycine 0 N--CA 1.427 -1.913 0 N-CA-C 110.782 -0.927 . . . . 64.4 110.782 -177.294 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.3 m -102.13 162.01 13.24 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 121.609 0.719 . . . . 43.13 111.146 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -141.0 153.13 45.42 Favored 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 114.252 -1.34 . . . . 71.04 108.325 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.88 83.17 4.33 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.018 -1.105 . . . . 73.13 108.018 175.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 21.4 t -89.77 -49.26 6.74 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.911 -0.774 . . . . 73.43 108.911 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -107.5 80.7 1.43 Allowed 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.39 -0.596 . . . . 75.5 109.39 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 92.4 t90 -55.79 139.73 69.07 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.413 -0.812 . . . . 63.35 110.033 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 17.6 Cg_endo -99.95 32.32 9.91 Favored 'Cis proline' 0 CA--C 1.534 0.493 0 C-N-CA 124.935 -0.86 . . . . 72.02 113.121 1.032 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 55.8 t -104.91 142.54 17.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.993 -0.743 . . . . 70.24 108.993 -179.691 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.401 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 71.3 m -87.89 144.93 26.3 Favored 'General case' 0 N--CA 1.415 -2.2 0 CA-C-O 122.707 1.241 . . . . 73.43 110.417 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -128.28 152.04 48.59 Favored 'General case' 0 C--N 1.259 -3.365 0 CA-C-N 113.104 -1.862 . . . . 53.3 111.101 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -94.82 -55.86 2.97 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-O 121.765 0.793 . . . . 64.33 111.237 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.414 -2.225 0 N-CA-C 105.01 -2.218 . . . . 51.13 105.01 -179.161 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.409 -3.134 0 N-CA-C 109.744 -1.342 . . . . 70.42 109.744 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.0 tp -103.79 116.27 62.04 Favored Pre-proline 0 C--O 1.241 0.614 0 N-CA-C 108.808 -0.812 . . . . 74.21 108.808 179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -78.37 76.69 4.31 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.179 1.919 . . . . 64.25 112.304 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -128.1 18.54 2.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.905 -1.043 . . . . 73.12 109.775 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.1 m -87.82 -26.35 22.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 CA-C-N 115.236 -0.893 . . . . 71.33 109.951 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.93 -0.88 64.78 Favored Glycine 0 N--CA 1.438 -1.17 0 CA-C-N 114.619 -1.173 . . . . 53.42 113.557 176.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.479 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 11.3 pt-20 -112.93 175.52 5.4 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.242 -0.583 . . . . 72.14 110.27 178.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 p -128.41 154.71 45.75 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 115.055 -0.975 . . . . 73.52 110.752 -174.5 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.415 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 7.6 p -129.86 89.68 2.85 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 109.622 -0.51 . . . . 74.13 109.622 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -80.18 -31.25 13.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 108.707 -0.849 . . . . 73.23 108.707 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.4 -12.21 61.6 Favored Glycine 0 N--CA 1.439 -1.167 0 CA-C-N 115.424 -0.807 . . . . 64.22 111.315 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 93.14 19.48 36.02 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.478 -0.868 . . . . 63.34 112.609 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.9 m -135.85 119.66 17.32 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.1 -0.704 . . . . 61.3 109.1 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 56.4 m -99.13 167.51 10.65 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.312 -0.858 . . . . 65.55 110.955 -176.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -103.83 -49.28 3.69 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.648 0.379 . . . . 73.43 111.875 -178.043 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.8 m -51.29 114.17 4.68 Favored Pre-proline 0 C--O 1.257 1.465 0 N-CA-C 113.081 0.771 . . . . 44.3 113.081 -179.046 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -62.93 115.67 3.08 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.883 2.389 . . . . 64.43 109.571 175.458 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -10.42 11.5 Favored Glycine 0 C--N 1.298 -1.568 0 N-CA-C 110.94 -0.864 . . . . 73.54 110.94 -176.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.4 m -112.95 162.37 15.93 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.235 0.54 . . . . 62.3 110.545 176.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 p -145.35 160.93 40.79 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 124.933 1.293 . . . . 71.31 108.337 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.48 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 46.2 t -92.27 85.24 5.36 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.536 -0.913 . . . . 45.54 108.536 177.483 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -103.36 -31.17 10.17 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.828 -0.623 . . . . 70.31 110.124 -178.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.1 m95 -112.66 64.84 0.63 Allowed 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.186 0.517 . . . . 74.13 109.701 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 89.1 t90 -52.88 135.32 47.18 Favored Pre-proline 0 C--O 1.247 0.971 0 CA-C-N 114.567 -1.197 . . . . 72.44 110.498 -176.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 9.7 Cg_endo -96.3 33.35 9.94 Favored 'Cis proline' 0 CA--C 1.549 1.261 0 N-CA-C 114.518 0.93 . . . . 75.45 114.518 3.052 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 69.1 t -111.09 143.69 20.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 108.861 -0.792 . . . . 63.12 108.861 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.479 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 63.0 m -88.69 145.49 25.62 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-O 122.301 1.048 . . . . 72.42 109.345 178.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.4 p -129.5 165.03 22.47 Favored 'General case' 0 C--N 1.254 -3.546 0 CA-C-N 113.786 -1.552 . . . . 71.1 110.688 -174.485 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -88.22 -67.43 0.83 Allowed 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.897 -0.779 . . . . 73.12 108.897 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 . . . . . 0 N--CA 1.423 -1.816 0 N-CA-C 105.906 -1.887 . . . . 64.33 105.906 176.068 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.654 0 N-CA-C 110.596 -1.002 . . . . 72.13 110.596 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.5 tp -112.59 110.04 52.9 Favored Pre-proline 0 C--O 1.239 0.516 0 N-CA-C 109.704 -0.48 . . . . 70.21 109.704 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -72.86 79.32 1.98 Allowed 'Trans proline' 0 C--O 1.24 0.586 0 C-N-CA 122.421 2.081 . . . . 61.44 112.528 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.8 m -137.09 23.37 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.93 -1.032 . . . . 75.52 109.737 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.3 m -84.99 -21.68 29.39 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.56 -0.745 . . . . 74.33 110.839 -178.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.07 -0.24 79.94 Favored Glycine 0 C--N 1.294 -1.781 0 CA-C-N 114.794 -1.094 . . . . 75.33 113.678 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -121.62 177.92 5.04 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.278 -0.569 . . . . 71.54 109.639 177.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.3 p -130.91 158.85 39.1 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 116.051 -0.522 . . . . 62.04 110.675 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -129.72 88.77 2.72 Favored 'General case' 0 C--N 1.282 -2.351 0 C-N-CA 123.041 0.536 . . . . 74.41 109.665 -179.04 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.7 t -76.76 -31.74 19.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 119.955 -0.698 . . . . 73.31 109.351 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.68 -19.71 47.11 Favored Glycine 0 C--N 1.306 -1.084 0 N-CA-C 111.068 -0.813 . . . . 73.12 111.068 176.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.488 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.21 17.08 19.09 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.806 -0.711 . . . . 55.5 112.136 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.6 m -122.73 122.19 38.16 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 108.706 -0.85 . . . . 55.22 108.706 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 60.5 m -102.47 147.59 26.56 Favored 'General case' 0 C--N 1.274 -2.704 0 CA-C-N 115.746 -0.661 . . . . 62.42 110.198 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -90.99 -49.83 6.2 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.921 -0.581 . . . . 73.11 110.909 -178.045 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.2 m -50.73 113.26 3.52 Favored Pre-proline 0 C--O 1.25 1.119 0 O-C-N 123.987 0.804 . . . . 74.15 112.194 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.45 116.77 3.48 Favored 'Trans proline' 0 C--N 1.358 1.047 0 C-N-CA 123.19 2.593 . . . . 75.44 110.831 179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.86 -10.85 20.89 Favored Glycine 0 N--CA 1.424 -2.121 0 C-N-CA 120.3 -0.952 . . . . 53.12 112.214 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 80.4 m -103.97 156.82 17.55 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 121.636 0.731 . . . . 75.34 111.31 178.239 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.79 154.94 47.51 Favored 'General case' 0 C--N 1.271 -2.811 0 CA-C-N 114.465 -1.243 . . . . 74.22 108.89 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.488 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 t -91.47 87.45 6.41 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.923 -0.769 . . . . 72.54 108.923 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.3 t -96.84 -59.87 1.71 Allowed 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 116.137 -0.483 . . . . 73.13 109.711 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 64.2 t-105 -92.07 77.74 5.32 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.678 -0.86 . . . . 72.2 108.678 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -54.98 139.53 63.24 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 114.818 -1.083 . . . . 74.14 110.553 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -98.18 36.94 6.53 Favored 'Cis proline' 0 C--N 1.353 0.793 0 C-N-CA 124.663 -0.974 . . . . 64.1 112.56 1.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -109.47 142.32 22.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 108.588 -0.893 . . . . 74.45 108.588 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.0 m -87.96 150.4 23.48 Favored 'General case' 0 N--CA 1.416 -2.155 0 C-N-CA 119.355 -0.938 . . . . 53.25 109.34 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.1 p -128.66 160.72 31.58 Favored 'General case' 0 C--N 1.254 -3.548 0 CA-C-N 113.735 -1.575 . . . . 55.3 109.472 -176.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -88.73 -67.75 0.81 Allowed 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 121.872 0.844 . . . . 72.45 110.083 -177.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 104.726 -2.324 . . . . 55.54 104.726 178.548 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.345 0 N-CA-C 109.39 -1.484 . . . . 73.24 109.39 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 39.4 tp -104.69 120.68 49.48 Favored Pre-proline 0 C--O 1.248 1.023 0 N-CA-C 108.932 -0.766 . . . . 74.41 108.932 -177.171 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.71 80.76 2.28 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.255 1.97 . . . . 75.34 112.741 -178.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.04 22.37 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.803 -1.09 . . . . 73.21 109.029 177.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 78.5 m -100.46 -27.91 13.2 Favored 'General case' 0 N--CA 1.431 -1.375 0 CA-C-N 115.303 -0.862 . . . . 64.2 110.381 -178.07 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.83 -10.99 43.5 Favored Glycine 0 C--N 1.303 -1.3 0 CA-C-N 114.977 -1.01 . . . . 64.15 113.484 177.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -109.9 176.64 4.99 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.768 0.794 . . . . 72.42 110.942 -177.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.3 p -128.05 163.22 25.05 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 114.315 -1.311 . . . . 71.23 109.747 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 6.7 p -128.82 87.38 2.57 Favored 'General case' 0 N--CA 1.408 -2.568 0 N-CA-C 108.894 -0.78 . . . . 74.33 108.894 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 25.7 t -77.96 -33.62 18.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 108.171 -1.048 . . . . 75.32 108.171 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.01 -20.05 44.46 Favored Glycine 0 N--CA 1.439 -1.106 0 CA-C-N 114.982 -1.008 . . . . 72.11 111.325 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.423 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 100.06 18.66 21.53 Favored Glycine 0 C--O 1.221 -0.674 0 C-N-CA 120.611 -0.804 . . . . 53.33 112.342 178.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.1 m -131.04 117.54 19.29 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 108.802 -0.814 . . . . 72.51 108.802 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 59.8 m -96.38 152.68 18.37 Favored 'General case' 0 C--N 1.281 -2.405 0 CA-C-N 115.94 -0.573 . . . . 63.2 111.838 -177.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -91.71 -54.1 4.02 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.689 -0.687 . . . . 74.14 111.194 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.1 m -51.47 112.29 3.0 Favored Pre-proline 0 C--O 1.249 1.04 0 O-C-N 123.952 0.783 . . . . 65.31 111.329 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.39 113.57 2.32 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.172 1.915 . . . . 60.35 110.981 -178.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.84 -10.63 8.93 Favored Glycine 0 N--CA 1.42 -2.431 0 N-CA-C 110.738 -0.945 . . . . 62.52 110.738 -177.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.6 m -104.25 155.31 18.84 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.314 0.578 . . . . 72.53 109.911 176.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 p -137.55 160.21 39.79 Favored 'General case' 0 C--N 1.275 -2.647 0 CA-C-N 115.043 -0.98 . . . . 74.54 108.835 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.423 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 12.3 t -85.63 63.54 8.12 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.948 -1.131 . . . . 64.43 107.948 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.4 t -69.09 -36.33 77.46 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.432 -0.804 . . . . 54.42 110.573 -177.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -129.91 87.81 2.58 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 108.713 -0.847 . . . . 74.24 108.713 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -58.17 138.56 84.24 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 123.34 0.656 . . . . 75.33 109.742 -177.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -99.54 40.19 4.49 Favored 'Cis proline' 0 CA--C 1.54 0.792 0 C-N-CA 125.129 -0.78 . . . . 63.12 112.956 1.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.1 t -112.53 136.17 49.62 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.794 -0.566 . . . . 73.53 110.303 -179.145 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.496 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 72.0 m -88.03 139.85 30.1 Favored 'General case' 0 N--CA 1.408 -2.531 0 N-CA-C 107.558 -1.275 . . . . 65.4 107.558 174.858 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -138.34 165.18 27.39 Favored 'General case' 1 C--N 1.238 -4.272 0 CA-C-N 113.514 -1.676 . . . . 74.11 109.582 -171.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -88.53 -68.1 0.79 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.598 -0.841 . . . . 74.41 110.232 -175.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 C--N 1.289 -2.062 0 N-CA-C 104.925 -2.25 . . . . 72.55 104.925 177.496 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.512 0 N-CA-C 111.109 -0.796 . . . . 70.55 111.109 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 24.2 tp -132.07 117.09 15.81 Favored Pre-proline 0 N--CA 1.45 -0.445 0 N-CA-C 108.866 -0.79 . . . . 65.02 108.866 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 5.6 Cg_exo -72.34 78.45 1.93 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.583 2.189 . . . . 51.23 112.482 -178.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.3 m -128.77 17.87 2.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 115.456 -0.793 . . . . 61.35 110.413 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.4 m -85.36 -25.43 27.09 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.433 -0.803 . . . . 64.25 110.371 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.29 2.73 89.49 Favored Glycine 0 N--CA 1.428 -1.849 0 CA-C-N 114.686 -1.143 . . . . 71.41 111.945 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.1 pt-20 -119.53 179.37 4.23 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-O 121.632 0.729 . . . . 74.34 111.707 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.1 p -129.58 162.13 28.95 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.397 -1.274 . . . . 75.22 110.513 -175.123 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -131.91 88.04 2.51 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.567 -0.742 . . . . 54.42 109.208 179.416 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.7 t -74.21 -35.36 40.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.834 0.826 . . . . 75.23 109.293 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.04 -17.97 48.88 Favored Glycine 0 C--N 1.311 -0.846 0 CA-C-N 115.289 -0.869 . . . . 64.1 111.139 176.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.9 14.54 20.81 Favored Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.423 -0.894 . . . . 51.1 112.385 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.9 m -126.11 132.54 51.86 Favored 'General case' 0 N--CA 1.416 -2.147 0 N-CA-C 109.051 -0.722 . . . . 75.13 109.051 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.0 m -109.7 149.39 29.82 Favored 'General case' 0 C--N 1.273 -2.753 0 CA-C-N 114.924 -1.035 . . . . 70.31 109.581 178.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -89.83 -50.29 6.13 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.474 0.484 . . . . 75.01 112.137 -176.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.421 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 84.8 m -50.73 123.37 18.02 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 113.184 0.809 . . . . 60.22 113.184 -176.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.421 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.6 Cg_endo -59.72 113.76 1.77 Allowed 'Trans proline' 0 C--N 1.357 0.997 0 C-N-CA 123.096 2.53 . . . . 65.0 111.462 178.738 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.88 -1.46 24.4 Favored Glycine 0 N--CA 1.424 -2.133 0 CA-C-N 115.596 -0.729 . . . . 70.12 111.524 -178.129 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.89 156.09 20.85 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-O 121.58 0.705 . . . . 52.41 111.119 178.216 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.39 160.88 42.05 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 113.889 -1.505 . . . . 71.22 108.207 178.335 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.2 t -97.86 84.87 3.41 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.411 -0.588 . . . . 74.22 109.411 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 20.4 m -93.08 -26.69 17.36 Favored 'General case' 0 N--CA 1.408 -2.573 0 CA-C-N 116.001 -0.545 . . . . 71.53 111.131 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -123.21 70.93 1.04 Allowed 'General case' 0 CA--C 1.503 -0.831 0 CA-C-O 120.713 0.292 . . . . 71.2 110.293 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 87.8 t90 -52.47 134.34 43.77 Favored Pre-proline 0 C--N 1.318 -0.77 0 CA-C-N 115.319 -0.855 . . . . 73.24 110.407 -178.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 40.0 Cg_endo -99.38 34.2 8.53 Favored 'Cis proline' 0 CA--C 1.543 0.935 0 CA-C-N 119.259 0.771 . . . . 51.11 113.824 3.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.51 142.07 23.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 108.744 -0.836 . . . . 65.13 108.744 178.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.414 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.5 m -88.03 154.82 20.18 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.322 1.058 . . . . 72.43 110.585 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.62 161.83 31.78 Favored 'General case' 0 C--N 1.247 -3.854 0 CA-C-N 113.468 -1.697 . . . . 74.31 108.777 -176.727 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -88.44 -66.76 0.89 Allowed 'General case' 0 N--CA 1.409 -2.477 0 N-CA-C 107.963 -1.125 . . . . 75.32 107.963 177.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.4 t30 . . . . . 0 N--CA 1.416 -2.167 0 N-CA-C 105.469 -2.048 . . . . 63.23 105.469 179.016 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.318 0 N-CA-C 109.774 -1.331 . . . . 54.32 109.774 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.2 tp -113.23 116.69 46.48 Favored Pre-proline 0 C--O 1.24 0.577 0 N-CA-C 109.091 -0.707 . . . . 70.42 109.091 -178.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.97 81.48 1.66 Allowed 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.089 1.859 . . . . 63.2 112.542 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.9 m -133.08 22.56 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 114.913 -1.04 . . . . 72.43 109.412 177.684 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 72.1 m -92.02 -18.3 23.84 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 122.017 0.913 . . . . 75.53 109.963 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.43 -19.7 17.73 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-N 114.15 -1.386 . . . . 74.1 113.599 174.353 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -102.83 177.15 4.93 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-O 121.505 0.669 . . . . 63.5 111.767 -174.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -124.14 154.75 39.59 Favored 'General case' 0 N--CA 1.414 -2.253 0 CA-C-N 114.555 -1.202 . . . . 75.1 110.597 -177.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.2 p -123.77 87.32 2.72 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 123.776 0.83 . . . . 61.53 108.826 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.1 t -73.19 -35.21 46.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 109.108 -0.701 . . . . 75.13 109.108 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.45 -5.18 63.6 Favored Glycine 0 C--N 1.312 -0.801 0 N-CA-C 111.35 -0.7 . . . . 31.33 111.35 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.05 9.67 61.99 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.903 -0.665 . . . . 53.32 112.731 178.152 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.2 m -122.53 120.32 33.49 Favored 'General case' 0 N--CA 1.427 -1.598 0 N-CA-C 107.987 -1.116 . . . . 62.4 107.987 -176.418 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 66.1 m -92.7 151.83 19.85 Favored 'General case' 0 C--N 1.274 -2.715 0 CA-C-N 115.838 -0.619 . . . . 72.11 111.808 -177.532 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -80.69 -55.8 4.59 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.52 -0.764 . . . . 74.31 109.716 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.4 m -51.26 111.13 2.13 Favored Pre-proline 0 C--O 1.251 1.179 0 C-N-CA 124.215 1.006 . . . . 72.32 111.791 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -65.58 110.73 1.69 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 122.266 1.977 . . . . 74.3 109.474 177.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.87 -20.75 5.38 Favored Glycine 0 C--N 1.293 -1.855 0 N-CA-C 110.892 -0.883 . . . . 71.21 110.892 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.1 m -100.76 157.37 16.75 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 121.332 0.587 . . . . 54.44 109.894 177.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -139.0 161.76 36.58 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 114.822 -1.081 . . . . 73.3 109.339 -178.482 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.1 t -95.18 82.58 3.77 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.523 -0.547 . . . . 70.15 109.523 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.0 t -96.31 -13.73 23.1 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 116.377 -0.374 . . . . 73.42 110.463 -178.808 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 55.6 t-105 -136.2 79.04 1.75 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 108.621 -0.881 . . . . 71.33 108.621 177.285 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.1 t90 -58.25 136.89 84.91 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 115.322 -0.854 . . . . 71.33 110.375 -176.564 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -100.53 36.05 6.78 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.717 -0.951 . . . . 52.25 113.529 2.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -110.31 144.4 18.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 109.124 -0.695 . . . . 61.42 109.124 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.5 m -88.62 147.62 24.47 Favored 'General case' 0 N--CA 1.418 -2.07 0 CA-C-O 122.592 1.187 . . . . 65.14 111.168 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.6 p -127.4 156.19 42.45 Favored 'General case' 0 C--N 1.256 -3.474 0 CA-C-N 113.258 -1.792 . . . . 75.53 110.789 -173.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 21.1 tpt180 -89.75 -67.1 0.86 Allowed 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.824 0.821 . . . . 72.22 111.154 -176.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 N--CA 1.42 -1.954 0 N-CA-C 104.978 -2.231 . . . . 74.23 104.978 179.377 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.408 -3.172 0 N-CA-C 109.997 -1.241 . . . . 73.14 109.997 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.8 tp -127.0 118.68 22.17 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.065 -0.717 . . . . 61.23 109.065 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -74.59 78.47 2.74 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 122.198 1.932 . . . . 74.33 112.998 -178.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 m -129.86 16.21 2.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 CA-C-N 114.897 -1.047 . . . . 72.4 110.362 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 83.2 m -84.2 -25.48 29.48 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 121.614 0.721 . . . . 64.41 109.801 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.26 -12.51 60.31 Favored Glycine 0 N--CA 1.425 -2.08 0 CA-C-N 114.455 -1.248 . . . . 74.33 112.814 176.498 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -104.69 178.1 4.66 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.823 0.82 . . . . 64.24 111.09 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.7 p -132.99 154.64 50.31 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 114.65 -1.159 . . . . 74.45 109.764 -177.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.9 p -110.98 89.9 3.18 Favored 'General case' 0 N--CA 1.41 -2.461 0 N-CA-C 108.416 -0.957 . . . . 64.31 108.416 177.334 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.1 t -80.18 -33.61 14.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 70.51 108.312 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.08 -16.76 57.26 Favored Glycine 0 N--CA 1.44 -1.089 0 N-CA-C 110.761 -0.936 . . . . 64.11 110.761 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.31 13.3 31.21 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.872 -0.68 . . . . 42.23 113.254 176.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -136.2 128.4 29.9 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.009 -1.108 . . . . 72.1 108.009 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.9 m -92.14 148.67 21.99 Favored 'General case' 0 C--N 1.271 -2.828 0 CA-C-N 116.255 -0.429 . . . . 74.22 110.657 -178.619 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 46.3 t30 -84.82 -55.89 3.86 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.847 -0.615 . . . . 70.5 110.371 -178.045 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.7 m -51.27 114.62 5.14 Favored Pre-proline 0 CA--C 1.554 1.106 0 O-C-N 124.148 0.905 . . . . 65.33 111.89 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.69 116.07 3.31 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 122.398 2.066 . . . . 74.11 110.183 178.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 118.14 -4.95 15.84 Favored Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 110.64 -0.984 . . . . 62.34 110.64 -176.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -112.76 150.6 31.37 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.483 0.658 . . . . 62.13 110.695 176.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.3 p -134.23 150.93 51.07 Favored 'General case' 0 C--N 1.275 -2.635 0 CA-C-N 114.81 -1.086 . . . . 75.12 110.044 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.6 t -91.07 85.59 5.97 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.751 -1.203 . . . . 63.44 107.751 177.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.1 t -77.76 -51.71 10.1 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.413 -0.812 . . . . 65.43 109.7 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 8.9 p-90 -125.49 102.11 7.24 Favored 'General case' 0 N--CA 1.427 -1.598 0 CA-C-O 122.12 0.962 . . . . 74.23 110.652 177.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 76.4 t90 -58.82 140.18 86.23 Favored Pre-proline 0 C--N 1.302 -1.463 0 CA-C-N 113.678 -1.601 . . . . 72.51 109.255 -178.035 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.3 Cg_endo -102.15 36.44 5.95 Favored 'Cis proline' 0 CA--C 1.543 0.941 0 C-N-CA 124.703 -0.957 . . . . 71.34 114.189 3.299 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -118.41 143.91 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.235 -0.915 . . . . 74.14 110.787 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.6 m -89.12 162.33 16.02 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 121.878 0.847 . . . . 75.24 110.774 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.8 p -136.93 160.43 38.93 Favored 'General case' 0 C--N 1.276 -2.605 0 CA-C-N 114.49 -1.232 . . . . 74.31 109.072 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 25.8 tpt180 -89.1 -69.2 0.72 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-O 121.819 0.819 . . . . 63.14 109.743 -178.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 N--CA 1.41 -2.455 0 N-CA-C 105.177 -2.156 . . . . 72.11 105.177 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.399 -3.808 0 N-CA-C 109.49 -1.444 . . . . 71.41 109.49 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.468 ' HG ' HG13 ' A' ' 4' ' ' VAL . 34.9 tp -124.38 117.8 26.54 Favored Pre-proline 0 N--CA 1.443 -0.823 0 N-CA-C 109.162 -0.681 . . . . 75.42 109.162 -177.502 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -72.17 83.5 1.21 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 122.07 1.847 . . . . 73.12 111.863 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.468 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.1 m -132.4 20.41 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.12 -0.946 . . . . 70.32 109.891 178.406 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 81.0 m -90.05 -22.87 21.63 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.076 -0.966 . . . . 73.31 110.595 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 78.95 -4.92 59.98 Favored Glycine 0 C--N 1.3 -1.47 0 CA-C-N 114.881 -1.054 . . . . 63.33 113.71 176.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -116.57 175.54 5.52 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 120.214 -0.595 . . . . 65.3 110.484 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -127.43 148.14 50.29 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.488 -0.778 . . . . 53.2 110.475 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.468 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 6.2 p -113.23 87.94 2.72 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 109.482 -0.562 . . . . 63.21 109.482 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.3 t -79.74 -30.18 13.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.661 -0.866 . . . . 70.14 108.661 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.49 -15.75 58.03 Favored Glycine 0 N--CA 1.435 -1.375 0 CA-C-N 115.213 -0.903 . . . . 72.03 110.996 177.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.98 15.89 34.86 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.449 -0.882 . . . . 51.31 112.827 177.518 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.7 m -143.18 125.79 15.89 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.334 -0.987 . . . . 55.32 108.334 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 33.3 m -96.79 154.44 17.29 Favored 'General case' 0 C--N 1.274 -2.678 0 CA-C-N 115.755 -0.657 . . . . 52.13 110.846 -176.638 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -77.56 -53.2 7.88 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.901 -0.59 . . . . 73.51 110.451 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 33.5 m -50.99 113.09 3.44 Favored Pre-proline 0 C--O 1.253 1.268 0 C-N-CA 124.049 0.939 . . . . 72.23 112.945 -177.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.72 119.43 6.65 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.565 2.177 . . . . 73.15 109.614 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.55 -3.77 27.84 Favored Glycine 0 N--CA 1.426 -1.978 0 C-N-CA 120.622 -0.799 . . . . 61.24 111.505 -179.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.3 m -111.01 154.77 23.71 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.683 0.754 . . . . 74.45 110.639 175.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -137.83 161.02 37.7 Favored 'General case' 0 C--N 1.274 -2.676 0 CA-C-N 114.683 -1.144 . . . . 70.43 109.754 -178.304 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 17.6 t -95.68 83.23 3.71 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 121.178 0.514 . . . . 70.4 109.694 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 t -89.15 -51.48 5.56 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.242 -0.435 . . . . 74.03 109.976 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.1 t-105 -105.47 80.86 1.62 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 109.527 -0.546 . . . . 73.44 109.527 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.6 t90 -57.03 136.57 80.25 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.432 -0.804 . . . . 71.3 109.984 -177.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -100.09 35.31 7.41 Favored 'Cis proline' 0 CA--C 1.544 1.017 0 C-N-CA 124.686 -0.964 . . . . 75.31 113.715 1.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.1 142.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 108.824 -0.806 . . . . 62.03 108.824 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.1 m -88.3 153.18 21.41 Favored 'General case' 0 N--CA 1.424 -1.737 0 C-N-CA 119.422 -0.911 . . . . 74.1 110.236 179.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -132.02 155.42 48.06 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.106 -1.406 . . . . 61.52 110.291 -177.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -91.99 -68.79 0.77 Allowed 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.993 0.901 . . . . 72.0 111.153 -176.43 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p30 . . . . . 0 C--N 1.299 -1.596 0 N-CA-C 105.505 -2.035 . . . . 61.15 105.505 179.944 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.564 0 N-CA-C 111.219 -0.752 . . . . 73.53 111.219 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.1 tp -109.1 113.48 59.01 Favored Pre-proline 0 C--N 1.328 -0.362 0 C-N-CA 120.108 -0.637 . . . . 60.03 110.529 -175.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -73.52 81.01 1.88 Allowed 'Trans proline' 0 N--CA 1.444 -1.427 0 C-N-CA 121.497 1.465 . . . . 73.23 112.674 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.5 m -126.78 24.18 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 122.326 1.06 . . . . 74.3 109.877 175.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 37.2 m -84.57 -27.59 27.18 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 114.554 -1.203 . . . . 63.04 108.051 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.54 -7.77 64.01 Favored Glycine 0 N--CA 1.438 -1.211 0 CA-C-N 113.507 -1.679 . . . . 73.53 112.702 177.518 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -107.52 -177.2 3.28 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.225 0.536 . . . . 52.34 110.893 -177.353 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 p -135.36 164.2 28.3 Favored 'General case' 0 N--CA 1.421 -1.915 0 CA-C-N 114.465 -1.243 . . . . 72.34 108.781 -179.088 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -126.73 80.2 1.92 Allowed 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 116.538 -0.301 . . . . 61.01 110.677 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.1 t -77.56 -26.51 15.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 108.423 -0.955 . . . . 74.24 108.423 178.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.74 -7.64 68.51 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 110.447 -1.061 . . . . 74.04 110.447 176.298 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.99 10.54 69.06 Favored Glycine 0 C--O 1.218 -0.861 0 C-N-CA 121.375 -0.441 . . . . 73.44 112.212 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -127.72 123.77 36.2 Favored 'General case' 0 N--CA 1.419 -2.01 0 N-CA-C 108.243 -1.021 . . . . 74.3 108.243 -176.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.1 m -95.65 149.7 21.17 Favored 'General case' 0 C--N 1.277 -2.564 0 N-CA-C 109.483 -0.562 . . . . 73.43 109.483 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -90.19 -54.56 3.97 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 123.12 0.568 . . . . 65.44 111.698 -177.387 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.478 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.1 m -51.22 119.39 12.36 Favored Pre-proline 0 CA--C 1.562 1.441 0 O-C-N 123.838 0.711 . . . . 74.42 112.75 -178.386 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.27 118.57 5.46 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 123.089 2.526 . . . . 70.22 111.174 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.42 5.13 37.28 Favored Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 120.728 -0.749 . . . . 60.21 111.389 -179.06 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.478 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.5 m -103.88 159.64 15.48 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-O 121.528 0.68 . . . . 74.22 111.057 175.139 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 p -140.34 146.34 38.34 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 114.76 -1.109 . . . . 75.44 109.627 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.1 t -92.68 87.35 5.86 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.218 -1.401 . . . . 61.12 107.218 176.281 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 19.6 t -88.16 -70.23 0.65 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 109.262 -0.644 . . . . 74.11 109.262 -177.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.8 m-90 -91.0 87.36 6.58 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 108.301 -1.0 . . . . 75.2 108.301 177.463 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 90.3 t90 -54.82 135.6 65.5 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.378 -0.601 . . . . 64.03 109.378 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.4 Cg_endo -102.13 39.93 4.14 Favored 'Cis proline' 0 CA--C 1.545 1.072 0 CA-C-N 119.365 0.809 . . . . 61.32 113.212 2.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.0 t -107.02 130.43 59.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.92 -0.487 . . . . 65.42 109.829 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -88.9 152.26 21.84 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-O 121.998 0.904 . . . . 62.32 110.177 178.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.5 p -134.01 171.0 14.81 Favored 'General case' 0 C--N 1.266 -3.03 0 CA-C-N 113.946 -1.479 . . . . 64.03 108.236 -178.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 28.1 mmm180 -87.94 -78.96 0.3 Allowed 'General case' 0 N--CA 1.4 -2.935 0 N-CA-C 107.926 -1.138 . . . . 65.54 107.926 175.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 C--N 1.292 -1.906 0 N-CA-C 105.136 -2.172 . . . . 74.13 105.136 174.514 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.926 0 N-CA-C 108.772 -1.731 . . . . 61.23 108.772 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.0 tp -123.24 119.0 27.65 Favored Pre-proline 0 C--O 1.247 0.945 0 CA-C-N 115.043 -0.578 . . . . 73.52 109.837 -178.024 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -73.73 81.28 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.432 2.088 . . . . 74.22 112.552 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.88 20.4 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.204 -0.907 . . . . 75.52 109.405 177.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.5 m -89.48 -30.09 18.53 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.211 -0.904 . . . . 74.14 109.753 178.427 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.94 -1.56 88.34 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-N 114.739 -1.119 . . . . 42.34 112.724 178.062 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -119.84 179.79 4.14 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.339 0.59 . . . . 64.53 111.436 -178.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 p -128.18 168.2 15.75 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.908 -1.042 . . . . 62.22 110.318 -177.042 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.1 p -135.28 86.89 2.28 Favored 'General case' 0 N--CA 1.419 -1.977 0 N-CA-C 109.315 -0.624 . . . . 64.04 109.315 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -77.0 -33.06 20.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 108.649 -0.871 . . . . 75.4 108.649 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.64 -28.23 17.11 Favored Glycine 0 N--CA 1.436 -1.362 0 N-CA-C 110.456 -1.058 . . . . 73.01 110.456 175.188 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.68 12.51 11.44 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.558 -0.829 . . . . 65.24 112.552 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -118.93 116.56 26.72 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.663 -0.866 . . . . 72.34 108.663 -176.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 40.7 m -95.13 137.21 34.48 Favored 'General case' 0 C--N 1.274 -2.684 0 N-CA-C 109.393 -0.595 . . . . 61.21 109.393 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -76.99 -51.4 11.19 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.47 -0.332 . . . . 55.31 110.462 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 61.9 m -51.77 116.59 8.25 Favored Pre-proline 0 C--O 1.259 1.584 0 O-C-N 124.011 0.82 . . . . 73.53 112.326 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.1 118.41 5.31 Favored 'Trans proline' 0 N--CA 1.446 -1.311 0 C-N-CA 122.227 1.952 . . . . 62.44 109.686 177.303 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.34 -4.13 23.51 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 120.256 -0.973 . . . . 20.14 111.092 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 58.4 m -109.37 148.13 31.6 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 119.353 -0.939 . . . . 62.33 110.363 175.569 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.5 p -134.53 148.52 50.52 Favored 'General case' 0 C--N 1.257 -3.448 0 CA-C-N 114.12 -1.4 . . . . 74.34 109.259 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.1 t -85.31 75.35 10.27 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.159 -1.052 . . . . 72.15 108.159 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 16.8 m -73.23 -44.01 60.25 Favored 'General case' 0 N--CA 1.407 -2.59 0 CA-C-N 115.437 -0.801 . . . . 71.03 110.633 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 62.0 t90 -125.36 97.2 5.11 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.771 -0.826 . . . . 73.43 108.771 178.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.405 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.4 t90 -58.56 138.97 85.77 Favored Pre-proline 0 C--N 1.303 -1.449 0 CA-C-N 114.913 -1.039 . . . . 72.12 109.597 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 86.0 Cg_endo -102.49 36.75 5.63 Favored 'Cis proline' 0 CA--C 1.54 0.813 0 C-N-CA 124.948 -0.855 . . . . 71.23 113.41 1.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.4 t -113.25 138.96 40.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 121.9 -0.5 . . . . 63.52 110.104 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -88.35 151.51 22.55 Favored 'General case' 0 N--CA 1.417 -2.098 0 N-CA-C 108.735 -0.839 . . . . 64.42 108.735 177.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.2 p -137.64 160.89 37.94 Favored 'General case' 0 C--N 1.252 -3.665 0 CA-C-N 114.539 -1.209 . . . . 64.11 109.582 -177.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -90.93 -60.8 1.82 Allowed 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 121.46 0.647 . . . . 73.4 111.106 -177.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 N--CA 1.424 -1.749 0 N-CA-C 105.58 -2.007 . . . . 64.33 105.58 178.556 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.405 -3.4 0 N-CA-C 110.326 -1.11 . . . . 74.4 110.326 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HG ' HG13 ' A' ' 4' ' ' VAL . 47.5 tp -110.46 116.64 52.47 Favored Pre-proline 0 C--O 1.24 0.591 0 N-CA-C 109.437 -0.579 . . . . 62.11 109.437 -177.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -73.2 81.32 1.74 Allowed 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.227 1.951 . . . . 51.33 112.122 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.432 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.5 m -131.66 12.45 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.293 -0.867 . . . . 75.24 110.731 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 64.7 m -80.89 -35.88 32.0 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.848 0.833 . . . . 75.45 109.105 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.26 -0.64 88.73 Favored Glycine 0 N--CA 1.426 -1.987 0 CA-C-N 114.84 -1.073 . . . . 52.33 112.032 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.57 177.21 4.73 Favored 'General case' 0 C--O 1.255 1.377 0 CA-C-O 121.399 0.618 . . . . 63.04 110.848 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 p -130.8 168.2 17.63 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 114.596 -1.184 . . . . 70.13 110.945 -175.46 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -135.81 87.36 2.31 Favored 'General case' 0 N--CA 1.417 -2.124 0 CA-C-N 115.577 -0.738 . . . . 74.13 109.782 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.13 -30.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 N-CA-C 108.082 -1.081 . . . . 74.11 108.082 177.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.66 -6.65 69.98 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.117 -0.947 . . . . 64.5 111.421 177.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.02 24.72 40.07 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 120.679 -0.772 . . . . 50.13 112.921 176.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 31.7 m -147.06 127.56 14.09 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.942 -0.762 . . . . 73.14 108.942 177.481 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.58 152.39 18.57 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.826 -0.624 . . . . 75.53 110.463 -178.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -83.8 -57.71 3.1 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.114 -0.494 . . . . 74.31 111.241 -176.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.402 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 49.8 m -51.96 117.78 10.62 Favored Pre-proline 0 C--O 1.248 0.999 0 O-C-N 123.735 0.647 . . . . 62.54 112.312 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -62.76 111.45 1.36 Allowed 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.446 2.097 . . . . 71.11 109.557 176.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 126.11 -10.62 7.37 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 111.089 -0.804 . . . . 63.01 111.089 -176.608 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.402 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 67.5 m -100.44 154.94 18.12 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-O 121.576 0.703 . . . . 74.25 109.85 175.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 p -136.19 143.49 44.43 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-N 114.759 -1.109 . . . . 71.12 109.15 -178.316 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.0 t -90.96 84.39 5.76 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 106.665 -1.606 . . . . 74.0 106.665 176.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 17.9 t -104.73 -16.28 15.0 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.802 -0.635 . . . . 75.5 110.642 -175.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 84.6 m95 -133.99 72.0 1.46 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.12 -1.066 . . . . 65.34 108.12 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 82.2 t90 -54.95 135.47 66.77 Favored Pre-proline 0 C--O 1.244 0.787 0 CA-C-N 114.41 -1.268 . . . . 73.12 110.331 -174.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 45.0 Cg_endo -99.43 34.54 8.22 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 C-N-CA 124.662 -0.974 . . . . 71.43 113.756 3.389 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.9 t -107.23 139.21 29.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 121.905 -0.497 . . . . 70.32 109.808 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 94.8 m -88.83 154.62 20.11 Favored 'General case' 0 N--CA 1.416 -2.155 0 CA-C-O 122.137 0.97 . . . . 62.23 109.758 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.2 p -138.93 166.02 25.57 Favored 'General case' 0 C--N 1.257 -3.414 0 CA-C-N 114.129 -1.396 . . . . 73.44 107.957 -178.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -88.93 -70.59 0.64 Allowed 'General case' 0 N--CA 1.419 -2.005 0 C-N-CA 119.001 -1.08 . . . . 74.35 108.93 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 C--N 1.303 -1.455 0 N-CA-C 104.797 -2.297 . . . . 52.13 104.797 179.513 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -2.138 0 N-CA-C 109.503 -1.439 . . . . 64.14 109.503 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.528 ' HG ' HG13 ' A' ' 4' ' ' VAL . 55.8 tp -110.37 109.78 58.3 Favored Pre-proline 0 C--O 1.246 0.897 0 CA-C-N 114.868 -0.666 . . . . 71.44 109.224 -177.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -75.46 83.7 1.85 Allowed 'Trans proline' 0 N--CA 1.434 -1.977 0 C-N-CA 121.945 1.763 . . . . 75.0 111.179 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.528 HG13 ' HG ' ' A' ' 2' ' ' LEU . 8.4 m -123.01 19.96 4.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.39 -0.823 . . . . 75.42 110.044 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 57.4 m -108.1 -24.25 11.64 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-N 115.611 -0.722 . . . . 61.24 111.86 177.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.76 -15.52 14.37 Favored Glycine 0 C--O 1.246 0.869 0 CA-C-N 115.421 -0.809 . . . . 64.31 114.361 176.439 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.45 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 15.7 pt-20 -94.98 174.27 7.17 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.635 0.731 . . . . 63.43 111.531 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.0 p -125.9 161.32 27.72 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 114.765 -1.107 . . . . 74.4 109.95 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -122.2 90.73 3.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.804 -0.813 . . . . 71.22 108.804 178.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.53 -37.08 18.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.841 -0.8 . . . . 72.43 108.841 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.43 -14.88 59.43 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.555 -0.748 . . . . 50.14 111.348 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.03 20.25 16.79 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.447 -0.882 . . . . 70.43 113.453 176.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 59.0 m -141.95 127.54 19.04 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.981 -0.748 . . . . 75.53 108.981 177.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 33.9 m -100.17 162.68 12.81 Favored 'General case' 0 C--N 1.278 -2.528 0 CA-C-N 115.541 -0.754 . . . . 64.23 109.887 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -94.96 -49.57 5.49 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.559 -0.291 . . . . 72.11 110.446 -177.371 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.5 m -52.47 120.37 17.8 Favored Pre-proline 0 C--O 1.264 1.86 0 O-C-N 123.96 0.787 . . . . 65.43 112.347 -176.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -62.78 114.23 2.32 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.136 1.891 . . . . 65.01 109.664 177.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.84 -21.87 6.96 Favored Glycine 0 N--CA 1.428 -1.843 0 C-N-CA 120.456 -0.878 . . . . 72.13 112.112 -177.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -107.1 154.26 21.42 Favored 'General case' 0 CA--C 1.481 -1.69 0 CA-C-O 122.246 1.022 . . . . 70.14 112.812 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 p -139.39 167.58 21.76 Favored 'General case' 0 C--N 1.274 -2.688 0 CA-C-N 113.274 -1.785 . . . . 71.41 108.848 -178.314 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 9.6 t -90.64 64.71 5.78 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.882 -1.155 . . . . 62.34 107.882 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.2 m -65.07 -26.58 68.3 Favored 'General case' 0 N--CA 1.423 -1.798 0 CA-C-N 115.174 -0.921 . . . . 53.14 111.024 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -145.87 106.96 4.15 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.726 -1.213 . . . . 75.11 107.726 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.5 t90 -67.35 139.31 94.58 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 108.962 -0.755 . . . . 74.34 108.962 -177.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 43.2 Cg_endo -104.9 36.7 4.76 Favored 'Cis proline' 0 CA--C 1.537 0.656 0 C-N-CA 125.107 -0.789 . . . . 75.51 113.03 1.004 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.5 p -112.6 136.54 48.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-O 121.618 0.723 . . . . 72.44 111.404 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 65.1 m -88.59 138.44 31.43 Favored 'General case' 0 N--CA 1.409 -2.515 0 CA-C-O 122.482 1.134 . . . . 61.12 109.19 179.034 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -139.92 164.51 29.81 Favored 'General case' 1 C--N 1.243 -4.045 0 CA-C-N 113.2 -1.818 . . . . 63.51 109.304 -175.105 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -87.48 -66.36 0.92 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.59 -0.892 . . . . 74.31 108.59 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.8 p30 . . . . . 0 N--CA 1.426 -1.663 0 N-CA-C 105.139 -2.171 . . . . 62.03 105.139 175.87 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.938 0 N-CA-C 109.083 -1.607 . . . . 74.51 109.083 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.402 ' HG ' HG13 ' A' ' 4' ' ' VAL . 46.5 tp -104.28 115.11 63.58 Favored Pre-proline 0 C--O 1.245 0.844 0 N-CA-C 109.038 -0.727 . . . . 74.3 109.038 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -73.5 80.27 2.01 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.268 1.979 . . . . 75.31 112.606 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.402 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.0 m -131.66 8.96 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 115.744 -0.662 . . . . 55.13 110.781 178.366 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.1 m -91.84 -30.29 16.27 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-O 121.784 0.802 . . . . 75.44 109.461 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.71 -12.61 46.8 Favored Glycine 0 N--CA 1.427 -1.934 0 CA-C-N 114.521 -1.218 . . . . 54.34 113.953 176.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -100.49 172.4 7.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.094 -1.042 . . . . 63.02 111.802 -176.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 p -126.51 154.75 43.37 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 114.337 -1.301 . . . . 74.33 109.802 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.45 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 5.5 p -120.57 86.06 2.5 Favored 'General case' 0 N--CA 1.408 -2.54 0 N-CA-C 107.818 -1.178 . . . . 75.31 107.818 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 44.5 t -69.89 -33.6 56.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 N-CA-C 108.655 -0.868 . . . . 61.22 108.655 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.32 -32.15 7.56 Favored Glycine 0 N--CA 1.429 -1.792 0 CA-C-N 115.403 -0.817 . . . . 71.43 111.41 176.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 118.45 13.89 6.64 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.042 -1.075 . . . . 62.2 112.436 -178.276 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.0 m -126.08 112.04 15.38 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.213 -0.662 . . . . 64.04 109.213 -177.823 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.0 m -95.28 150.11 20.61 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.261 -0.881 . . . . 73.04 110.766 -176.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -90.84 -54.93 3.76 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 123.203 0.601 . . . . 72.15 111.065 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 57.5 m -50.19 117.97 8.5 Favored Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 113.169 0.803 . . . . 74.24 113.169 -176.042 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.9 123.01 12.71 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 123.249 2.633 . . . . 54.52 111.028 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.06 57.08 Favored Glycine 0 N--CA 1.427 -1.931 0 C-N-CA 120.733 -0.746 . . . . 42.51 112.148 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.9 m -100.77 155.26 18.01 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.291 -0.564 . . . . 62.45 109.644 177.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -140.85 155.43 46.34 Favored 'General case' 0 C--N 1.277 -2.575 0 CA-C-N 115.111 -0.95 . . . . 55.31 109.528 -174.529 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.415 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 24.5 t -84.78 79.6 9.56 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.409 -1.7 . . . . 71.44 106.409 175.168 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.449 ' HB3' ' OG1' ' A' ' 28' ' ' THR . 23.1 t -87.03 -28.36 22.65 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 115.036 -0.984 . . . . 42.43 110.389 -175.416 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.0 t-105 -135.94 85.46 2.16 Favored 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 107.95 -1.13 . . . . 75.44 107.95 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -58.45 135.84 85.58 Favored Pre-proline 0 C--N 1.307 -1.252 0 N-CA-C 109.396 -0.594 . . . . 73.1 109.396 -179.177 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -99.09 35.64 7.47 Favored 'Cis proline' 0 CA--C 1.553 1.445 0 N-CA-C 114.888 1.072 . . . . 71.31 114.888 5.132 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.6 t -112.81 135.51 52.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.607 -0.683 . . . . 75.23 109.669 179.166 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 63.4 m -88.96 146.7 24.73 Favored 'General case' 0 N--CA 1.415 -2.182 0 N-CA-C 106.721 -1.585 . . . . 63.11 106.721 174.719 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.449 ' OG1' ' HB3' ' A' ' 22' ' ' SER . 15.0 p -139.59 179.04 6.8 Favored 'General case' 0 C--N 1.248 -3.809 0 N-CA-C 108.286 -1.005 . . . . 64.13 108.286 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 20.0 tpt180 -88.49 -73.86 0.48 Allowed 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.77 -0.772 . . . . 70.24 109.513 -177.399 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.427 -1.583 0 N-CA-C 104.972 -2.233 . . . . 71.25 104.972 176.68 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.398 -3.885 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.414 ' HG ' HG13 ' A' ' 4' ' ' VAL . 24.8 tp -120.93 120.91 29.12 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -177.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -70.89 83.26 0.91 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.295 1.997 . . . . 0.0 111.804 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.414 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.0 m -130.61 11.02 2.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.483 179.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.1 m -80.56 -28.4 37.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.443 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.24 4.69 90.43 Favored Glycine 0 N--CA 1.427 -1.95 0 CA-C-N 114.93 -1.032 . . . . 0.0 112.009 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.28 -176.65 3.56 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.237 0.541 . . . . 0.0 110.204 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.7 p -133.23 160.33 37.57 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.124 -177.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.5 p -126.49 84.84 2.31 Favored 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.461 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.65 -31.3 41.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.18 5.09 55.61 Favored Glycine 0 N--CA 1.44 -1.081 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.795 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 81.44 11.93 82.6 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.198 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 m -116.64 110.72 18.87 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -178.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.7 m -89.54 146.5 24.55 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-O 120.981 0.42 . . . . 0.0 110.479 177.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -81.38 -62.14 1.74 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.255 -177.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.426 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.5 m -51.19 118.18 10.19 Favored Pre-proline 0 C--O 1.251 1.133 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -59.45 118.49 5.39 Favored 'Trans proline' 0 C--N 1.354 0.858 0 C-N-CA 122.887 2.391 . . . . 0.0 109.936 175.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.23 -12.12 14.32 Favored Glycine 0 C--N 1.293 -1.857 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 78.8 m -99.13 154.98 17.7 Favored 'General case' 0 N--CA 1.433 -1.314 0 CA-C-O 121.633 0.73 . . . . 0.0 110.082 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -141.55 153.26 44.74 Favored 'General case' 0 C--N 1.268 -2.958 0 C-N-CA 125.465 1.506 . . . . 0.0 107.697 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.483 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 31.0 t -96.69 83.91 3.54 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-O 121.38 0.61 . . . . 0.0 110.06 -179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.4 m -88.11 -51.78 5.6 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.017 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.5 m95 -102.03 75.27 1.51 Allowed 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.064 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 88.7 t90 -55.6 136.43 70.91 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.13 -178.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 18.0 Cg_endo -99.42 36.22 6.95 Favored 'Cis proline' 0 CA--C 1.541 0.85 0 C-N-CA 124.874 -0.886 . . . . 0.0 113.918 4.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.6 t -110.58 143.06 21.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.2 m -87.76 155.32 19.96 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-O 122.201 1.0 . . . . 0.0 110.5 -178.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.8 p -138.79 153.66 48.43 Favored 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.814 -1.539 . . . . 0.0 109.329 -174.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.9 tpp180 -89.82 -67.37 0.85 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.873 -0.731 . . . . 0.0 109.91 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 -177.026 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -3.001 0 N-CA-C 108.918 -1.673 . . . . 73.030000000000001 108.918 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -120.94 111.49 34.12 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.517 -1.29 . . . . 70.329999999999998 107.517 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.61 78.63 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 122.093 1.862 . . . . 54.32 113.604 -177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.01 27.84 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 122.381 1.086 . . . . 72.049999999999997 108.645 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.4 m -90.2 -21.79 22.0 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 114.129 -1.396 . . . . 55.539999999999999 110.468 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.87 -4.29 53.57 Favored Glycine 0 C--N 1.303 -1.298 0 CA-C-N 114.42 -1.263 . . . . 72.340000000000003 113.983 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.428 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.6 pt-20 -117.11 179.33 4.06 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 122.24 -0.565 . . . . 75.019999999999996 111.438 -178.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.3 p -124.21 157.36 34.98 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.359 -0.837 . . . . 63.210000000000001 110.979 -175.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -127.89 83.66 2.18 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.718 -0.475 . . . . 73.420000000000002 109.718 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.36 -35.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.481 -0.933 . . . . 54.100000000000001 108.481 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.8 -14.57 59.35 Favored Glycine 0 N--CA 1.435 -1.368 0 CA-C-N 115.237 -0.892 . . . . 54.420000000000002 110.977 177.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.27 32.9 7.97 Favored Glycine 0 N--CA 1.432 -1.594 0 C-N-CA 120.131 -1.033 . . . . 74.109999999999999 111.537 179.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -142.84 122.45 13.3 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-O 121.274 0.559 . . . . 73.109999999999999 109.777 177.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.3 m -104.06 145.38 30.26 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 115.057 -0.974 . . . . 61.420000000000002 110.572 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 38.3 m-80 -86.57 -49.87 7.23 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.522 0.729 . . . . 71.319999999999993 111.527 -176.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 65.4 m -50.27 116.2 6.33 Favored Pre-proline 0 C--O 1.249 1.072 0 O-C-N 124.039 0.837 . . . . 71.329999999999998 112.101 -178.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.81 118.87 5.71 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 123.365 2.71 . . . . 75.230000000000004 111.611 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.13 -3.23 33.33 Favored Glycine 0 N--CA 1.426 -1.977 0 CA-C-N 115.699 -0.682 . . . . 44.240000000000002 111.552 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.482 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 84.9 m -102.44 155.53 18.2 Favored 'General case' 0 N--CA 1.432 -1.351 0 CA-C-O 122.043 0.925 . . . . 73.319999999999993 111.582 178.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -140.5 156.8 46.22 Favored 'General case' 0 C--N 1.27 -2.863 0 CA-C-N 113.715 -1.584 . . . . 74.510000000000005 107.903 179.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.4 t -92.64 80.93 4.76 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.901 -0.778 . . . . 73.239999999999995 108.901 175.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.2 m -83.66 -39.92 19.61 Favored 'General case' 0 N--CA 1.405 -2.69 0 CA-C-N 115.779 -0.646 . . . . 65.549999999999997 111.221 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.528 ' CD1' HG21 ' A' ' 28' ' ' THR . 23.3 m95 -118.08 82.4 1.83 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.014 -0.735 . . . . 75.219999999999999 109.014 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.411 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.0 t90 -57.99 132.71 83.61 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.517 0.727 . . . . 74.430000000000007 110.752 -175.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 90.9 Cg_endo -104.97 41.73 2.95 Favored 'Cis proline' 0 CA--C 1.545 1.037 0 CA-C-N 119.157 0.735 . . . . 74.420000000000002 113.797 4.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.95 139.86 31.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.178 -1.045 . . . . 71.319999999999993 108.178 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.428 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 88.6 m -87.97 146.89 25.29 Favored 'General case' 0 CA--C 1.474 -1.948 0 CA-C-O 122.562 1.172 . . . . 62.140000000000001 110.55 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.528 HG21 ' CD1' ' A' ' 23' ' ' TRP . 15.5 p -135.19 157.69 46.26 Favored 'General case' 0 C--N 1.256 -3.487 0 CA-C-N 113.0 -1.909 . . . . 74.120000000000005 110.325 -171.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.482 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 27.0 mmm180 -88.87 -65.42 1.02 Allowed 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.866 0.841 . . . . 53.340000000000003 110.61 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 C--N 1.284 -2.251 0 N-CA-C 105.415 -2.068 . . . . 75.409999999999997 105.415 -177.976 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.397 -3.922 0 N-CA-C 108.749 -1.74 . . . . 43.219999999999999 108.749 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 tp -120.23 115.32 32.96 Favored Pre-proline 0 N--CA 1.442 -0.871 0 N-CA-C 107.844 -1.169 . . . . 71.319999999999993 107.844 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.34 81.38 1.5 Allowed 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.309 2.006 . . . . 65.230000000000004 112.442 -177.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 m -132.62 9.63 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 115.038 -0.983 . . . . 65.439999999999998 110.64 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.7 m -76.66 -22.7 53.67 Favored 'General case' 0 CA--C 1.491 -1.307 0 CA-C-O 121.473 0.654 . . . . 30.350000000000001 111.295 -177.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.96 -2.01 82.27 Favored Glycine 0 N--CA 1.422 -2.249 0 CA-C-N 114.713 -1.13 . . . . 63.439999999999998 112.939 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -122.51 177.71 5.3 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.548 -0.861 . . . . 72.409999999999997 111.121 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.1 p -124.76 154.36 41.02 Favored 'General case' 0 N--CA 1.422 -1.858 0 CA-C-N 114.513 -1.222 . . . . 60.299999999999997 110.656 -178.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -122.14 85.52 2.43 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 123.549 0.74 . . . . 43.149999999999999 109.162 178.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -72.12 -33.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-O 121.566 0.698 . . . . 73.420000000000002 109.338 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.28 -16.77 56.89 Favored Glycine 0 N--CA 1.438 -1.227 0 CA-C-N 115.384 -0.826 . . . . 61.420000000000002 111.636 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.444 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.31 15.27 23.83 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.075 -1.059 . . . . 74.209999999999994 112.907 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.4 m -137.31 124.46 21.68 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.938 -1.134 . . . . 71.430000000000007 107.938 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.98 149.35 21.89 Favored 'General case' 0 C--N 1.273 -2.717 0 CA-C-N 115.953 -0.567 . . . . 51.240000000000002 111.44 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -75.06 -54.04 7.85 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.596 -0.729 . . . . 64.150000000000006 109.646 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -51.71 111.52 2.49 Favored Pre-proline 0 C--O 1.256 1.41 0 C-N-CA 124.144 0.978 . . . . 43.549999999999997 112.241 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -62.87 118.06 4.96 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.385 2.057 . . . . 74.140000000000001 109.556 176.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.9 -11.31 13.52 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 111.363 -0.695 . . . . 40.240000000000002 111.363 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.5 m -102.39 155.64 18.12 Favored 'General case' 0 CA--C 1.499 -0.996 0 CA-C-O 122.244 1.021 . . . . 51.420000000000002 111.802 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.5 p -132.16 151.69 51.66 Favored 'General case' 0 N--CA 1.401 -2.905 0 CA-C-N 113.797 -1.547 . . . . 71.310000000000002 108.858 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.444 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 20.8 t -93.18 53.08 1.88 Allowed 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.858 0.837 . . . . 73.109999999999999 108.989 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 m -70.53 -22.81 62.57 Favored 'General case' 0 N--CA 1.414 -2.244 0 CA-C-N 115.587 -0.733 . . . . 63.140000000000001 111.938 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.9 t-105 -128.99 80.43 1.97 Allowed 'General case' 0 C--O 1.205 -1.278 0 N-CA-C 108.237 -1.023 . . . . 71.430000000000007 108.237 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 77.2 t90 -62.88 135.32 95.98 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 116.094 -0.503 . . . . 72.340000000000003 110.898 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 52.5 Cg_endo -102.31 36.4 5.91 Favored 'Cis proline' 0 C--N 1.354 0.851 0 C-N-CA 125.008 -0.83 . . . . 74.540000000000006 113.304 2.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.8 t -105.35 141.44 20.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 109.275 -0.639 . . . . 73.0 109.275 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 74.7 m -88.92 144.58 26.09 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-O 122.794 1.283 . . . . 44.140000000000001 111.029 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 p -129.74 155.05 46.55 Favored 'General case' 0 C--N 1.258 -3.371 0 CA-C-N 112.867 -1.97 . . . . 73.040000000000006 110.037 -173.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 -89.55 -66.42 0.92 Allowed 'General case' 0 N--CA 1.425 -1.706 0 CA-C-O 121.763 0.792 . . . . 63.229999999999997 109.878 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 105.388 -2.079 . . . . 74.540000000000006 105.388 -178.708 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.971 0 N-CA-C 109.961 -1.255 . . . . 72.140000000000001 109.961 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.0 tp -118.24 111.53 38.45 Favored Pre-proline 0 N--CA 1.439 -0.998 0 N-CA-C 108.279 -1.008 . . . . 73.0 108.279 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -74.96 79.11 2.73 Favored 'Trans proline' 0 N--CA 1.444 -1.41 0 C-N-CA 121.879 1.719 . . . . 64.239999999999995 112.675 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.88 22.65 2.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 CA-C-O 121.821 0.819 . . . . 74.319999999999993 109.662 176.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 52.2 m -85.12 -32.65 22.66 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.906 -1.146 . . . . 62.32 107.906 176.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.51 -2.58 87.04 Favored Glycine 0 N--CA 1.43 -1.759 0 CA-C-N 114.055 -1.43 . . . . 75.430000000000007 112.694 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -112.12 175.83 5.27 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.647 0.737 . . . . 60.130000000000003 111.624 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -127.32 158.64 36.7 Favored 'General case' 0 C--N 1.284 -2.273 0 CA-C-N 114.465 -1.243 . . . . 64.209999999999994 109.732 -177.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.1 p -119.64 96.6 5.26 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.37 -0.974 . . . . 65.319999999999993 108.37 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.8 t -80.0 -38.87 19.09 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 109.084 -0.71 . . . . 73.230000000000004 109.084 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.88 -10.69 61.15 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.402 -0.817 . . . . 53.130000000000003 111.149 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.491 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 99.56 13.73 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.522 -0.847 . . . . 72.230000000000004 112.573 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.6 m -127.66 128.78 46.07 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 107.925 -1.139 . . . . 75.310000000000002 107.925 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 36.1 m -104.48 159.38 15.79 Favored 'General case' 0 C--N 1.272 -2.779 0 CA-C-N 115.741 -0.663 . . . . 54.509999999999998 109.578 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -91.62 -58.07 2.55 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.386 -0.37 . . . . 74.140000000000001 110.519 -179.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.452 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 35.6 m -46.65 116.95 4.1 Favored Pre-proline 0 CA--C 1.545 0.771 0 O-C-N 124.374 1.046 . . . . 71.409999999999997 112.219 -175.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.93 117.09 3.73 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 123.257 2.638 . . . . 53.100000000000001 110.941 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.09 -2.51 31.46 Favored Glycine 0 N--CA 1.427 -1.936 0 CA-C-N 115.554 -0.748 . . . . 72.140000000000001 111.543 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.486 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 63.2 m -106.25 150.21 26.14 Favored 'General case' 0 CA--C 1.488 -1.435 0 CA-C-O 121.789 0.804 . . . . 72.25 110.113 176.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 p -136.72 152.46 50.38 Favored 'General case' 0 C--N 1.268 -2.973 0 CA-C-N 114.165 -1.38 . . . . 73.349999999999994 109.927 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.491 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 38.8 t -88.58 65.17 7.72 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.855 -1.165 . . . . 51.119999999999997 107.855 176.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.6 m -72.7 -29.39 63.34 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-N 114.489 -1.232 . . . . 72.230000000000004 110.798 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.3 t-105 -134.29 82.77 1.99 Allowed 'General case' 0 N--CA 1.433 -1.322 0 CA-C-O 121.179 0.514 . . . . 72.319999999999993 110.135 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.1 t90 -56.1 139.12 72.38 Favored Pre-proline 0 C--O 1.244 0.799 0 CA-C-N 115.245 -0.889 . . . . 65.040000000000006 109.875 -177.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -97.87 30.19 13.62 Favored 'Cis proline' 0 CA--C 1.538 0.711 0 C-N-CA 125.033 -0.82 . . . . 74.019999999999996 113.483 1.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 44.5 t -107.64 136.73 41.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 N-CA-C 109.558 -0.534 . . . . 62.219999999999999 109.558 -178.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.7 m -88.46 152.49 21.85 Favored 'General case' 0 N--CA 1.419 -1.996 0 C-N-CA 119.268 -0.973 . . . . 72.030000000000001 109.113 177.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -139.25 164.32 30.13 Favored 'General case' 0 C--N 1.264 -3.149 0 CA-C-N 114.742 -1.117 . . . . 74.120000000000005 109.016 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.486 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 24.3 mmm180 -88.14 -74.14 0.46 Allowed 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.775 0.798 . . . . 64.120000000000005 110.463 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 . . . . . 0 C--N 1.275 -2.631 0 N-CA-C 104.647 -2.353 . . . . 73.310000000000002 104.647 -179.42 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.415 -2.713 0 N-CA-C 109.68 -1.368 . . . . 74.319999999999993 109.68 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -121.06 112.92 33.04 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.514 -0.55 . . . . 75.129999999999995 109.514 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -71.79 81.56 1.33 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.3 2.0 . . . . 74.140000000000001 112.981 -179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m -133.24 15.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 114.982 -1.008 . . . . 75.140000000000001 110.187 177.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.2 m -88.73 -26.75 21.61 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.725 -0.67 . . . . 50.520000000000003 111.05 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.32 6.09 86.09 Favored Glycine 0 N--CA 1.427 -1.914 0 CA-C-N 114.875 -1.057 . . . . 74.329999999999998 112.987 177.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.3 pt-20 -120.09 173.97 6.77 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.249 -0.98 . . . . 72.219999999999999 111.557 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.8 p -124.45 153.71 41.56 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-N 114.191 -1.368 . . . . 71.420000000000002 110.001 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -123.26 85.12 2.37 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 123.54 0.736 . . . . 64.230000000000004 110.389 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.0 t -80.75 -23.87 11.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.89 0.852 . . . . 73.340000000000003 108.838 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -13.7 60.22 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.594 -1.002 . . . . 55.229999999999997 110.594 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.33 17.37 46.53 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.508 -0.853 . . . . 74.049999999999997 112.071 177.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 m -139.36 131.16 27.54 Favored 'General case' 0 N--CA 1.419 -2.005 0 N-CA-C 108.368 -0.975 . . . . 73.530000000000001 108.368 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.76 156.79 16.18 Favored 'General case' 0 C--N 1.275 -2.636 0 CA-C-N 115.853 -0.612 . . . . 72.409999999999997 109.5 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -94.42 -49.71 5.56 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 116.235 -0.439 . . . . 75.219999999999999 110.947 -176.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.524 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 13.2 m -51.27 118.27 10.47 Favored Pre-proline 0 C--O 1.246 0.919 0 C-N-CA 123.913 0.885 . . . . 52.25 111.169 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.99 118.18 4.99 Favored 'Trans proline' 0 C--N 1.354 0.855 0 C-N-CA 122.728 2.285 . . . . 60.439999999999998 110.529 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.32 -1.44 32.93 Favored Glycine 0 N--CA 1.427 -1.906 0 C-N-CA 120.963 -0.636 . . . . 44.229999999999997 111.993 -178.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.524 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.3 m -105.01 154.81 19.63 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.982 0.896 . . . . 63.310000000000002 112.067 178.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 p -137.8 153.52 49.65 Favored 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 125.126 1.37 . . . . 74.519999999999996 109.74 -176.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.9 t -97.13 87.22 4.14 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.316 -0.994 . . . . 55.310000000000002 108.316 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.1 t -81.65 -57.86 3.26 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.365 -0.605 . . . . 41.32 109.365 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -107.29 96.54 6.48 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 109.223 -0.658 . . . . 65.439999999999998 109.223 -178.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 75.7 t90 -63.93 138.23 97.34 Favored Pre-proline 0 C--N 1.296 -1.717 0 N-CA-C 109.233 -0.654 . . . . 74.150000000000006 109.233 -178.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 61.4 Cg_endo -102.63 37.84 5.03 Favored 'Cis proline' 0 CA--C 1.544 0.984 0 C-N-CA 124.464 -1.057 . . . . 74.239999999999995 114.018 1.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.5 p -108.97 143.6 18.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 O-C-N 121.516 -0.74 . . . . 70.219999999999999 110.059 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.6 m -88.5 160.75 17.36 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 122.288 1.042 . . . . 64.150000000000006 111.353 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.2 p -142.14 166.17 25.43 Favored 'General case' 0 C--N 1.267 -3.002 0 CA-C-N 113.613 -1.631 . . . . 72.209999999999994 108.154 -178.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 22.1 tpt180 -89.01 -70.93 0.62 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.736 -0.838 . . . . 73.120000000000005 108.736 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.417 -2.109 0 N-CA-C 104.775 -2.305 . . . . 72.430000000000007 104.775 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.417 -2.627 0 N-CA-C 109.219 -1.552 . . . . 50.420000000000002 109.219 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.6 tp -115.08 111.69 44.81 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 114.658 -0.771 . . . . 73.439999999999998 109.023 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.93 74.67 3.37 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 122.671 2.247 . . . . 54.32 113.678 -176.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -125.32 18.49 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 115.459 -0.792 . . . . 74.140000000000001 109.908 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.7 m -88.21 -22.26 24.09 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-O 121.996 0.903 . . . . 75.430000000000007 109.562 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.08 -15.79 19.95 Favored Glycine 0 N--CA 1.438 -1.197 0 CA-C-N 114.116 -1.402 . . . . 63.229999999999997 113.549 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -99.52 175.5 5.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 121.557 0.694 . . . . 73.349999999999994 110.733 -177.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.8 p -125.38 149.0 48.55 Favored 'General case' 0 N--CA 1.409 -2.482 0 CA-C-N 114.54 -1.209 . . . . 70.420000000000002 110.28 -178.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -116.76 93.11 4.07 Favored 'General case' 0 C--N 1.284 -2.244 0 N-CA-C 108.749 -0.834 . . . . 52.130000000000003 108.749 177.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 65.7 t -80.3 -35.22 15.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.158 -0.682 . . . . 74.140000000000001 109.158 179.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.52 -10.44 65.47 Favored Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.389 -1.085 . . . . 62.509999999999998 110.389 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 92.82 17.21 45.33 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.707 -0.759 . . . . 32.520000000000003 111.802 178.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 m -123.24 122.49 38.5 Favored 'General case' 0 N--CA 1.418 -2.049 0 N-CA-C 108.474 -0.935 . . . . 64.329999999999998 108.474 -178.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 67.6 m -99.38 141.2 32.48 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-N 115.836 -0.62 . . . . 71.010000000000005 111.89 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -83.07 -50.96 7.97 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.038 -0.983 . . . . 74.219999999999999 111.639 -176.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 53.4 m -52.29 118.56 12.76 Favored Pre-proline 0 C--O 1.254 1.318 0 C-N-CA 122.531 0.333 . . . . 73.219999999999999 111.74 176.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -67.38 114.0 3.1 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.163 1.908 . . . . 74.340000000000003 109.724 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 121.19 -7.28 10.7 Favored Glycine 0 N--CA 1.417 -2.618 0 C-N-CA 120.246 -0.978 . . . . 43.219999999999999 110.916 -176.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.2 m -108.77 153.27 23.71 Favored 'General case' 0 CA--C 1.495 -1.14 0 CA-C-O 121.433 0.635 . . . . 73.340000000000003 110.54 176.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.7 p -134.25 152.86 52.04 Favored 'General case' 0 N--CA 1.406 -2.634 0 CA-C-N 114.571 -1.195 . . . . 63.409999999999997 108.137 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.473 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 36.0 t -89.28 83.06 6.44 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.26 -1.015 . . . . 73.420000000000002 108.26 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.8 t -105.23 1.04 27.8 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.632 -0.713 . . . . 71.129999999999995 110.451 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.7 t-105 -147.57 63.88 1.14 Allowed 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.341 -0.985 . . . . 72.310000000000002 108.341 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.5 t90 -51.61 132.8 35.97 Favored Pre-proline 0 C--N 1.318 -0.797 0 CA-C-N 114.615 -1.175 . . . . 73.140000000000001 110.482 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 73.1 Cg_endo -101.24 34.22 7.75 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.662 -0.974 . . . . 73.420000000000002 113.64 4.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -109.89 142.02 23.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.866 -0.79 . . . . 73.340000000000003 108.866 179.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.9 m -88.26 147.23 24.92 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.711 1.243 . . . . 72.109999999999999 110.835 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -130.0 158.88 38.37 Favored 'General case' 0 C--N 1.26 -3.318 0 CA-C-N 112.889 -1.959 . . . . 50.329999999999998 109.733 -172.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -89.42 -66.93 0.87 Allowed 'General case' 0 N--CA 1.416 -2.149 0 C-N-CA 119.751 -0.78 . . . . 74.340000000000003 109.767 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 N--CA 1.426 -1.67 0 N-CA-C 105.541 -2.022 . . . . 72.230000000000004 105.541 -179.324 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.331 0 N-CA-C 109.937 -1.265 . . . . 64.209999999999994 109.937 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.9 tp -118.5 120.67 31.68 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.623 -0.51 . . . . 63.109999999999999 109.623 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -70.61 82.87 0.89 Allowed 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.127 1.885 . . . . 75.120000000000005 112.521 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.4 m -130.47 19.45 2.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-O 121.759 0.79 . . . . 63.229999999999997 109.391 176.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 79.4 m -93.0 -29.61 15.75 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 115.007 -0.997 . . . . 53.520000000000003 110.251 -178.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.87 3.43 73.98 Favored Glycine 0 N--CA 1.432 -1.593 0 CA-C-N 114.832 -1.076 . . . . 73.400000000000006 113.621 177.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -120.3 175.27 6.04 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.742 0.782 . . . . 75.150000000000006 111.254 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -128.88 155.45 45.24 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-N 114.427 -1.26 . . . . 43.539999999999999 109.759 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -125.64 85.81 2.45 Favored 'General case' 0 C--N 1.278 -2.529 0 CA-C-N 116.234 -0.439 . . . . 74.150000000000006 109.924 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 41.2 t -80.3 -25.25 11.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.291 -0.963 . . . . 74.319999999999993 109.005 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.95 -15.94 56.98 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 110.927 -0.869 . . . . 55.200000000000003 110.927 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.96 14.79 38.45 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.811 -0.709 . . . . 63.100000000000001 112.263 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.8 m -130.76 124.36 31.25 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.206 -0.665 . . . . 70.030000000000001 109.206 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.9 m -98.92 152.93 19.23 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 115.847 -0.615 . . . . 64.150000000000006 109.686 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -87.88 -55.96 3.54 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.595 -0.275 . . . . 72.140000000000001 111.18 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.403 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 19.9 m -50.97 112.15 2.77 Favored Pre-proline 0 CA--C 1.56 1.34 0 O-C-N 124.29 0.994 . . . . 60.439999999999998 112.728 -176.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -58.61 121.97 10.86 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 123.115 2.543 . . . . 72.420000000000002 110.512 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.75 -3.73 30.6 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 110.766 -0.934 . . . . 72.540000000000006 110.766 -177.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.403 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 86.0 m -104.81 159.17 16.0 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.539 0.685 . . . . 72.019999999999996 110.824 176.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.5 p -137.82 146.09 43.09 Favored 'General case' 0 C--N 1.28 -2.442 0 C-N-CA 124.924 1.289 . . . . 72.409999999999997 109.233 -176.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 49.2 t -91.44 77.2 5.81 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.26 -1.385 . . . . 43.0 107.26 174.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -90.28 -36.29 14.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.689 -0.687 . . . . 75.409999999999997 110.96 -175.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 92.6 m95 -120.34 76.03 1.15 Allowed 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.209 -0.663 . . . . 53.299999999999997 109.209 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 79.9 t90 -53.75 136.91 54.51 Favored Pre-proline 0 C--N 1.313 -1.008 0 CA-C-N 114.895 -1.048 . . . . 73.150000000000006 110.372 -175.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -97.24 32.85 10.39 Favored 'Cis proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.523 -1.032 . . . . 74.120000000000005 113.295 2.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.0 t -106.15 138.18 32.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 109.549 -0.537 . . . . 75.25 109.549 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.95 153.51 20.97 Favored 'General case' 0 N--CA 1.41 -2.438 0 CA-C-O 122.104 0.954 . . . . 73.549999999999997 109.225 177.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 5.2 p -133.08 165.5 24.6 Favored 'General case' 0 C--N 1.252 -3.633 0 CA-C-N 114.408 -1.269 . . . . 64.420000000000002 108.572 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpt180 -88.95 -76.63 0.4 Allowed 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 108.678 -0.86 . . . . 73.310000000000002 108.678 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.42 -1.928 0 N-CA-C 104.852 -2.277 . . . . 65.420000000000002 104.852 179.471 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.407 -3.244 0 N-CA-C 109.27 -1.532 . . . . 73.340000000000003 109.27 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 35.0 tp -123.86 121.35 26.48 Favored Pre-proline 0 N--CA 1.44 -0.942 0 N-CA-C 108.94 -0.763 . . . . 73.319999999999993 108.94 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.83 84.52 0.41 Allowed 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.624 2.216 . . . . 53.219999999999999 111.97 178.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 m -136.42 30.53 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 CA-C-N 114.997 -1.001 . . . . 54.020000000000003 108.48 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.2 m -101.19 -24.69 14.22 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 114.836 -1.075 . . . . 65.230000000000004 110.492 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.84 -14.06 33.58 Favored Glycine 0 C--N 1.305 -1.193 0 CA-C-N 114.959 -1.019 . . . . 61.43 113.754 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.401 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 10.6 pt-20 -110.68 -178.05 3.38 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 121.154 0.502 . . . . 74.340000000000003 110.887 -177.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 p -131.2 154.86 47.96 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.987 -1.006 . . . . 50.420000000000002 111.386 -176.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -121.66 88.25 2.9 Favored 'General case' 0 N--CA 1.416 -2.129 0 N-CA-C 108.874 -0.787 . . . . 74.540000000000006 108.874 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -74.43 -36.25 41.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.046 -0.724 . . . . 42.039999999999999 109.046 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 -22.72 35.55 Favored Glycine 0 N--CA 1.436 -1.35 0 CA-C-N 115.392 -0.822 . . . . 70.239999999999995 111.08 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.07 12.79 13.26 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.017 -1.087 . . . . 72.439999999999998 113.325 178.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 46.7 m -136.99 124.98 22.76 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.652 -0.87 . . . . 44.329999999999998 108.652 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 38.3 m -91.97 169.86 10.32 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 115.352 -0.84 . . . . 75.409999999999997 110.874 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -92.77 -52.56 4.56 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 123.315 0.646 . . . . 74.109999999999999 110.468 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.7 m -51.13 113.94 4.36 Favored Pre-proline 0 C--O 1.25 1.117 0 C-N-CA 123.947 0.899 . . . . 71.519999999999996 113.095 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -65.48 105.98 0.81 Allowed 'Trans proline' 0 C--N 1.359 1.1 0 C-N-CA 122.53 2.153 . . . . 62.420000000000002 109.629 176.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.95 5.33 Favored Glycine 0 N--CA 1.427 -1.913 0 N-CA-C 110.782 -0.927 . . . . 64.400000000000006 110.782 -177.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.3 m -102.13 162.01 13.24 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 121.609 0.719 . . . . 43.130000000000003 111.146 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -141.0 153.13 45.42 Favored 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 114.252 -1.34 . . . . 71.040000000000006 108.325 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.88 83.17 4.33 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.018 -1.105 . . . . 73.129999999999995 108.018 175.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 21.4 t -89.77 -49.26 6.74 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.911 -0.774 . . . . 73.430000000000007 108.911 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -107.5 80.7 1.43 Allowed 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.39 -0.596 . . . . 75.5 109.39 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 92.4 t90 -55.79 139.73 69.07 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.413 -0.812 . . . . 63.350000000000001 110.033 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 17.6 Cg_endo -99.95 32.32 9.91 Favored 'Cis proline' 0 CA--C 1.534 0.493 0 C-N-CA 124.935 -0.86 . . . . 72.019999999999996 113.121 1.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 55.8 t -104.91 142.54 17.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.993 -0.743 . . . . 70.239999999999995 108.993 -179.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.401 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 71.3 m -87.89 144.93 26.3 Favored 'General case' 0 N--CA 1.415 -2.2 0 CA-C-O 122.707 1.241 . . . . 73.430000000000007 110.417 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -128.28 152.04 48.59 Favored 'General case' 0 C--N 1.259 -3.365 0 CA-C-N 113.104 -1.862 . . . . 53.299999999999997 111.101 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -94.82 -55.86 2.97 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-O 121.765 0.793 . . . . 64.329999999999998 111.237 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.414 -2.225 0 N-CA-C 105.01 -2.218 . . . . 51.130000000000003 105.01 -179.161 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.409 -3.134 0 N-CA-C 109.744 -1.342 . . . . 70.420000000000002 109.744 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.0 tp -103.79 116.27 62.04 Favored Pre-proline 0 C--O 1.241 0.614 0 N-CA-C 108.808 -0.812 . . . . 74.209999999999994 108.808 179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -78.37 76.69 4.31 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.179 1.919 . . . . 64.25 112.304 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -128.1 18.54 2.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.905 -1.043 . . . . 73.120000000000005 109.775 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.1 m -87.82 -26.35 22.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 CA-C-N 115.236 -0.893 . . . . 71.329999999999998 109.951 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.93 -0.88 64.78 Favored Glycine 0 N--CA 1.438 -1.17 0 CA-C-N 114.619 -1.173 . . . . 53.420000000000002 113.557 176.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.479 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 11.3 pt-20 -112.93 175.52 5.4 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.242 -0.583 . . . . 72.140000000000001 110.27 178.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 p -128.41 154.71 45.75 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 115.055 -0.975 . . . . 73.519999999999996 110.752 -174.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.415 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 7.6 p -129.86 89.68 2.85 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 109.622 -0.51 . . . . 74.129999999999995 109.622 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -80.18 -31.25 13.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 108.707 -0.849 . . . . 73.230000000000004 108.707 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.4 -12.21 61.6 Favored Glycine 0 N--CA 1.439 -1.167 0 CA-C-N 115.424 -0.807 . . . . 64.219999999999999 111.315 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 93.14 19.48 36.02 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.478 -0.868 . . . . 63.340000000000003 112.609 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.9 m -135.85 119.66 17.32 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.1 -0.704 . . . . 61.299999999999997 109.1 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 56.4 m -99.13 167.51 10.65 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.312 -0.858 . . . . 65.549999999999997 110.955 -176.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -103.83 -49.28 3.69 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.648 0.379 . . . . 73.430000000000007 111.875 -178.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.8 m -51.29 114.17 4.68 Favored Pre-proline 0 C--O 1.257 1.465 0 N-CA-C 113.081 0.771 . . . . 44.299999999999997 113.081 -179.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -62.93 115.67 3.08 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.883 2.389 . . . . 64.430000000000007 109.571 175.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -10.42 11.5 Favored Glycine 0 C--N 1.298 -1.568 0 N-CA-C 110.94 -0.864 . . . . 73.540000000000006 110.94 -176.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.4 m -112.95 162.37 15.93 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.235 0.54 . . . . 62.299999999999997 110.545 176.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 p -145.35 160.93 40.79 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 124.933 1.293 . . . . 71.310000000000002 108.337 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.48 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 46.2 t -92.27 85.24 5.36 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.536 -0.913 . . . . 45.539999999999999 108.536 177.483 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -103.36 -31.17 10.17 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.828 -0.623 . . . . 70.310000000000002 110.124 -178.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.1 m95 -112.66 64.84 0.63 Allowed 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.186 0.517 . . . . 74.129999999999995 109.701 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 89.1 t90 -52.88 135.32 47.18 Favored Pre-proline 0 C--O 1.247 0.971 0 CA-C-N 114.567 -1.197 . . . . 72.439999999999998 110.498 -176.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 9.7 Cg_endo -96.3 33.35 9.94 Favored 'Cis proline' 0 CA--C 1.549 1.261 0 N-CA-C 114.518 0.93 . . . . 75.450000000000003 114.518 3.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 69.1 t -111.09 143.69 20.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 108.861 -0.792 . . . . 63.119999999999997 108.861 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.479 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 63.0 m -88.69 145.49 25.62 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-O 122.301 1.048 . . . . 72.420000000000002 109.345 178.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.4 p -129.5 165.03 22.47 Favored 'General case' 0 C--N 1.254 -3.546 0 CA-C-N 113.786 -1.552 . . . . 71.099999999999994 110.688 -174.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -88.22 -67.43 0.83 Allowed 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.897 -0.779 . . . . 73.120000000000005 108.897 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 . . . . . 0 N--CA 1.423 -1.816 0 N-CA-C 105.906 -1.887 . . . . 64.329999999999998 105.906 176.068 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.654 0 N-CA-C 110.596 -1.002 . . . . 72.129999999999995 110.596 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.5 tp -112.59 110.04 52.9 Favored Pre-proline 0 C--O 1.239 0.516 0 N-CA-C 109.704 -0.48 . . . . 70.209999999999994 109.704 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -72.86 79.32 1.98 Allowed 'Trans proline' 0 C--O 1.24 0.586 0 C-N-CA 122.421 2.081 . . . . 61.439999999999998 112.528 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.8 m -137.09 23.37 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.93 -1.032 . . . . 75.519999999999996 109.737 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.3 m -84.99 -21.68 29.39 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.56 -0.745 . . . . 74.329999999999998 110.839 -178.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.07 -0.24 79.94 Favored Glycine 0 C--N 1.294 -1.781 0 CA-C-N 114.794 -1.094 . . . . 75.329999999999998 113.678 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -121.62 177.92 5.04 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.278 -0.569 . . . . 71.540000000000006 109.639 177.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.3 p -130.91 158.85 39.1 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 116.051 -0.522 . . . . 62.039999999999999 110.675 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -129.72 88.77 2.72 Favored 'General case' 0 C--N 1.282 -2.351 0 C-N-CA 123.041 0.536 . . . . 74.409999999999997 109.665 -179.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.7 t -76.76 -31.74 19.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 119.955 -0.698 . . . . 73.310000000000002 109.351 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.68 -19.71 47.11 Favored Glycine 0 C--N 1.306 -1.084 0 N-CA-C 111.068 -0.813 . . . . 73.120000000000005 111.068 176.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.488 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.21 17.08 19.09 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.806 -0.711 . . . . 55.5 112.136 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.6 m -122.73 122.19 38.16 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 108.706 -0.85 . . . . 55.219999999999999 108.706 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 60.5 m -102.47 147.59 26.56 Favored 'General case' 0 C--N 1.274 -2.704 0 CA-C-N 115.746 -0.661 . . . . 62.420000000000002 110.198 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -90.99 -49.83 6.2 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.921 -0.581 . . . . 73.109999999999999 110.909 -178.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.2 m -50.73 113.26 3.52 Favored Pre-proline 0 C--O 1.25 1.119 0 O-C-N 123.987 0.804 . . . . 74.150000000000006 112.194 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.45 116.77 3.48 Favored 'Trans proline' 0 C--N 1.358 1.047 0 C-N-CA 123.19 2.593 . . . . 75.439999999999998 110.831 179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.86 -10.85 20.89 Favored Glycine 0 N--CA 1.424 -2.121 0 C-N-CA 120.3 -0.952 . . . . 53.119999999999997 112.214 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 80.4 m -103.97 156.82 17.55 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 121.636 0.731 . . . . 75.340000000000003 111.31 178.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.79 154.94 47.51 Favored 'General case' 0 C--N 1.271 -2.811 0 CA-C-N 114.465 -1.243 . . . . 74.219999999999999 108.89 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.488 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 t -91.47 87.45 6.41 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.923 -0.769 . . . . 72.540000000000006 108.923 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.3 t -96.84 -59.87 1.71 Allowed 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 116.137 -0.483 . . . . 73.129999999999995 109.711 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 64.2 t-105 -92.07 77.74 5.32 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.678 -0.86 . . . . 72.200000000000003 108.678 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -54.98 139.53 63.24 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 114.818 -1.083 . . . . 74.140000000000001 110.553 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -98.18 36.94 6.53 Favored 'Cis proline' 0 C--N 1.353 0.793 0 C-N-CA 124.663 -0.974 . . . . 64.099999999999994 112.56 1.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -109.47 142.32 22.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 108.588 -0.893 . . . . 74.450000000000003 108.588 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.0 m -87.96 150.4 23.48 Favored 'General case' 0 N--CA 1.416 -2.155 0 C-N-CA 119.355 -0.938 . . . . 53.25 109.34 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.1 p -128.66 160.72 31.58 Favored 'General case' 0 C--N 1.254 -3.548 0 CA-C-N 113.735 -1.575 . . . . 55.299999999999997 109.472 -176.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -88.73 -67.75 0.81 Allowed 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 121.872 0.844 . . . . 72.450000000000003 110.083 -177.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 104.726 -2.324 . . . . 55.539999999999999 104.726 178.548 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.345 0 N-CA-C 109.39 -1.484 . . . . 73.239999999999995 109.39 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 39.4 tp -104.69 120.68 49.48 Favored Pre-proline 0 C--O 1.248 1.023 0 N-CA-C 108.932 -0.766 . . . . 74.409999999999997 108.932 -177.171 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.71 80.76 2.28 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.255 1.97 . . . . 75.340000000000003 112.741 -178.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.04 22.37 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.803 -1.09 . . . . 73.209999999999994 109.029 177.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 78.5 m -100.46 -27.91 13.2 Favored 'General case' 0 N--CA 1.431 -1.375 0 CA-C-N 115.303 -0.862 . . . . 64.200000000000003 110.381 -178.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.83 -10.99 43.5 Favored Glycine 0 C--N 1.303 -1.3 0 CA-C-N 114.977 -1.01 . . . . 64.150000000000006 113.484 177.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -109.9 176.64 4.99 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.768 0.794 . . . . 72.420000000000002 110.942 -177.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.3 p -128.05 163.22 25.05 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 114.315 -1.311 . . . . 71.230000000000004 109.747 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 6.7 p -128.82 87.38 2.57 Favored 'General case' 0 N--CA 1.408 -2.568 0 N-CA-C 108.894 -0.78 . . . . 74.329999999999998 108.894 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 25.7 t -77.96 -33.62 18.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 108.171 -1.048 . . . . 75.319999999999993 108.171 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.01 -20.05 44.46 Favored Glycine 0 N--CA 1.439 -1.106 0 CA-C-N 114.982 -1.008 . . . . 72.109999999999999 111.325 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.423 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 100.06 18.66 21.53 Favored Glycine 0 C--O 1.221 -0.674 0 C-N-CA 120.611 -0.804 . . . . 53.329999999999998 112.342 178.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.1 m -131.04 117.54 19.29 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 108.802 -0.814 . . . . 72.510000000000005 108.802 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 59.8 m -96.38 152.68 18.37 Favored 'General case' 0 C--N 1.281 -2.405 0 CA-C-N 115.94 -0.573 . . . . 63.200000000000003 111.838 -177.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -91.71 -54.1 4.02 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.689 -0.687 . . . . 74.140000000000001 111.194 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.1 m -51.47 112.29 3.0 Favored Pre-proline 0 C--O 1.249 1.04 0 O-C-N 123.952 0.783 . . . . 65.310000000000002 111.329 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.39 113.57 2.32 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.172 1.915 . . . . 60.350000000000001 110.981 -178.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.84 -10.63 8.93 Favored Glycine 0 N--CA 1.42 -2.431 0 N-CA-C 110.738 -0.945 . . . . 62.520000000000003 110.738 -177.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.6 m -104.25 155.31 18.84 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.314 0.578 . . . . 72.530000000000001 109.911 176.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 p -137.55 160.21 39.79 Favored 'General case' 0 C--N 1.275 -2.647 0 CA-C-N 115.043 -0.98 . . . . 74.540000000000006 108.835 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.423 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 12.3 t -85.63 63.54 8.12 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.948 -1.131 . . . . 64.430000000000007 107.948 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.4 t -69.09 -36.33 77.46 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.432 -0.804 . . . . 54.420000000000002 110.573 -177.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -129.91 87.81 2.58 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 108.713 -0.847 . . . . 74.239999999999995 108.713 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -58.17 138.56 84.24 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 123.34 0.656 . . . . 75.329999999999998 109.742 -177.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -99.54 40.19 4.49 Favored 'Cis proline' 0 CA--C 1.54 0.792 0 C-N-CA 125.129 -0.78 . . . . 63.119999999999997 112.956 1.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.1 t -112.53 136.17 49.62 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.794 -0.566 . . . . 73.530000000000001 110.303 -179.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.496 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 72.0 m -88.03 139.85 30.1 Favored 'General case' 0 N--CA 1.408 -2.531 0 N-CA-C 107.558 -1.275 . . . . 65.400000000000006 107.558 174.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -138.34 165.18 27.39 Favored 'General case' 1 C--N 1.238 -4.272 0 CA-C-N 113.514 -1.676 . . . . 74.109999999999999 109.582 -171.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -88.53 -68.1 0.79 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.598 -0.841 . . . . 74.409999999999997 110.232 -175.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 C--N 1.289 -2.062 0 N-CA-C 104.925 -2.25 . . . . 72.549999999999997 104.925 177.496 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.512 0 N-CA-C 111.109 -0.796 . . . . 70.549999999999997 111.109 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 24.2 tp -132.07 117.09 15.81 Favored Pre-proline 0 N--CA 1.45 -0.445 0 N-CA-C 108.866 -0.79 . . . . 65.019999999999996 108.866 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 5.6 Cg_exo -72.34 78.45 1.93 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.583 2.189 . . . . 51.229999999999997 112.482 -178.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.3 m -128.77 17.87 2.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 115.456 -0.793 . . . . 61.350000000000001 110.413 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.4 m -85.36 -25.43 27.09 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.433 -0.803 . . . . 64.25 110.371 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.29 2.73 89.49 Favored Glycine 0 N--CA 1.428 -1.849 0 CA-C-N 114.686 -1.143 . . . . 71.409999999999997 111.945 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.1 pt-20 -119.53 179.37 4.23 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-O 121.632 0.729 . . . . 74.340000000000003 111.707 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.1 p -129.58 162.13 28.95 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.397 -1.274 . . . . 75.219999999999999 110.513 -175.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -131.91 88.04 2.51 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.567 -0.742 . . . . 54.420000000000002 109.208 179.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.7 t -74.21 -35.36 40.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.834 0.826 . . . . 75.230000000000004 109.293 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.04 -17.97 48.88 Favored Glycine 0 C--N 1.311 -0.846 0 CA-C-N 115.289 -0.869 . . . . 64.099999999999994 111.139 176.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.9 14.54 20.81 Favored Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.423 -0.894 . . . . 51.100000000000001 112.385 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.9 m -126.11 132.54 51.86 Favored 'General case' 0 N--CA 1.416 -2.147 0 N-CA-C 109.051 -0.722 . . . . 75.129999999999995 109.051 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.0 m -109.7 149.39 29.82 Favored 'General case' 0 C--N 1.273 -2.753 0 CA-C-N 114.924 -1.035 . . . . 70.310000000000002 109.581 178.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -89.83 -50.29 6.13 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.474 0.484 . . . . 75.010000000000005 112.137 -176.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.421 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 84.8 m -50.73 123.37 18.02 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 113.184 0.809 . . . . 60.219999999999999 113.184 -176.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.421 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.6 Cg_endo -59.72 113.76 1.77 Allowed 'Trans proline' 0 C--N 1.357 0.997 0 C-N-CA 123.096 2.53 . . . . 65.0 111.462 178.738 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.88 -1.46 24.4 Favored Glycine 0 N--CA 1.424 -2.133 0 CA-C-N 115.596 -0.729 . . . . 70.120000000000005 111.524 -178.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.89 156.09 20.85 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-O 121.58 0.705 . . . . 52.409999999999997 111.119 178.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.39 160.88 42.05 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 113.889 -1.505 . . . . 71.219999999999999 108.207 178.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.2 t -97.86 84.87 3.41 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.411 -0.588 . . . . 74.219999999999999 109.411 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 20.4 m -93.08 -26.69 17.36 Favored 'General case' 0 N--CA 1.408 -2.573 0 CA-C-N 116.001 -0.545 . . . . 71.530000000000001 111.131 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -123.21 70.93 1.04 Allowed 'General case' 0 CA--C 1.503 -0.831 0 CA-C-O 120.713 0.292 . . . . 71.200000000000003 110.293 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 87.8 t90 -52.47 134.34 43.77 Favored Pre-proline 0 C--N 1.318 -0.77 0 CA-C-N 115.319 -0.855 . . . . 73.239999999999995 110.407 -178.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 40.0 Cg_endo -99.38 34.2 8.53 Favored 'Cis proline' 0 CA--C 1.543 0.935 0 CA-C-N 119.259 0.771 . . . . 51.109999999999999 113.824 3.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.51 142.07 23.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 108.744 -0.836 . . . . 65.129999999999995 108.744 178.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.414 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.5 m -88.03 154.82 20.18 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.322 1.058 . . . . 72.430000000000007 110.585 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.62 161.83 31.78 Favored 'General case' 0 C--N 1.247 -3.854 0 CA-C-N 113.468 -1.697 . . . . 74.310000000000002 108.777 -176.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -88.44 -66.76 0.89 Allowed 'General case' 0 N--CA 1.409 -2.477 0 N-CA-C 107.963 -1.125 . . . . 75.319999999999993 107.963 177.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.405 HD22 ' HA ' ' A' ' 30' ' ' ASN . 1.9 t-20 . . . . . 0 N--CA 1.416 -2.167 0 N-CA-C 105.469 -2.048 . . . . 63.229999999999997 105.469 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.318 0 N-CA-C 109.774 -1.331 . . . . 54.32 109.774 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.2 tp -113.23 116.69 46.48 Favored Pre-proline 0 C--O 1.24 0.577 0 N-CA-C 109.091 -0.707 . . . . 70.420000000000002 109.091 -178.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.97 81.48 1.66 Allowed 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.089 1.859 . . . . 63.200000000000003 112.542 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.9 m -133.08 22.56 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 114.913 -1.04 . . . . 72.430000000000007 109.412 177.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 72.1 m -92.02 -18.3 23.84 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 122.017 0.913 . . . . 75.530000000000001 109.963 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.43 -19.7 17.73 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-N 114.15 -1.386 . . . . 74.099999999999994 113.599 174.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -102.83 177.15 4.93 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-O 121.505 0.669 . . . . 63.5 111.767 -174.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -124.14 154.75 39.59 Favored 'General case' 0 N--CA 1.414 -2.253 0 CA-C-N 114.555 -1.202 . . . . 75.099999999999994 110.597 -177.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.2 p -123.77 87.32 2.72 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 123.776 0.83 . . . . 61.530000000000001 108.826 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.1 t -73.19 -35.21 46.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 109.108 -0.701 . . . . 75.129999999999995 109.108 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.45 -5.18 63.6 Favored Glycine 0 C--N 1.312 -0.801 0 N-CA-C 111.35 -0.7 . . . . 31.329999999999998 111.35 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.05 9.67 61.99 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.903 -0.665 . . . . 53.32 112.731 178.152 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.2 m -122.53 120.32 33.49 Favored 'General case' 0 N--CA 1.427 -1.598 0 N-CA-C 107.987 -1.116 . . . . 62.399999999999999 107.987 -176.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 66.1 m -92.7 151.83 19.85 Favored 'General case' 0 C--N 1.274 -2.715 0 CA-C-N 115.838 -0.619 . . . . 72.109999999999999 111.808 -177.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -80.69 -55.8 4.59 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.52 -0.764 . . . . 74.310000000000002 109.716 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.4 m -51.26 111.13 2.13 Favored Pre-proline 0 C--O 1.251 1.179 0 C-N-CA 124.215 1.006 . . . . 72.319999999999993 111.791 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -65.58 110.73 1.69 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 122.266 1.977 . . . . 74.299999999999997 109.474 177.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.87 -20.75 5.38 Favored Glycine 0 C--N 1.293 -1.855 0 N-CA-C 110.892 -0.883 . . . . 71.209999999999994 110.892 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.1 m -100.76 157.37 16.75 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 121.332 0.587 . . . . 54.439999999999998 109.894 177.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -139.0 161.76 36.58 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 114.822 -1.081 . . . . 73.299999999999997 109.339 -178.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.1 t -95.18 82.58 3.77 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.523 -0.547 . . . . 70.150000000000006 109.523 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.0 t -96.31 -13.73 23.1 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 116.377 -0.374 . . . . 73.420000000000002 110.463 -178.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 55.6 t-105 -136.2 79.04 1.75 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 108.621 -0.881 . . . . 71.329999999999998 108.621 177.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.1 t90 -58.25 136.89 84.91 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 115.322 -0.854 . . . . 71.329999999999998 110.375 -176.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -100.53 36.05 6.78 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.717 -0.951 . . . . 52.25 113.529 2.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -110.31 144.4 18.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 109.124 -0.695 . . . . 61.420000000000002 109.124 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.5 m -88.62 147.62 24.47 Favored 'General case' 0 N--CA 1.418 -2.07 0 CA-C-O 122.592 1.187 . . . . 65.140000000000001 111.168 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.6 p -127.4 156.19 42.45 Favored 'General case' 0 C--N 1.256 -3.474 0 CA-C-N 113.258 -1.792 . . . . 75.530000000000001 110.789 -173.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 21.1 tpt180 -89.75 -67.1 0.86 Allowed 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.824 0.821 . . . . 72.219999999999999 111.154 -176.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 N--CA 1.42 -1.954 0 N-CA-C 104.978 -2.231 . . . . 74.230000000000004 104.978 179.377 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.408 -3.172 0 N-CA-C 109.997 -1.241 . . . . 73.140000000000001 109.997 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.8 tp -127.0 118.68 22.17 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.065 -0.717 . . . . 61.229999999999997 109.065 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -74.59 78.47 2.74 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 122.198 1.932 . . . . 74.329999999999998 112.998 -178.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 m -129.86 16.21 2.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 CA-C-N 114.897 -1.047 . . . . 72.400000000000006 110.362 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 83.2 m -84.2 -25.48 29.48 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 121.614 0.721 . . . . 64.409999999999997 109.801 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.26 -12.51 60.31 Favored Glycine 0 N--CA 1.425 -2.08 0 CA-C-N 114.455 -1.248 . . . . 74.329999999999998 112.814 176.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -104.69 178.1 4.66 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.823 0.82 . . . . 64.239999999999995 111.09 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.7 p -132.99 154.64 50.31 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 114.65 -1.159 . . . . 74.450000000000003 109.764 -177.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.9 p -110.98 89.9 3.18 Favored 'General case' 0 N--CA 1.41 -2.461 0 N-CA-C 108.416 -0.957 . . . . 64.310000000000002 108.416 177.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.1 t -80.18 -33.61 14.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 70.510000000000005 108.312 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.08 -16.76 57.26 Favored Glycine 0 N--CA 1.44 -1.089 0 N-CA-C 110.761 -0.936 . . . . 64.109999999999999 110.761 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.31 13.3 31.21 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.872 -0.68 . . . . 42.229999999999997 113.254 176.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -136.2 128.4 29.9 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.009 -1.108 . . . . 72.099999999999994 108.009 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.9 m -92.14 148.67 21.99 Favored 'General case' 0 C--N 1.271 -2.828 0 CA-C-N 116.255 -0.429 . . . . 74.219999999999999 110.657 -178.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 46.3 t30 -84.82 -55.89 3.86 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.847 -0.615 . . . . 70.5 110.371 -178.045 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.7 m -51.27 114.62 5.14 Favored Pre-proline 0 CA--C 1.554 1.106 0 O-C-N 124.148 0.905 . . . . 65.329999999999998 111.89 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.69 116.07 3.31 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 122.398 2.066 . . . . 74.109999999999999 110.183 178.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 118.14 -4.95 15.84 Favored Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 110.64 -0.984 . . . . 62.340000000000003 110.64 -176.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -112.76 150.6 31.37 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.483 0.658 . . . . 62.130000000000003 110.695 176.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.3 p -134.23 150.93 51.07 Favored 'General case' 0 C--N 1.275 -2.635 0 CA-C-N 114.81 -1.086 . . . . 75.120000000000005 110.044 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.6 t -91.07 85.59 5.97 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.751 -1.203 . . . . 63.439999999999998 107.751 177.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.1 t -77.76 -51.71 10.1 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.413 -0.812 . . . . 65.430000000000007 109.7 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 8.9 p-90 -125.49 102.11 7.24 Favored 'General case' 0 N--CA 1.427 -1.598 0 CA-C-O 122.12 0.962 . . . . 74.230000000000004 110.652 177.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 76.4 t90 -58.82 140.18 86.23 Favored Pre-proline 0 C--N 1.302 -1.463 0 CA-C-N 113.678 -1.601 . . . . 72.510000000000005 109.255 -178.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.3 Cg_endo -102.15 36.44 5.95 Favored 'Cis proline' 0 CA--C 1.543 0.941 0 C-N-CA 124.703 -0.957 . . . . 71.340000000000003 114.189 3.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -118.41 143.91 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.235 -0.915 . . . . 74.140000000000001 110.787 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.6 m -89.12 162.33 16.02 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 121.878 0.847 . . . . 75.239999999999995 110.774 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.8 p -136.93 160.43 38.93 Favored 'General case' 0 C--N 1.276 -2.605 0 CA-C-N 114.49 -1.232 . . . . 74.310000000000002 109.072 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 25.8 tpt180 -89.1 -69.2 0.72 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-O 121.819 0.819 . . . . 63.140000000000001 109.743 -178.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 N--CA 1.41 -2.455 0 N-CA-C 105.177 -2.156 . . . . 72.109999999999999 105.177 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.399 -3.808 0 N-CA-C 109.49 -1.444 . . . . 71.409999999999997 109.49 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.468 ' HG ' HG13 ' A' ' 4' ' ' VAL . 34.9 tp -124.38 117.8 26.54 Favored Pre-proline 0 N--CA 1.443 -0.823 0 N-CA-C 109.162 -0.681 . . . . 75.420000000000002 109.162 -177.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -72.17 83.5 1.21 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 122.07 1.847 . . . . 73.120000000000005 111.863 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.468 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.1 m -132.4 20.41 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.12 -0.946 . . . . 70.319999999999993 109.891 178.406 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 81.0 m -90.05 -22.87 21.63 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.076 -0.966 . . . . 73.310000000000002 110.595 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 78.95 -4.92 59.98 Favored Glycine 0 C--N 1.3 -1.47 0 CA-C-N 114.881 -1.054 . . . . 63.329999999999998 113.71 176.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -116.57 175.54 5.52 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 120.214 -0.595 . . . . 65.299999999999997 110.484 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -127.43 148.14 50.29 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.488 -0.778 . . . . 53.200000000000003 110.475 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.468 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 6.2 p -113.23 87.94 2.72 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 109.482 -0.562 . . . . 63.210000000000001 109.482 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.3 t -79.74 -30.18 13.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.661 -0.866 . . . . 70.140000000000001 108.661 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.49 -15.75 58.03 Favored Glycine 0 N--CA 1.435 -1.375 0 CA-C-N 115.213 -0.903 . . . . 72.030000000000001 110.996 177.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.98 15.89 34.86 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.449 -0.882 . . . . 51.310000000000002 112.827 177.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.7 m -143.18 125.79 15.89 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.334 -0.987 . . . . 55.32 108.334 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 33.3 m -96.79 154.44 17.29 Favored 'General case' 0 C--N 1.274 -2.678 0 CA-C-N 115.755 -0.657 . . . . 52.130000000000003 110.846 -176.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -77.56 -53.2 7.88 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.901 -0.59 . . . . 73.510000000000005 110.451 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 33.5 m -50.99 113.09 3.44 Favored Pre-proline 0 C--O 1.253 1.268 0 C-N-CA 124.049 0.939 . . . . 72.230000000000004 112.945 -177.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.72 119.43 6.65 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.565 2.177 . . . . 73.150000000000006 109.614 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.55 -3.77 27.84 Favored Glycine 0 N--CA 1.426 -1.978 0 C-N-CA 120.622 -0.799 . . . . 61.240000000000002 111.505 -179.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.3 m -111.01 154.77 23.71 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.683 0.754 . . . . 74.450000000000003 110.639 175.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -137.83 161.02 37.7 Favored 'General case' 0 C--N 1.274 -2.676 0 CA-C-N 114.683 -1.144 . . . . 70.430000000000007 109.754 -178.304 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 17.6 t -95.68 83.23 3.71 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 121.178 0.514 . . . . 70.400000000000006 109.694 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 t -89.15 -51.48 5.56 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.242 -0.435 . . . . 74.030000000000001 109.976 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.1 t-105 -105.47 80.86 1.62 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 109.527 -0.546 . . . . 73.439999999999998 109.527 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.6 t90 -57.03 136.57 80.25 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.432 -0.804 . . . . 71.299999999999997 109.984 -177.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -100.09 35.31 7.41 Favored 'Cis proline' 0 CA--C 1.544 1.017 0 C-N-CA 124.686 -0.964 . . . . 75.310000000000002 113.715 1.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.1 142.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 108.824 -0.806 . . . . 62.030000000000001 108.824 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.1 m -88.3 153.18 21.41 Favored 'General case' 0 N--CA 1.424 -1.737 0 C-N-CA 119.422 -0.911 . . . . 74.099999999999994 110.236 179.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -132.02 155.42 48.06 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.106 -1.406 . . . . 61.520000000000003 110.291 -177.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -91.99 -68.79 0.77 Allowed 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.993 0.901 . . . . 72.0 111.153 -176.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p30 . . . . . 0 C--N 1.299 -1.596 0 N-CA-C 105.505 -2.035 . . . . 61.149999999999999 105.505 179.944 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.564 0 N-CA-C 111.219 -0.752 . . . . 73.530000000000001 111.219 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.1 tp -109.1 113.48 59.01 Favored Pre-proline 0 C--N 1.328 -0.362 0 C-N-CA 120.108 -0.637 . . . . 60.030000000000001 110.529 -175.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -73.52 81.01 1.88 Allowed 'Trans proline' 0 N--CA 1.444 -1.427 0 C-N-CA 121.497 1.465 . . . . 73.230000000000004 112.674 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.5 m -126.78 24.18 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 122.326 1.06 . . . . 74.299999999999997 109.877 175.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 37.2 m -84.57 -27.59 27.18 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 114.554 -1.203 . . . . 63.039999999999999 108.051 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.54 -7.77 64.01 Favored Glycine 0 N--CA 1.438 -1.211 0 CA-C-N 113.507 -1.679 . . . . 73.530000000000001 112.702 177.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -107.52 -177.2 3.28 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.225 0.536 . . . . 52.340000000000003 110.893 -177.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 p -135.36 164.2 28.3 Favored 'General case' 0 N--CA 1.421 -1.915 0 CA-C-N 114.465 -1.243 . . . . 72.340000000000003 108.781 -179.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -126.73 80.2 1.92 Allowed 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 116.538 -0.301 . . . . 61.009999999999998 110.677 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.1 t -77.56 -26.51 15.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 108.423 -0.955 . . . . 74.239999999999995 108.423 178.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.74 -7.64 68.51 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 110.447 -1.061 . . . . 74.040000000000006 110.447 176.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.99 10.54 69.06 Favored Glycine 0 C--O 1.218 -0.861 0 C-N-CA 121.375 -0.441 . . . . 73.439999999999998 112.212 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -127.72 123.77 36.2 Favored 'General case' 0 N--CA 1.419 -2.01 0 N-CA-C 108.243 -1.021 . . . . 74.299999999999997 108.243 -176.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.1 m -95.65 149.7 21.17 Favored 'General case' 0 C--N 1.277 -2.564 0 N-CA-C 109.483 -0.562 . . . . 73.430000000000007 109.483 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -90.19 -54.56 3.97 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 123.12 0.568 . . . . 65.439999999999998 111.698 -177.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.478 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.1 m -51.22 119.39 12.36 Favored Pre-proline 0 CA--C 1.562 1.441 0 O-C-N 123.838 0.711 . . . . 74.420000000000002 112.75 -178.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.27 118.57 5.46 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 123.089 2.526 . . . . 70.219999999999999 111.174 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.42 5.13 37.28 Favored Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 120.728 -0.749 . . . . 60.210000000000001 111.389 -179.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.478 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.5 m -103.88 159.64 15.48 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-O 121.528 0.68 . . . . 74.219999999999999 111.057 175.139 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 p -140.34 146.34 38.34 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 114.76 -1.109 . . . . 75.439999999999998 109.627 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.1 t -92.68 87.35 5.86 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.218 -1.401 . . . . 61.119999999999997 107.218 176.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 19.6 t -88.16 -70.23 0.65 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 109.262 -0.644 . . . . 74.109999999999999 109.262 -177.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.8 m-90 -91.0 87.36 6.58 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 108.301 -1.0 . . . . 75.200000000000003 108.301 177.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 90.3 t90 -54.82 135.6 65.5 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.378 -0.601 . . . . 64.030000000000001 109.378 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.4 Cg_endo -102.13 39.93 4.14 Favored 'Cis proline' 0 CA--C 1.545 1.072 0 CA-C-N 119.365 0.809 . . . . 61.32 113.212 2.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.0 t -107.02 130.43 59.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.92 -0.487 . . . . 65.420000000000002 109.829 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -88.9 152.26 21.84 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-O 121.998 0.904 . . . . 62.32 110.177 178.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.5 p -134.01 171.0 14.81 Favored 'General case' 0 C--N 1.266 -3.03 0 CA-C-N 113.946 -1.479 . . . . 64.030000000000001 108.236 -178.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.474 ' C ' HD22 ' A' ' 30' ' ' ASN . 28.1 mmm180 -87.94 -78.96 0.3 Allowed 'General case' 0 N--CA 1.4 -2.935 0 N-CA-C 107.926 -1.138 . . . . 65.540000000000006 107.926 175.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.474 HD22 ' C ' ' A' ' 29' ' ' ARG . 0.9 OUTLIER . . . . . 0 C--N 1.292 -1.906 0 N-CA-C 105.136 -2.172 . . . . 74.129999999999995 105.136 174.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.926 0 N-CA-C 108.772 -1.731 . . . . 61.229999999999997 108.772 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.0 tp -123.24 119.0 27.65 Favored Pre-proline 0 C--O 1.247 0.945 0 CA-C-N 115.043 -0.578 . . . . 73.519999999999996 109.837 -178.024 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -73.73 81.28 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.432 2.088 . . . . 74.219999999999999 112.552 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.88 20.4 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.204 -0.907 . . . . 75.519999999999996 109.405 177.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.5 m -89.48 -30.09 18.53 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.211 -0.904 . . . . 74.140000000000001 109.753 178.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.94 -1.56 88.34 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-N 114.739 -1.119 . . . . 42.340000000000003 112.724 178.062 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -119.84 179.79 4.14 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.339 0.59 . . . . 64.530000000000001 111.436 -178.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 p -128.18 168.2 15.75 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.908 -1.042 . . . . 62.219999999999999 110.318 -177.042 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.1 p -135.28 86.89 2.28 Favored 'General case' 0 N--CA 1.419 -1.977 0 N-CA-C 109.315 -0.624 . . . . 64.040000000000006 109.315 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -77.0 -33.06 20.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 108.649 -0.871 . . . . 75.400000000000006 108.649 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.64 -28.23 17.11 Favored Glycine 0 N--CA 1.436 -1.362 0 N-CA-C 110.456 -1.058 . . . . 73.010000000000005 110.456 175.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.68 12.51 11.44 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.558 -0.829 . . . . 65.239999999999995 112.552 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -118.93 116.56 26.72 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.663 -0.866 . . . . 72.340000000000003 108.663 -176.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 40.7 m -95.13 137.21 34.48 Favored 'General case' 0 C--N 1.274 -2.684 0 N-CA-C 109.393 -0.595 . . . . 61.210000000000001 109.393 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -76.99 -51.4 11.19 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.47 -0.332 . . . . 55.310000000000002 110.462 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 61.9 m -51.77 116.59 8.25 Favored Pre-proline 0 C--O 1.259 1.584 0 O-C-N 124.011 0.82 . . . . 73.530000000000001 112.326 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.1 118.41 5.31 Favored 'Trans proline' 0 N--CA 1.446 -1.311 0 C-N-CA 122.227 1.952 . . . . 62.439999999999998 109.686 177.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.34 -4.13 23.51 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 120.256 -0.973 . . . . 20.140000000000001 111.092 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 58.4 m -109.37 148.13 31.6 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 119.353 -0.939 . . . . 62.329999999999998 110.363 175.569 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.5 p -134.53 148.52 50.52 Favored 'General case' 0 C--N 1.257 -3.448 0 CA-C-N 114.12 -1.4 . . . . 74.340000000000003 109.259 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.1 t -85.31 75.35 10.27 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.159 -1.052 . . . . 72.150000000000006 108.159 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 16.8 m -73.23 -44.01 60.25 Favored 'General case' 0 N--CA 1.407 -2.59 0 CA-C-N 115.437 -0.801 . . . . 71.030000000000001 110.633 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 62.0 t90 -125.36 97.2 5.11 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.771 -0.826 . . . . 73.430000000000007 108.771 178.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.405 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.4 t90 -58.56 138.97 85.77 Favored Pre-proline 0 C--N 1.303 -1.449 0 CA-C-N 114.913 -1.039 . . . . 72.120000000000005 109.597 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 86.0 Cg_endo -102.49 36.75 5.63 Favored 'Cis proline' 0 CA--C 1.54 0.813 0 C-N-CA 124.948 -0.855 . . . . 71.230000000000004 113.41 1.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.4 t -113.25 138.96 40.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 121.9 -0.5 . . . . 63.520000000000003 110.104 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -88.35 151.51 22.55 Favored 'General case' 0 N--CA 1.417 -2.098 0 N-CA-C 108.735 -0.839 . . . . 64.420000000000002 108.735 177.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.2 p -137.64 160.89 37.94 Favored 'General case' 0 C--N 1.252 -3.665 0 CA-C-N 114.539 -1.209 . . . . 64.109999999999999 109.582 -177.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -90.93 -60.8 1.82 Allowed 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 121.46 0.647 . . . . 73.400000000000006 111.106 -177.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 N--CA 1.424 -1.749 0 N-CA-C 105.58 -2.007 . . . . 64.329999999999998 105.58 178.556 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.405 -3.4 0 N-CA-C 110.326 -1.11 . . . . 74.400000000000006 110.326 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HG ' HG13 ' A' ' 4' ' ' VAL . 47.5 tp -110.46 116.64 52.47 Favored Pre-proline 0 C--O 1.24 0.591 0 N-CA-C 109.437 -0.579 . . . . 62.109999999999999 109.437 -177.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -73.2 81.32 1.74 Allowed 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.227 1.951 . . . . 51.329999999999998 112.122 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.432 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.5 m -131.66 12.45 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.293 -0.867 . . . . 75.239999999999995 110.731 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 64.7 m -80.89 -35.88 32.0 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.848 0.833 . . . . 75.450000000000003 109.105 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.26 -0.64 88.73 Favored Glycine 0 N--CA 1.426 -1.987 0 CA-C-N 114.84 -1.073 . . . . 52.329999999999998 112.032 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.57 177.21 4.73 Favored 'General case' 0 C--O 1.255 1.377 0 CA-C-O 121.399 0.618 . . . . 63.039999999999999 110.848 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 p -130.8 168.2 17.63 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 114.596 -1.184 . . . . 70.129999999999995 110.945 -175.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -135.81 87.36 2.31 Favored 'General case' 0 N--CA 1.417 -2.124 0 CA-C-N 115.577 -0.738 . . . . 74.129999999999995 109.782 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.13 -30.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 N-CA-C 108.082 -1.081 . . . . 74.109999999999999 108.082 177.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.66 -6.65 69.98 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.117 -0.947 . . . . 64.5 111.421 177.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.02 24.72 40.07 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 120.679 -0.772 . . . . 50.130000000000003 112.921 176.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 31.7 m -147.06 127.56 14.09 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.942 -0.762 . . . . 73.140000000000001 108.942 177.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.58 152.39 18.57 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.826 -0.624 . . . . 75.530000000000001 110.463 -178.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -83.8 -57.71 3.1 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.114 -0.494 . . . . 74.310000000000002 111.241 -176.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.402 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 49.8 m -51.96 117.78 10.62 Favored Pre-proline 0 C--O 1.248 0.999 0 O-C-N 123.735 0.647 . . . . 62.539999999999999 112.312 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -62.76 111.45 1.36 Allowed 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.446 2.097 . . . . 71.109999999999999 109.557 176.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 126.11 -10.62 7.37 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 111.089 -0.804 . . . . 63.009999999999998 111.089 -176.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.402 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 67.5 m -100.44 154.94 18.12 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-O 121.576 0.703 . . . . 74.25 109.85 175.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 p -136.19 143.49 44.43 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-N 114.759 -1.109 . . . . 71.120000000000005 109.15 -178.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.0 t -90.96 84.39 5.76 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 106.665 -1.606 . . . . 74.0 106.665 176.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 17.9 t -104.73 -16.28 15.0 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.802 -0.635 . . . . 75.5 110.642 -175.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 84.6 m95 -133.99 72.0 1.46 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.12 -1.066 . . . . 65.340000000000003 108.12 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 82.2 t90 -54.95 135.47 66.77 Favored Pre-proline 0 C--O 1.244 0.787 0 CA-C-N 114.41 -1.268 . . . . 73.120000000000005 110.331 -174.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 45.0 Cg_endo -99.43 34.54 8.22 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 C-N-CA 124.662 -0.974 . . . . 71.430000000000007 113.756 3.389 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.9 t -107.23 139.21 29.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 121.905 -0.497 . . . . 70.319999999999993 109.808 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 94.8 m -88.83 154.62 20.11 Favored 'General case' 0 N--CA 1.416 -2.155 0 CA-C-O 122.137 0.97 . . . . 62.229999999999997 109.758 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.2 p -138.93 166.02 25.57 Favored 'General case' 0 C--N 1.257 -3.414 0 CA-C-N 114.129 -1.396 . . . . 73.439999999999998 107.957 -178.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -88.93 -70.59 0.64 Allowed 'General case' 0 N--CA 1.419 -2.005 0 C-N-CA 119.001 -1.08 . . . . 74.349999999999994 108.93 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 C--N 1.303 -1.455 0 N-CA-C 104.797 -2.297 . . . . 52.130000000000003 104.797 179.513 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -2.138 0 N-CA-C 109.503 -1.439 . . . . 64.140000000000001 109.503 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.528 ' HG ' HG13 ' A' ' 4' ' ' VAL . 55.8 tp -110.37 109.78 58.3 Favored Pre-proline 0 C--O 1.246 0.897 0 CA-C-N 114.868 -0.666 . . . . 71.439999999999998 109.224 -177.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -75.46 83.7 1.85 Allowed 'Trans proline' 0 N--CA 1.434 -1.977 0 C-N-CA 121.945 1.763 . . . . 75.0 111.179 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.528 HG13 ' HG ' ' A' ' 2' ' ' LEU . 8.4 m -123.01 19.96 4.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.39 -0.823 . . . . 75.420000000000002 110.044 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 57.4 m -108.1 -24.25 11.64 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-N 115.611 -0.722 . . . . 61.240000000000002 111.86 177.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.76 -15.52 14.37 Favored Glycine 0 C--O 1.246 0.869 0 CA-C-N 115.421 -0.809 . . . . 64.310000000000002 114.361 176.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.45 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 15.7 pt-20 -94.98 174.27 7.17 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.635 0.731 . . . . 63.43 111.531 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.0 p -125.9 161.32 27.72 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 114.765 -1.107 . . . . 74.400000000000006 109.95 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -122.2 90.73 3.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.804 -0.813 . . . . 71.219999999999999 108.804 178.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.53 -37.08 18.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.841 -0.8 . . . . 72.430000000000007 108.841 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.43 -14.88 59.43 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.555 -0.748 . . . . 50.140000000000001 111.348 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.03 20.25 16.79 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.447 -0.882 . . . . 70.430000000000007 113.453 176.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 59.0 m -141.95 127.54 19.04 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.981 -0.748 . . . . 75.530000000000001 108.981 177.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 33.9 m -100.17 162.68 12.81 Favored 'General case' 0 C--N 1.278 -2.528 0 CA-C-N 115.541 -0.754 . . . . 64.230000000000004 109.887 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -94.96 -49.57 5.49 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.559 -0.291 . . . . 72.109999999999999 110.446 -177.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.5 m -52.47 120.37 17.8 Favored Pre-proline 0 C--O 1.264 1.86 0 O-C-N 123.96 0.787 . . . . 65.430000000000007 112.347 -176.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -62.78 114.23 2.32 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.136 1.891 . . . . 65.010000000000005 109.664 177.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.84 -21.87 6.96 Favored Glycine 0 N--CA 1.428 -1.843 0 C-N-CA 120.456 -0.878 . . . . 72.129999999999995 112.112 -177.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -107.1 154.26 21.42 Favored 'General case' 0 CA--C 1.481 -1.69 0 CA-C-O 122.246 1.022 . . . . 70.140000000000001 112.812 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 p -139.39 167.58 21.76 Favored 'General case' 0 C--N 1.274 -2.688 0 CA-C-N 113.274 -1.785 . . . . 71.409999999999997 108.848 -178.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 9.6 t -90.64 64.71 5.78 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.882 -1.155 . . . . 62.340000000000003 107.882 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.2 m -65.07 -26.58 68.3 Favored 'General case' 0 N--CA 1.423 -1.798 0 CA-C-N 115.174 -0.921 . . . . 53.140000000000001 111.024 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -145.87 106.96 4.15 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.726 -1.213 . . . . 75.109999999999999 107.726 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.5 t90 -67.35 139.31 94.58 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 108.962 -0.755 . . . . 74.340000000000003 108.962 -177.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 43.2 Cg_endo -104.9 36.7 4.76 Favored 'Cis proline' 0 CA--C 1.537 0.656 0 C-N-CA 125.107 -0.789 . . . . 75.510000000000005 113.03 1.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.5 p -112.6 136.54 48.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-O 121.618 0.723 . . . . 72.439999999999998 111.404 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 65.1 m -88.59 138.44 31.43 Favored 'General case' 0 N--CA 1.409 -2.515 0 CA-C-O 122.482 1.134 . . . . 61.119999999999997 109.19 179.034 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -139.92 164.51 29.81 Favored 'General case' 1 C--N 1.243 -4.045 0 CA-C-N 113.2 -1.818 . . . . 63.509999999999998 109.304 -175.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -87.48 -66.36 0.92 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.59 -0.892 . . . . 74.310000000000002 108.59 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.8 p30 . . . . . 0 N--CA 1.426 -1.663 0 N-CA-C 105.139 -2.171 . . . . 62.030000000000001 105.139 175.87 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.938 0 N-CA-C 109.083 -1.607 . . . . 74.510000000000005 109.083 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.402 ' HG ' HG13 ' A' ' 4' ' ' VAL . 46.5 tp -104.28 115.11 63.58 Favored Pre-proline 0 C--O 1.245 0.844 0 N-CA-C 109.038 -0.727 . . . . 74.299999999999997 109.038 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -73.5 80.27 2.01 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.268 1.979 . . . . 75.310000000000002 112.606 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.402 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.0 m -131.66 8.96 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 115.744 -0.662 . . . . 55.130000000000003 110.781 178.366 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.1 m -91.84 -30.29 16.27 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-O 121.784 0.802 . . . . 75.439999999999998 109.461 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.71 -12.61 46.8 Favored Glycine 0 N--CA 1.427 -1.934 0 CA-C-N 114.521 -1.218 . . . . 54.340000000000003 113.953 176.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -100.49 172.4 7.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.094 -1.042 . . . . 63.020000000000003 111.802 -176.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 p -126.51 154.75 43.37 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 114.337 -1.301 . . . . 74.329999999999998 109.802 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.45 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 5.5 p -120.57 86.06 2.5 Favored 'General case' 0 N--CA 1.408 -2.54 0 N-CA-C 107.818 -1.178 . . . . 75.310000000000002 107.818 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 44.5 t -69.89 -33.6 56.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 N-CA-C 108.655 -0.868 . . . . 61.219999999999999 108.655 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.32 -32.15 7.56 Favored Glycine 0 N--CA 1.429 -1.792 0 CA-C-N 115.403 -0.817 . . . . 71.430000000000007 111.41 176.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 118.45 13.89 6.64 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.042 -1.075 . . . . 62.200000000000003 112.436 -178.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.0 m -126.08 112.04 15.38 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.213 -0.662 . . . . 64.040000000000006 109.213 -177.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.0 m -95.28 150.11 20.61 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.261 -0.881 . . . . 73.040000000000006 110.766 -176.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -90.84 -54.93 3.76 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 123.203 0.601 . . . . 72.150000000000006 111.065 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 57.5 m -50.19 117.97 8.5 Favored Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 113.169 0.803 . . . . 74.239999999999995 113.169 -176.042 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.9 123.01 12.71 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 123.249 2.633 . . . . 54.520000000000003 111.028 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.06 57.08 Favored Glycine 0 N--CA 1.427 -1.931 0 C-N-CA 120.733 -0.746 . . . . 42.509999999999998 112.148 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.9 m -100.77 155.26 18.01 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.291 -0.564 . . . . 62.450000000000003 109.644 177.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -140.85 155.43 46.34 Favored 'General case' 0 C--N 1.277 -2.575 0 CA-C-N 115.111 -0.95 . . . . 55.310000000000002 109.528 -174.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.415 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 24.5 t -84.78 79.6 9.56 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.409 -1.7 . . . . 71.439999999999998 106.409 175.168 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.449 ' HB3' ' OG1' ' A' ' 28' ' ' THR . 23.1 t -87.03 -28.36 22.65 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 115.036 -0.984 . . . . 42.43 110.389 -175.416 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.0 t-105 -135.94 85.46 2.16 Favored 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 107.95 -1.13 . . . . 75.439999999999998 107.95 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -58.45 135.84 85.58 Favored Pre-proline 0 C--N 1.307 -1.252 0 N-CA-C 109.396 -0.594 . . . . 73.099999999999994 109.396 -179.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -99.09 35.64 7.47 Favored 'Cis proline' 0 CA--C 1.553 1.445 0 N-CA-C 114.888 1.072 . . . . 71.310000000000002 114.888 5.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.6 t -112.81 135.51 52.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.607 -0.683 . . . . 75.230000000000004 109.669 179.166 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 63.4 m -88.96 146.7 24.73 Favored 'General case' 0 N--CA 1.415 -2.182 0 N-CA-C 106.721 -1.585 . . . . 63.109999999999999 106.721 174.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.449 ' OG1' ' HB3' ' A' ' 22' ' ' SER . 15.0 p -139.59 179.04 6.8 Favored 'General case' 0 C--N 1.248 -3.809 0 N-CA-C 108.286 -1.005 . . . . 64.129999999999995 108.286 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 20.0 tpt180 -88.49 -73.86 0.48 Allowed 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.77 -0.772 . . . . 70.239999999999995 109.513 -177.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.427 -1.583 0 N-CA-C 104.972 -2.233 . . . . 71.25 104.972 176.68 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.398 -3.885 0 N-CA-C 109.746 -1.341 . . . . 0.0 109.746 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.414 ' HG ' HG13 ' A' ' 4' ' ' VAL . 24.8 tp -120.93 120.91 29.12 Favored Pre-proline 0 C--N 1.32 -0.685 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -177.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -70.89 83.26 0.91 Allowed 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.295 1.997 . . . . 0.0 111.804 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.414 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.0 m -130.61 11.02 2.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.483 179.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.1 m -80.56 -28.4 37.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.443 -177.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.24 4.69 90.43 Favored Glycine 0 N--CA 1.427 -1.95 0 CA-C-N 114.93 -1.032 . . . . 0.0 112.009 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.28 -176.65 3.56 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.237 0.541 . . . . 0.0 110.204 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.7 p -133.23 160.33 37.57 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.124 -177.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.5 p -126.49 84.84 2.31 Favored 'General case' 0 C--N 1.287 -2.116 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.461 178.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.65 -31.3 41.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.18 5.09 55.61 Favored Glycine 0 N--CA 1.44 -1.081 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.795 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 81.44 11.93 82.6 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.198 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.0 m -116.64 110.72 18.87 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -178.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.7 m -89.54 146.5 24.55 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-O 120.981 0.42 . . . . 0.0 110.479 177.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -81.38 -62.14 1.74 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.255 -177.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.426 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.5 m -51.19 118.18 10.19 Favored Pre-proline 0 C--O 1.251 1.133 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -59.45 118.49 5.39 Favored 'Trans proline' 0 C--N 1.354 0.858 0 C-N-CA 122.887 2.391 . . . . 0.0 109.936 175.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.23 -12.12 14.32 Favored Glycine 0 C--N 1.293 -1.857 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 78.8 m -99.13 154.98 17.7 Favored 'General case' 0 N--CA 1.433 -1.314 0 CA-C-O 121.633 0.73 . . . . 0.0 110.082 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -141.55 153.26 44.74 Favored 'General case' 0 C--N 1.268 -2.958 0 C-N-CA 125.465 1.506 . . . . 0.0 107.697 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.483 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 31.0 t -96.69 83.91 3.54 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-O 121.38 0.61 . . . . 0.0 110.06 -179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.4 m -88.11 -51.78 5.6 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.017 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.5 m95 -102.03 75.27 1.51 Allowed 'General case' 0 N--CA 1.444 -0.765 0 C-N-CA 120.247 -0.581 . . . . 0.0 110.064 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 88.7 t90 -55.6 136.43 70.91 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.13 -178.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 18.0 Cg_endo -99.42 36.22 6.95 Favored 'Cis proline' 0 CA--C 1.541 0.85 0 C-N-CA 124.874 -0.886 . . . . 0.0 113.918 4.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 53.6 t -110.58 143.06 21.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.2 m -87.76 155.32 19.96 Favored 'General case' 0 N--CA 1.42 -1.937 0 CA-C-O 122.201 1.0 . . . . 0.0 110.5 -178.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.8 p -138.79 153.66 48.43 Favored 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.814 -1.539 . . . . 0.0 109.329 -174.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.9 tpp180 -89.82 -67.37 0.85 Allowed 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 119.873 -0.731 . . . . 0.0 109.91 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 105.032 -2.21 . . . . 0.0 105.032 -177.026 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -3.001 0 N-CA-C 108.918 -1.673 . . . . 73.030000000000001 108.918 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -120.94 111.49 34.12 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.517 -1.29 . . . . 70.329999999999998 107.517 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.61 78.63 2.0 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 122.093 1.862 . . . . 54.32 113.604 -177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.01 27.84 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 122.381 1.086 . . . . 72.049999999999997 108.645 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.4 m -90.2 -21.79 22.0 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 114.129 -1.396 . . . . 55.539999999999999 110.468 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.87 -4.29 53.57 Favored Glycine 0 C--N 1.303 -1.298 0 CA-C-N 114.42 -1.263 . . . . 72.340000000000003 113.983 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.428 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.6 pt-20 -117.11 179.33 4.06 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 122.24 -0.565 . . . . 75.019999999999996 111.438 -178.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.3 p -124.21 157.36 34.98 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.359 -0.837 . . . . 63.210000000000001 110.979 -175.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -127.89 83.66 2.18 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.718 -0.475 . . . . 73.420000000000002 109.718 178.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.36 -35.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.481 -0.933 . . . . 54.100000000000001 108.481 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.8 -14.57 59.35 Favored Glycine 0 N--CA 1.435 -1.368 0 CA-C-N 115.237 -0.892 . . . . 54.420000000000002 110.977 177.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.27 32.9 7.97 Favored Glycine 0 N--CA 1.432 -1.594 0 C-N-CA 120.131 -1.033 . . . . 74.109999999999999 111.537 179.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -142.84 122.45 13.3 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-O 121.274 0.559 . . . . 73.109999999999999 109.777 177.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.3 m -104.06 145.38 30.26 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 115.057 -0.974 . . . . 61.420000000000002 110.572 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 38.3 m-80 -86.57 -49.87 7.23 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.522 0.729 . . . . 71.319999999999993 111.527 -176.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 65.4 m -50.27 116.2 6.33 Favored Pre-proline 0 C--O 1.249 1.072 0 O-C-N 124.039 0.837 . . . . 71.329999999999998 112.101 -178.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.81 118.87 5.71 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 123.365 2.71 . . . . 75.230000000000004 111.611 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.13 -3.23 33.33 Favored Glycine 0 N--CA 1.426 -1.977 0 CA-C-N 115.699 -0.682 . . . . 44.240000000000002 111.552 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.482 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 84.9 m -102.44 155.53 18.2 Favored 'General case' 0 N--CA 1.432 -1.351 0 CA-C-O 122.043 0.925 . . . . 73.319999999999993 111.582 178.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -140.5 156.8 46.22 Favored 'General case' 0 C--N 1.27 -2.863 0 CA-C-N 113.715 -1.584 . . . . 74.510000000000005 107.903 179.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.4 t -92.64 80.93 4.76 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.901 -0.778 . . . . 73.239999999999995 108.901 175.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.2 m -83.66 -39.92 19.61 Favored 'General case' 0 N--CA 1.405 -2.69 0 CA-C-N 115.779 -0.646 . . . . 65.549999999999997 111.221 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.528 ' CD1' HG21 ' A' ' 28' ' ' THR . 23.3 m95 -118.08 82.4 1.83 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.014 -0.735 . . . . 75.219999999999999 109.014 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.411 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.0 t90 -57.99 132.71 83.61 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.517 0.727 . . . . 74.430000000000007 110.752 -175.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 90.9 Cg_endo -104.97 41.73 2.95 Favored 'Cis proline' 0 CA--C 1.545 1.037 0 CA-C-N 119.157 0.735 . . . . 74.420000000000002 113.797 4.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.95 139.86 31.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.178 -1.045 . . . . 71.319999999999993 108.178 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.428 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 88.6 m -87.97 146.89 25.29 Favored 'General case' 0 CA--C 1.474 -1.948 0 CA-C-O 122.562 1.172 . . . . 62.140000000000001 110.55 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.528 HG21 ' CD1' ' A' ' 23' ' ' TRP . 15.5 p -135.19 157.69 46.26 Favored 'General case' 0 C--N 1.256 -3.487 0 CA-C-N 113.0 -1.909 . . . . 74.120000000000005 110.325 -171.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.482 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 27.0 mmm180 -88.87 -65.42 1.02 Allowed 'General case' 0 C--N 1.292 -1.931 0 CA-C-O 121.866 0.841 . . . . 53.340000000000003 110.61 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 . . . . . 0 C--N 1.284 -2.251 0 N-CA-C 105.415 -2.068 . . . . 75.409999999999997 105.415 -177.976 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.397 -3.922 0 N-CA-C 108.749 -1.74 . . . . 43.219999999999999 108.749 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 tp -120.23 115.32 32.96 Favored Pre-proline 0 N--CA 1.442 -0.871 0 N-CA-C 107.844 -1.169 . . . . 71.319999999999993 107.844 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.34 81.38 1.5 Allowed 'Trans proline' 0 N--CA 1.454 -0.833 0 C-N-CA 122.309 2.006 . . . . 65.230000000000004 112.442 -177.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 m -132.62 9.63 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 115.038 -0.983 . . . . 65.439999999999998 110.64 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.7 m -76.66 -22.7 53.67 Favored 'General case' 0 CA--C 1.491 -1.307 0 CA-C-O 121.473 0.654 . . . . 30.350000000000001 111.295 -177.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.96 -2.01 82.27 Favored Glycine 0 N--CA 1.422 -2.249 0 CA-C-N 114.713 -1.13 . . . . 63.439999999999998 112.939 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -122.51 177.71 5.3 Favored 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.548 -0.861 . . . . 72.409999999999997 111.121 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.1 p -124.76 154.36 41.02 Favored 'General case' 0 N--CA 1.422 -1.858 0 CA-C-N 114.513 -1.222 . . . . 60.299999999999997 110.656 -178.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -122.14 85.52 2.43 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 123.549 0.74 . . . . 43.149999999999999 109.162 178.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -72.12 -33.77 47.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 CA-C-O 121.566 0.698 . . . . 73.420000000000002 109.338 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.28 -16.77 56.89 Favored Glycine 0 N--CA 1.438 -1.227 0 CA-C-N 115.384 -0.826 . . . . 61.420000000000002 111.636 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.444 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.31 15.27 23.83 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.075 -1.059 . . . . 74.209999999999994 112.907 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.4 m -137.31 124.46 21.68 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.938 -1.134 . . . . 71.430000000000007 107.938 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.98 149.35 21.89 Favored 'General case' 0 C--N 1.273 -2.717 0 CA-C-N 115.953 -0.567 . . . . 51.240000000000002 111.44 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -75.06 -54.04 7.85 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.596 -0.729 . . . . 64.150000000000006 109.646 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -51.71 111.52 2.49 Favored Pre-proline 0 C--O 1.256 1.41 0 C-N-CA 124.144 0.978 . . . . 43.549999999999997 112.241 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -62.87 118.06 4.96 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.385 2.057 . . . . 74.140000000000001 109.556 176.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 117.9 -11.31 13.52 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 111.363 -0.695 . . . . 40.240000000000002 111.363 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.5 m -102.39 155.64 18.12 Favored 'General case' 0 CA--C 1.499 -0.996 0 CA-C-O 122.244 1.021 . . . . 51.420000000000002 111.802 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.5 p -132.16 151.69 51.66 Favored 'General case' 0 N--CA 1.401 -2.905 0 CA-C-N 113.797 -1.547 . . . . 71.310000000000002 108.858 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.444 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 20.8 t -93.18 53.08 1.88 Allowed 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.858 0.837 . . . . 73.109999999999999 108.989 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 m -70.53 -22.81 62.57 Favored 'General case' 0 N--CA 1.414 -2.244 0 CA-C-N 115.587 -0.733 . . . . 63.140000000000001 111.938 -177.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.9 t-105 -128.99 80.43 1.97 Allowed 'General case' 0 C--O 1.205 -1.278 0 N-CA-C 108.237 -1.023 . . . . 71.430000000000007 108.237 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 77.2 t90 -62.88 135.32 95.98 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 116.094 -0.503 . . . . 72.340000000000003 110.898 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 52.5 Cg_endo -102.31 36.4 5.91 Favored 'Cis proline' 0 C--N 1.354 0.851 0 C-N-CA 125.008 -0.83 . . . . 74.540000000000006 113.304 2.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.8 t -105.35 141.44 20.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 N-CA-C 109.275 -0.639 . . . . 73.0 109.275 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 74.7 m -88.92 144.58 26.09 Favored 'General case' 0 N--CA 1.412 -2.355 0 CA-C-O 122.794 1.283 . . . . 44.140000000000001 111.029 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.4 p -129.74 155.05 46.55 Favored 'General case' 0 C--N 1.258 -3.371 0 CA-C-N 112.867 -1.97 . . . . 73.040000000000006 110.037 -173.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 -89.55 -66.42 0.92 Allowed 'General case' 0 N--CA 1.425 -1.706 0 CA-C-O 121.763 0.792 . . . . 63.229999999999997 109.878 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 105.388 -2.079 . . . . 74.540000000000006 105.388 -178.708 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.411 -2.971 0 N-CA-C 109.961 -1.255 . . . . 72.140000000000001 109.961 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.0 tp -118.24 111.53 38.45 Favored Pre-proline 0 N--CA 1.439 -0.998 0 N-CA-C 108.279 -1.008 . . . . 73.0 108.279 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -74.96 79.11 2.73 Favored 'Trans proline' 0 N--CA 1.444 -1.41 0 C-N-CA 121.879 1.719 . . . . 64.239999999999995 112.675 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.88 22.65 2.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.975 0 CA-C-O 121.821 0.819 . . . . 74.319999999999993 109.662 176.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 52.2 m -85.12 -32.65 22.66 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.906 -1.146 . . . . 62.32 107.906 176.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.51 -2.58 87.04 Favored Glycine 0 N--CA 1.43 -1.759 0 CA-C-N 114.055 -1.43 . . . . 75.430000000000007 112.694 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -112.12 175.83 5.27 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.647 0.737 . . . . 60.130000000000003 111.624 -179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.7 p -127.32 158.64 36.7 Favored 'General case' 0 C--N 1.284 -2.273 0 CA-C-N 114.465 -1.243 . . . . 64.209999999999994 109.732 -177.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.1 p -119.64 96.6 5.26 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.37 -0.974 . . . . 65.319999999999993 108.37 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.8 t -80.0 -38.87 19.09 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 109.084 -0.71 . . . . 73.230000000000004 109.084 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.88 -10.69 61.15 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.402 -0.817 . . . . 53.130000000000003 111.149 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.491 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 99.56 13.73 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.522 -0.847 . . . . 72.230000000000004 112.573 177.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 28.6 m -127.66 128.78 46.07 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 107.925 -1.139 . . . . 75.310000000000002 107.925 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 36.1 m -104.48 159.38 15.79 Favored 'General case' 0 C--N 1.272 -2.779 0 CA-C-N 115.741 -0.663 . . . . 54.509999999999998 109.578 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -91.62 -58.07 2.55 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 116.386 -0.37 . . . . 74.140000000000001 110.519 -179.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.452 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 35.6 m -46.65 116.95 4.1 Favored Pre-proline 0 CA--C 1.545 0.771 0 O-C-N 124.374 1.046 . . . . 71.409999999999997 112.219 -175.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.93 117.09 3.73 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 123.257 2.638 . . . . 53.100000000000001 110.941 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.09 -2.51 31.46 Favored Glycine 0 N--CA 1.427 -1.936 0 CA-C-N 115.554 -0.748 . . . . 72.140000000000001 111.543 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.486 ' SG ' ' HD2' ' A' ' 29' ' ' ARG . 63.2 m -106.25 150.21 26.14 Favored 'General case' 0 CA--C 1.488 -1.435 0 CA-C-O 121.789 0.804 . . . . 72.25 110.113 176.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 p -136.72 152.46 50.38 Favored 'General case' 0 C--N 1.268 -2.973 0 CA-C-N 114.165 -1.38 . . . . 73.349999999999994 109.927 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.491 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 38.8 t -88.58 65.17 7.72 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.855 -1.165 . . . . 51.119999999999997 107.855 176.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.6 m -72.7 -29.39 63.34 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-N 114.489 -1.232 . . . . 72.230000000000004 110.798 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.3 t-105 -134.29 82.77 1.99 Allowed 'General case' 0 N--CA 1.433 -1.322 0 CA-C-O 121.179 0.514 . . . . 72.319999999999993 110.135 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 87.1 t90 -56.1 139.12 72.38 Favored Pre-proline 0 C--O 1.244 0.799 0 CA-C-N 115.245 -0.889 . . . . 65.040000000000006 109.875 -177.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -97.87 30.19 13.62 Favored 'Cis proline' 0 CA--C 1.538 0.711 0 C-N-CA 125.033 -0.82 . . . . 74.019999999999996 113.483 1.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 44.5 t -107.64 136.73 41.96 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.326 0 N-CA-C 109.558 -0.534 . . . . 62.219999999999999 109.558 -178.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 72.7 m -88.46 152.49 21.85 Favored 'General case' 0 N--CA 1.419 -1.996 0 C-N-CA 119.268 -0.973 . . . . 72.030000000000001 109.113 177.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -139.25 164.32 30.13 Favored 'General case' 0 C--N 1.264 -3.149 0 CA-C-N 114.742 -1.117 . . . . 74.120000000000005 109.016 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.486 ' HD2' ' SG ' ' A' ' 19' ' ' CYS . 24.3 mmm180 -88.14 -74.14 0.46 Allowed 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.775 0.798 . . . . 64.120000000000005 110.463 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 . . . . . 0 C--N 1.275 -2.631 0 N-CA-C 104.647 -2.353 . . . . 73.310000000000002 104.647 -179.42 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.415 -2.713 0 N-CA-C 109.68 -1.368 . . . . 74.319999999999993 109.68 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 38.6 tp -121.06 112.92 33.04 Favored Pre-proline 0 C--N 1.323 -0.586 0 N-CA-C 109.514 -0.55 . . . . 75.129999999999995 109.514 -178.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -71.79 81.56 1.33 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.3 2.0 . . . . 74.140000000000001 112.981 -179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 18.2 m -133.24 15.63 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 114.982 -1.008 . . . . 75.140000000000001 110.187 177.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.2 m -88.73 -26.75 21.61 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.725 -0.67 . . . . 50.520000000000003 111.05 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.32 6.09 86.09 Favored Glycine 0 N--CA 1.427 -1.914 0 CA-C-N 114.875 -1.057 . . . . 74.329999999999998 112.987 177.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.3 pt-20 -120.09 173.97 6.77 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 119.249 -0.98 . . . . 72.219999999999999 111.557 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.8 p -124.45 153.71 41.56 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-N 114.191 -1.368 . . . . 71.420000000000002 110.001 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -123.26 85.12 2.37 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 123.54 0.736 . . . . 64.230000000000004 110.389 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.0 t -80.75 -23.87 11.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.89 0.852 . . . . 73.340000000000003 108.838 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -13.7 60.22 Favored Glycine 0 C--N 1.309 -0.971 0 N-CA-C 110.594 -1.002 . . . . 55.229999999999997 110.594 176.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.33 17.37 46.53 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.508 -0.853 . . . . 74.049999999999997 112.071 177.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 m -139.36 131.16 27.54 Favored 'General case' 0 N--CA 1.419 -2.005 0 N-CA-C 108.368 -0.975 . . . . 73.530000000000001 108.368 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.76 156.79 16.18 Favored 'General case' 0 C--N 1.275 -2.636 0 CA-C-N 115.853 -0.612 . . . . 72.409999999999997 109.5 178.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -94.42 -49.71 5.56 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 116.235 -0.439 . . . . 75.219999999999999 110.947 -176.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.524 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 13.2 m -51.27 118.27 10.47 Favored Pre-proline 0 C--O 1.246 0.919 0 C-N-CA 123.913 0.885 . . . . 52.25 111.169 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.99 118.18 4.99 Favored 'Trans proline' 0 C--N 1.354 0.855 0 C-N-CA 122.728 2.285 . . . . 60.439999999999998 110.529 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.32 -1.44 32.93 Favored Glycine 0 N--CA 1.427 -1.906 0 C-N-CA 120.963 -0.636 . . . . 44.229999999999997 111.993 -178.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.524 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 62.3 m -105.01 154.81 19.63 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.982 0.896 . . . . 63.310000000000002 112.067 178.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 p -137.8 153.52 49.65 Favored 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 125.126 1.37 . . . . 74.519999999999996 109.74 -176.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.9 t -97.13 87.22 4.14 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.316 -0.994 . . . . 55.310000000000002 108.316 179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.1 t -81.65 -57.86 3.26 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.365 -0.605 . . . . 41.32 109.365 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 94.0 m95 -107.29 96.54 6.48 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 109.223 -0.658 . . . . 65.439999999999998 109.223 -178.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 75.7 t90 -63.93 138.23 97.34 Favored Pre-proline 0 C--N 1.296 -1.717 0 N-CA-C 109.233 -0.654 . . . . 74.150000000000006 109.233 -178.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 61.4 Cg_endo -102.63 37.84 5.03 Favored 'Cis proline' 0 CA--C 1.544 0.984 0 C-N-CA 124.464 -1.057 . . . . 74.239999999999995 114.018 1.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.5 p -108.97 143.6 18.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 O-C-N 121.516 -0.74 . . . . 70.219999999999999 110.059 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.6 m -88.5 160.75 17.36 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 122.288 1.042 . . . . 64.150000000000006 111.353 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.2 p -142.14 166.17 25.43 Favored 'General case' 0 C--N 1.267 -3.002 0 CA-C-N 113.613 -1.631 . . . . 72.209999999999994 108.154 -178.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 22.1 tpt180 -89.01 -70.93 0.62 Allowed 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.736 -0.838 . . . . 73.120000000000005 108.736 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.417 -2.109 0 N-CA-C 104.775 -2.305 . . . . 72.430000000000007 104.775 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.417 -2.627 0 N-CA-C 109.219 -1.552 . . . . 50.420000000000002 109.219 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.6 tp -115.08 111.69 44.81 Favored Pre-proline 0 CA--C 1.532 0.283 0 CA-C-N 114.658 -0.771 . . . . 73.439999999999998 109.023 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.93 74.67 3.37 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 122.671 2.247 . . . . 54.32 113.678 -176.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -125.32 18.49 4.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 115.459 -0.792 . . . . 74.140000000000001 109.908 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 84.7 m -88.21 -22.26 24.09 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-O 121.996 0.903 . . . . 75.430000000000007 109.562 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.08 -15.79 19.95 Favored Glycine 0 N--CA 1.438 -1.197 0 CA-C-N 114.116 -1.402 . . . . 63.229999999999997 113.549 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -99.52 175.5 5.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-O 121.557 0.694 . . . . 73.349999999999994 110.733 -177.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 16.8 p -125.38 149.0 48.55 Favored 'General case' 0 N--CA 1.409 -2.482 0 CA-C-N 114.54 -1.209 . . . . 70.420000000000002 110.28 -178.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -116.76 93.11 4.07 Favored 'General case' 0 C--N 1.284 -2.244 0 N-CA-C 108.749 -0.834 . . . . 52.130000000000003 108.749 177.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 65.7 t -80.3 -35.22 15.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.158 -0.682 . . . . 74.140000000000001 109.158 179.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.52 -10.44 65.47 Favored Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.389 -1.085 . . . . 62.509999999999998 110.389 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.473 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 92.82 17.21 45.33 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.707 -0.759 . . . . 32.520000000000003 111.802 178.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 m -123.24 122.49 38.5 Favored 'General case' 0 N--CA 1.418 -2.049 0 N-CA-C 108.474 -0.935 . . . . 64.329999999999998 108.474 -178.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 67.6 m -99.38 141.2 32.48 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-N 115.836 -0.62 . . . . 71.010000000000005 111.89 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -83.07 -50.96 7.97 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.038 -0.983 . . . . 74.219999999999999 111.639 -176.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 53.4 m -52.29 118.56 12.76 Favored Pre-proline 0 C--O 1.254 1.318 0 C-N-CA 122.531 0.333 . . . . 73.219999999999999 111.74 176.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -67.38 114.0 3.1 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 122.163 1.908 . . . . 74.340000000000003 109.724 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 121.19 -7.28 10.7 Favored Glycine 0 N--CA 1.417 -2.618 0 C-N-CA 120.246 -0.978 . . . . 43.219999999999999 110.916 -176.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.2 m -108.77 153.27 23.71 Favored 'General case' 0 CA--C 1.495 -1.14 0 CA-C-O 121.433 0.635 . . . . 73.340000000000003 110.54 176.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.7 p -134.25 152.86 52.04 Favored 'General case' 0 N--CA 1.406 -2.634 0 CA-C-N 114.571 -1.195 . . . . 63.409999999999997 108.137 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.473 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 36.0 t -89.28 83.06 6.44 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 108.26 -1.015 . . . . 73.420000000000002 108.26 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 31.8 t -105.23 1.04 27.8 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.632 -0.713 . . . . 71.129999999999995 110.451 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 63.7 t-105 -147.57 63.88 1.14 Allowed 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.341 -0.985 . . . . 72.310000000000002 108.341 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 84.5 t90 -51.61 132.8 35.97 Favored Pre-proline 0 C--N 1.318 -0.797 0 CA-C-N 114.615 -1.175 . . . . 73.140000000000001 110.482 -177.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 73.1 Cg_endo -101.24 34.22 7.75 Favored 'Cis proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.662 -0.974 . . . . 73.420000000000002 113.64 4.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -109.89 142.02 23.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 108.866 -0.79 . . . . 73.340000000000003 108.866 179.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 89.9 m -88.26 147.23 24.92 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.711 1.243 . . . . 72.109999999999999 110.835 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -130.0 158.88 38.37 Favored 'General case' 0 C--N 1.26 -3.318 0 CA-C-N 112.889 -1.959 . . . . 50.329999999999998 109.733 -172.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 8.8 tpp180 -89.42 -66.93 0.87 Allowed 'General case' 0 N--CA 1.416 -2.149 0 C-N-CA 119.751 -0.78 . . . . 74.340000000000003 109.767 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 N--CA 1.426 -1.67 0 N-CA-C 105.541 -2.022 . . . . 72.230000000000004 105.541 -179.324 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.331 0 N-CA-C 109.937 -1.265 . . . . 64.209999999999994 109.937 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.9 tp -118.5 120.67 31.68 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.623 -0.51 . . . . 63.109999999999999 109.623 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -70.61 82.87 0.89 Allowed 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.127 1.885 . . . . 75.120000000000005 112.521 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.4 m -130.47 19.45 2.07 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-O 121.759 0.79 . . . . 63.229999999999997 109.391 176.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 79.4 m -93.0 -29.61 15.75 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 115.007 -0.997 . . . . 53.520000000000003 110.251 -178.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.87 3.43 73.98 Favored Glycine 0 N--CA 1.432 -1.593 0 CA-C-N 114.832 -1.076 . . . . 73.400000000000006 113.621 177.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -120.3 175.27 6.04 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 121.742 0.782 . . . . 75.150000000000006 111.254 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -128.88 155.45 45.24 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-N 114.427 -1.26 . . . . 43.539999999999999 109.759 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -125.64 85.81 2.45 Favored 'General case' 0 C--N 1.278 -2.529 0 CA-C-N 116.234 -0.439 . . . . 74.150000000000006 109.924 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 41.2 t -80.3 -25.25 11.51 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 C-N-CA 119.291 -0.963 . . . . 74.319999999999993 109.005 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.95 -15.94 56.98 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 110.927 -0.869 . . . . 55.200000000000003 110.927 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.96 14.79 38.45 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.811 -0.709 . . . . 63.100000000000001 112.263 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.8 m -130.76 124.36 31.25 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 109.206 -0.665 . . . . 70.030000000000001 109.206 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.9 m -98.92 152.93 19.23 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 115.847 -0.615 . . . . 64.150000000000006 109.686 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -87.88 -55.96 3.54 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.595 -0.275 . . . . 72.140000000000001 111.18 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.403 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 19.9 m -50.97 112.15 2.77 Favored Pre-proline 0 CA--C 1.56 1.34 0 O-C-N 124.29 0.994 . . . . 60.439999999999998 112.728 -176.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -58.61 121.97 10.86 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 123.115 2.543 . . . . 72.420000000000002 110.512 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.75 -3.73 30.6 Favored Glycine 0 N--CA 1.425 -2.052 0 N-CA-C 110.766 -0.934 . . . . 72.540000000000006 110.766 -177.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.403 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 86.0 m -104.81 159.17 16.0 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.539 0.685 . . . . 72.019999999999996 110.824 176.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.5 p -137.82 146.09 43.09 Favored 'General case' 0 C--N 1.28 -2.442 0 C-N-CA 124.924 1.289 . . . . 72.409999999999997 109.233 -176.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 49.2 t -91.44 77.2 5.81 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.26 -1.385 . . . . 43.0 107.26 174.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -90.28 -36.29 14.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.689 -0.687 . . . . 75.409999999999997 110.96 -175.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 92.6 m95 -120.34 76.03 1.15 Allowed 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.209 -0.663 . . . . 53.299999999999997 109.209 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 79.9 t90 -53.75 136.91 54.51 Favored Pre-proline 0 C--N 1.313 -1.008 0 CA-C-N 114.895 -1.048 . . . . 73.150000000000006 110.372 -175.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -97.24 32.85 10.39 Favored 'Cis proline' 0 CA--C 1.537 0.633 0 C-N-CA 124.523 -1.032 . . . . 74.120000000000005 113.295 2.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 76.0 t -106.15 138.18 32.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 109.549 -0.537 . . . . 75.25 109.549 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.95 153.51 20.97 Favored 'General case' 0 N--CA 1.41 -2.438 0 CA-C-O 122.104 0.954 . . . . 73.549999999999997 109.225 177.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 5.2 p -133.08 165.5 24.6 Favored 'General case' 0 C--N 1.252 -3.633 0 CA-C-N 114.408 -1.269 . . . . 64.420000000000002 108.572 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpt180 -88.95 -76.63 0.4 Allowed 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 108.678 -0.86 . . . . 73.310000000000002 108.678 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.42 -1.928 0 N-CA-C 104.852 -2.277 . . . . 65.420000000000002 104.852 179.471 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.407 -3.244 0 N-CA-C 109.27 -1.532 . . . . 73.340000000000003 109.27 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 35.0 tp -123.86 121.35 26.48 Favored Pre-proline 0 N--CA 1.44 -0.942 0 N-CA-C 108.94 -0.763 . . . . 73.319999999999993 108.94 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.83 84.52 0.41 Allowed 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.624 2.216 . . . . 53.219999999999999 111.97 178.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 m -136.42 30.53 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 CA-C-N 114.997 -1.001 . . . . 54.020000000000003 108.48 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 73.2 m -101.19 -24.69 14.22 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 114.836 -1.075 . . . . 65.230000000000004 110.492 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.84 -14.06 33.58 Favored Glycine 0 C--N 1.305 -1.193 0 CA-C-N 114.959 -1.019 . . . . 61.43 113.754 178.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.401 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 10.6 pt-20 -110.68 -178.05 3.38 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 121.154 0.502 . . . . 74.340000000000003 110.887 -177.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.9 p -131.2 154.86 47.96 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.987 -1.006 . . . . 50.420000000000002 111.386 -176.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 p -121.66 88.25 2.9 Favored 'General case' 0 N--CA 1.416 -2.129 0 N-CA-C 108.874 -0.787 . . . . 74.540000000000006 108.874 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.8 t -74.43 -36.25 41.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.046 -0.724 . . . . 42.039999999999999 109.046 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.73 -22.72 35.55 Favored Glycine 0 N--CA 1.436 -1.35 0 CA-C-N 115.392 -0.822 . . . . 70.239999999999995 111.08 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 112.07 12.79 13.26 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.017 -1.087 . . . . 72.439999999999998 113.325 178.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 46.7 m -136.99 124.98 22.76 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.652 -0.87 . . . . 44.329999999999998 108.652 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 38.3 m -91.97 169.86 10.32 Favored 'General case' 0 C--N 1.272 -2.794 0 CA-C-N 115.352 -0.84 . . . . 75.409999999999997 110.874 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -92.77 -52.56 4.56 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 123.315 0.646 . . . . 74.109999999999999 110.468 179.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.7 m -51.13 113.94 4.36 Favored Pre-proline 0 C--O 1.25 1.117 0 C-N-CA 123.947 0.899 . . . . 71.519999999999996 113.095 -179.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -65.48 105.98 0.81 Allowed 'Trans proline' 0 C--N 1.359 1.1 0 C-N-CA 122.53 2.153 . . . . 62.420000000000002 109.629 176.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.95 5.33 Favored Glycine 0 N--CA 1.427 -1.913 0 N-CA-C 110.782 -0.927 . . . . 64.400000000000006 110.782 -177.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 72.3 m -102.13 162.01 13.24 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 121.609 0.719 . . . . 43.130000000000003 111.146 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -141.0 153.13 45.42 Favored 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 114.252 -1.34 . . . . 71.040000000000006 108.325 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 19.8 t -93.88 83.17 4.33 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.018 -1.105 . . . . 73.129999999999995 108.018 175.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 21.4 t -89.77 -49.26 6.74 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.911 -0.774 . . . . 73.430000000000007 108.911 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -107.5 80.7 1.43 Allowed 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.39 -0.596 . . . . 75.5 109.39 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 92.4 t90 -55.79 139.73 69.07 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.413 -0.812 . . . . 63.350000000000001 110.033 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 17.6 Cg_endo -99.95 32.32 9.91 Favored 'Cis proline' 0 CA--C 1.534 0.493 0 C-N-CA 124.935 -0.86 . . . . 72.019999999999996 113.121 1.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 55.8 t -104.91 142.54 17.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 108.993 -0.743 . . . . 70.239999999999995 108.993 -179.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.401 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 71.3 m -87.89 144.93 26.3 Favored 'General case' 0 N--CA 1.415 -2.2 0 CA-C-O 122.707 1.241 . . . . 73.430000000000007 110.417 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.9 p -128.28 152.04 48.59 Favored 'General case' 0 C--N 1.259 -3.365 0 CA-C-N 113.104 -1.862 . . . . 53.299999999999997 111.101 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 -94.82 -55.86 2.97 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-O 121.765 0.793 . . . . 64.329999999999998 111.237 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.414 -2.225 0 N-CA-C 105.01 -2.218 . . . . 51.130000000000003 105.01 -179.161 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.409 -3.134 0 N-CA-C 109.744 -1.342 . . . . 70.420000000000002 109.744 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.0 tp -103.79 116.27 62.04 Favored Pre-proline 0 C--O 1.241 0.614 0 N-CA-C 108.808 -0.812 . . . . 74.209999999999994 108.808 179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -78.37 76.69 4.31 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.179 1.919 . . . . 64.25 112.304 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -128.1 18.54 2.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.905 -1.043 . . . . 73.120000000000005 109.775 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 66.1 m -87.82 -26.35 22.86 Favored 'General case' 0 N--CA 1.432 -1.337 0 CA-C-N 115.236 -0.893 . . . . 71.329999999999998 109.951 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.93 -0.88 64.78 Favored Glycine 0 N--CA 1.438 -1.17 0 CA-C-N 114.619 -1.173 . . . . 53.420000000000002 113.557 176.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.479 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 11.3 pt-20 -112.93 175.52 5.4 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.242 -0.583 . . . . 72.140000000000001 110.27 178.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.3 p -128.41 154.71 45.75 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 115.055 -0.975 . . . . 73.519999999999996 110.752 -174.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.415 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 7.6 p -129.86 89.68 2.85 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 109.622 -0.51 . . . . 74.129999999999995 109.622 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -80.18 -31.25 13.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 108.707 -0.849 . . . . 73.230000000000004 108.707 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.4 -12.21 61.6 Favored Glycine 0 N--CA 1.439 -1.167 0 CA-C-N 115.424 -0.807 . . . . 64.219999999999999 111.315 177.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.48 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 93.14 19.48 36.02 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.478 -0.868 . . . . 63.340000000000003 112.609 177.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.9 m -135.85 119.66 17.32 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.1 -0.704 . . . . 61.299999999999997 109.1 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 56.4 m -99.13 167.51 10.65 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.312 -0.858 . . . . 65.549999999999997 110.955 -176.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -103.83 -49.28 3.69 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.648 0.379 . . . . 73.430000000000007 111.875 -178.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.8 m -51.29 114.17 4.68 Favored Pre-proline 0 C--O 1.257 1.465 0 N-CA-C 113.081 0.771 . . . . 44.299999999999997 113.081 -179.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -62.93 115.67 3.08 Favored 'Trans proline' 0 C--N 1.354 0.857 0 C-N-CA 122.883 2.389 . . . . 64.430000000000007 109.571 175.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 119.51 -10.42 11.5 Favored Glycine 0 C--N 1.298 -1.568 0 N-CA-C 110.94 -0.864 . . . . 73.540000000000006 110.94 -176.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 77.4 m -112.95 162.37 15.93 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.235 0.54 . . . . 62.299999999999997 110.545 176.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 p -145.35 160.93 40.79 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 124.933 1.293 . . . . 71.310000000000002 108.337 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.48 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 46.2 t -92.27 85.24 5.36 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.536 -0.913 . . . . 45.539999999999999 108.536 177.483 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 23.2 t -103.36 -31.17 10.17 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.828 -0.623 . . . . 70.310000000000002 110.124 -178.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.1 m95 -112.66 64.84 0.63 Allowed 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.186 0.517 . . . . 74.129999999999995 109.701 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 89.1 t90 -52.88 135.32 47.18 Favored Pre-proline 0 C--O 1.247 0.971 0 CA-C-N 114.567 -1.197 . . . . 72.439999999999998 110.498 -176.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 9.7 Cg_endo -96.3 33.35 9.94 Favored 'Cis proline' 0 CA--C 1.549 1.261 0 N-CA-C 114.518 0.93 . . . . 75.450000000000003 114.518 3.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 69.1 t -111.09 143.69 20.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 N-CA-C 108.861 -0.792 . . . . 63.119999999999997 108.861 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.479 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 63.0 m -88.69 145.49 25.62 Favored 'General case' 0 N--CA 1.416 -2.151 0 CA-C-O 122.301 1.048 . . . . 72.420000000000002 109.345 178.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.4 p -129.5 165.03 22.47 Favored 'General case' 0 C--N 1.254 -3.546 0 CA-C-N 113.786 -1.552 . . . . 71.099999999999994 110.688 -174.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.6 tpp180 -88.22 -67.43 0.83 Allowed 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.897 -0.779 . . . . 73.120000000000005 108.897 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 . . . . . 0 N--CA 1.423 -1.816 0 N-CA-C 105.906 -1.887 . . . . 64.329999999999998 105.906 176.068 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.416 -2.654 0 N-CA-C 110.596 -1.002 . . . . 72.129999999999995 110.596 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.5 tp -112.59 110.04 52.9 Favored Pre-proline 0 C--O 1.239 0.516 0 N-CA-C 109.704 -0.48 . . . . 70.209999999999994 109.704 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -72.86 79.32 1.98 Allowed 'Trans proline' 0 C--O 1.24 0.586 0 C-N-CA 122.421 2.081 . . . . 61.439999999999998 112.528 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.8 m -137.09 23.37 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.93 -1.032 . . . . 75.519999999999996 109.737 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 71.3 m -84.99 -21.68 29.39 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 115.56 -0.745 . . . . 74.329999999999998 110.839 -178.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.07 -0.24 79.94 Favored Glycine 0 C--N 1.294 -1.781 0 CA-C-N 114.794 -1.094 . . . . 75.329999999999998 113.678 176.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -121.62 177.92 5.04 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.278 -0.569 . . . . 71.540000000000006 109.639 177.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.3 p -130.91 158.85 39.1 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 116.051 -0.522 . . . . 62.039999999999999 110.675 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.3 p -129.72 88.77 2.72 Favored 'General case' 0 C--N 1.282 -2.351 0 C-N-CA 123.041 0.536 . . . . 74.409999999999997 109.665 -179.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.7 t -76.76 -31.74 19.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 119.955 -0.698 . . . . 73.310000000000002 109.351 178.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.68 -19.71 47.11 Favored Glycine 0 C--N 1.306 -1.084 0 N-CA-C 111.068 -0.813 . . . . 73.120000000000005 111.068 176.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.488 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 103.21 17.08 19.09 Favored Glycine 0 N--CA 1.447 -0.628 0 C-N-CA 120.806 -0.711 . . . . 55.5 112.136 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.6 m -122.73 122.19 38.16 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 108.706 -0.85 . . . . 55.219999999999999 108.706 -178.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 60.5 m -102.47 147.59 26.56 Favored 'General case' 0 C--N 1.274 -2.704 0 CA-C-N 115.746 -0.661 . . . . 62.420000000000002 110.198 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -90.99 -49.83 6.2 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.921 -0.581 . . . . 73.109999999999999 110.909 -178.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.2 m -50.73 113.26 3.52 Favored Pre-proline 0 C--O 1.25 1.119 0 O-C-N 123.987 0.804 . . . . 74.150000000000006 112.194 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.45 116.77 3.48 Favored 'Trans proline' 0 C--N 1.358 1.047 0 C-N-CA 123.19 2.593 . . . . 75.439999999999998 110.831 179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.86 -10.85 20.89 Favored Glycine 0 N--CA 1.424 -2.121 0 C-N-CA 120.3 -0.952 . . . . 53.119999999999997 112.214 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 80.4 m -103.97 156.82 17.55 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 121.636 0.731 . . . . 75.340000000000003 111.31 178.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.79 154.94 47.51 Favored 'General case' 0 C--N 1.271 -2.811 0 CA-C-N 114.465 -1.243 . . . . 74.219999999999999 108.89 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.488 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 23.9 t -91.47 87.45 6.41 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.923 -0.769 . . . . 72.540000000000006 108.923 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.3 t -96.84 -59.87 1.71 Allowed 'General case' 0 C--N 1.298 -1.655 0 CA-C-N 116.137 -0.483 . . . . 73.129999999999995 109.711 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 64.2 t-105 -92.07 77.74 5.32 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.678 -0.86 . . . . 72.200000000000003 108.678 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -54.98 139.53 63.24 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 114.818 -1.083 . . . . 74.140000000000001 110.553 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -98.18 36.94 6.53 Favored 'Cis proline' 0 C--N 1.353 0.793 0 C-N-CA 124.663 -0.974 . . . . 64.099999999999994 112.56 1.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -109.47 142.32 22.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 108.588 -0.893 . . . . 74.450000000000003 108.588 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.0 m -87.96 150.4 23.48 Favored 'General case' 0 N--CA 1.416 -2.155 0 C-N-CA 119.355 -0.938 . . . . 53.25 109.34 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.1 p -128.66 160.72 31.58 Favored 'General case' 0 C--N 1.254 -3.548 0 CA-C-N 113.735 -1.575 . . . . 55.299999999999997 109.472 -176.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 13.7 tpp180 -88.73 -67.75 0.81 Allowed 'General case' 0 C--N 1.296 -1.746 0 CA-C-O 121.872 0.844 . . . . 72.450000000000003 110.083 -177.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 104.726 -2.324 . . . . 55.539999999999999 104.726 178.548 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.345 0 N-CA-C 109.39 -1.484 . . . . 73.239999999999995 109.39 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 39.4 tp -104.69 120.68 49.48 Favored Pre-proline 0 C--O 1.248 1.023 0 N-CA-C 108.932 -0.766 . . . . 74.409999999999997 108.932 -177.171 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.71 80.76 2.28 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 122.255 1.97 . . . . 75.340000000000003 112.741 -178.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.04 22.37 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.803 -1.09 . . . . 73.209999999999994 109.029 177.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 78.5 m -100.46 -27.91 13.2 Favored 'General case' 0 N--CA 1.431 -1.375 0 CA-C-N 115.303 -0.862 . . . . 64.200000000000003 110.381 -178.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.83 -10.99 43.5 Favored Glycine 0 C--N 1.303 -1.3 0 CA-C-N 114.977 -1.01 . . . . 64.150000000000006 113.484 177.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -109.9 176.64 4.99 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.768 0.794 . . . . 72.420000000000002 110.942 -177.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.3 p -128.05 163.22 25.05 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 114.315 -1.311 . . . . 71.230000000000004 109.747 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 6.7 p -128.82 87.38 2.57 Favored 'General case' 0 N--CA 1.408 -2.568 0 N-CA-C 108.894 -0.78 . . . . 74.329999999999998 108.894 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 25.7 t -77.96 -33.62 18.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 108.171 -1.048 . . . . 75.319999999999993 108.171 -179.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.01 -20.05 44.46 Favored Glycine 0 N--CA 1.439 -1.106 0 CA-C-N 114.982 -1.008 . . . . 72.109999999999999 111.325 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.423 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 100.06 18.66 21.53 Favored Glycine 0 C--O 1.221 -0.674 0 C-N-CA 120.611 -0.804 . . . . 53.329999999999998 112.342 178.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.1 m -131.04 117.54 19.29 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 108.802 -0.814 . . . . 72.510000000000005 108.802 -177.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 59.8 m -96.38 152.68 18.37 Favored 'General case' 0 C--N 1.281 -2.405 0 CA-C-N 115.94 -0.573 . . . . 63.200000000000003 111.838 -177.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -91.71 -54.1 4.02 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.689 -0.687 . . . . 74.140000000000001 111.194 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.1 m -51.47 112.29 3.0 Favored Pre-proline 0 C--O 1.249 1.04 0 O-C-N 123.952 0.783 . . . . 65.310000000000002 111.329 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.39 113.57 2.32 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.172 1.915 . . . . 60.350000000000001 110.981 -178.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.84 -10.63 8.93 Favored Glycine 0 N--CA 1.42 -2.431 0 N-CA-C 110.738 -0.945 . . . . 62.520000000000003 110.738 -177.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.6 m -104.25 155.31 18.84 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 121.314 0.578 . . . . 72.530000000000001 109.911 176.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.8 p -137.55 160.21 39.79 Favored 'General case' 0 C--N 1.275 -2.647 0 CA-C-N 115.043 -0.98 . . . . 74.540000000000006 108.835 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.423 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 12.3 t -85.63 63.54 8.12 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.948 -1.131 . . . . 64.430000000000007 107.948 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.4 t -69.09 -36.33 77.46 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.432 -0.804 . . . . 54.420000000000002 110.573 -177.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -129.91 87.81 2.58 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 108.713 -0.847 . . . . 74.239999999999995 108.713 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -58.17 138.56 84.24 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 123.34 0.656 . . . . 75.329999999999998 109.742 -177.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -99.54 40.19 4.49 Favored 'Cis proline' 0 CA--C 1.54 0.792 0 C-N-CA 125.129 -0.78 . . . . 63.119999999999997 112.956 1.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.1 t -112.53 136.17 49.62 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.794 -0.566 . . . . 73.530000000000001 110.303 -179.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.496 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 72.0 m -88.03 139.85 30.1 Favored 'General case' 0 N--CA 1.408 -2.531 0 N-CA-C 107.558 -1.275 . . . . 65.400000000000006 107.558 174.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -138.34 165.18 27.39 Favored 'General case' 1 C--N 1.238 -4.272 0 CA-C-N 113.514 -1.676 . . . . 74.109999999999999 109.582 -171.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 7.4 tpp180 -88.53 -68.1 0.79 Allowed 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.598 -0.841 . . . . 74.409999999999997 110.232 -175.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 C--N 1.289 -2.062 0 N-CA-C 104.925 -2.25 . . . . 72.549999999999997 104.925 177.496 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.512 0 N-CA-C 111.109 -0.796 . . . . 70.549999999999997 111.109 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 24.2 tp -132.07 117.09 15.81 Favored Pre-proline 0 N--CA 1.45 -0.445 0 N-CA-C 108.866 -0.79 . . . . 65.019999999999996 108.866 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 2' ' ' LEU . 5.6 Cg_exo -72.34 78.45 1.93 Allowed 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.583 2.189 . . . . 51.229999999999997 112.482 -178.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.3 m -128.77 17.87 2.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 115.456 -0.793 . . . . 61.350000000000001 110.413 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 76.4 m -85.36 -25.43 27.09 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.433 -0.803 . . . . 64.25 110.371 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 80.29 2.73 89.49 Favored Glycine 0 N--CA 1.428 -1.849 0 CA-C-N 114.686 -1.143 . . . . 71.409999999999997 111.945 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 12.1 pt-20 -119.53 179.37 4.23 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-O 121.632 0.729 . . . . 74.340000000000003 111.707 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.1 p -129.58 162.13 28.95 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.397 -1.274 . . . . 75.219999999999999 110.513 -175.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -131.91 88.04 2.51 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.567 -0.742 . . . . 54.420000000000002 109.208 179.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.7 t -74.21 -35.36 40.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.834 0.826 . . . . 75.230000000000004 109.293 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.04 -17.97 48.88 Favored Glycine 0 C--N 1.311 -0.846 0 CA-C-N 115.289 -0.869 . . . . 64.099999999999994 111.139 176.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.9 14.54 20.81 Favored Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.423 -0.894 . . . . 51.100000000000001 112.385 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.9 m -126.11 132.54 51.86 Favored 'General case' 0 N--CA 1.416 -2.147 0 N-CA-C 109.051 -0.722 . . . . 75.129999999999995 109.051 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.0 m -109.7 149.39 29.82 Favored 'General case' 0 C--N 1.273 -2.753 0 CA-C-N 114.924 -1.035 . . . . 70.310000000000002 109.581 178.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -89.83 -50.29 6.13 Favored 'General case' 0 C--N 1.312 -1.051 0 O-C-N 123.474 0.484 . . . . 75.010000000000005 112.137 -176.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.421 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 84.8 m -50.73 123.37 18.02 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 113.184 0.809 . . . . 60.219999999999999 113.184 -176.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.421 ' HD2' ' HA ' ' A' ' 16' ' ' THR . 19.6 Cg_endo -59.72 113.76 1.77 Allowed 'Trans proline' 0 C--N 1.357 0.997 0 C-N-CA 123.096 2.53 . . . . 65.0 111.462 178.738 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 113.88 -1.46 24.4 Favored Glycine 0 N--CA 1.424 -2.133 0 CA-C-N 115.596 -0.729 . . . . 70.120000000000005 111.524 -178.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.89 156.09 20.85 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-O 121.58 0.705 . . . . 52.409999999999997 111.119 178.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.39 160.88 42.05 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 113.889 -1.505 . . . . 71.219999999999999 108.207 178.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 46.2 t -97.86 84.87 3.41 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 109.411 -0.588 . . . . 74.219999999999999 109.411 -178.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 20.4 m -93.08 -26.69 17.36 Favored 'General case' 0 N--CA 1.408 -2.573 0 CA-C-N 116.001 -0.545 . . . . 71.530000000000001 111.131 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -123.21 70.93 1.04 Allowed 'General case' 0 CA--C 1.503 -0.831 0 CA-C-O 120.713 0.292 . . . . 71.200000000000003 110.293 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 87.8 t90 -52.47 134.34 43.77 Favored Pre-proline 0 C--N 1.318 -0.77 0 CA-C-N 115.319 -0.855 . . . . 73.239999999999995 110.407 -178.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 40.0 Cg_endo -99.38 34.2 8.53 Favored 'Cis proline' 0 CA--C 1.543 0.935 0 CA-C-N 119.259 0.771 . . . . 51.109999999999999 113.824 3.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.51 142.07 23.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 108.744 -0.836 . . . . 65.129999999999995 108.744 178.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.414 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 90.5 m -88.03 154.82 20.18 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.322 1.058 . . . . 72.430000000000007 110.585 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.62 161.83 31.78 Favored 'General case' 0 C--N 1.247 -3.854 0 CA-C-N 113.468 -1.697 . . . . 74.310000000000002 108.777 -176.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 12.3 tpp180 -88.44 -66.76 0.89 Allowed 'General case' 0 N--CA 1.409 -2.477 0 N-CA-C 107.963 -1.125 . . . . 75.319999999999993 107.963 177.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.405 HD22 ' HA ' ' A' ' 30' ' ' ASN . 1.9 t-20 . . . . . 0 N--CA 1.416 -2.167 0 N-CA-C 105.469 -2.048 . . . . 63.229999999999997 105.469 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.406 -3.318 0 N-CA-C 109.774 -1.331 . . . . 54.32 109.774 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.2 tp -113.23 116.69 46.48 Favored Pre-proline 0 C--O 1.24 0.577 0 N-CA-C 109.091 -0.707 . . . . 70.420000000000002 109.091 -178.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.97 81.48 1.66 Allowed 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.089 1.859 . . . . 63.200000000000003 112.542 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.9 m -133.08 22.56 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 CA-C-N 114.913 -1.04 . . . . 72.430000000000007 109.412 177.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 72.1 m -92.02 -18.3 23.84 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-O 122.017 0.913 . . . . 75.530000000000001 109.963 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.43 -19.7 17.73 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-N 114.15 -1.386 . . . . 74.099999999999994 113.599 174.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -102.83 177.15 4.93 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-O 121.505 0.669 . . . . 63.5 111.767 -174.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.5 p -124.14 154.75 39.59 Favored 'General case' 0 N--CA 1.414 -2.253 0 CA-C-N 114.555 -1.202 . . . . 75.099999999999994 110.597 -177.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.2 p -123.77 87.32 2.72 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 123.776 0.83 . . . . 61.530000000000001 108.826 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.1 t -73.19 -35.21 46.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 N-CA-C 109.108 -0.701 . . . . 75.129999999999995 109.108 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.45 -5.18 63.6 Favored Glycine 0 C--N 1.312 -0.801 0 N-CA-C 111.35 -0.7 . . . . 31.329999999999998 111.35 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.05 9.67 61.99 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.903 -0.665 . . . . 53.32 112.731 178.152 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.2 m -122.53 120.32 33.49 Favored 'General case' 0 N--CA 1.427 -1.598 0 N-CA-C 107.987 -1.116 . . . . 62.399999999999999 107.987 -176.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 66.1 m -92.7 151.83 19.85 Favored 'General case' 0 C--N 1.274 -2.715 0 CA-C-N 115.838 -0.619 . . . . 72.109999999999999 111.808 -177.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -80.69 -55.8 4.59 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.52 -0.764 . . . . 74.310000000000002 109.716 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 36.4 m -51.26 111.13 2.13 Favored Pre-proline 0 C--O 1.251 1.179 0 C-N-CA 124.215 1.006 . . . . 72.319999999999993 111.791 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -65.58 110.73 1.69 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 122.266 1.977 . . . . 74.299999999999997 109.474 177.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 128.87 -20.75 5.38 Favored Glycine 0 C--N 1.293 -1.855 0 N-CA-C 110.892 -0.883 . . . . 71.209999999999994 110.892 -177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 74.1 m -100.76 157.37 16.75 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-O 121.332 0.587 . . . . 54.439999999999998 109.894 177.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -139.0 161.76 36.58 Favored 'General case' 0 C--N 1.269 -2.909 0 CA-C-N 114.822 -1.081 . . . . 73.299999999999997 109.339 -178.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 25.1 t -95.18 82.58 3.77 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 109.523 -0.547 . . . . 70.150000000000006 109.523 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 27.0 t -96.31 -13.73 23.1 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 116.377 -0.374 . . . . 73.420000000000002 110.463 -178.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 55.6 t-105 -136.2 79.04 1.75 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 108.621 -0.881 . . . . 71.329999999999998 108.621 177.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 82.1 t90 -58.25 136.89 84.91 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 115.322 -0.854 . . . . 71.329999999999998 110.375 -176.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -100.53 36.05 6.78 Favored 'Cis proline' 0 CA--C 1.541 0.868 0 C-N-CA 124.717 -0.951 . . . . 52.25 113.529 2.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 45.7 t -110.31 144.4 18.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 109.124 -0.695 . . . . 61.420000000000002 109.124 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.5 m -88.62 147.62 24.47 Favored 'General case' 0 N--CA 1.418 -2.07 0 CA-C-O 122.592 1.187 . . . . 65.140000000000001 111.168 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 7.6 p -127.4 156.19 42.45 Favored 'General case' 0 C--N 1.256 -3.474 0 CA-C-N 113.258 -1.792 . . . . 75.530000000000001 110.789 -173.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 21.1 tpt180 -89.75 -67.1 0.86 Allowed 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 121.824 0.821 . . . . 72.219999999999999 111.154 -176.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 N--CA 1.42 -1.954 0 N-CA-C 104.978 -2.231 . . . . 74.230000000000004 104.978 179.377 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.408 -3.172 0 N-CA-C 109.997 -1.241 . . . . 73.140000000000001 109.997 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.8 tp -127.0 118.68 22.17 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.065 -0.717 . . . . 61.229999999999997 109.065 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -74.59 78.47 2.74 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 122.198 1.932 . . . . 74.329999999999998 112.998 -178.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 m -129.86 16.21 2.38 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 CA-C-N 114.897 -1.047 . . . . 72.400000000000006 110.362 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 83.2 m -84.2 -25.48 29.48 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 121.614 0.721 . . . . 64.409999999999997 109.801 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 86.26 -12.51 60.31 Favored Glycine 0 N--CA 1.425 -2.08 0 CA-C-N 114.455 -1.248 . . . . 74.329999999999998 112.814 176.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -104.69 178.1 4.66 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-O 121.823 0.82 . . . . 64.239999999999995 111.09 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.7 p -132.99 154.64 50.31 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 114.65 -1.159 . . . . 74.450000000000003 109.764 -177.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.9 p -110.98 89.9 3.18 Favored 'General case' 0 N--CA 1.41 -2.461 0 N-CA-C 108.416 -0.957 . . . . 64.310000000000002 108.416 177.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 47.1 t -80.18 -33.61 14.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 70.510000000000005 108.312 179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.08 -16.76 57.26 Favored Glycine 0 N--CA 1.44 -1.089 0 N-CA-C 110.761 -0.936 . . . . 64.109999999999999 110.761 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.31 13.3 31.21 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.872 -0.68 . . . . 42.229999999999997 113.254 176.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 25.5 m -136.2 128.4 29.9 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.009 -1.108 . . . . 72.099999999999994 108.009 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.9 m -92.14 148.67 21.99 Favored 'General case' 0 C--N 1.271 -2.828 0 CA-C-N 116.255 -0.429 . . . . 74.219999999999999 110.657 -178.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 46.3 t30 -84.82 -55.89 3.86 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.847 -0.615 . . . . 70.5 110.371 -178.045 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.7 m -51.27 114.62 5.14 Favored Pre-proline 0 CA--C 1.554 1.106 0 O-C-N 124.148 0.905 . . . . 65.329999999999998 111.89 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.69 116.07 3.31 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 122.398 2.066 . . . . 74.109999999999999 110.183 178.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 118.14 -4.95 15.84 Favored Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 110.64 -0.984 . . . . 62.340000000000003 110.64 -176.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 57.8 m -112.76 150.6 31.37 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.483 0.658 . . . . 62.130000000000003 110.695 176.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.3 p -134.23 150.93 51.07 Favored 'General case' 0 C--N 1.275 -2.635 0 CA-C-N 114.81 -1.086 . . . . 75.120000000000005 110.044 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 44.6 t -91.07 85.59 5.97 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.751 -1.203 . . . . 63.439999999999998 107.751 177.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 33.1 t -77.76 -51.71 10.1 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.413 -0.812 . . . . 65.430000000000007 109.7 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 8.9 p-90 -125.49 102.11 7.24 Favored 'General case' 0 N--CA 1.427 -1.598 0 CA-C-O 122.12 0.962 . . . . 74.230000000000004 110.652 177.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 76.4 t90 -58.82 140.18 86.23 Favored Pre-proline 0 C--N 1.302 -1.463 0 CA-C-N 113.678 -1.601 . . . . 72.510000000000005 109.255 -178.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.401 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.3 Cg_endo -102.15 36.44 5.95 Favored 'Cis proline' 0 CA--C 1.543 0.941 0 C-N-CA 124.703 -0.957 . . . . 71.340000000000003 114.189 3.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.8 p -118.41 143.91 28.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.235 -0.915 . . . . 74.140000000000001 110.787 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.6 m -89.12 162.33 16.02 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 121.878 0.847 . . . . 75.239999999999995 110.774 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.8 p -136.93 160.43 38.93 Favored 'General case' 0 C--N 1.276 -2.605 0 CA-C-N 114.49 -1.232 . . . . 74.310000000000002 109.072 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 25.8 tpt180 -89.1 -69.2 0.72 Allowed 'General case' 0 C--N 1.291 -1.968 0 CA-C-O 121.819 0.819 . . . . 63.140000000000001 109.743 -178.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 . . . . . 0 N--CA 1.41 -2.455 0 N-CA-C 105.177 -2.156 . . . . 72.109999999999999 105.177 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.399 -3.808 0 N-CA-C 109.49 -1.444 . . . . 71.409999999999997 109.49 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.468 ' HG ' HG13 ' A' ' 4' ' ' VAL . 34.9 tp -124.38 117.8 26.54 Favored Pre-proline 0 N--CA 1.443 -0.823 0 N-CA-C 109.162 -0.681 . . . . 75.420000000000002 109.162 -177.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -72.17 83.5 1.21 Allowed 'Trans proline' 0 N--CA 1.45 -1.052 0 C-N-CA 122.07 1.847 . . . . 73.120000000000005 111.863 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.468 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.1 m -132.4 20.41 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.12 -0.946 . . . . 70.319999999999993 109.891 178.406 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 81.0 m -90.05 -22.87 21.63 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.076 -0.966 . . . . 73.310000000000002 110.595 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 78.95 -4.92 59.98 Favored Glycine 0 C--N 1.3 -1.47 0 CA-C-N 114.881 -1.054 . . . . 63.329999999999998 113.71 176.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -116.57 175.54 5.52 Favored 'General case' 0 C--N 1.303 -1.418 0 C-N-CA 120.214 -0.595 . . . . 65.299999999999997 110.484 -179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.8 p -127.43 148.14 50.29 Favored 'General case' 0 C--N 1.292 -1.905 0 CA-C-N 115.488 -0.778 . . . . 53.200000000000003 110.475 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.468 ' HB3' ' SG ' ' A' ' 14' ' ' CYS . 6.2 p -113.23 87.94 2.72 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 109.482 -0.562 . . . . 63.210000000000001 109.482 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 61.3 t -79.74 -30.18 13.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.661 -0.866 . . . . 70.140000000000001 108.661 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.49 -15.75 58.03 Favored Glycine 0 N--CA 1.435 -1.375 0 CA-C-N 115.213 -0.903 . . . . 72.030000000000001 110.996 177.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.98 15.89 34.86 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.449 -0.882 . . . . 51.310000000000002 112.827 177.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.7 m -143.18 125.79 15.89 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.334 -0.987 . . . . 55.32 108.334 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.468 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 33.3 m -96.79 154.44 17.29 Favored 'General case' 0 C--N 1.274 -2.678 0 CA-C-N 115.755 -0.657 . . . . 52.130000000000003 110.846 -176.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.2 t30 -77.56 -53.2 7.88 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.901 -0.59 . . . . 73.510000000000005 110.451 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 33.5 m -50.99 113.09 3.44 Favored Pre-proline 0 C--O 1.253 1.268 0 C-N-CA 124.049 0.939 . . . . 72.230000000000004 112.945 -177.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.72 119.43 6.65 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.565 2.177 . . . . 73.150000000000006 109.614 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.55 -3.77 27.84 Favored Glycine 0 N--CA 1.426 -1.978 0 C-N-CA 120.622 -0.799 . . . . 61.240000000000002 111.505 -179.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 66.3 m -111.01 154.77 23.71 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.683 0.754 . . . . 74.450000000000003 110.639 175.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -137.83 161.02 37.7 Favored 'General case' 0 C--N 1.274 -2.676 0 CA-C-N 114.683 -1.144 . . . . 70.430000000000007 109.754 -178.304 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 17.6 t -95.68 83.23 3.71 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 121.178 0.514 . . . . 70.400000000000006 109.694 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 44.0 t -89.15 -51.48 5.56 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.242 -0.435 . . . . 74.030000000000001 109.976 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.1 t-105 -105.47 80.86 1.62 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 109.527 -0.546 . . . . 73.439999999999998 109.527 -179.349 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 86.6 t90 -57.03 136.57 80.25 Favored Pre-proline 0 C--N 1.318 -0.784 0 CA-C-N 115.432 -0.804 . . . . 71.299999999999997 109.984 -177.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_endo -100.09 35.31 7.41 Favored 'Cis proline' 0 CA--C 1.544 1.017 0 C-N-CA 124.686 -0.964 . . . . 75.310000000000002 113.715 1.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.1 t -107.1 142.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 108.824 -0.806 . . . . 62.030000000000001 108.824 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.1 m -88.3 153.18 21.41 Favored 'General case' 0 N--CA 1.424 -1.737 0 C-N-CA 119.422 -0.911 . . . . 74.099999999999994 110.236 179.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -132.02 155.42 48.06 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.106 -1.406 . . . . 61.520000000000003 110.291 -177.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -91.99 -68.79 0.77 Allowed 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.993 0.901 . . . . 72.0 111.153 -176.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.1 p30 . . . . . 0 C--N 1.299 -1.596 0 N-CA-C 105.505 -2.035 . . . . 61.149999999999999 105.505 179.944 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.403 -3.564 0 N-CA-C 111.219 -0.752 . . . . 73.530000000000001 111.219 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.1 tp -109.1 113.48 59.01 Favored Pre-proline 0 C--N 1.328 -0.362 0 C-N-CA 120.108 -0.637 . . . . 60.030000000000001 110.529 -175.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -73.52 81.01 1.88 Allowed 'Trans proline' 0 N--CA 1.444 -1.427 0 C-N-CA 121.497 1.465 . . . . 73.230000000000004 112.674 179.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.5 m -126.78 24.18 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 122.326 1.06 . . . . 74.299999999999997 109.877 175.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 37.2 m -84.57 -27.59 27.18 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 114.554 -1.203 . . . . 63.039999999999999 108.051 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.54 -7.77 64.01 Favored Glycine 0 N--CA 1.438 -1.211 0 CA-C-N 113.507 -1.679 . . . . 73.530000000000001 112.702 177.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -107.52 -177.2 3.28 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 121.225 0.536 . . . . 52.340000000000003 110.893 -177.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.7 p -135.36 164.2 28.3 Favored 'General case' 0 N--CA 1.421 -1.915 0 CA-C-N 114.465 -1.243 . . . . 72.340000000000003 108.781 -179.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.0 p -126.73 80.2 1.92 Allowed 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 116.538 -0.301 . . . . 61.009999999999998 110.677 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.1 t -77.56 -26.51 15.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 108.423 -0.955 . . . . 74.239999999999995 108.423 178.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.74 -7.64 68.51 Favored Glycine 0 N--CA 1.438 -1.184 0 N-CA-C 110.447 -1.061 . . . . 74.040000000000006 110.447 176.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.99 10.54 69.06 Favored Glycine 0 C--O 1.218 -0.861 0 C-N-CA 121.375 -0.441 . . . . 73.439999999999998 112.212 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -127.72 123.77 36.2 Favored 'General case' 0 N--CA 1.419 -2.01 0 N-CA-C 108.243 -1.021 . . . . 74.299999999999997 108.243 -176.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.1 m -95.65 149.7 21.17 Favored 'General case' 0 C--N 1.277 -2.564 0 N-CA-C 109.483 -0.562 . . . . 73.430000000000007 109.483 177.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -90.19 -54.56 3.97 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 123.12 0.568 . . . . 65.439999999999998 111.698 -177.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.478 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 44.1 m -51.22 119.39 12.36 Favored Pre-proline 0 CA--C 1.562 1.441 0 O-C-N 123.838 0.711 . . . . 74.420000000000002 112.75 -178.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.27 118.57 5.46 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 123.089 2.526 . . . . 70.219999999999999 111.174 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.42 5.13 37.28 Favored Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 120.728 -0.749 . . . . 60.210000000000001 111.389 -179.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.478 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 84.5 m -103.88 159.64 15.48 Favored 'General case' 0 N--CA 1.433 -1.313 0 CA-C-O 121.528 0.68 . . . . 74.219999999999999 111.057 175.139 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.6 p -140.34 146.34 38.34 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 114.76 -1.109 . . . . 75.439999999999998 109.627 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.1 t -92.68 87.35 5.86 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.218 -1.401 . . . . 61.119999999999997 107.218 176.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 19.6 t -88.16 -70.23 0.65 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 109.262 -0.644 . . . . 74.109999999999999 109.262 -177.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 9.8 m-90 -91.0 87.36 6.58 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 108.301 -1.0 . . . . 75.200000000000003 108.301 177.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 90.3 t90 -54.82 135.6 65.5 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 109.378 -0.601 . . . . 64.030000000000001 109.378 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 72.4 Cg_endo -102.13 39.93 4.14 Favored 'Cis proline' 0 CA--C 1.545 1.072 0 CA-C-N 119.365 0.809 . . . . 61.32 113.212 2.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.0 t -107.02 130.43 59.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.92 -0.487 . . . . 65.420000000000002 109.829 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 71.0 m -88.9 152.26 21.84 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-O 121.998 0.904 . . . . 62.32 110.177 178.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 24.5 p -134.01 171.0 14.81 Favored 'General case' 0 C--N 1.266 -3.03 0 CA-C-N 113.946 -1.479 . . . . 64.030000000000001 108.236 -178.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.474 ' C ' HD22 ' A' ' 30' ' ' ASN . 28.1 mmm180 -87.94 -78.96 0.3 Allowed 'General case' 0 N--CA 1.4 -2.935 0 N-CA-C 107.926 -1.138 . . . . 65.540000000000006 107.926 175.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.474 HD22 ' C ' ' A' ' 29' ' ' ARG . 0.9 OUTLIER . . . . . 0 C--N 1.292 -1.906 0 N-CA-C 105.136 -2.172 . . . . 74.129999999999995 105.136 174.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.926 0 N-CA-C 108.772 -1.731 . . . . 61.229999999999997 108.772 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.0 tp -123.24 119.0 27.65 Favored Pre-proline 0 C--O 1.247 0.945 0 CA-C-N 115.043 -0.578 . . . . 73.519999999999996 109.837 -178.024 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -73.73 81.28 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.432 2.088 . . . . 74.219999999999999 112.552 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.1 m -130.88 20.4 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.204 -0.907 . . . . 75.519999999999996 109.405 177.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.5 m -89.48 -30.09 18.53 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.211 -0.904 . . . . 74.140000000000001 109.753 178.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.94 -1.56 88.34 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-N 114.739 -1.119 . . . . 42.340000000000003 112.724 178.062 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -119.84 179.79 4.14 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.339 0.59 . . . . 64.530000000000001 111.436 -178.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 p -128.18 168.2 15.75 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.908 -1.042 . . . . 62.219999999999999 110.318 -177.042 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.1 p -135.28 86.89 2.28 Favored 'General case' 0 N--CA 1.419 -1.977 0 N-CA-C 109.315 -0.624 . . . . 64.040000000000006 109.315 178.557 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 51.3 t -77.0 -33.06 20.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 108.649 -0.871 . . . . 75.400000000000006 108.649 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.64 -28.23 17.11 Favored Glycine 0 N--CA 1.436 -1.362 0 N-CA-C 110.456 -1.058 . . . . 73.010000000000005 110.456 175.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.68 12.51 11.44 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.558 -0.829 . . . . 65.239999999999995 112.552 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.2 m -118.93 116.56 26.72 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.663 -0.866 . . . . 72.340000000000003 108.663 -176.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 40.7 m -95.13 137.21 34.48 Favored 'General case' 0 C--N 1.274 -2.684 0 N-CA-C 109.393 -0.595 . . . . 61.210000000000001 109.393 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.9 t30 -76.99 -51.4 11.19 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.47 -0.332 . . . . 55.310000000000002 110.462 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 61.9 m -51.77 116.59 8.25 Favored Pre-proline 0 C--O 1.259 1.584 0 O-C-N 124.011 0.82 . . . . 73.530000000000001 112.326 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.1 118.41 5.31 Favored 'Trans proline' 0 N--CA 1.446 -1.311 0 C-N-CA 122.227 1.952 . . . . 62.439999999999998 109.686 177.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.34 -4.13 23.51 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 120.256 -0.973 . . . . 20.140000000000001 111.092 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 58.4 m -109.37 148.13 31.6 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 119.353 -0.939 . . . . 62.329999999999998 110.363 175.569 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.5 p -134.53 148.52 50.52 Favored 'General case' 0 C--N 1.257 -3.448 0 CA-C-N 114.12 -1.4 . . . . 74.340000000000003 109.259 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.1 t -85.31 75.35 10.27 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.159 -1.052 . . . . 72.150000000000006 108.159 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 16.8 m -73.23 -44.01 60.25 Favored 'General case' 0 N--CA 1.407 -2.59 0 CA-C-N 115.437 -0.801 . . . . 71.030000000000001 110.633 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 62.0 t90 -125.36 97.2 5.11 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.771 -0.826 . . . . 73.430000000000007 108.771 178.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.405 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.4 t90 -58.56 138.97 85.77 Favored Pre-proline 0 C--N 1.303 -1.449 0 CA-C-N 114.913 -1.039 . . . . 72.120000000000005 109.597 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 86.0 Cg_endo -102.49 36.75 5.63 Favored 'Cis proline' 0 CA--C 1.54 0.813 0 C-N-CA 124.948 -0.855 . . . . 71.230000000000004 113.41 1.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 66.4 t -113.25 138.96 40.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 121.9 -0.5 . . . . 63.520000000000003 110.104 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -88.35 151.51 22.55 Favored 'General case' 0 N--CA 1.417 -2.098 0 N-CA-C 108.735 -0.839 . . . . 64.420000000000002 108.735 177.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.2 p -137.64 160.89 37.94 Favored 'General case' 0 C--N 1.252 -3.665 0 CA-C-N 114.539 -1.209 . . . . 64.109999999999999 109.582 -177.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -90.93 -60.8 1.82 Allowed 'General case' 0 C--N 1.309 -1.181 0 CA-C-O 121.46 0.647 . . . . 73.400000000000006 111.106 -177.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 N--CA 1.424 -1.749 0 N-CA-C 105.58 -2.007 . . . . 64.329999999999998 105.58 178.556 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.405 -3.4 0 N-CA-C 110.326 -1.11 . . . . 74.400000000000006 110.326 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HG ' HG13 ' A' ' 4' ' ' VAL . 47.5 tp -110.46 116.64 52.47 Favored Pre-proline 0 C--O 1.24 0.591 0 N-CA-C 109.437 -0.579 . . . . 62.109999999999999 109.437 -177.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -73.2 81.32 1.74 Allowed 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.227 1.951 . . . . 51.329999999999998 112.122 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.432 HG13 ' HG ' ' A' ' 2' ' ' LEU . 15.5 m -131.66 12.45 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.293 -0.867 . . . . 75.239999999999995 110.731 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 64.7 m -80.89 -35.88 32.0 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.848 0.833 . . . . 75.450000000000003 109.105 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 85.26 -0.64 88.73 Favored Glycine 0 N--CA 1.426 -1.987 0 CA-C-N 114.84 -1.073 . . . . 52.329999999999998 112.032 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.57 177.21 4.73 Favored 'General case' 0 C--O 1.255 1.377 0 CA-C-O 121.399 0.618 . . . . 63.039999999999999 110.848 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.3 p -130.8 168.2 17.63 Favored 'General case' 0 C--N 1.285 -2.212 0 CA-C-N 114.596 -1.184 . . . . 70.129999999999995 110.945 -175.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.7 p -135.81 87.36 2.31 Favored 'General case' 0 N--CA 1.417 -2.124 0 CA-C-N 115.577 -0.738 . . . . 74.129999999999995 109.782 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.13 -30.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.044 0 N-CA-C 108.082 -1.081 . . . . 74.109999999999999 108.082 177.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.66 -6.65 69.98 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 115.117 -0.947 . . . . 64.5 111.421 177.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.02 24.72 40.07 Favored Glycine 0 N--CA 1.444 -0.802 0 C-N-CA 120.679 -0.772 . . . . 50.130000000000003 112.921 176.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 31.7 m -147.06 127.56 14.09 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 108.942 -0.762 . . . . 73.140000000000001 108.942 177.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.1 m -94.58 152.39 18.57 Favored 'General case' 0 C--N 1.282 -2.352 0 CA-C-N 115.826 -0.624 . . . . 75.530000000000001 110.463 -178.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -83.8 -57.71 3.1 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.114 -0.494 . . . . 74.310000000000002 111.241 -176.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.402 ' HB ' ' SG ' ' A' ' 19' ' ' CYS . 49.8 m -51.96 117.78 10.62 Favored Pre-proline 0 C--O 1.248 0.999 0 O-C-N 123.735 0.647 . . . . 62.539999999999999 112.312 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_exo -62.76 111.45 1.36 Allowed 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.446 2.097 . . . . 71.109999999999999 109.557 176.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 126.11 -10.62 7.37 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 111.089 -0.804 . . . . 63.009999999999998 111.089 -176.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.402 ' SG ' ' HB ' ' A' ' 16' ' ' THR . 67.5 m -100.44 154.94 18.12 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-O 121.576 0.703 . . . . 74.25 109.85 175.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 p -136.19 143.49 44.43 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-N 114.759 -1.109 . . . . 71.120000000000005 109.15 -178.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 37.0 t -90.96 84.39 5.76 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 106.665 -1.606 . . . . 74.0 106.665 176.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 17.9 t -104.73 -16.28 15.0 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.802 -0.635 . . . . 75.5 110.642 -175.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 84.6 m95 -133.99 72.0 1.46 Allowed 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.12 -1.066 . . . . 65.340000000000003 108.12 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 82.2 t90 -54.95 135.47 66.77 Favored Pre-proline 0 C--O 1.244 0.787 0 CA-C-N 114.41 -1.268 . . . . 73.120000000000005 110.331 -174.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 45.0 Cg_endo -99.43 34.54 8.22 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 C-N-CA 124.662 -0.974 . . . . 71.430000000000007 113.756 3.389 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.9 t -107.23 139.21 29.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 121.905 -0.497 . . . . 70.319999999999993 109.808 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 94.8 m -88.83 154.62 20.11 Favored 'General case' 0 N--CA 1.416 -2.155 0 CA-C-O 122.137 0.97 . . . . 62.229999999999997 109.758 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.2 p -138.93 166.02 25.57 Favored 'General case' 0 C--N 1.257 -3.414 0 CA-C-N 114.129 -1.396 . . . . 73.439999999999998 107.957 -178.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 10.3 tpp180 -88.93 -70.59 0.64 Allowed 'General case' 0 N--CA 1.419 -2.005 0 C-N-CA 119.001 -1.08 . . . . 74.349999999999994 108.93 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 C--N 1.303 -1.455 0 N-CA-C 104.797 -2.297 . . . . 52.130000000000003 104.797 179.513 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.424 -2.138 0 N-CA-C 109.503 -1.439 . . . . 64.140000000000001 109.503 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.528 ' HG ' HG13 ' A' ' 4' ' ' VAL . 55.8 tp -110.37 109.78 58.3 Favored Pre-proline 0 C--O 1.246 0.897 0 CA-C-N 114.868 -0.666 . . . . 71.439999999999998 109.224 -177.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -75.46 83.7 1.85 Allowed 'Trans proline' 0 N--CA 1.434 -1.977 0 C-N-CA 121.945 1.763 . . . . 75.0 111.179 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.528 HG13 ' HG ' ' A' ' 2' ' ' LEU . 8.4 m -123.01 19.96 4.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.39 -0.823 . . . . 75.420000000000002 110.044 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 57.4 m -108.1 -24.25 11.64 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-N 115.611 -0.722 . . . . 61.240000000000002 111.86 177.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.76 -15.52 14.37 Favored Glycine 0 C--O 1.246 0.869 0 CA-C-N 115.421 -0.809 . . . . 64.310000000000002 114.361 176.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.45 ' HG3' ' SG ' ' A' ' 27' ' ' CYS . 15.7 pt-20 -94.98 174.27 7.17 Favored 'General case' 0 C--N 1.29 -1.994 0 CA-C-O 121.635 0.731 . . . . 63.43 111.531 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.0 p -125.9 161.32 27.72 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 114.765 -1.107 . . . . 74.400000000000006 109.95 -179.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.4 p -122.2 90.73 3.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.804 -0.813 . . . . 71.219999999999999 108.804 178.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.53 -37.08 18.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.841 -0.8 . . . . 72.430000000000007 108.841 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.43 -14.88 59.43 Favored Glycine 0 N--CA 1.439 -1.107 0 CA-C-N 115.555 -0.748 . . . . 50.140000000000001 111.348 177.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 100.03 20.25 16.79 Favored Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.447 -0.882 . . . . 70.430000000000007 113.453 176.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 59.0 m -141.95 127.54 19.04 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 108.981 -0.748 . . . . 75.530000000000001 108.981 177.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 33.9 m -100.17 162.68 12.81 Favored 'General case' 0 C--N 1.278 -2.528 0 CA-C-N 115.541 -0.754 . . . . 64.230000000000004 109.887 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -94.96 -49.57 5.49 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-N 116.559 -0.291 . . . . 72.109999999999999 110.446 -177.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.5 m -52.47 120.37 17.8 Favored Pre-proline 0 C--O 1.264 1.86 0 O-C-N 123.96 0.787 . . . . 65.430000000000007 112.347 -176.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_endo -62.78 114.23 2.32 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.136 1.891 . . . . 65.010000000000005 109.664 177.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.84 -21.87 6.96 Favored Glycine 0 N--CA 1.428 -1.843 0 C-N-CA 120.456 -0.878 . . . . 72.129999999999995 112.112 -177.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -107.1 154.26 21.42 Favored 'General case' 0 CA--C 1.481 -1.69 0 CA-C-O 122.246 1.022 . . . . 70.140000000000001 112.812 178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 p -139.39 167.58 21.76 Favored 'General case' 0 C--N 1.274 -2.688 0 CA-C-N 113.274 -1.785 . . . . 71.409999999999997 108.848 -178.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 9.6 t -90.64 64.71 5.78 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.882 -1.155 . . . . 62.340000000000003 107.882 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 15.2 m -65.07 -26.58 68.3 Favored 'General case' 0 N--CA 1.423 -1.798 0 CA-C-N 115.174 -0.921 . . . . 53.140000000000001 111.024 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -145.87 106.96 4.15 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 107.726 -1.213 . . . . 75.109999999999999 107.726 176.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 25' ' ' PRO . 83.5 t90 -67.35 139.31 94.58 Favored Pre-proline 0 C--N 1.295 -1.774 0 N-CA-C 108.962 -0.755 . . . . 74.340000000000003 108.962 -177.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 24' ' ' TRP . 43.2 Cg_endo -104.9 36.7 4.76 Favored 'Cis proline' 0 CA--C 1.537 0.656 0 C-N-CA 125.107 -0.789 . . . . 75.510000000000005 113.03 1.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.5 p -112.6 136.54 48.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-O 121.618 0.723 . . . . 72.439999999999998 111.404 -177.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HG3' ' A' ' 7' ' ' GLU . 65.1 m -88.59 138.44 31.43 Favored 'General case' 0 N--CA 1.409 -2.515 0 CA-C-O 122.482 1.134 . . . . 61.119999999999997 109.19 179.034 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 3.0 p -139.92 164.51 29.81 Favored 'General case' 1 C--N 1.243 -4.045 0 CA-C-N 113.2 -1.818 . . . . 63.509999999999998 109.304 -175.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -87.48 -66.36 0.92 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.59 -0.892 . . . . 74.310000000000002 108.59 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.8 p30 . . . . . 0 N--CA 1.426 -1.663 0 N-CA-C 105.139 -2.171 . . . . 62.030000000000001 105.139 175.87 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.412 -2.938 0 N-CA-C 109.083 -1.607 . . . . 74.510000000000005 109.083 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.402 ' HG ' HG13 ' A' ' 4' ' ' VAL . 46.5 tp -104.28 115.11 63.58 Favored Pre-proline 0 C--O 1.245 0.844 0 N-CA-C 109.038 -0.727 . . . . 74.299999999999997 109.038 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -73.5 80.27 2.01 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.268 1.979 . . . . 75.310000000000002 112.606 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.402 HG13 ' HG ' ' A' ' 2' ' ' LEU . 16.0 m -131.66 8.96 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 115.744 -0.662 . . . . 55.130000000000003 110.781 178.366 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 61.1 m -91.84 -30.29 16.27 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-O 121.784 0.802 . . . . 75.439999999999998 109.461 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.71 -12.61 46.8 Favored Glycine 0 N--CA 1.427 -1.934 0 CA-C-N 114.521 -1.218 . . . . 54.340000000000003 113.953 176.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -100.49 172.4 7.15 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.094 -1.042 . . . . 63.020000000000003 111.802 -176.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 p -126.51 154.75 43.37 Favored 'General case' 0 C--N 1.282 -2.332 0 CA-C-N 114.337 -1.301 . . . . 74.329999999999998 109.802 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.45 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 5.5 p -120.57 86.06 2.5 Favored 'General case' 0 N--CA 1.408 -2.54 0 N-CA-C 107.818 -1.178 . . . . 75.310000000000002 107.818 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 44.5 t -69.89 -33.6 56.44 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 N-CA-C 108.655 -0.868 . . . . 61.219999999999999 108.655 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.32 -32.15 7.56 Favored Glycine 0 N--CA 1.429 -1.792 0 CA-C-N 115.403 -0.817 . . . . 71.430000000000007 111.41 176.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.415 ' HA2' ' SG ' ' A' ' 21' ' ' CYS . . . 118.45 13.89 6.64 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.042 -1.075 . . . . 62.200000000000003 112.436 -178.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.0 m -126.08 112.04 15.38 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.213 -0.662 . . . . 64.040000000000006 109.213 -177.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.0 m -95.28 150.11 20.61 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.261 -0.881 . . . . 73.040000000000006 110.766 -176.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -90.84 -54.93 3.76 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 123.203 0.601 . . . . 72.150000000000006 111.065 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 57.5 m -50.19 117.97 8.5 Favored Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 113.169 0.803 . . . . 74.239999999999995 113.169 -176.042 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -57.9 123.01 12.71 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 123.249 2.633 . . . . 54.520000000000003 111.028 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.06 57.08 Favored Glycine 0 N--CA 1.427 -1.931 0 C-N-CA 120.733 -0.746 . . . . 42.509999999999998 112.148 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.9 m -100.77 155.26 18.01 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.291 -0.564 . . . . 62.450000000000003 109.644 177.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -140.85 155.43 46.34 Favored 'General case' 0 C--N 1.277 -2.575 0 CA-C-N 115.111 -0.95 . . . . 55.310000000000002 109.528 -174.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.415 ' SG ' ' HA2' ' A' ' 12' ' ' GLY . 24.5 t -84.78 79.6 9.56 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.409 -1.7 . . . . 71.439999999999998 106.409 175.168 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.449 ' HB3' ' OG1' ' A' ' 28' ' ' THR . 23.1 t -87.03 -28.36 22.65 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 115.036 -0.984 . . . . 42.43 110.389 -175.416 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.0 t-105 -135.94 85.46 2.16 Favored 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 107.95 -1.13 . . . . 75.439999999999998 107.95 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -58.45 135.84 85.58 Favored Pre-proline 0 C--N 1.307 -1.252 0 N-CA-C 109.396 -0.594 . . . . 73.099999999999994 109.396 -179.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -99.09 35.64 7.47 Favored 'Cis proline' 0 CA--C 1.553 1.445 0 N-CA-C 114.888 1.072 . . . . 71.310000000000002 114.888 5.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 57.6 t -112.81 135.51 52.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.607 -0.683 . . . . 75.230000000000004 109.669 179.166 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.45 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 63.4 m -88.96 146.7 24.73 Favored 'General case' 0 N--CA 1.415 -2.182 0 N-CA-C 106.721 -1.585 . . . . 63.109999999999999 106.721 174.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.449 ' OG1' ' HB3' ' A' ' 22' ' ' SER . 15.0 p -139.59 179.04 6.8 Favored 'General case' 0 C--N 1.248 -3.809 0 N-CA-C 108.286 -1.005 . . . . 64.129999999999995 108.286 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 20.0 tpt180 -88.49 -73.86 0.48 Allowed 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.77 -0.772 . . . . 70.239999999999995 109.513 -177.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.427 -1.583 0 N-CA-C 104.972 -2.233 . . . . 71.25 104.972 176.68 . . . . . . . . 0 0 . 1 stop_ save_